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ABSTRACT	  	  Many	  intracellular	  proteins	  are	  either	  conditionally	  or	  constitutively	  short-­‐lived,	  with	  in	  vivo	  half-­‐lives	  that	  can	  be	  as	  brief	  as	  a	  few	  minutes.	  The	  regulated	  and	  processive	  degradation	  of	  intracellular	  proteins	  is	  carried	  out	  largely	  by	  the	  ubiquitin	  (Ub)-­‐proteasome	  system	  (UPS).	  In	  eukaryotes,	  the	  N-­‐end	  rule	  pathway	  is	  a	  part	  of	  the	  UPS.	  The	  N-­‐end	  rule	  relates	  the	  regulation	  of	  the	  in	  vivo	  half-­‐life	  of	  a	  protein	  to	  the	  identity	  of	  its	  N-­‐terminal	  residue.	  Degradation	  signals	  (degrons)	  that	  are	  targeted	  by	  the	  N-­‐end	  rule	  pathway	  include	  a	  set	  called	  N-­‐degrons.	  E3	  Ub	  ligases	  of	  the	  N-­‐end	  rule	  pathway	  are	  called	  N-­‐recognins.	  They	  bind	  to	  primary	  destabilizing	  N-­‐terminal	  residues	  of	  N-­‐end	  rule	  substrates.	  The	  N-­‐end	  rule	  pathway	  comprises	  two	  major	  branches,	  the	  Arg/N-­‐end	  rule	  pathway	  and	  the	  Ac/N-­‐end	  rule	  pathway.	  	  	  The	  Arg/N-­‐end	  rule	  branch	  involves	  the	  N-­‐terminal	  arginylation	  of	  protein	  substrates	  and	  also	  the	  targeting	  of	  specific	  unmodified	  N-­‐terminal	  residues	  by	  E3	  N-­‐recognins.	  The	  S.	  cerevisiae	  Arg/N-­‐end	  rule	  pathway	  contains	  a	  single	  N-­‐recognin,	  Ubr1.	  The	  Ub-­‐fusion	  degradation	  (UFD)	  pathway	  is	  also	  a	  part	  of	  the	  UPS.	  This	  pathway	  recognizes	  a	  ‘‘nonremovable’’	  N-­‐terminal	  Ub	  moiety	  of	  a	  Ub	  fusion	  as	  a	  primary	  degron.	  My	  collaborator,	  Cheol-­‐Sang	  Hwang,	  and	  I	  demonstrated	  that	  the	  RING-­‐type	  Ubr1	  E3	  and	  the	  HECT-­‐type	  Ufd4	  E3	  interact,	  both	  physically	  and	  functionally.	  We	  showed	  that	  the	  Ubr1-­‐Ufd4	  complex	  targets	  the	  S.	  cerevisiae	  Mgt1	  DNA	  repair	  enzyme	  through	  a	  degron	  near	  its	  N-­‐terminus,	  in	  addition	  to	  mediating	  the	  Arg/N-­‐end	  rule	  pathway	  and	  a	  part	  of	  the	  UFD	  pathway	  as	  well.	  We	  also	  further	  characterized	  the	  physical	  interaction	  between	  Ubr1	  and	  Ufd4.	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The	  Ubiquitin-­‐Proteasome	  System	  	  Intracellular	  proteolysis	  involves	  both	  nonprocessive	  (single)	  cleavages	  of	  polypeptide	  chains	  of	  cellular	  proteins	  and	  the	  processive	  (complete	  or	  nearly	  complete)	  degradation	  of	  specific	  proteins	  to	  short	  peptides	  and/or	  individual	  amino	  acids.	  Many	  intracellular	  proteins	  are	  either	  conditionally	  or	  constitutively	  short-­‐lived,	  with	  in	  vivo	  half-­‐lives	  that	  can	  be	  as	  brief	  as	  a	  few	  minutes.	  One	  major	  role	  of	  proteolytic	  pathways	  is	  the	  selective	  destruction	  of	  regulatory	  proteins	  whose	  concentrations	  must	  vary	  with	  time	  and	  alterations	  in	  the	  state	  of	  a	  cell.	  Among	  the	  other	  functions	  of	  intracellular	  proteolysis	  are	  the	  elimination	  of	  misfolded	  or	  otherwise	  abnormal	  proteins,	  the	  maintenance	  of	  amino	  acid	  pools	  in	  cells	  affected	  by	  stresses	  such	  as	  starvation,	  and	  the	  generation	  of	  protein	  fragments	  that	  act	  as	  hormones,	  antigens,	  or	  other	  effectors	  (1).	  A	  short	  in	  vivo	  half-­‐life	  of	  a	  protein	  provides	  a	  way	  to	  generate	  its	  spatial	  gradient	  and	  to	  rapidly	  adjust	  its	  concentration	  or	  subunit	  composition	  through	  changes	  in	  the	  rate	  of	  its	  degradation	  (2).	  In	  conjunction	  with	  molecular	  chaperones,	  autophagy,	  and	  lysosomal	  proteolysis,	  selective	  degradation	  of	  proteins	  largely	  occurs	  through	  the	  ubiquitin-­‐proteasome	  system	  (UPS)	  (1,3).	  In	  this	  multipathway	  system,	  proteins	  are	  marked	  for	  degradation	  by	  the	  covalent	  conjugation	  of	  ubiquitin	  (Ub)	  to	  the	  target	  protein	  (4).	  	   Ub	  is	  a	  76-­‐residue	  protein	  that	  mediates	  proteolysis	  through	  the	  enzymatic	  conjugation	  of	  Ub	  to	  proteins	  that	  contain	  primary	  degradation	  signals,	  called	  degrons	  (5).	  Ub-­‐protein	  conjugation	  marks	  proteins	  for	  their	  recognition	  and	  degradation	  by	  the	  26S	  proteasome,	  a	  processive,	  ATP-­‐dependent	  protease	  (6).	  Ub	  
	   3	  
is	  conjugated	  to	  proteins	  either	  as	  a	  single	  moiety	  or	  as	  a	  poly-­‐Ub	  chain	  that	  is	  linked	  (in	  most	  cases)	  to	  the	  ε-­‐amino	  group	  of	  an	  internal	  Lys	  residue	  in	  a	  substrate	  protein,	  although	  other	  residues	  have	  been	  shown	  to	  conjugate	  Ub	  (7).	  The	  number	  of	  topologically	  distinct	  poly-­‐Ub	  chains	  can	  be	  very	  large,	  as	  all	  seven	  Lys	  residues	  of	  Ub	  can	  contribute,	  in	  specific	  in	  vivo	  contexts,	  to	  the	  synthesis	  of	  poly-­‐Ub	  linked	  to	  protein	  substrates.	  The	  delivery	  of	  ubiquitylated	  proteins	  to	  the	  26S	  proteasome	  can	  be	  mediated	  by	  either	  K48-­‐type,	  K11-­‐type	  or	  K29-­‐type	  chains,	  and	  possibly	  by	  poly-­‐Ub	  of	  other	  topologies	  as	  well	  (8-­‐10).	  	  The	  26S	  proteasome	  is	  a	  multisubunit	  ATP-­‐dependent	  protease	  that	  degrades	  polyubiquitylated	  proteins	  (11,12).	  The	  26S	  proteasome	  is	  composed	  of	  the	  19S	  regulatory	  particle	  (RP)	  and	  the	  20S	  core	  particle	  (CP)	  (3,6,13).	  The	  RP	  is	  responsible	  for	  recognizing	  the	  proteins	  to	  be	  degraded,	  to	  a	  large	  extent	  through	  conjugated	  poly-­‐Ub	  chains.	  Substrates	  are	  recognized	  by	  specific	  ubiquitin	  receptor	  proteins	  located	  in	  the	  RP.	  The	  substrate-­‐linked	  poly-­‐Ub	  chains	  are	  disassembled	  by	  deubiquitylating	  enzymes	  (DUBs),	  some	  of	  which	  are	  subunits	  of	  the	  RP.	  The	  targeted	  substrate	  is	  at	  least	  partially	  unfolded	  by	  ATPase	  subunits	  of	  the	  RP	  and	  thereafter	  is	  threaded	  through	  a	  channel	  into	  the	  CP,	  which	  processively	  degrades	  the	  protein	  to	  short	  peptides.	  	  The	  conjugation	  of	  Ub	  to	  other	  proteins	  involves	  a	  preliminary	  ATP-­‐dependent	  step	  in	  which	  the	  last	  residue	  of	  Ub	  (Gly76)	  is	  joined,	  via	  a	  thioester	  bond,	  to	  a	  Cys	  residue	  of	  the	  E1	  (Ub-­‐activating)	  enzyme.	  The	  ‘‘activated’’	  Ub	  moiety	  is	  transferred	  to	  a	  Cys	  residue	  in	  one	  of	  several	  Ub-­‐conjugating	  (E2)	  enzymes,	  and	  from	  there,	  through	  an	  isopeptide	  bond,	  to	  a	  Lys	  residue	  of	  an	  ultimate	  acceptor.	  E2	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enzymes	  function	  as	  subunits	  of	  E2-­‐E3	  Ub	  ligase	  complexes	  that	  can	  produce	  substrate-­‐linked	  poly-­‐Ub	  chains.	  This	  process	  is	  illustrated	  in	  figure	  1.1.	  	  One	  role	  of	  the	  E3	  is	  the	  recognition	  of	  a	  substrate’s	  degradation	  signal	  (degron	  (5)).	  Individual	  mammalian	  genomes	  encode	  at	  least	  1000	  distinct	  E3	  Ub	  ligases.	  There	  are	  2	  major	  types	  of	  E3	  ligases	  in	  eukaryotes,	  defined	  by	  their	  catalytic	  domain	  (14).	  One	  type	  of	  E3	  contains	  a	  RING	  (or	  RING-­‐like)	  domain	  and	  a	  conserved	  cysteine	  and	  histidine	  residue	  that	  coordinate	  2	  zinc	  ions	  (15).	  The	  RING	  E3s	  mediate	  the	  direct	  transfer	  of	  the	  Ub	  moiety	  from	  the	  E2	  to	  the	  target	  protein.	  The	  other	  type	  of	  E3,	  with	  a	  HECT	  domain,	  transfers	  the	  Ub	  molecule	  to	  a	  cysteine	  within	  itself	  and	  then	  transfers	  the	  Ub	  molecule	  to	  the	  substrate	  (16).	  	  	  
The	  N-­‐end	  Rule	  Pathway	  	   The	  1986	  discovery	  of	  the	  N-­‐end	  rule	  pathway	  identified	  the	  first	  specific	  pathway	  of	  the	  Ub	  system	  (17-­‐20).	  The	  N-­‐end	  rule	  relates	  the	  regulation	  of	  the	  in	  vivo	  half-­‐life	  of	  a	  protein	  to	  the	  identity	  of	  its	  N-­‐terminal	  residue.	  N-­‐terminal	  degradation	  signals	  of	  the	  N-­‐end	  rule	  pathway	  are	  called	  N-­‐degrons.	  The	  main	  determinant	  of	  an	  N-­‐degron	  is	  a	  destabilizing	  N-­‐terminal	  residue	  of	  a	  protein.	  Recognition	  components	  of	  the	  N-­‐end	  rule	  pathway	  are	  called	  N-­‐recognins	  and	  in	  eukaryotes,	  these	  are	  the	  E3	  Ub	  ligases	  that	  bind	  to	  specific	  N-­‐degrons.	  In	  eukaryotes,	  the	  N-­‐end	  rule	  pathway	  comprises	  two	  branches,	  the	  Arg/N-­‐end	  rule	  pathway	  and	  the	  Ac/N-­‐end	  rule	  pathway.	  	  
	  
	   5	  
The	  Arg/N-­‐end	  Rule	  Pathway	  	   This	  branch	  involves	  the	  N-­‐terminal	  arginylation	  (Nt-­‐arginylation)	  of	  protein	  substrates	  and	  also	  the	  targeting	  of	  specific	  unmodified	  N-­‐terminal	  residues	  by	  E3	  N-­‐recognins.	  N-­‐terminal	  Arg,	  Lys,	  His,	  Leu,	  Phe,	  Tyr,	  Trp,	  Ile,	  Asp,	  Glu,	  Asn,	  Gln,	  and	  Cys	  comprise	  the	  main	  determinants	  of	  N-­‐degrons	  in	  the	  Arg/N-­‐end	  rule	  pathway.	  These	  residues	  become	  N-­‐terminal	  by	  either	  the	  cotranslational	  removal	  of	  Met	  by	  Met-­‐aminopeptidases	  (MetAPs)	  or	  by	  the	  posttranslational	  (and	  conditional)	  cleavage	  by	  nonprocessive	  proteases	  that	  include	  caspases,	  calpains,	  or	  separases.	  Among	  these	  N-­‐degrons,	  the	  unmodified	  basic	  (Arg,	  Lys,	  His)	  and	  bulky	  hydrophobic	  (Leu,	  Phe,	  Tyr,	  Trp,	  Ile)	  N-­‐terminal	  residues	  are	  recognized	  directly	  by	  cognate	  E3	  N-­‐recognins.	  These	  E3s	  contain	  highly	  spalogous	  (spatially	  similar	  (21))	  ~80-­‐residue	  regions	  called	  UBR	  domains	  or	  Type-­‐1	  binding	  sites.	  Folded	  around	  3	  zinc	  ions,	  a	  UBR	  domain	  binds	  to	  N-­‐terminal	  Arg,	  Lys,	  or	  His,	  the	  Type-­‐1	  primary	  destabilizing	  residues	  of	  N-­‐end	  rule	  substrates	  (22,23).	  Another	  (usually	  adjacent)	  region	  of	  UBR-­‐type	  N-­‐recognins,	  called	  the	  Type-­‐2	  binding	  site,	  recognizes	  N-­‐terminal	  Leu,	  Phe,	  Tyr,	  Trp,	  or	  Ile,	  which	  are	  called	  the	  Type-­‐2	  primary	  destabilizing	  residues.	  Together,	  the	  directly	  recognized	  N-­‐terminal	  Arg,	  Lys,	  His,	  Leu,	  Phe,	  Tyr,	  Trp,	  and	  Ile	  are	  denoted	  as	  primary	  destabilizing	  residues	  (24,25).	  	  In	  contrast	  to	  these	  residues,	  the	  N-­‐terminal	  Asp,	  Glu,	  Asn,	  Gln,	  and	  Cys	  function	  as	  secondary	  or	  tertiary	  destabilizing	  residues	  through	  their	  preliminary	  modification,	  depending	  on	  the	  number	  of	  specific	  modifications	  that	  precede	  their	  targeting	  by	  N-­‐recognins.	  One	  of	  these	  modifications	  is	  Nt-­‐arginylation.	  Arg-­‐tRNA-­‐protein	  transferase	  (R-­‐transferase)	  conjugates	  Arg	  to	  N-­‐terminal	  Asp,	  Glu,	  or	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oxidized	  Cys	  of	  proteins	  or	  short	  peptides,	  with	  Arg-­‐tRNA	  as	  the	  cosubstrate	  and	  the	  donor	  of	  Arg	  (26).	  R-­‐transferases	  are	  encoded	  by	  Ate1	  and	  its	  sequelogs	  from	  yeast	  to	  mammals	  but	  are	  absent	  from	  examined	  prokaryotes.	  In	  contrast	  to	  N-­‐terminal	  Asp,	  Glu	  and	  oxidized	  Cys,	  the	  N-­‐terminal	  Asn	  and	  Gln	  residues	  cannot	  be	  arginylated	  by	  R-­‐transferase.	  However,	  the	  Arg/N-­‐end	  rule	  pathway	  contains	  specific	  N-­‐terminal	  amidases	  (Nt-­‐amidases)	  that	  convert	  N-­‐terminal	  Asn	  and	  Gln	  to	  Asp	  and	  Glu,	  respectively,	  followed	  by	  their	  Nt-­‐arginylation	  (27).	  	  The	  unmodified	  N-­‐terminal	  Cys	  residue	  of	  a	  protein	  substrate	  is	  formally	  a	  tertiary	  destabilizing	  residue	  in	  the	  Arg/N-­‐end	  rule	  pathway,	  as	  it	  must	  undergo	  two	  modifications	  (oxidation	  and	  arginylation)	  prior	  to	  substrate’s	  binding	  by	  an	  N-­‐recognin.	  If	  the	  protein’s	  N-­‐terminal	  Cys	  can	  be	  oxidized	  through	  (apparently	  nonenzymatic)	  reactions	  that	  require	  both	  nitric	  oxide	  (NO)	  and	  oxygen,	  and	  if	  these	  compounds	  are	  present	  in	  a	  cell	  at	  sufficient	  levels,	  the	  resulting	  N-­‐terminal	  Cys-­‐sulfinate	  or	  Cys-­‐sulfonate	  (but	  not	  the	  original	  Cys)	  can	  be	  Nt-­‐arginylated	  by	  the	  Ate1	  R-­‐transferase.	  The	  necessity	  of	  NO	  and	  oxygen	  for	  the	  destabilizing	  activity	  of	  N-­‐terminal	  Cys	  makes	  the	  Arg/N-­‐end	  rule	  pathway	  a	  sensor	  of	  both	  NO	  and	  oxygen	  (28).	   Until	  recently,	  polyubiquitylation	  of	  substrates	  by	  the	  S.	  cerevisiae	  Arg/N-­‐end	  rule	  pathway	  was	  thought	  to	  be	  mediated	  by	  a	  dimer	  comprising	  the	  225-­‐kDa	  Ubr1	  E3	  and	  the	  Ubr1-­‐bound	  20-­‐kDa	  Rad6	  E2	  enzyme	  (25,29-­‐31).	  As	  described	  in	  chapters	  2	  and	  3	  and	  appendix	  1,	  we	  discovered	  that	  the	  targeting	  ensemble	  is	  more	  elaborate.	  It	  comprises	  a	  physical	  complex	  of	  the	  RING-­‐type	  Ubr1	  E3	  (N-­‐recognin)	  and	  the	  HECT-­‐type	  Ufd4	  E3,	  in	  association	  with	  their	  cognate	  E2s	  Rad6	  and	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Ubc4/Ubc5,	  respectively	  (32,33).	  Ufd4	  is	  the	  168	  kDa	  HECT-­‐type	  E3	  of	  the	  Ub-­‐fusion	  degradation	  (UFD)	  pathway	  that	  recognizes	  a	  ‘‘nonremovable’’	  N-­‐terminal	  Ub	  moiety	  of	  a	  Ub	  fusion	  as	  a	  primary	  degron	  and	  polyubiquitylates	  the	  Ub	  moiety,	  a	  prerequisite	  for	  the	  fusion’s	  degradation	  by	  the	  26S	  proteasome	  (34,35).	  The	  UFD	  pathway	  was	  discovered	  by	  this	  laboratory	  in	  1986	  through	  analyses	  of	  N-­‐terminal	  Ub	  fusions	  in	  which	  an	  alteration	  of	  either	  the	  Ub	  moiety	  or	  a	  junctional	  amino	  acid	  residue	  inhibits	  the	  cleavage	  of	  a	  fusion	  by	  deubiquitylases	  and	  thereby	  results	  in	  the	  fusion’s	  degradation	  by	  the	  UFD	  pathway.	  The	  UFD	  pathway	  is	  present	  in	  both	  yeast	  and	  mammals,	  suggesting	  that	  the	  Ubr1-­‐Ufd4	  double-­‐E3	  organization	  of	  the	  S.	  
cerevisiae	  Arg/N-­‐end	  rule	  pathway	  is	  universal	  among	  eukaryotes	  (36,37).	  Figure	  1.A,	  B	  diagram	  the	  Arg/N-­‐end	  rule	  pathway	  in	  mammals	  (A)	  and	  S.	  cerevisiae	  (B).	  	  Physiological	  functions	  of	  the	  N-­‐end	  rule	  pathway	  are	  strikingly	  broad	  and	  continue	  to	  be	  discovered.	  Regulated	  degradation	  of	  proteins	  by	  the	  eukaryotic	  Arg/N-­‐end	  rule	  pathway	  mediates	  the	  sensing	  of	  heme,	  NO,	  oxygen,	  and	  short	  peptides;	  the	  selective	  elimination	  of	  misfolded	  proteins;	  the	  regulation	  of	  DNA	  repair	  (through	  degradation	  of	  Mgt1,	  a	  DNA	  repair	  protein);	  the	  cohesion/segregation	  of	  chromosomes	  (through	  degradation	  of	  a	  subunit	  of	  cohesin);	  the	  signaling	  by	  transmembrane	  receptors	  (through	  degradation	  of	  the	  G-­‐protein	  regulators	  Rgs4,	  Rgs5,	  and	  Rgs16);	  the	  control	  of	  peptide	  import	  (through	  degradation	  of	  Cup9,	  the	  import’s	  transcriptional	  repressor);	  the	  regulation	  of	  apoptosis,	  meiosis,	  viral	  and	  bacterial	  infections,	  fat	  metabolism,	  cell	  migration,	  actin	  filaments,	  cardiovascular	  development,	  spermatogenesis,	  neurogenesis,	  and	  memory;	  the	  functioning	  of	  adult	  organs,	  including	  the	  brain,	  muscle,	  testis,	  and	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pancreas;	  and	  the	  regulation	  of	  leaf	  and	  shoot	  development,	  leaf	  senescence,	  and	  seed	  germination	  in	  plants	  (24,27,38-­‐66).	  Mutations	  in	  UBR1,	  an	  E3	  N-­‐recognin	  of	  the	  human	  Arg/N-­‐end	  rule	  pathway,	  cause	  Johanson–Blizzard	  syndrome	  (JBS)(67).	  	  
The	  Ac/N-­‐End	  Rule	  Pathway	  The	  other	  branch	  is	  termed	  the	  Ac/N-­‐end	  rule	  pathway.	  The	  Ac/N-­‐end	  rule	  pathway	  was	  discovered	  by	  us	  in	  2010,	  24	  years	  after	  the	  Arg/N-­‐end	  rule	  pathway	  (chapter	  4)	  (68).	  It	  involves	  the	  cotranslational	  Nα-­‐terminal	  acetylation	  (Nt-­‐acetylation)	  of	  nascent	  proteins	  whose	  N-­‐termini	  bear	  either	  Met	  or	  the	  small	  uncharged	  residues	  Ala,	  Val,	  Ser,	  Thr,	  or	  Cys.	  These	  residues	  become	  N-­‐terminal	  after	  the	  cotranslational	  removal	  of	  N-­‐terminal	  Met	  by	  Met-­‐aminopeptidases	  (MetAPs)	  (69,70).	  	  The	  Nt-­‐acetylated	  Met,	  Ala,	  Val,	  Ser,	  Thr,	  and	  Cys	  residues	  of	  newly	  formed	  proteins	  comprise	  a	  specific	  class	  of	  N-­‐degrons,	  termed	  Ac/N-­‐degrons.	  The	  cotranslational	  Nt-­‐acetylation	  of	  nascent	  proteins	  is	  both	  enzymatically	  and	  functionally	  distinct	  from	  the	  largely	  posttranslational	  acetylation	  of	  internal	  residues	  in	  many	  proteins.	  The	  Nt-­‐acetylation	  and	  internal	  acetylation	  are	  carried	  out	  by	  (mostly)	  nonoverlapping	  sets	  of	  specific	  acetylases.	  Previous	  studies	  of	  Nt-­‐acetylation	  have	  characterized	  Nt-­‐acetylated	  proteins	  and	  Nα-­‐terminal	  acetyltransferases	  (Nt-­‐acetylases)	  that	  catalyze	  this	  cotranslational	  modification	  (71-­‐76).	  A	  diagram	  of	  the	  specificities	  of	  Nt-­‐acetylases	  is	  shown	  in	  figure	  1.4.	  Nt-­‐acetylation	  is	  apparently	  irreversible.	  No	  Nt-­‐deacetylases	  have	  been	  identified,	  in	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contrast	  to	  a	  dynamic	  internal	  acetylation/deacetylation,	  with	  specific	  deacetylases	  removing	  internally	  conjugated	  acetyl	  groups.	  	  In	  S.	  cerevisiae,	  Ac/N-­‐degrons	  of	  the	  Ac/N-­‐end	  rule	  pathway	  are	  recognized	  by	  the	  Doa10	  E3	  Ub	  ligase	  and	  apparently	  by	  other	  E3s	  as	  well,	  as	  shown	  in	  chapter	  5.	  The	  151-­‐kDa	  RING-­‐type	  Doa10	  E3	  is	  a	  multispanning	  integral	  membrane	  protein	  located	  in	  the	  ER	  membrane	  and	  in	  the	  inner	  nuclear	  membrane	  (77-­‐79).	  The	  Doa10	  E3	  functions	  together	  with	  the	  Ubc6	  and	  Ubc7	  E2	  enzymes	  and	  targets	  both	  ‘‘soluble’’	  (nuclear	  and	  cytosolic)	  and	  transmembrane	  proteins	  (78).	  Isolated	  S.	  
cerevisiae	  Doa10	  selectively	  binds	  to	  the	  Nt-­‐acetylated	  N-­‐terminal	  Met,	  Ala,	  Val,	  Ser,	  Thr,	  Cys,	  Gly,	  and	  Pro	  residues	  of	  model	  peptides.	  Remarkably,	  the	  binding	  of	  Doa10	  to	  Nt-­‐acetylated	  residues	  of	  these	  peptides	  is	  precluded	  by	  the	  presence	  of	  a	  basic	  residue	  such	  as	  Lys	  at	  Position	  2.	  Thus,	  the	  S.	  cerevisiae	  Ac/N-­‐end	  rule	  pathway	  avoids	  the	  targeting	  of	  proteins	  with	  a	  basic	  residue	  at	  Position	  2	  through	  two	  independent	  constraints:	  first,	  such	  proteins	  are	  not	  Nt-­‐acetylated	  in	  yeast	  (75);	  and	  second,	  the	  cognate	  Doa10	  E3	  apparently	  does	  not	  recognize	  Nt-­‐acetylated	  proteins	  that	  bear	  a	  second-­‐position	  basic	  residue.	  The	  proteolytic	  function	  of	  Nt-­‐acetylation	  is	  likely	  to	  be	  relevant	  to	  more	  than	  80%	  of	  the	  entire	  proteome,	  that	  is,	  to	  many	  thousands	  of	  Nt-­‐acetylated	  proteins.	  In	  contrast,	  either	  an	  identified	  or	  inferred	  necessity	  of	  Nt-­‐acetylation	  for	  other	  (nonproteolytic)	  functions	  involves,	  at	  present,	  only	  ~10	  Nt-­‐acetylated	  proteins	  (80-­‐85).	  What	  functions	  are	  subserved	  by	  such	  a	  massive	  production	  of	  degradation	  signals	  (Ac/N-­‐degrons)	  in	  nascent	  proteins,	  if	  many	  of	  these	  proteins	  are	  destined	  for	  long	  half-­‐lives?	  In	  2010,	  we	  suggested	  that	  a	  major	  role	  of	  these	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degradation	  signals	  involves	  quality-­‐control	  mechanisms	  and	  the	  regulation	  of	  protein	  stoichiometries	  in	  a	  cell.	  A	  key	  feature	  of	  such	  mechanisms	  would	  be	  conditionality	  of	  AcN-­‐degrons.	  We	  went	  on	  to	  verify	  and	  prove	  this	  hypothesis,	  as	  shown	  in	  chapter	  5.	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FIGURE	  1.1.	  The	  ubiquitin-­‐proteasome	  system	  (UPS).	  The	  conjugation	  of	  Ub	  to	  other	  proteins	  involves	  a	  preliminary	  ATP-­‐dependent	  step	  in	  which	  the	  last	  residue	  of	  Ub	  (Gly76)	  is	  joined,	  via	  a	  thioester	  bond,	  to	  a	  Cys	  residue	  of	  the	  E1	  (Ub-­‐activating)	  enzyme.	  The	  ‘‘activated’’	  Ub	  moiety	  is	  transferred	  to	  a	  Cys	  residue	  in	  one	  of	  several	  Ub-­‐conjugating	  (E2)	  enzymes,	  and	  from	  there,	  through	  an	  isopeptide	  bond,	  to	  a	  Lys	  residue	  of	  an	  ultimate	  acceptor,	  denoted	  as	  ‘‘protein.”	  E2	  enzymes	  function	  as	  subunits	  of	  E2-­‐E3	  Ub	  ligase	  complexes	  that	  can	  produce	  substrate-­‐linked	  poly-­‐Ub	  chains.	  Such	  chains	  have	  specific	  Ub-­‐Ub	  topologies,	  depending	  on	  the	  identity	  of	  a	  Lys	  residue	  of	  Ub	  (which	  contains	  several	  lysines)	  that	  forms	  an	  isopeptide	  bond	  with	  C-­‐terminal	  Gly76	  of	  the	  adjacent	  Ub	  moiety	  in	  a	  chain.	  Specific	  poly-­‐Ub	  chains	  can	  confer	  the	  degradation	  of	  a	  substrate	  by	  the	  26S	  proteasome	  or	  other	  metabolic	  fates.	  Monoubiquitylation	  of	  some	  protein	  substrates	  can	  also	  occur,	  and	  has	  specific	  functions.	  One	  role	  of	  E3	  is	  the	  recognition	  of	  a	  substrate’s	  degradation	  signal	  (degron).	  Individual	  mammalian	  genomes	  encode	  at	  least	  a	  1000	  distinct	  E3	  Ub	  ligases.	  	  
	  
N-terminal residue. The 1986 discovery of the N-end
rule pathway identified the first specific pathway of
the Ub system.4–6 It was also the discovery of the
first primary degradation signals (degrons2) in
short-lived proteins.4 Ub, a 76-residue protein, is a
‘‘secondary’’ degron in that Ub is conjugated to pro-
teins that contain primary degradation signals. For
accounts of the early history of the Ub field, see
Refs. 6–8 .
Overview of the N-End Rule Pathway
N-terminal degradation signals of the N-end rule
pathway are called N-degrons. The main determi-
nant of an N-degron is a destabilizing N-terminal
residue of a protein3–6,9–44 (Figs. 2–5). In eukar-
yotes, the N-end rule pathway is a part of the Ub
system, which mediates selective protein turnover
through the conjugation of Ub to specific proteins,
thereby marking them for degradation by the 26S
proteasome, a multisubunit ATP-dependent pro-
tease6,45–65 [Fig. 1(A)]. Prokaryotes, that is, bacteria
and archaea, contain Ub-like proteolytic pathways
but lack the bona fide Ub system.66–70 Never-
theless, prokaryotes contain specific versions of
the N-end rule pathway that do not involve
ubiquitylation5,6,14–16,37,71–78 (Fig. 5).
Recognition components of the N-end rule path-
way are called N-recognins.5 In bacteria, the 12-kDa
ClpS, identified as an N-recognin by the Bukau labo-
ratory,72 binds to N-degrons of N-end rule substrates
and delivers them to the ATP-dependent ClpAP pro-
tease16,72,74,76–82 [Figs. 5 and 6(B–D)]. In eukaryotes,
N-recognins are E3 Ub ligases that bind to specific
N-degrons3,5,6,22,30,38,39,43,83–85 (Figs. 7 and 8). A
Figure 1. The ubiquitin-proteasome system, the ubiquitin fusion technique, and N-terminal processing of newly formed
proteins. A: The ubiquitin-proteasome system (Ub system).6,45–65 The conjugation of Ub to other proteins involves a
preliminary ATP-dependent step in which the last residue of Ub (Gly76) is joined, via a thioester bond, to a Cys residue of the
E1 (Ub-activating) enzyme. The ‘‘activated’’ Ub moiety is transferred to a Cys residue in one of several Ub-conjugating (E2)
enzymes, and from there, through an isopeptide bond, to a Lys residue of an ultimate acceptor, denoted as ‘‘protein’’. E2
enzymes function as subunits of E2-E3 Ub ligase complexes that can produce substrate-linked poly-Ub chains. Such chains
have specific Ub-Ub topologies, depending on the identity of a Lys residue of Ub (which contains several lysines) that forms
an isopeptide bond with C-terminal Gly76 of the adjacent Ub moiety in a chain. Specific poly-Ub chains can confer the
degradation of a substrate by the 26S proteasome or other metabolic fates. Monoubiquitylation of some protein substrates
can also occur, and has specific functions. One role of E3 is the recognition of a substrate’s degradation signal (degron).
Individual mammalian genomes encode at least a 1,000 distinct E3 Ub ligases. B: The Ub fusion technique.4,213 In
eukaryotes, linear fusions of Ub to other proteins are cotranslationally cleaved by deubiquitylases at the last residue of Ub,
making it possible to produce, in vivo, different residues at the N-termini of otherwise identical proteins. C: N-terminal
processing of nascent proteins by Na-terminal acetylases (Nt-acetylases) and Met-aminopeptidases (MetAPs). ‘‘Ac’’ denotes
the Na-terminal acetyl moiety. M, Met. X and Z, single-letter abbreviations for any amino acid residue. Yellow ovals denote
the rest of a protein. D: Met-aminopeptidases (MetAPs) cleave off the N-terminal Met residue if a residue at Position 2
belongs to the set of residues shown.101 Gly and Pro at Position 2 are depicted in a different color because these residues, in
contrast to other small residues, are rarely Nt-acetylated after the removal of N-terminal Met [Fig. 2(B)]. [Color figure can be
viewed in the online issue, which is available at wileyonlinelibrary.com.]
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FIGURE	  1.2.	  Overview	  of	  the	  Arg/N-­‐end	  rule	  pathway	  	  	  A.	  The	  mammalian	  Arg/N-­‐end	  rule	  pathway.	  N-­‐terminal	  residues	  are	  indicated	  by	  single-­‐	  letter	  abbreviations	  for	  amino	  acids.	  Yellow	  ovals	  denote	  the	  rest	  of	  a	  protein	  substrate.	  ‘‘Primary,’’	  ‘‘secondary,’’	  and	  ‘‘tertiary’’	  denote	  mechanistically	  distinct	  subsets	  of	  destabilizing	  N-­‐terminal	  residues.	  C*	  denotes	  oxidized	  N-­‐terminal	  Cys,	  either	  Cys-­‐	  sulfinate	  or	  Cys-­‐sulfonate,	  produced	  in	  vivo	  through	  reactions	  that	  require	  both	  nitric	  oxide	  (NO)	  and	  oxygen.	  The	  mammalian	  N-­‐recognins	  Ubr1,	  Ubr2,	  Ubr4,	  and	  Ubr5	  (Edd)	  have	  multiple	  substrate	  binding	  sites	  that	  also	  recognize	  internal	  (non-­‐N-­‐terminal)	  degrons	  in	  other	  substrates	  of	  the	  Arg/N-­‐end	  rule	  pathway,	  the	  ones	  that	  lack	  N-­‐degrons.	  A	  question	  mark	  after	  Trip12	  (which	  mediates	  the	  mammalian	  UFD	  pathway	  (36,37)	  and	  is	  a	  sequelog	  of	  the	  S.	  cerevisiae	  Ufd4	  E3)	  denotes	  the	  untested	  possibility	  that	  mammalian	  Ubr1	  and/or	  Ubr2	  form	  complexes	  with	  Trip12,	  by	  analogy	  with	  the	  Ubr1–Ufd4	  complex	  in	  S.	  cerevisiae.	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  B.	  The	  Arg/N-­‐end	  rule	  pathway	  in	  S.	  cerevisiae.	  Yellow	  ovals	  denote	  the	  rest	  of	  a	  protein	  substrate.	  ‘‘Primary,’’	  ‘‘secondary,’’	  and	  ‘‘tertiary’’	  denote	  mechanistically	  distinct	  subsets	  of	  destabilizing	  N-­‐terminal	  residues.	  The	  physically	  associated	  Ubr1	  (N-­‐recognin)	  and	  Ufd4	  E3s	  have	  substrate-­‐binding	  sites	  that	  recognize	  internal	  (non-­‐N-­‐terminal)	  degrons	  in	  substrates	  of	  the	  Arg/N-­‐end	  rule	  pathway	  that	  lack	  N-­‐degrons.	  Ubr1	  (but	  not	  Ufd4)	  recognizes	  N-­‐degrons	  as	  well.	  
	  
	  
internal acetylation are carried out by (mostly) nono-
verlapping sets of specific acetylases. In addition, Nt-
acetylation is appar ntly irreversible. No Nt-deacety-
lases have been identified, in contrast to a dynamic
internal acetylation/deacetylation, with specific
deacetylases removing internally conjugated acetyl
groups (Ref. 104 and references therein). As described
below, the proteolytic function of Nt-acetylation [Fig.
2(B)] is likely to be relevant to more than 80% of the
entire proteome, that is, to thousands of Nt-acetylated
proteins.3 In contrast, either an identified or inferred
necessity of Nt-acetylation for other (nonproteolytic)
functions involves, at present, only !10 Nt-acetylated
proteins (Refs. 92,105–110 and references therein).
Apart from expanding the N-end rule and its
functions, the 2010 discovery of the Ac/N-end rule
pathway3 has also revealed the main physiological
roles of two classes of enzymes, Nt-acetylases, and
Met-aminopeptidases. Specifically, Nt-acetylases pro-
duce AcN-degrons while the ‘‘upstream’’ Met-amino-
peptidases, by cleaving off the N-terminal Met resi-
due, make these degradation signals possible, all of
them save for those AcN-degrons that contain the
Nt-acetylated N-terminal Met [Figs. 1(C,D) and
2(B)]. Nt-acetylases and Met-aminopeptidases are
essential and universally present enzymes86–101
whose physiological functions had been largely
unknown. These enzymes are now specific compo-
nents of the Ac/N-end rule pathway3 [Fig. 2(B)].
N-terminal Arg, Lys, His, Leu, Phe, Tyr, Trp,
Ile, Asp, Glu, Asn, Gln, and Cys comprise the main
determinants of N-degrons in the Arg/N-end rule
pathway [Figs. 2(A) and 3]. Among these N-degrons,
the unmodified basic (Arg, Lys, His) and bulky
hydrophobic (Leu, Phe, Tyr, Trp, Ile) N-terminal res-
idues are recognized directly by cognate E3 N-recog-
nins [Figs. 2(A), 3, 7, and 8]. These E3s contain
highly spalogous (spatially similar1) !80-residue
regions called UBR domains or Type-1 binding
sites.83–85 Folded around three zinc ions, a UBR
domain binds to N-terminal Arg, Lys, or His, the
Type-1 primary destabilizing residues of N-end rule
substrates (Figs. 3 and 8). Another (usually adja-
cent) region of UBR-type N-recognins, called the
Type-2 binding site, recognizes N-terminal Leu, Phe,
Tyr, Trp, or Ile, which are called the Type-2 primary
destabilizing residues [Fig. 7(A)]. Together, the
directly recognized primary destabilizing N-terminal
Arg, Lys, His, Leu, Phe, Tyr, Trp, and Ile are
denoted as Ndp residues (N, N-terminal; d, destabi-
lizing; p, primary).6,43,83–85 In contrast to these resi-
dues, the N-terminal Asp, Glu, Asn, Gln, and Cys
function as destabilizing residues through their pre-
liminary modifications. One of these modifications is
Figure 3. The mammalian Arg/N-end rule pathway. See the main text for details. N-terminal residues are indicated by single-
letter abbreviations for amino acids. Yellow ovals denote the rest of a protein substrate. ‘‘Primary’’, ‘‘secondary’’ and ‘‘tertiary’’
denote mechanistically distinct subsets of destabilizing N-terminal residues. C* denotes oxidized N-terminal Cys, either Cys-
sulfinate or Cys-sulfonate, produced in vivo through reactions that require both nitric oxide (NO) and oxygen.32,33 The
mammalian N-recognins Ubr1, Ubr2, Ubr4, and Ubr5 (Edd) have multiple substrate binding sites that also recognize internal
(non-N-terminal) degrons in other subst ates of the Arg/N-e d rule pathway, the ones that lack N-d grons. A que tion mark
after Trip12 (which mediates the mammalian UFD pathway258 and is a sequelog of the S. cerevisiae Ufd4 E3) denotes the
untested possibility that mammalian Ubr1 and/or Ubr2 form complexes with Trip12, by analogy with the Ubr1–Ufd4 complex
in S. cerevisiae [Fig. 2(A)]. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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complex of an E3 N-recognin and its cognate E2 Ub-
conjugating enzyme polyubiquitylates N-end rule
substrates at their internal Lys residues, thereby
targeting these proteins for degradation by the 26S
proteasome9,11 (Figs. 2 and 3). The term ‘‘Ub ligase’’
denotes either an E2-E3 complex or its E3 compo-
nent.6,54,57,62 In eukaryotes, the N-end rule pathway
comprises two major branches, one of which is
termed the Arg/N-end rule pathway. This branch
involves the N-terminal arginylation (Nt-arginyla-
tion) of protein substrates and also the targeting of
specific unmodified N-terminal residues by E3 N-rec-
ognins [Figs. 2(A) and 3]. The other branch is
termed the Ac/N-end rule pathway.3 It involves the
cotranslational Na-terminal acetylation (Nt-acetyla-
tion) of nascent proteins86–95 whose N-termini bear
either Met or the small uncharged residues Ala, Val,
Ser, Thr, or Cys. These residues become N-terminal
after the cotranslational removal of N-terminal Met
by Met-aminopeptidases96–101 [Fig. 1(C,D)]. Nt-ace-
tylated proteins are targeted for regulated degrada-
tion by the Ac/N-end rule pathway3 [Fig. 2(B)].
The Nt-acetylated Met, Ala, Val, Ser, Thr, and
Cys residues of newly formed proteins comprise a
specific class of N-degrons, termed AcN-degrons3
[Figs. 2(B) and 4(A)]. The cotranslational Nt-acetyla-
tion of nascent proteins87–95,102 [Fig. 1(C)] is both
enzymatically and functionally distinct from the
largely posttranslational acetylation of internal resi-
dues in many proteins.103,104 Nt-acetylation and
Figure 2. The N-end rule pathway in Saccharomyces cerevisiae. A: The Arg/N-end rule pathway.44 See the main text for
details. Yellow ovals denote the rest of a protein substrate. ‘‘Primary’’, ‘‘secondary’’ and ‘‘tertiary’’ denote mechanistically
distinct subsets of destabilizing N-terminal residues. The physically associated Ubr1 (N-recognin) and Ufd4 E3s have
substrate-binding sites that recognize internal (non-N-terminal) degrons in substrates of the Arg/N-end rule pathway that lack
N-degrons. Ubr1 (but not Ufd4) recognizes N-degrons as well.44 B: The Ac/N-end rule pathway.3 Red arrow on the left
indicates the removal of N-terminal Met by Met-aminopeptidases (MetAPs). This Met residue is retained if a residue at
Position 2 is nonpermissive (too large) for Met-aminopeptidases [Fig. 1(D)]. If the (retained) N-terminal Met or N-terminal Ala,
Val, Ser, Thr and Cys are followed by residues that allow Nt-acetylation (see the main text), these N-terminal residues are
usually Nt-acetylated.91–93 The resulting N-degrons are called AcN-degrons. The term ‘‘secondary’’ refers to the necessity of
modification (Nt-acetylation) of a destabilizing N-terminal residue before a protein can be recognized by a cognate Ub ligase.
Proteins containing AcN-degrons are targeted for ubiquitylation and proteasome-mediated degradation by the Doa10 E3 N-
recognin, in conjunction with the Ubc6 and Ubc7 E2 enzymes.44 Although Gly and Pro can be made N-terminal by MetAPs,
and although Doa10 can recognize Nt-acetylated Gly and Pro, few proteins with N-terminal Gly or Pro are Nt-acetylated.91–93
[Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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FIGURE	  1.3.	  Overview	  of	  the	  Ac/N-­‐end	  rule	  pathway.	  Red	  arrow	  on	  the	  left	  indicates	  the	  removal	  of	  N-­‐terminal	  Met	  by	  Met-­‐aminopeptidases	  (MetAPs).	  This	  Met	  residue	  is	  retained	  if	  a	  residue	  at	  Position	  2	  is	  nonpermissive	  (too	  large)	  for	  Met-­‐aminopeptidases.	  If	  the	  (retained)	  N-­‐terminal	  Met	  or	  N-­‐terminal	  Ala,	  Val,	  Ser,	  Thr	  and	  Cys	  are	  followed	  by	  residues	  that	  allow	  Nt-­‐acetylation,	  these	  N-­‐terminal	  residues	  are	  usually	  Nt-­‐acetylated.	  The	  resulting	  N-­‐degrons	  are	  called	  Ac/N-­‐degrons.	  The	  term	  ‘‘secondary’’	  refers	  to	  the	  necessity	  of	  modification	  (Nt-­‐acetylation)	  of	  a	  destabilizing	  N-­‐terminal	  residue	  before	  a	  protein	  can	  be	  recognized	  by	  a	  cognate	  Ub	  ligase.	  Proteins	  containing	  AcN-­‐degrons	  are	  targeted	  for	  ubiquitylation	  and	  proteasome-­‐mediated	  degradation	  by	  the	  Doa10	  E3	  N-­‐	  recognin,	  in	  conjunction	  with	  the	  Ubc6	  and	  Ubc7	  E2	  enzymes.	  Although	  Gly	  and	  Pro	  can	  be	  made	  N-­‐terminal	  by	  MetAPs,	  and	  although	  Doa10	  can	  recognize	  Nt-­‐acetylated	  Gly	  and	  Pro,	  few	  proteins	  with	  N-­‐terminal	  Gly	  or	  Pro	  are	  Nt-­‐acetylated.	  	  
	   	  
	   	  
complex of an E3 N-recognin and its cognate E2 Ub-
conjugating enzyme polyubiquitylates N-end rule
substrates at their internal Lys residues, thereby
targeting these proteins for degradation by the 26S
proteasome9,11 (Figs. 2 and 3). The term ‘‘Ub ligase’’
denotes either an E2-E3 complex or its E3 compo-
nent.6,54,57,62 In eukaryotes, the N-end rule pathway
comprises two major branches, one of which is
termed the Arg/N-end rule pathway. This branch
involves the N-terminal arginylation (Nt-arginyla-
tion) of protein substrates and also the targeting of
specific unmodified N-terminal residues by E3 N-rec-
ognins [Figs. 2(A) and 3]. The other branch is
termed the Ac/N-end rule pathway.3 It involves the
cotranslational Na-terminal acetylation (Nt-acetyla-
tion) of nascent proteins86–95 whose N-termini bear
either Met or the small uncharged residues Ala, Val,
Ser, Thr, or Cys. These residues become N-terminal
after the cotranslational removal of N-terminal Met
by Met-aminopeptidases96–101 [Fig. 1(C,D)]. Nt-ace-
tylated proteins are targeted for regulated degrada-
tion by the Ac/N-end rule pathway3 [Fig. 2(B)].
The Nt-acetylated Met, Ala, Val, Ser, Thr, and
Cys residues of newly formed proteins comprise a
specific class of N-degrons, termed AcN-degrons3
[Figs. 2(B) and 4(A)]. The cotranslational Nt-acetyla-
tion of nascent proteins87–95,102 [Fig. 1(C)] is both
enzymatically and functionally distinct from the
largely posttranslational acetylation of internal resi-
dues in many proteins.103,104 Nt-acetylation and
Figure 2. The N-end rule pathway in Saccharomyces cerevisiae. A: The Arg/N-end rule pathway.44 See the main text for
details. Yellow ovals denote the rest of a protein substrate. ‘‘Primary’’, ‘‘secondary’’ and ‘‘tertiary’’ denote mechanistically
distinct subsets of destabilizing N-terminal residues. The physically associated Ubr1 (N-recognin) and Ufd4 E3s have
substrate-binding sites that recognize internal (non-N-terminal) degrons in substrates of the Arg/N-end rule pathway that lack
N-degrons. Ubr1 (but not Ufd4) recognizes N-degrons as well.44 B: The Ac/N-end rule pathway.3 Red arrow on the left
indicates the removal of N-terminal Met by Met-aminopeptidases (MetAPs). This Met residue is retained if a residue at
Position 2 is nonpermissive (too large) for Met-aminopeptidases [Fig. 1(D)]. If the (retained) N-terminal Met or N-terminal Ala,
Val, Ser, Thr and Cys are followed by residues that allow Nt-acetylation (see the main text), these N-terminal residues are
usually Nt-acetylated.91–93 The resulting N-degrons are called AcN-degrons. The term ‘‘secondary’’ refers to the necessity of
modification (Nt-acetylation) of a destabilizing N-terminal residue before a protein can be recognized by a cognate Ub ligase.
Proteins containing AcN-degrons are targeted for ubiquitylation and proteasome-mediated degradation by the Doa10 E3 N-
recognin, in conjunction with the Ubc6 and Ubc7 E2 enzymes.44 Although Gly and Pro can be made N-terminal by MetAPs,
and although Doa10 can recognize Nt-acetylated Gly and Pro, few proteins with N-terminal Gly or Pro are Nt-acetylated.91–93
[Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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FIGURE	  1.4	  Substrate	  specificities	  and	  subunit	  compositions	  of	  S.	  cerevisiae	  Nt-­‐acetylases.	  This	  compilation	  is	  derived	  from	  data	  in	  the	  literature.	  The	  present	  paper	  uses	  the	  revised	  nomenclature	  for	  specific	  subunits	  of	  Nt-­‐acetylases	  and	  cites	  the	  older	  names	  of	  these	  subunits	  in	  parentheses.	  	  
	   	  































Pro:  virtually never Nt-acetylated.
Cys: rarely Nt-acetylated.




Gly:  rarely Nt-acetylated; often N-myristoylated.









of S. cerevisiae Nt-acetylases:
NatB: Naa20 (Nat3); Naa25 (Mdm20).
NatC: Naa30 (Mak3); Naa35 (Mak10);
Naa38 (Mak31).



































	   16	  
	  REFERENCES	  1.	   Varshavsky,	  A.	  (2011)	  Protein	  science	  :	  a	  publication	  of	  the	  Protein	  Society	  	  2.	   Ang,	  X.	  L.,	  and	  Wade	  Harper,	  J.	  (2005)	  Oncogene	  24,	  2860-­‐2870	  3.	   Finley,	  D.,	  Ulrich,	  H.	  D.,	  Sommer,	  T.,	  and	  Kaiser,	  P.	  (2012)	  Genetics	  192,	  319-­‐360	  4.	   Varshavsky,	  A.	  (2006)	  Protein	  science	  :	  a	  publication	  of	  the	  Protein	  Society	  15,	  647-­‐654	  5.	   Varshavsky,	  A.	  (1991)	  Cell	  64,	  13-­‐15	  6.	   Finley,	  D.	  (2009)	  Annual	  review	  of	  biochemistry	  78,	  477-­‐513	  7.	   Kravtsova-­‐Ivantsiv,	  Y.,	  and	  Ciechanover,	  A.	  (2012)	  Journal	  of	  cell	  science	  125,	  539-­‐548	  8.	   Hochstrasser,	  M.	  (2006)	  Cell	  124,	  27-­‐34	  9.	   Kulathu,	  Y.,	  and	  Komander,	  D.	  (2012)	  Nature	  reviews.	  Molecular	  cell	  biology	  
13,	  508-­‐523	  10.	   Behrends,	  C.,	  and	  Harper,	  J.	  W.	  (2011)	  Nature	  structural	  &	  molecular	  biology	  
18,	  520-­‐528	  11.	   Gallastegui,	  N.,	  and	  Groll,	  M.	  (2010)	  Trends	  in	  biochemical	  sciences	  35,	  634-­‐642	  12.	   Marques,	  A.	  J.,	  Palanimurugan,	  R.,	  Matias,	  A.	  C.,	  Ramos,	  P.	  C.,	  and	  Dohmen,	  R.	  J.	  (2009)	  Chemical	  reviews	  109,	  1509-­‐1536	  13.	   Xie,	  Y.,	  and	  Varshavsky,	  A.	  (2000)	  Proceedings	  of	  the	  National	  Academy	  of	  
Sciences	  of	  the	  United	  States	  of	  America	  97,	  2497-­‐2502	  
	   17	  
14.	   Metzger,	  M.	  B.,	  Hristova,	  V.	  A.,	  and	  Weissman,	  A.	  M.	  (2012)	  Journal	  of	  cell	  
science	  125,	  531-­‐537	  15.	   Deshaies,	  R.	  J.,	  and	  Joazeiro,	  C.	  A.	  (2009)	  Annual	  review	  of	  biochemistry	  78,	  399-­‐434	  16.	   Rotin,	  D.,	  and	  Kumar,	  S.	  (2009)	  Nature	  reviews.	  Molecular	  cell	  biology	  10,	  398-­‐409	  17.	   Bachmair,	  A.,	  Finley,	  D.,	  and	  Varshavsky,	  A.	  (1986)	  Science	  234,	  179-­‐186	  18.	   Bachmair,	  A.,	  and	  Varshavsky,	  A.	  (1989)	  Cell	  56,	  1019-­‐1032	  19.	   Varshavsky,	  A.,	  Bachmair,	  A.,	  and	  Finley,	  D.	  (1987)	  Biochemical	  Society	  
transactions	  15,	  815-­‐816	  20.	   Varshavsky,	  A.,	  Bachmair,	  A.,	  Finley,	  D.,	  Gonda,	  D.	  K.,	  and	  Wunning,	  I.	  (1989)	  
Biotechnology	  13,	  109-­‐143	  21.	   Varshavsky,	  A.	  (2004)	  Current	  biology	  :	  CB	  14,	  R181-­‐183	  22.	   Choi,	  W.	  S.,	  Jeong,	  B.	  C.,	  Joo,	  Y.	  J.,	  Lee,	  M.	  R.,	  Kim,	  J.,	  Eck,	  M.	  J.,	  and	  Song,	  H.	  K.	  (2010)	  Nature	  structural	  &	  molecular	  biology	  17,	  1175-­‐1181	  23.	   Matta-­‐Camacho,	  E.,	  Kozlov,	  G.,	  Li,	  F.	  F.,	  and	  Gehring,	  K.	  (2010)	  Nature	  
structural	  &	  molecular	  biology	  17,	  1182-­‐1187	  24.	   Tasaki,	  T.,	  and	  Kwon,	  Y.	  T.	  (2007)	  Trends	  in	  biochemical	  sciences	  32,	  520-­‐528	  25.	   Xia,	  Z.,	  Webster,	  A.,	  Du,	  F.,	  Piatkov,	  K.,	  Ghislain,	  M.,	  and	  Varshavsky,	  A.	  (2008)	  
The	  Journal	  of	  biological	  chemistry	  283,	  24011-­‐24028	  26.	   Hu,	  R.	  G.,	  Brower,	  C.	  S.,	  Wang,	  H.,	  Davydov,	  I.	  V.,	  Sheng,	  J.,	  Zhou,	  J.,	  Kwon,	  Y.	  T.,	  and	  Varshavsky,	  A.	  (2006)	  The	  Journal	  of	  biological	  chemistry	  281,	  32559-­‐32573	  
	   18	  
27.	   Wang,	  H.,	  Piatkov,	  K.	  I.,	  Brower,	  C.	  S.,	  and	  Varshavsky,	  A.	  (2009)	  Molecular	  cell	  
34,	  686-­‐695	  28.	   Hu,	  R.	  G.,	  Sheng,	  J.,	  Qi,	  X.,	  Xu,	  Z.,	  Takahashi,	  T.	  T.,	  and	  Varshavsky,	  A.	  (2005)	  
Nature	  437,	  981-­‐986	  29.	   Xia,	  Z.,	  Turner,	  G.	  C.,	  Hwang,	  C.	  S.,	  Byrd,	  C.,	  and	  Varshavsky,	  A.	  (2008)	  The	  
Journal	  of	  biological	  chemistry	  283,	  28958-­‐28968	  30.	   Du,	  F.,	  Navarro-­‐Garcia,	  F.,	  Xia,	  Z.,	  Tasaki,	  T.,	  and	  Varshavsky,	  A.	  (2002)	  
Proceedings	  of	  the	  National	  Academy	  of	  Sciences	  of	  the	  United	  States	  of	  
America	  99,	  14110-­‐14115	  31.	   Dohmen,	  R.	  J.,	  Madura,	  K.,	  Bartel,	  B.,	  and	  Varshavsky,	  A.	  (1991)	  Proceedings	  of	  
the	  National	  Academy	  of	  Sciences	  of	  the	  United	  States	  of	  America	  88,	  7351-­‐7355	  32.	   Hwang,	  C.	  S.,	  Shemorry,	  A.,	  Auerbach,	  D.,	  and	  Varshavsky,	  A.	  (2010)	  Nature	  
cell	  biology	  12,	  1177-­‐1185	  33.	   Hwang,	  C.	  S.,	  Shemorry,	  A.,	  and	  Varshavsky,	  A.	  (2009)	  Proceedings	  of	  the	  
National	  Academy	  of	  Sciences	  of	  the	  United	  States	  of	  America	  106,	  2142-­‐2147	  34.	   Johnson,	  E.	  S.,	  Ma,	  P.	  C.,	  Ota,	  I.	  M.,	  and	  Varshavsky,	  A.	  (1995)	  The	  Journal	  of	  
biological	  chemistry	  270,	  17442-­‐17456	  35.	   Johnson,	  E.	  S.,	  Bartel,	  B.,	  Seufert,	  W.,	  and	  Varshavsky,	  A.	  (1992)	  The	  EMBO	  
journal	  11,	  497-­‐505	  36.	   Park,	  Y.,	  Yoon,	  S.	  K.,	  and	  Yoon,	  J.	  B.	  (2009)	  The	  Journal	  of	  biological	  chemistry	  
284,	  1540-­‐1549	  
	   19	  
37.	   Park,	  Y.,	  Yoon,	  S.	  K.,	  and	  Yoon,	  J.	  B.	  (2008)	  Biochemical	  and	  biophysical	  
research	  communications	  374,	  294-­‐298	  38.	   Hu,	  R.	  G.,	  Wang,	  H.,	  Xia,	  Z.,	  and	  Varshavsky,	  A.	  (2008)	  Proceedings	  of	  the	  
National	  Academy	  of	  Sciences	  of	  the	  United	  States	  of	  America	  105,	  76-­‐81	  39.	   Varshavsky,	  A.	  (2008)	  The	  Journal	  of	  biological	  chemistry	  283,	  34469-­‐34489	  40.	   Mogk,	  A.,	  Schmidt,	  R.,	  and	  Bukau,	  B.	  (2007)	  Trends	  in	  cell	  biology	  17,	  165-­‐172	  41.	   Graciet,	  E.,	  and	  Wellmer,	  F.	  (2010)	  Trends	  in	  plant	  science	  15,	  447-­‐453	  42.	   An,	  J.	  Y.,	  Seo,	  J.	  W.,	  Tasaki,	  T.,	  Lee,	  M.	  J.,	  Varshavsky,	  A.,	  and	  Kwon,	  Y.	  T.	  (2006)	  
Proceedings	  of	  the	  National	  Academy	  of	  Sciences	  of	  the	  United	  States	  of	  
America	  103,	  6212-­‐6217	  43.	   Kwon,	  Y.	  T.,	  Xia,	  Z.,	  An,	  J.	  Y.,	  Tasaki,	  T.,	  Davydov,	  I.	  V.,	  Seo,	  J.	  W.,	  Sheng,	  J.,	  Xie,	  Y.,	  and	  Varshavsky,	  A.	  (2003)	  Molecular	  and	  cellular	  biology	  23,	  8255-­‐8271	  44.	   Kwon,	  Y.	  T.,	  Kashina,	  A.	  S.,	  Davydov,	  I.	  V.,	  Hu,	  R.	  G.,	  An,	  J.	  Y.,	  Seo,	  J.	  W.,	  Du,	  F.,	  and	  Varshavsky,	  A.	  (2002)	  Science	  297,	  96-­‐99	  45.	   Kwon,	  Y.	  T.,	  Xia,	  Z.,	  Davydov,	  I.	  V.,	  Lecker,	  S.	  H.,	  and	  Varshavsky,	  A.	  (2001)	  
Molecular	  and	  cellular	  biology	  21,	  8007-­‐8021	  46.	   Kwon,	  Y.	  T.,	  Balogh,	  S.	  A.,	  Davydov,	  I.	  V.,	  Kashina,	  A.	  S.,	  Yoon,	  J.	  K.,	  Xie,	  Y.,	  Gaur,	  A.,	  Hyde,	  L.,	  Denenberg,	  V.	  H.,	  and	  Varshavsky,	  A.	  (2000)	  Molecular	  and	  
cellular	  biology	  20,	  4135-­‐4148	  47.	   Hwang,	  C.	  S.,	  and	  Varshavsky,	  A.	  (2008)	  Proceedings	  of	  the	  National	  Academy	  
of	  Sciences	  of	  the	  United	  States	  of	  America	  105,	  19188-­‐19193	  48.	   Brower,	  C.	  S.,	  and	  Varshavsky,	  A.	  (2009)	  PloS	  one	  4,	  e7757	  
	   20	  
49.	   Graciet,	  E.,	  Walter,	  F.,	  Maoileidigh,	  D.	  O.,	  Pollmann,	  S.,	  Meyerowitz,	  E.	  M.,	  Varshavsky,	  A.,	  and	  Wellmer,	  F.	  (2009)	  Proceedings	  of	  the	  National	  Academy	  
of	  Sciences	  of	  the	  United	  States	  of	  America	  106,	  13618-­‐13623	  50.	   Eisele,	  F.,	  and	  Wolf,	  D.	  H.	  (2008)	  FEBS	  letters	  582,	  4143-­‐4146	  51.	   Heck,	  J.	  W.,	  Cheung,	  S.	  K.,	  and	  Hampton,	  R.	  Y.	  (2010)	  Proceedings	  of	  the	  
National	  Academy	  of	  Sciences	  of	  the	  United	  States	  of	  America	  107,	  1106-­‐1111	  52.	   Prasad,	  R.,	  Kawaguchi,	  S.,	  and	  Ng,	  D.	  T.	  (2010)	  Molecular	  biology	  of	  the	  cell	  21,	  2117-­‐2127	  53.	   Nillegoda,	  N.	  B.,	  Theodoraki,	  M.	  A.,	  Mandal,	  A.	  K.,	  Mayo,	  K.	  J.,	  Ren,	  H.	  Y.,	  Sultana,	  R.,	  Wu,	  K.,	  Johnson,	  J.,	  Cyr,	  D.	  M.,	  and	  Caplan,	  A.	  J.	  (2010)	  Molecular	  
biology	  of	  the	  cell	  21,	  2102-­‐2116	  54.	   Ouyang,	  Y.,	  Kwon,	  Y.	  T.,	  An,	  J.	  Y.,	  Eller,	  D.,	  Tsai,	  S.	  C.,	  Diaz-­‐Perez,	  S.,	  Troke,	  J.	  J.,	  Teitell,	  M.	  A.,	  and	  Marahrens,	  Y.	  (2006)	  Mutation	  research	  596,	  64-­‐75	  55.	   Yoshida,	  S.,	  Ito,	  M.,	  Callis,	  J.,	  Nishida,	  I.,	  and	  Watanabe,	  A.	  (2002)	  The	  Plant	  
journal	  :	  for	  cell	  and	  molecular	  biology	  32,	  129-­‐137	  56.	   Holman,	  T.	  J.,	  Jones,	  P.	  D.,	  Russell,	  L.,	  Medhurst,	  A.,	  Ubeda	  Tomas,	  S.,	  Talloji,	  P.,	  Marquez,	  J.,	  Schmuths,	  H.,	  Tung,	  S.	  A.,	  Taylor,	  I.,	  Footitt,	  S.,	  Bachmair,	  A.,	  Theodoulou,	  F.	  L.,	  and	  Holdsworth,	  M.	  J.	  (2009)	  Proceedings	  of	  the	  National	  
Academy	  of	  Sciences	  of	  the	  United	  States	  of	  America	  106,	  4549-­‐4554	  57.	   Rai,	  R.,	  Wong,	  C.	  C.,	  Xu,	  T.,	  Leu,	  N.	  A.,	  Dong,	  D.	  W.,	  Guo,	  C.,	  McLaughlin,	  K.	  J.,	  Yates,	  J.	  R.,	  3rd,	  and	  Kashina,	  A.	  (2008)	  Development	  135,	  3881-­‐3889	  58.	   Zhang,	  F.,	  Saha,	  S.,	  Shabalina,	  S.	  A.,	  and	  Kashina,	  A.	  (2010)	  Science	  329,	  1534-­‐1537	  
	   21	  
59.	   Kurosaka,	  S.,	  Leu,	  N.	  A.,	  Zhang,	  F.,	  Bunte,	  R.,	  Saha,	  S.,	  Wang,	  J.,	  Guo,	  C.,	  He,	  W.,	  and	  Kashina,	  A.	  (2010)	  PLoS	  genetics	  6,	  e1000878	  60.	   Saha,	  S.,	  Mundia,	  M.	  M.,	  Zhang,	  F.,	  Demers,	  R.	  W.,	  Korobova,	  F.,	  Svitkina,	  T.,	  Perieteanu,	  A.	  A.,	  Dawson,	  J.	  F.,	  and	  Kashina,	  A.	  (2010)	  Molecular	  biology	  of	  
the	  cell	  21,	  1350-­‐1361	  61.	   de	  Groot,	  R.	  J.,	  Rumenapf,	  T.,	  Kuhn,	  R.	  J.,	  Strauss,	  E.	  G.,	  and	  Strauss,	  J.	  H.	  (1991)	  
Proceedings	  of	  the	  National	  Academy	  of	  Sciences	  of	  the	  United	  States	  of	  
America	  88,	  8967-­‐8971	  62.	   Lloyd,	  A.	  G.,	  Ng,	  Y.	  S.,	  Muesing,	  M.	  A.,	  Simon,	  V.,	  and	  Mulder,	  L.	  C.	  (2007)	  
Virology	  360,	  129-­‐135	  63.	   Mulder,	  L.	  C.,	  and	  Muesing,	  M.	  A.	  (2000)	  The	  Journal	  of	  biological	  chemistry	  
275,	  29749-­‐29753	  64.	   Lecker,	  S.	  H.,	  Solomon,	  V.,	  Price,	  S.	  R.,	  Kwon,	  Y.	  T.,	  Mitch,	  W.	  E.,	  and	  Goldberg,	  A.	  L.	  (1999)	  The	  Journal	  of	  clinical	  investigation	  104,	  1411-­‐1420	  65.	   Lecker,	  S.	  H.,	  Solomon,	  V.,	  Mitch,	  W.	  E.,	  and	  Goldberg,	  A.	  L.	  (1999)	  The	  Journal	  
of	  nutrition	  129,	  227S-­‐237S	  66.	   Carpio,	  M.	  A.,	  Lopez	  Sambrooks,	  C.,	  Durand,	  E.	  S.,	  and	  Hallak,	  M.	  E.	  (2010)	  The	  
Biochemical	  journal	  429,	  63-­‐72	  67.	   Zenker,	  M.,	  Mayerle,	  J.,	  Lerch,	  M.	  M.,	  Tagariello,	  A.,	  Zerres,	  K.,	  Durie,	  P.	  R.,	  Beier,	  M.,	  Hulskamp,	  G.,	  Guzman,	  C.,	  Rehder,	  H.,	  Beemer,	  F.	  A.,	  Hamel,	  B.,	  Vanlieferinghen,	  P.,	  Gershoni-­‐Baruch,	  R.,	  Vieira,	  M.	  W.,	  Dumic,	  M.,	  Auslender,	  R.,	  Gil-­‐da-­‐Silva-­‐Lopes,	  V.	  L.,	  Steinlicht,	  S.,	  Rauh,	  M.,	  Shalev,	  S.	  A.,	  Thiel,	  C.,	  Ekici,	  
	   22	  
A.	  B.,	  Winterpacht,	  A.,	  Kwon,	  Y.	  T.,	  Varshavsky,	  A.,	  and	  Reis,	  A.	  (2005)	  Nature	  
genetics	  37,	  1345-­‐1350	  68.	   Hwang,	  C.	  S.,	  Shemorry,	  A.,	  and	  Varshavsky,	  A.	  (2010)	  Science	  327,	  973-­‐977	  69.	   Moerschell,	  R.	  P.,	  Hosokawa,	  Y.,	  Tsunasawa,	  S.,	  and	  Sherman,	  F.	  (1990)	  The	  
Journal	  of	  biological	  chemistry	  265,	  19638-­‐19643	  70.	   Li,	  X.,	  and	  Chang,	  Y.	  H.	  (1995)	  Proceedings	  of	  the	  National	  Academy	  of	  Sciences	  
of	  the	  United	  States	  of	  America	  92,	  12357-­‐12361	  71.	   Van	  Damme,	  P.,	  Lasa,	  M.,	  Polevoda,	  B.,	  Gazquez,	  C.,	  Elosegui-­‐Artola,	  A.,	  Kim,	  D.	  S.,	  De	  Juan-­‐Pardo,	  E.,	  Demeyer,	  K.,	  Hole,	  K.,	  Larrea,	  E.,	  Timmerman,	  E.,	  Prieto,	  J.,	  Arnesen,	  T.,	  Sherman,	  F.,	  Gevaert,	  K.,	  and	  Aldabe,	  R.	  (2012)	  Proceedings	  of	  
the	  National	  Academy	  of	  Sciences	  of	  the	  United	  States	  of	  America	  109,	  12449-­‐12454	  72.	   Starheim,	  K.	  K.,	  Gevaert,	  K.,	  and	  Arnesen,	  T.	  (2012)	  Trends	  in	  biochemical	  
sciences	  37,	  152-­‐161	  73.	   Van	  Damme,	  P.,	  Arnesen,	  T.,	  and	  Gevaert,	  K.	  (2011)	  The	  FEBS	  journal	  278,	  3822-­‐3834	  74.	   Helsens,	  K.,	  Van	  Damme,	  P.,	  Degroeve,	  S.,	  Martens,	  L.,	  Arnesen,	  T.,	  Vandekerckhove,	  J.,	  and	  Gevaert,	  K.	  (2011)	  Journal	  of	  proteome	  research	  10,	  3578-­‐3589	  75.	   Arnesen,	  T.,	  Van	  Damme,	  P.,	  Polevoda,	  B.,	  Helsens,	  K.,	  Evjenth,	  R.,	  Colaert,	  N.,	  Varhaug,	  J.	  E.,	  Vandekerckhove,	  J.,	  Lillehaug,	  J.	  R.,	  Sherman,	  F.,	  and	  Gevaert,	  K.	  (2009)	  Proceedings	  of	  the	  National	  Academy	  of	  Sciences	  of	  the	  United	  States	  of	  
America	  106,	  8157-­‐8162	  
	   23	  
76.	   Polevoda,	  B.,	  Brown,	  S.,	  Cardillo,	  T.	  S.,	  Rigby,	  S.,	  and	  Sherman,	  F.	  (2008)	  
Journal	  of	  cellular	  biochemistry	  103,	  492-­‐508	  77.	   Kreft,	  S.	  G.,	  and	  Hochstrasser,	  M.	  (2011)	  The	  Journal	  of	  biological	  chemistry	  
286,	  20163-­‐20174	  78.	   Ravid,	  T.,	  Kreft,	  S.	  G.,	  and	  Hochstrasser,	  M.	  (2006)	  The	  EMBO	  journal	  25,	  533-­‐543	  79.	   Kreft,	  S.	  G.,	  Wang,	  L.,	  and	  Hochstrasser,	  M.	  (2006)	  The	  Journal	  of	  biological	  
chemistry	  281,	  4646-­‐4653	  80.	   Behnia,	  R.,	  Panic,	  B.,	  Whyte,	  J.	  R.,	  and	  Munro,	  S.	  (2004)	  Nature	  cell	  biology	  6,	  405-­‐413	  81.	   Setty,	  S.	  R.,	  Strochlic,	  T.	  I.,	  Tong,	  A.	  H.,	  Boone,	  C.,	  and	  Burd,	  C.	  G.	  (2004)	  Nature	  
cell	  biology	  6,	  414-­‐419	  82.	   Jackson,	  C.	  L.	  (2004)	  Nature	  cell	  biology	  6,	  379-­‐380	  83.	   Hofmann,	  I.,	  and	  Munro,	  S.	  (2006)	  Journal	  of	  cell	  science	  119,	  1494-­‐1503	  84.	   Graham,	  T.	  R.	  (2004)	  Current	  biology	  :	  CB	  14,	  R483-­‐485	  85.	   Coulton,	  A.	  T.,	  East,	  D.	  A.,	  Galinska-­‐Rakoczy,	  A.,	  Lehman,	  W.,	  and	  Mulvihill,	  D.	  P.	  (2010)	  Journal	  of	  cell	  science	  123,	  3235-­‐3243	  	  	  
	   	  
	   24	  
	  
CHAPTER	  2:	  
THE	  N-­‐END	  RULE	  PATHWAY	  IS	  MEDIATED	  BY	  A	  COMPLEX	  OF	  THE	  RING-­‐TYPE	  
UBR1	  AND	  HECT-­‐TYPE	  UFD4	  UBIQUITIN	  LIGASES	  
From	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  Varshavsky,	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  cell	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Abstract	  
	   Substrates	  of	  the	  N-­‐end	  rule	  pathway	  are	  recognized	  by	  the	  Ubr1	  E3	  ubiquitin	  ligase	  through	  their	  destabilizing	  N-­‐terminal	  residues.	  Our	  previous	  work	  showed	  that	  the	  Ubr1	  E3	  and	  the	  Ufd4	  E3	  co-­‐target	  an	  internal	  degron	  of	  the	  Mgt1	  DNA	  repair	  protein.	  Ufd4	  is	  an	  E3	  of	  the	  ubiquitin-­‐fusion	  degradation	  (UFD)	  pathway	  that	  recognizes	  an	  N-­‐terminal	  ubiquitin	  moiety.	  Here	  we	  report	  that	  the	  RING-­‐type	  Ubr1	  E3	  and	  the	  HECT-­‐type	  Ufd4	  E3	  interact,	  both	  physically	  and	  functionally.	  Although	  Ubr1	  can	  recognize	  and	  polyubiquitylate	  an	  N-­‐end	  rule	  substrate	  in	  the	  absence	  of	  Ufd4,	  the	  Ubr1-­‐Ufd4	  complex	  is	  more	  processive	  in	  that	  it	  produces	  a	  longer	  substrate-­‐linked	  polyubiquitin	  chain.	  Conversely,	  Ubr1	  can	  function	  as	  a	  polyubiquitylation-­‐enhancing	  component	  of	  the	  Ubr1-­‐Ufd4	  complex	  in	  its	  targeting	  of	  UFD	  substrates.	  We	  also	  found	  that	  Ubr1	  can	  recognize	  the	  N-­‐terminal	  ubiquitin	  moiety.	  These	  and	  related	  advances	  unify	  two	  proteolytic	  systems	  that	  have	  been	  studied	  separately	  over	  two	  decades.	  
Introduction	  
Here	  we	  report	  that	  the	  RING-­‐type	  Ubr1	  E3	  and	  the	  HECT-­‐type	  Ufd4	  E3	  interact,	  both	  physically	  and	  functionally.	  Using	  in	  vitro	  and	  in	  vivo	  approaches,	  we	  show	  that	  the	  Ubr1-­‐Ufd4	  complex	  mediates	  the	  Arg/N-­‐end	  rule	  pathway	  and	  a	  part	  of	  the	  UFD	  pathway	  as	  well.	  Cooperation,	  in	  their	  physical	  complex,	  between	  Ubr1	  and	  Ufd4	  includes	  their	  ability	  to	  increase	  the	  processivity	  of	  polyubiquitylation	  of	  both	  Arg/N-­‐end	  rule	  and	  UFD	  substrates,	  in	  comparison	  to	  targeting	  by	  Ubr1	  or	  Ufd4	  alone.	  Thus,	  operationally,	  the	  complex	  of	  Ubr1	  and	  Ufd4	  functions	  as	  an	  E3–
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E4	  pair	  in	  which	  the	  ‘assignment’	  of	  an	  E3	  or	  E4	  function	  depends	  on	  the	  substrate	  and	  the	  nature	  of	  its	  degron.	  We	  also	  found	  that	  Ubr1,	  similarly	  to	  Ufd4,	  contains	  a	  domain	  that	  specifically	  binds	  to	  N-­‐terminal	  Ub	  but	  not	  to	  free	  Ub.	  S.	  cerevisiae	  lacking	  the	  Ufd4	  component	  of	  the	  Ubr1-­‐Ufd4	  complex	  retained	  the	  Arg/N-­‐end	  rule	  pathway	  but	  its	  proteolytic	  activity	  was	  lower	  than	  in	  wild-­‐type	  cells.	  This	  could	  be	  seen	  not	  only	  with	  Arg/N-­‐end	  rule	  substrates	  (i.e.,	  substrates	  containing	  N-­‐degrons)	  but	  also	  with	  Cup9,	  a	  transcriptional	  repressor	  of	  peptide	  import	  that	  is	  targeted	  by	  Ubr1	  through	  an	  internal	  degron	  of	  Cup9.	  These	  and	  other	  results	  unified	  two	  proteolytic	  systems	  that	  have	  been	  studied	  separately	  over	  two	  decades.	  
	   The	  Arg/N-­‐end	  rule	  pathway	  in	  the	  yeast	  Saccharomyces	  cerevisiae	  is	  mediated	  by	  the	  225	  kDa	  RING-­‐type	  Ubr1	  E3	  Ub	  ligase	  (Fig.	  1a).	  The	  type-­‐1	  and	  type-­‐2	  substrate-­‐binding	  sites	  of	  Ubr1	  recognize	  the	  unmodified	  basic	  (Arg,	  Lys,	  His)	  and	  bulky	  hydrophobic	  (Leu,	  Phe,	  Tyr,	  Trp,	  Ile)	  N-­‐terminal	  residues,	  respectively	  (3,	  11,	  22,	  23).	  The	  type-­‐1	  binding	  site	  of	  Ubr1	  resides	  in	  the	  ~70-­‐residue	  UBR	  domain	  (3,	  17)	  that	  was	  recently	  solved	  at	  atomic	  resolution	  (24–26).	  In	  addition	  to	  the	  type-­‐1/2	  sites,	  Ubr1	  contains	  binding	  sites	  that	  recognize	  internal	  (non-­‐N-­‐terminal)	  degrons	  of	  proteins	  that	  include	  the	  Cup9	  transcriptional	  repressor,	  the	  Mgt1	  DNA	  repair	  protein	  (O6-­‐alkylguanine	  DNA	  alkyltransferase)	  (5,	  12,	  22,	  27),	  and	  misfolded	  proteins	  (28–31).	  In	  contrast	  to	  the	  ‘primary’	  destabilizing	  N-­‐terminal	  residues	  (Arg,	  Lys,	  His,	  Leu,	  Phe,	  Tyr,	  Trp,	  Ile),	  the	  N-­‐terminal	  residues	  Asp,	  Glu,	  Asn	  and	  Gln	  can	  be	  targeted	  by	  Ubr1	  only	  after	  their	  Nt-­‐arginylation	  by	  the	  Ate1	  Arg-­‐tRNA-­‐protein	  transferase	  (R-­‐transferase)	  (Fig.	  1a).	  These	  destabilizing	  residues	  are	  called	  ‘secondary’	  or	  ‘tertiary’,	  depending	  on	  the	  number	  of	  steps	  (arginylation	  of	  Asp	  and	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Glu;	  deamidation/arginylation	  of	  Asn	  and	  Gln)	  that	  precede	  the	  targeting	  and	  polyubiquitylation,	  by	  Ubr1,	  of	  Nt-­‐arginylated	  N-­‐end	  rule	  substrates	  (8,	  10,	  15,	  16,	  32).	  
	   Regulated	  degradation	  of	  specific	  proteins	  by	  the	  Arg/N-­‐end	  rule	  pathway	  mediates	  a	  legion	  of	  physiological	  functions,	  including	  the	  sensing	  of	  haem,	  nitric	  oxide,	  oxygen,	  and	  short	  peptides;	  the	  degradation	  of	  misfolded	  proteins;	  the	  fidelity	  of	  chromosome	  segregation;	  the	  regulation	  of	  DNA	  repair	  and	  peptide	  import;	  the	  signaling	  by	  G-­‐coupled	  transmembrane	  receptors;	  the	  regulation	  of	  apoptosis,	  meiosis,	  fat	  metabolism,	  cell	  migration,	  cardiovascular	  development,	  spermatogenesis	  and	  neurogenesis;	  the	  functioning	  of	  adult	  organs,	  including	  the	  brain,	  muscle,	  testis	  and	  pancreas;	  and	  the	  regulation	  of	  leaf	  and	  shoot	  development,	  leaf	  senescence	  and	  seed	  germination	  in	  plants	  (refs.	  3,	  5,	  6,	  8–12,	  15,	  16,	  18,	  22,	  28–35,	  and	  refs.	  therein).	  The	  recently	  discovered	  Ac/N-­‐end	  rule	  pathway	  is	  likely	  to	  mediate,	  among	  other	  things,	  protein	  quality	  control	  and	  degradation	  of	  long-­‐lived	  proteins	  (18).	  Partial	  Nt-­‐arginylation	  of	  apparently	  long-­‐lived	  proteins	  such	  as	  β-­‐actin	  and	  calreticulin	  (36,	  37)	  suggests	  that	  Nt-­‐arginylation	  may	  have	  nonproteolytic	  roles	  as	  well.	  
	   Our	  previous	  study	  showed	  that	  the	  S.	  cerevisiae	  Mgt1	  DNA	  repair	  protein	  is	  co-­‐targeted	  for	  degradation	  by	  the	  Ubr1/Rad6-­‐mediated	  Arg/N-­‐end	  rule	  pathway	  and	  the	  Ufd4/Ubc4-­‐mediated	  Ub-­‐fusion	  degradation	  (UFD)	  pathway	  (12).	  Rad6	  and	  Ubc4/Ubc5	  are	  E2	  enzymes	  that	  function	  with	  the	  E3s	  Ubr1	  and	  Ufd4,	  respectively.	  Ufd4	  is	  the	  168	  kDa	  HECT-­‐type	  E3	  of	  the	  UFD	  pathway	  (38–43).	  The	  UFD	  pathway	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was	  discovered	  through	  analyses	  of	  N-­‐terminal	  Ub	  fusions	  in	  which	  the	  Pro	  residue	  at	  the	  Ub-­‐reporter	  junction	  or	  mutations	  of	  the	  Ub	  moiety	  were	  found	  to	  inhibit	  the	  cleavage	  of	  a	  fusion	  by	  deubiquitylases	  (DUBs)	  (1,	  38,	  44,	  45).	  Such	  UFD	  substrates	  are	  targeted	  for	  polyubiquitylation	  and	  degradation	  through	  their	  N-­‐terminal	  Ub	  moieties	  (Fig.	  1b).	  
	   A	  priori,	  the	  number	  of	  topologically	  distinct	  poly-­‐Ub	  chains	  can	  be	  very	  large,	  as	  all	  seven	  Lys	  residues	  of	  Ub	  can	  contribute,	  in	  specific	  in	  vivo	  contexts,	  to	  the	  synthesis	  of	  poly-­‐Ub	  linked	  to	  protein	  substrates	  (46,	  47).	  The	  delivery	  of	  ubiquitylated	  proteins	  to	  the	  26S	  proteasome	  can	  be	  mediated	  by	  either	  K48-­‐type,	  K11-­‐type	  or	  K29-­‐type	  chains,	  and	  possibly	  by	  poly-­‐Ub	  of	  other	  topologies	  as	  well	  (refs.	  3,	  19,	  46–48	  and	  refs.	  therein).	  A	  single	  E3	  can	  cooperate,	  in	  some	  settings,	  with	  two	  distinct	  E2	  enzymes	  that	  mediate,	  sequentially,	  the	  synthesis	  of	  a	  substrate-­‐linked	  poly-­‐Ub	  chain	  (49).	  Two	  E3s	  can	  also	  cooperate	  in	  producing	  a	  poly-­‐Ub	  chain.	  Studies	  by	  Jentsch	  and	  colleagues	  (45)	  (see	  also	  refs.	  46,	  50,	  51	  and	  refs.	  therein)	  introduced	  the	  concept	  of	  an	  E4	  as	  an	  E3-­‐like	  enzyme	  that	  cooperates	  with	  a	  specific	  E3	  and	  its	  cognate	  E2	  enzyme	  to	  increase	  the	  processivity	  of	  polyubiquitylation.	  Given	  the	  mechanistic	  and	  regulatory	  complexity	  of	  polyubiquitylation	  that	  remains	  to	  be	  understood,	  it	  would	  be	  constructive,	  at	  present,	  to	  define	  E4	  operationally,	  as	  an	  E3-­‐like	  enzyme	  that	  cooperates	  with	  a	  substrate-­‐specific	  ubiquitylation	  machinery	  to	  increase	  the	  efficacy	  (including	  processivity)	  of	  polyubiquitylation,	  and	  in	  some	  cases	  to	  alter	  topology	  of	  a	  poly-­‐Ub	  chain	  as	  well.	  This	  definition	  of	  E4	  does	  not	  constrain	  its	  possible	  modes	  of	  action.	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   Here	  we	  report	  that	  the	  RING-­‐type	  Ubr1	  E3	  and	  the	  HECT-­‐type	  Ufd4	  E3	  interact,	  both	  physically	  and	  functionally.	  Using	  in	  vitro	  and	  in	  vivo	  approaches,	  we	  show	  that	  the	  Ubr1-­‐Ufd4	  complex	  mediates	  the	  Arg/N-­‐end	  rule	  pathway	  and	  a	  part	  of	  the	  UFD	  pathway	  as	  well.	  Cooperation,	  in	  their	  physical	  complex,	  between	  Ubr1	  and	  Ufd4	  includes	  their	  ability	  to	  increase	  the	  processivity	  of	  polyubiquitylation	  of	  both	  Arg/N-­‐end	  rule	  and	  UFD	  substrates,	  in	  comparison	  to	  targeting	  by	  Ubr1	  or	  Ufd4	  alone.	  Thus,	  operationally,	  the	  complex	  of	  Ubr1	  and	  Ufd4	  functions	  as	  an	  E3–E4	  pair	  in	  which	  the	  ‘assignment’	  of	  an	  E3	  or	  E4	  function	  depends	  on	  the	  substrate	  and	  the	  nature	  of	  its	  degron.	  We	  also	  found	  that	  Ubr1,	  similarly	  to	  Ufd4,	  contains	  a	  domain	  that	  specifically	  binds	  to	  N-­‐terminal	  Ub	  but	  not	  to	  free	  Ub.	  S.	  cerevisiae	  lacking	  the	  Ufd4	  component	  of	  the	  Ubr1-­‐Ufd4	  complex	  retained	  the	  Arg/N-­‐end	  rule	  pathway	  but	  its	  proteolytic	  activity	  was	  lower	  than	  in	  wild-­‐type	  cells.	  This	  could	  be	  seen	  not	  only	  with	  Arg/N-­‐end	  rule	  substrates	  (i.e.,	  substrates	  containing	  N-­‐degrons)	  but	  also	  with	  Cup9,	  a	  transcriptional	  repressor	  of	  peptide	  import	  that	  is	  targeted	  by	  Ubr1	  through	  an	  internal	  degron	  of	  Cup9.	  These	  and	  other	  results	  unified	  two	  proteolytic	  systems	  that	  have	  been	  studied	  separately	  over	  two	  decades.	  
Results	  
Ubiquitylation	  of	  Mgt1	  by	  Ubr1	  and	  Ufd4.	  	  
Although	  Mgt1	  could	  be	  ubiquitylated	  (and	  subsequently	  degraded)	  by	  either	  the	  Arg/N-­‐end	  rule	  or	  UFD	  pathways,	  strong	  polyubiquitylation	  of	  Mgt1	  was	  observed	  only	  in	  the	  presence	  of	  both	  pathways	  (12).	  To	  further	  address	  this	  interplay	  between	  Ubr1	  and	  Ufd4,	  we	  employed	  a	  ubiquitylation	  assay	  that	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comprised	  35S-­‐labeled	  Mgt1f3	  (C-­‐terminally	  tagged	  with	  flag	  epitopes)	  that	  had	  been	  produced	  in	  reticulocyte	  extract	  (12),	  and	  the	  following	  purified	  components:	  Ub;	  Uba1	  (E1);	  Rad6	  and/or	  Ubc4	  (cognate	  E2s);	  Ubr1	  and/or	  Ufd4;	  and	  ATP.	  
The	  assays	  were	  performed	  using	  wild-­‐type	  Ub,	  UbK29R,	  UbK48R,	  or	  UbK63R,	  with	  Ub	  mutants	  of	  this	  set	  precluding	  formation	  of	  Ub-­‐Ub	  isopeptide	  bonds	  of	  the	  K48,	  K29	  or	  K63	  topologies,	  respectively.	  Ubr1/Rad6	  alone	  polyubiquitylated	  Mgt1	  to	  comparable	  extents	  with	  either	  wild-­‐type	  Ub,	  UbK29R,	  or	  UbK63R	  (Fig.	  2,	  lanes	  2,	  3,	  5).	  In	  contrast,	  little	  polyubiquitylation	  was	  observed	  with	  UbK48R	  (Fig.	  2,	  lane	  4),	  in	  agreement	  with	  evidence	  that	  Ubr1/Rad6	  preferentially	  produces	  K48-­‐type	  chains	  (	  48).	  Together,	  Ubr1/Rad6	  and	  Ufd4/Ubc4	  polyubiquitylated	  Mgt1	  both	  more	  strongly	  and	  more	  processively	  than	  Ubr1/Rad6	  alone.	  Specifically,	  ubiquitylated	  
35S-­‐Mgt1f3	  produced	  with	  wild-­‐type	  Ub	  and	  Ubr1/Rad6	  plus	  Ufd4/Ubc4	  migrated	  as	  high-­‐yield	  polyubiquitylated	  derivatives	  in	  a	  narrow	  size	  range,	  ~200	  kDa	  on	  average,	  corresponding	  to	  ~21	  Ub	  moieties	  in	  a	  substrate-­‐linked	  chain	  (Fig.	  2,	  lane	  7).	  In	  contrast,	  a	  broader	  distribution	  of	  much	  shorter	  chains	  was	  observed	  with	  Ubr1/Rad6	  alone	  (Fig.	  2,	  lane	  2;	  cf.	  lane	  7).	  When	  Ubr1/Rad6	  and	  Ufd4/Ubc4	  were	  assayed	  together	  in	  the	  presence	  of	  UbK29R,	  both	  high	  yield	  and	  processivity	  of	  Mgt1	  polyubiquitylation	  were	  diminished,	  in	  comparison	  to	  results	  with	  wild-­‐type	  Ub	  (Fig.	  2,	  lane	  8;	  cf.	  lanes	  2,	  3	  and	  7).	  When	  Ubr1/Rad6	  and	  Ufd4/Ubc4	  were	  assayed	  in	  the	  presence	  of	  UbK48R,	  the	  yield	  of	  Mgt1-­‐linked	  chains	  was	  also	  much	  lower	  than	  with	  wild-­‐type	  Ub,	  but	  their	  large	  average	  size	  and	  narrow	  size	  distribution	  were	  retained	  (Fig.	  2,	  lane	  9;	  cf.	  lanes	  4	  and	  7).	  Similar	  results	  were	  obtained	  with	  Ufd4/Ubc4	  alone,	  using	  either	  wild-­‐type	  Ub	  or	  its	  mutants	  (Fig.	  2,	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lanes	  11–15).	  Thus,	  the	  presence	  of	  both	  Ubr1/Rad6	  and	  Ufd4/Ubc4,	  and	  also	  of	  Ub	  containing	  wild-­‐type	  Lys48	  and	  Lys29	  are	  required	  for	  the	  high-­‐yield	  production	  of	  larger	  Mgt1-­‐linked	  chains,	  and	  for	  their	  narrow	  size	  distribution	  as	  well	  (Fig.	  2,	  lanes	  7	  and	  10).	  
Physical	  interaction	  between	  Ubr1	  and	  Ufd4.	  
To	  test	  for	  a	  possible	  interaction	  between	  Ubr1	  and	  Ufd4,	  we	  performed	  coimmunoprecipitations	  with	  extracts	  from	  cells	  expressing	  flag-­‐tagged	  Ubr1	  (fUbr1)	  and	  ha-­‐tagged	  Ufd4	  (haUfd4)	  (Fig.	  3a–c).	  haUfd4	  was	  coimmunoprecipitated	  with	  fUbr1	  by	  anti-­‐flag	  (Fig.	  3a).	  Conversely,	  fUbr1	  was	  coimmunoprecipitated	  with	  
haUfd4	  by	  anti-­‐ha	  (Fig.	  3b).	  To	  determine	  whether	  these	  results	  signified	  a	  direct	  interaction	  between	  Ubr1	  and	  Ufd4,	  we	  also	  performed	  a	  coimmunoprecipitation	  with	  equal	  amounts	  of	  purified	  fUbr1	  and	  fUfd4.	  The	  results	  (Figs.	  3c	  and	  S1a)	  confirmed	  a	  direct	  interaction	  between	  Ubr1	  and	  Ufd4.	  
To	  examine	  the	  Ubr1-­‐Ufd4	  interaction	  in	  vivo,	  we	  employed	  the	  split-­‐Ub	  technique	  (52,	  53).	  Co-­‐expression	  of	  Ubr1	  as	  the	  bait	  and	  Ufd4	  as	  the	  prey	  produced	  the	  interaction-­‐positive	  Ade+	  His+	  phenotype	  reproducibly	  and	  robustly,	  whereas	  no	  Ade+	  His+	  cells	  were	  observed	  with	  negative	  controls	  (Fig.	  3d).	  A	  reciprocal	  assay,	  with	  Ufd4	  as	  the	  bait	  and	  Ubr1	  as	  the	  prey,	  also	  indicated	  an	  in	  vivo	  interaction	  between	  Ubr1	  and	  Ufd4	  (Fig.	  3d).	  To	  delineate	  the	  Ufd4-­‐interacting	  region	  of	  Ubr1,	  coimmunoprecipitations	  (Fig.	  3a,	  b)	  were	  carried	  out	  using	  anti-­‐ha	  and	  extracts	  from	  S.	  cerevisiae	  that	  expressed	  full-­‐length	  haUfd4	  and	  one	  of	  the	  following	  Ubr1	  fragments:	  fUbr11-­‐1175,	  fUbr11-­‐717,	  fUbr11-­‐510,	  Ubr1454-­‐1140f	  and	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fUbr1454-­‐795	  (Fig.	  3e).	  haUfd4	  was	  coimmunoprecipitated	  with	  all	  of	  these	  fragments	  except	  fUbr11-­‐510	  (Fig.	  3f,	  g).	  A	  reciprocal	  coimmunoprecipitation	  with	  anti-­‐flag	  confirmed	  that	  fUbr1454-­‐795,	  encompassing	  342	  residues	  of	  the	  1,950-­‐residue	  Ubr1,	  could	  interact	  with	  haUfd4	  (Fig.	  3h).	  
Ufd4	  contributes	  to	  ubiquitylation	  and	  degradation	  of	  Arg/N-­‐end	  rule	  substrates.	  
Since	  the	  degradation	  signal	  of	  Mgt1	  is	  distinct	  from	  an	  N-­‐degron	  (12),	  we	  asked	  whether	  cooperation	  between	  Ubr1	  and	  Ufd4	  could	  also	  be	  detected	  with	  Arg/N-­‐end	  rule	  substrates,	  i.e.,	  with	  proteins	  containing	  N-­‐degrons.	  Ubiquitylation	  of	  purified	  X-­‐DHFRha	  (X=Met,	  Arg,	  Leu),	  a	  set	  of	  previously	  characterized	  Arg/N-­‐end	  rule	  reporters	  based	  on	  the	  mouse	  dihydrofolate	  reductase	  (DHFR)	  moiety	  and	  produced	  from	  Ub-­‐X-­‐DHFRha	  by	  the	  Ub	  fusion	  technique	  (54,	  55)	  (Fig.	  S1b),	  was	  examined	  with	  wild-­‐type	  Ub	  using	  either	  purified	  fUbr1/Rad6	  alone,	  fUfd4/Ubc4	  alone,	  or	  fUbr1/Rad6	  plus	  fUfd4/Ubc4	  (Fig.	  4a).	  As	  expected	  (38),	  Ufd4/Ubc4	  alone	  did	  not	  polyubiquitylate	  Arg/N-­‐end	  rule	  substrates	  (Fig.	  4a,	  lanes	  11	  and	  17),	  confirming	  that	  Ufd4	  is	  not	  an	  N-­‐recognin.	  As	  also	  expected	  (5,	  23),	  Ubr1/Rad6	  polyubiquitylated	  both	  Arg-­‐DHFRha	  and	  Leu-­‐DHFRha	  (type-­‐1	  and	  type-­‐2	  Arg/N-­‐end	  rule	  substrates,	  respectively)	  but	  was	  virtually	  inactive	  with	  Met-­‐DHFRha	  (Fig.	  4a).	  Addition	  of	  Ufd4/Ubc4	  to	  Ubr1/Rad6	  resulted	  in	  longer	  substrate-­‐linked	  poly-­‐Ub	  chains	  (Fig.	  4a),	  similarly	  to	  processivity	  enhancement	  that	  was	  observed	  with	  Mgt1	  (Fig.	  2).	  
Ubiquitylation	  assays	  were	  also	  carried	  out	  with	  Arg-­‐DHFRha	  and	  the	  Ub	  mutants	  UbK29	  (Ub	  in	  which	  all	  lysines	  except	  K29	  were	  replaced	  by	  Arg)	  (Fig.	  4b,	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lanes	  1–3);	  UbK48	  (Ub	  in	  which	  all	  lysines	  except	  K48	  were	  replaced	  by	  Arg)	  (Fig.	  4b,	  lanes	  4–6);	  an	  equimolar	  mixture	  of	  UbK29	  and	  UbK48	  (Fig.	  4b,	  lanes	  7–9);	  UbK29R	  (Ub	  in	  which	  one	  lysine,	  K29,	  was	  replaced	  by	  Arg)	  (Fig.	  4b,	  lanes	  10–12);	  UbK48R	  (Ub	  in	  which	  one	  lysine,	  K48,	  was	  replaced	  by	  Arg)	  (Fig.	  4b,	  lanes	  13–15);	  and	  an	  equimolar	  mixture	  of	  UbK29R	  and	  UbK48R	  (Fig.	  4b,	  lanes	  16–18).	  There	  was	  virtually	  no	  polyubiquitylation	  of	  Arg-­‐DHFRha	  by	  Ufd4/Ubc4	  alone	  in	  the	  presence	  of	  any	  Ub	  mutant	  (Fig.	  4b,	  lanes	  1,	  4,	  7,	  10,	  13,	  and	  16),	  in	  agreement	  with	  Ufd4	  not	  being	  an	  N-­‐recognin.	  In	  contrast,	  Ubr1/Rad6	  polyubiquitylated	  Arg-­‐DHFRha	  in	  the	  presence	  of	  either	  UbK29R,	  UbK48R,	  or	  both	  of	  them	  together	  (Fig.	  4b,	  lanes	  11,	  14	  and	  17,	  cf.	  lanes	  10,	  13	  and	  16,	  respectively).	  To	  our	  knowledge,	  this	  is	  the	  first	  evidence	  that	  Ubr1/Rad6	  can	  produce,	  at	  least	  in	  vitro,	  non-­‐K48	  poly-­‐Ub	  chains.	  Similarly	  to	  results	  with	  wild-­‐type	  Ub	  (Fig.	  4a,	  lane	  12;	  cf.	  lane	  9),	  both	  the	  yields	  and	  average	  sizes	  of	  substrate-­‐linked	  poly-­‐Ub	  chains	  were	  significantly	  larger	  in	  the	  presence	  of	  Ubr1/Rad6	  plus	  Ufd4/Ubc4,	  using	  either	  UbK29R,	  UbK48R,	  or	  two	  of	  them	  together	  (Fig.	  4b,	  lanes12,	  15	  and	  18;	  cf.	  lanes	  11,	  14	  and	  17).	  
With	  UbK29,	  either	  Ubr1/Rad6	  alone	  or	  Ubr1/Rad6	  plus	  Ufd4/Ubc4	  could	  produce	  only	  short	  poly-­‐Ub	  chains,	  i.e.,	  no	  significant	  increase	  in	  processivity	  was	  observed	  with	  Ubr1/Rad6	  and	  Ufd4/Ubc4	  together	  (Fig.	  4b,	  lanes	  2,	  3).	  It	  is	  possible	  that	  UbK29	  was	  too	  perturbed	  by	  six	  mutations	  to	  be	  an	  efficacious	  substrate	  for	  polyubiquitylation	  by	  Ubr1/Rad6-­‐Ufd4/Ubc4.	  In	  contrast,	  with	  UbK48	  (only	  K48-­‐type	  chains	  could	  be	  produced	  with	  this	  Ub	  mutant),	  there	  was	  a	  significant	  increase	  in	  the	  yield	  and	  processivity	  of	  polyubiquitylation	  in	  the	  presence	  of	  Ubr1/Rad6	  plus	  Ufd4/Ubc4	  (Fig.	  4b,	  lanes	  5,	  6;	  cf.	  lanes	  2,	  3	  and	  11,	  12).	  In	  one	  model	  that	  is	  
	   34	  
consistent	  with	  our	  findings	  (Figs.	  2	  and	  4a,	  b),	  a	  physical	  interaction	  between	  Ubr1	  and	  Ufd4	  (Fig.	  3)	  increases,	  allosterically,	  the	  efficacy	  and	  processivity	  of	  the	  Ubr1/Rad6	  Ub	  ligase	  that	  is	  bound	  to	  Ufd4/Ubc4.	  In	  another	  plausible	  model,	  the	  Ufd4/Ubc4	  component	  of	  the	  Ubr1/Rad6-­‐Ufd4/Ubc4	  complex	  may	  utilize	  a	  specific	  Lys	  residue	  of	  Ub	  (e.g.,	  Lys48;	  see	  above)	  to	  elongate	  a	  poly-­‐Ub	  chain	  that	  had	  been	  initiated	  (‘primed’)	  by	  Ubr1/Rad6.	  
We	  also	  employed	  a	  degradation	  assay	  with	  the	  purified	  26S	  proteasome	  (56)	  (Fig.	  4c).	  The	  in	  vitro	  half-­‐lives	  of	  Leu-­‐DHFRha	  that	  had	  been	  polyubiquitylated	  by	  Ubr1	  alone	  versus	  Ubr1	  plus	  Ufd4	  were	  ~23	  min	  versus	  ~7	  min,	  respectively	  (Fig.	  4d,	  e).	  To	  increase	  the	  yields	  of	  polyubiquitylated	  reporters	  before	  the	  addition	  of	  the	  26S	  proteasome,	  ubiquitylation	  was	  carried	  out	  for	  18	  hr	  at	  30°C,	  as	  opposed	  to	  15	  min	  in	  the	  assay	  of	  Fig.	  4a	  (lanes	  13–18),	  resulting	  in	  the	  absence	  of	  non-­‐ubiquitylated	  Leu-­‐DHFRha	  and	  most	  likely	  accounting	  for	  a	  marginal	  difference,	  in	  this	  experiment,	  between	  the	  longest	  chains	  in	  the	  presence	  of	  Ubr1	  versus	  Ubr1	  plus	  Ufd4	  (Fig.	  4d,	  lanes	  1	  and	  4).	  In	  addition	  to	  effects	  of	  poly-­‐Ub	  chains,	  the	  faster	  degradation	  of	  polyubiquitylated	  Leu-­‐DHFRha	  that	  had	  been	  produced	  by	  Ubr1-­‐Ufd4	  (Fig.	  4d,	  e)	  may	  also	  stem	  from	  previously	  described	  (and	  possibly	  synergistic)	  interactions	  of	  Ubr1	  and	  Ufd4	  with	  the	  26S	  proteasome	  (41,	  42).	  These	  issues	  await	  more	  detailed	  studies	  with	  proteasome-­‐based	  assays.	  
To	  determine	  whether	  the	  in	  vitro	  effect	  of	  Ufd4	  on	  Arg/N-­‐end	  rule	  substrates	  (Fig.	  4)	  occurred	  in	  vivo	  as	  well,	  we	  employed	  X-­‐β-­‐galactosidase	  (X-­‐β	  gal)	  reporters,	  produced	  by	  the	  cotranslational	  deubiquitylation	  of	  Ub-­‐X-­‐β	  gal	  (X=His,	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Tyr)	  (1,	  57).	  The	  activity	  of	  β	  gal	  in	  extracts	  from	  cells	  that	  express	  X-­‐βgal	  is	  a	  reliable	  measure	  of	  the	  reporter’s	  metabolic	  stability	  (54).	  In	  agreement	  with	  in	  vitro	  data	  (Fig.	  4),	  His-­‐βgal	  and	  Tyr-­‐βgal	  became	  partially	  stabilized	  in	  the	  absence	  of	  Ufd4	  (Fig.	  5a).	  35S-­‐pulse-­‐chases	  confirmed	  these	  results:	  the	  in	  vivo	  half-­‐life	  of	  His-­‐βgal	  was	  ~18	  min	  in	  wild-­‐type	  cells	  and	  doubled	  to	  ~41	  min	  in	  ufd4Δ	  cells	  (Fig.	  5b,	  d).	  The	  in	  vivo	  half-­‐life	  of	  Tyr-­‐β	  gal	  was	  ~28	  min	  in	  wild	  type	  cells	  and	  ~99	  min	  in	  
ufd4Δ	  cells	  (Fig.	  5c,	  d).	  Half-­‐lives	  of	  X-­‐βgals	  in	  ubr1Δ	  cells	  exceeded	  20	  h	  (data	  not	  shown),	  in	  agreement	  with	  earlier	  data	  (1,	  3).	  
Ufd4	  contributes	  to	  regulation	  of	  peptide	  import	  by	  the	  Arg/N-­‐end	  rule	  pathway.	  
The	  binding	  of	  short	  peptides	  with	  destabilizing	  N-­‐terminal	  residues	  to	  the	  type-­‐1/2	  sites	  of	  Ubr1	  (see	  Introduction)	  allosterically	  activates	  the	  third	  substrate-­‐binding	  site	  of	  Ubr1	  that	  recognizes	  an	  internal	  degron	  of	  Cup9,	  a	  transcriptional	  repressor	  (5,	  22).	  Genes	  down-­‐regulated	  by	  Cup9	  include	  PTR2,	  which	  encodes	  the	  transporter	  of	  di-­‐	  and	  tripeptides	  (33).	  This	  positive-­‐feedback	  circuit,	  in	  which	  Cup9	  degradation	  is	  induced	  by	  type-­‐1/2	  peptides,	  allows	  S.	  cerevisiae	  to	  sense	  the	  presence	  of	  extracellular	  peptides	  and	  to	  react	  by	  accelerating	  their	  uptake	  (5,	  22,	  27).	  In	  agreement	  with	  earlier	  findings	  (5,	  23),	  ubiquitylation	  assays	  with	  35S-­‐labeled	  Cup9	  and	  Ubr1/Rad6	  showed	  that	  low-­‐μM	  levels	  of	  the	  type-­‐1/2	  dipeptides	  Arg-­‐Ala/Leu-­‐Ala	  greatly	  increased	  the	  Ubr1-­‐mediated	  polyubiquitylation	  of	  Cup9	  (Fig.	  5e,	  lanes	  1–8).	  Ufd4/Ubc4	  plus	  Ubr1/Rad6	  significantly	  increased	  the	  processivity	  of	  Cup9	  polyubiquitylation	  at	  an	  even	  lower	  (0.1	  μM)	  concentration	  of	  the	  same	  dipeptides	  (Fig.	  5e,	  lanes	  12,	  13).	  Moreover,	  in	  the	  presence	  of	  Ufd4/Ubc4	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plus	  Ubr1/Rad6,	  dipeptides	  increased	  the	  average	  size	  of	  Cup9-­‐linked	  poly-­‐Ub	  chains,	  in	  comparison	  to	  chains	  (at	  the	  same	  levels	  of	  dipeptides)	  by	  Ubr1/Rad6	  alone	  (Fig.	  5e,	  lane	  14;	  cf.	  lane	  5).	  The	  effect	  of	  dipeptides	  required	  the	  presence	  of	  both	  type-­‐1	  and	  type-­‐2	  dipeptides	  together,	  and	  also	  the	  presence	  of	  Ub	  that	  was	  able	  to	  form	  K29-­‐type	  chains	  (Fig.	  5f).	  
In	  vivo	  induction	  of	  the	  transporter	  Ptr2	  by	  low-­‐μM	  levels	  of	  Arg-­‐Ala/Leu-­‐Ala	  dipeptides	  (5,	  23)	  was	  diminished	  in	  the	  absence	  of	  Ufd4	  (Fig.	  5g),	  in	  agreement	  with	  in	  vitro	  results	  (Fig.	  5e,	  f).	  To	  determine	  whether	  Ufd4	  contributes	  to	  degradation	  of	  Cup9	  in	  vivo,	  we	  employed	  the	  Ub-­‐reference	  technique	  (URT),	  a	  method	  that	  increases	  the	  accuracy	  of	  a	  pulse-­‐chase	  assay	  by	  providing	  a	  ‘built-­‐in’	  reference	  protein	  (5,27,54)	  (see	  the	  legend	  to	  Fig.	  S2a,	  b).	  In	  agreement	  with	  other	  data	  (Fig.	  5e-­‐g),	  the	  in	  vivo	  half-­‐life	  of	  Cup9	  was	  ~5	  min	  in	  wild-­‐type	  cells	  and	  ~14	  min	  in	  ufd4Δ	  cells	  (Fig.	  S2a,	  b).	  
The	  Ubr1-­‐Ufd4	  complex	  and	  the	  UFD	  pathway.	  
Ufd4,	  as	  a	  part	  of	  the	  Ubr1-­‐Ufd4	  complex,	  augments	  the	  Ubr1-­‐based	  Arg/N-­‐end	  rule	  pathway	  (Figs.	  4	  and	  5).	  Might	  Ubr1	  have	  a	  ‘reciprocal’	  effect	  on	  the	  Ufd4-­‐mediated	  UFD	  pathway?	  We	  employed	  a	  ubiquitylation	  assay	  with	  purified	  UFD	  substrates	  such	  as	  Ub-­‐ProtA	  (Protein	  A)	  and	  Ub-­‐GST	  (glutathione	  S-­‐transferase)	  (Fig.	  S1c).	  As	  expected	  (38,	  45),	  the	  cognate	  Ufd4/Ubc4	  Ub	  ligase	  of	  the	  UFD	  pathway	  ubiquitylated,	  with	  a	  low	  processivity,	  both	  Ub-­‐ProtA	  and	  Ub-­‐GST	  (Fig.	  6a,	  b,	  lanes	  3;	  cf.	  lanes	  1).	  Remarkably,	  the	  Ubr1/Rad6	  Ub	  ligase	  of	  the	  Arg/N-­‐end	  rule	  pathway	  could	  also	  ubiquitylate	  (with	  a	  low	  processivity)	  these	  UFD	  substrates	  in	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the	  absence	  of	  Ufd4	  (Fig.	  6a,	  b,	  lanes	  2;	  cf.	  lanes	  1).	  Moreover,	  the	  processivity	  of	  polyubiquitylation	  of	  Ub-­‐ProtA	  and	  Ub-­‐GST	  was	  strongly	  increased	  in	  the	  presence	  of	  both	  Ubr1/Rad6	  and	  Ufd4/Ubc4	  (Fig.	  6a,	  b,	  lanes	  4;	  cf.	  lanes	  1–3).	  Ufd2,	  an	  E4-­‐type	  enzyme	  of	  the	  UFD	  pathway	  (38,	  45,	  58,	  59),	  also	  increased	  the	  processivity	  of	  the	  Ufd4	  E3	  in	  this	  system	  (Fig.	  6a,	  b,	  lanes	  7;	  cf.	  lanes	  1–3,	  5).	  However,	  in	  contrast	  to	  Ufd4,	  Ufd2	  had	  only	  a	  weak	  effect	  on	  ubiquitylation	  by	  Ubr1	  (Fig.	  6a,	  b,	  lanes	  6;	  cf.	  lanes	  1–3,	  5).	  In	  sum,	  Ufd4	  and	  Ubr1	  can	  function	  as	  mutually	  cooperative,	  physically	  interacting	  E3	  enzymes	  not	  only	  with	  Arg/N-­‐end	  rule	  substrates	  but	  with	  UFD	  substrates	  as	  well.	  To	  gauge	  the	  extent	  of	  substrate	  specificity	  of	  Ubr1	  and	  Ufd4	  in	  these	  assays	  (Figs.	  2,	  4a,	  b,	  5e,	  f,	  and	  6a,	  b),	  we	  asked	  whether	  an	  unrelated	  substrate	  could	  be	  ubiquitylated	  by	  Ubr1	  and/or	  Ufd4.	  These	  experiments	  employed	  purified	  Sic1PY	  (Fig.	  S1c),	  an	  engineered	  substrate	  of	  the	  Rsp5	  E3	  Ub	  ligase.	  Whereas	  purified	  Rsp5	  (with	  the	  cognate	  Ubc4	  E2)	  polyubiquitylated	  Sic1PY,	  neither	  Ubr1/Rad6	  nor	  Ufd4/Ubc4	  could	  utilize	  Sic1PY	  as	  a	  substrate	  (Fig.	  6e).	  
Because	  Ubr1	  could	  ubiquitylate	  UFD	  substrates	  in	  the	  absence	  of	  Ufd4	  (Fig.	  6a,	  b),	  we	  asked	  whether	  Ubr1	  contained	  a	  Ub-­‐binding	  site.	  GST-­‐pulldowns	  showed	  that	  the	  binding	  of	  fUbr1	  to	  Ub-­‐GST	  could	  be	  efficaciously	  competed	  out	  by	  other	  UFD-­‐type	  fusions	  such	  as	  Ub-­‐ProtA	  or	  Ub-­‐Met-­‐DHFRha,	  whereas	  a	  large	  molar	  excess	  of	  free	  Ub	  did	  not	  significantly	  decrease	  the	  binding	  of	  fUbr1	  to	  Ub-­‐GST	  (Fig.	  6c).	  Thus	  Ubr1	  contains	  a	  previously	  overlooked	  Ub-­‐binding	  site	  that	  can	  distinguish	  between	  conjugated	  and	  free	  Ub	  (Fig.	  6c),	  analogously	  to	  a	  Ub-­‐binding	  site	  of	  the	  Ufd4	  E3	  Ub	  ligase	  (40).	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Neither	  Ubr1	  nor	  Ufd4	  are	  essential	  proteins	  under	  normal	  growth	  conditions	  (3,	  38).	  Both	  ufd4Δ	  and	  ubr1Δ	  mutants	  were	  moderately	  hypersensitive	  to	  treatments	  that	  increased	  protein	  misfolding,	  such	  as	  6%	  ethanol	  or	  canavanine,	  an	  analog	  of	  arginine	  (45)	  (Fig.	  6f,	  g).	  Interestingly,	  ubr1Δ	  ufd4Δ	  double	  mutants	  were	  much	  more	  sensitive	  to	  ethanol	  or	  canavanine	  than	  their	  single-­‐mutant	  counterparts	  (Fig.	  6f,	  g),	  in	  agreement	  with	  demonstrated	  interactions	  and	  interdependence	  between	  the	  Arg/N-­‐end	  rule	  and	  UFD	  pathways.	  
Given	  the	  in	  vivo	  interaction	  between	  Ubr1	  and	  Ufd4	  (Fig.	  3),	  we	  wished	  to	  determine	  their	  approximate	  molar	  ratio	  in	  wild-­‐type	  cells.	  Previous	  work	  indicated	  that	  haploid	  S.	  cerevisiae	  contained	  ~7300	  Ufd4	  molecules	  per	  cell	  (60),	  but	  there	  was	  no	  information	  about	  Ubr1	  levels	  in	  that	  study	  or	  elsewhere.	  To	  estimate	  in	  vivo	  levels	  of	  Ubr1,	  we	  immunoblotted	  extracts	  of	  wild-­‐type	  S.	  cerevisiae	  using	  the	  previously	  characterized,	  affinity-­‐purified	  anti-­‐Ubr1	  antibody	  (11)	  and	  calibrated	  these	  assays	  with	  known	  amounts	  of	  purified	  fUbr1.	  The	  results	  (Fig.	  6d)	  indicated	  that	  ‘wild-­‐type’,	  haploid	  S.	  cerevisiae	  in	  YPD	  medium	  contained	  500	  to	  1,000	  Ubr1	  molecules	  per	  cell.	  Thus	  Ubr1	  is	  ~10-­‐fold	  less	  abundant	  than	  the	  Ufd4,	  suggesting	  a	  minor	  contribution	  of	  Ubr1	  to	  the	  activity	  of	  the	  UFD	  pathway.	  Indeed,	  no	  significant	  decrease	  in	  the	  rate	  of	  degradation	  of	  UbV76-­‐Val-­‐βgal,	  a	  UFD	  substrate,	  was	  observed	  in	  ubr1Δ	  S.	  cerevisiae,	  whereas	  in	  ufd4Δ	  cells	  this	  UFD	  reporter	  was	  nearly	  completely	  stabilized	  (Fig.	  S2c,	  d).	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Discussion	  
The	  Arg/N-­‐end	  rule	  and	  UFD	  pathways	  have	  been	  studied	  separately	  for	  more	  than	  two	  decades	  (1,	  3,	  38,	  40,	  44,	  45).	  In	  2009,	  we	  found	  that	  an	  internal	  degron	  of	  S.	  
cerevisiae	  Mgt1	  was	  co-­‐targeted	  by	  the	  Arg/N-­‐end	  rule	  and	  UFD	  pathways	  (12).	  We	  now	  report	  that	  the	  Arg/N-­‐end	  rule	  pathway	  is	  mediated	  by	  a	  physical	  complex	  of	  the	  RING-­‐type	  Ubr1	  E3	  and	  the	  HECT-­‐type	  Ufd4	  E3,	  together	  with	  their	  cognate	  E2	  enzymes	  Rad6	  and	  Ubc4/Ubc5,	  respectively	  (Fig.	  1c).	  The	  earlier	  examples	  of	  a	  complex	  between	  a	  RING-­‐type	  E3	  and	  a	  HECT-­‐type	  E3	  are	  distinct	  from	  the	  present	  case.	  Specifically,	  the	  complexes	  of	  the	  RING-­‐type	  CBLC	  E3	  with	  the	  HECT-­‐type	  AIP/ITCH	  E3	  and	  of	  the	  RING-­‐type	  Rnf11	  E3	  with	  the	  HECT-­‐type	  WWP1	  E3	  remain	  to	  be	  analyzed	  functionally	  (61,	  62).	  Furthermore,	  specific	  HECT-­‐type	  E3s	  were	  shown	  to	  bind	  RING-­‐type	  E3s	  and	  target	  them	  for	  polyubiquitylation	  and	  degradation	  (63,	  64),	  in	  contrast	  to	  Ubr1-­‐Ufd4	  (Fig.	  1c),	  where	  intra-­‐complex	  targeting	  has	  not	  been	  observed,	  thus	  far.	  Multicellular	  eukaryotes	  contain	  functionally	  overlapping	  E3	  N-­‐recognins	  that	  are	  sequelogous	  (similar	  in	  sequence)	  (65)	  to	  yeast	  Ubr1,	  in	  part	  because	  they	  contain	  the	  UBR	  domain	  (3,	  17,	  24–26).	  Trip12,	  a	  human	  HECT-­‐type	  E3,	  is	  a	  sequelog	  (65)	  of	  S.	  cerevisiae	  Ufd4	  and	  mediates	  degradation	  of	  human	  UFD	  substrates	  (66).	  Thus	  our	  results	  with	  yeast	  Ubr1-­‐Ufd4	  are	  likely	  to	  be	  relevant	  to	  all	  eukaryotes.	  
S.	  cerevisiae	  Ufd4	  is	  not	  an	  N-­‐recognin,	  i.e.,	  it	  does	  not,	  by	  itself,	  recognize	  N-­‐degrons,	  in	  contrast	  to	  Ubr1	  (Fig.	  4a,	  b).	  But	  through	  its	  physical	  interaction	  with	  the	  Ubr1	  E3,	  the	  Ufd4	  E3	  functions	  as	  a	  novel	  component	  of	  the	  Arg/N-­‐end	  rule	  pathway	  that	  increases	  the	  efficacy	  of	  Ubr1,	  at	  least	  in	  part	  by	  augmenting	  the	  processivity	  of	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polyubiquitylation	  of	  Arg/N-­‐end	  rule	  substrates	  (Fig.	  1a,	  c).	  Interestingly,	  the	  function	  of	  Ufd4	  in	  the	  Arg/N-­‐end	  rule	  pathway	  is	  broader	  than	  that	  of	  a	  processivity-­‐enhancing	  component	  of	  the	  Ubr1-­‐Ufd4	  complex	  because	  Ufd4	  can	  target	  the	  internal	  degron	  of	  Mgt1	  even	  in	  ubr1Δ	  cells	  (12).	  Although	  Ufd4	  is	  not	  strictly	  essential	  for	  the	  ability	  of	  Ubr1	  to	  mediate	  the	  Arg/N-­‐end	  rule	  pathway,	  this	  pathway	  is	  detectably	  impaired	  in	  ufd4Δ	  cells	  (Figs.	  5a–d	  and	  S2a,	  b).	  As	  mentioned	  above,	  Ufd4	  does	  not	  recognize	  N-­‐degrons	  but	  functions	  to	  increase	  the	  processivity	  of	  polyubiquitylation	  of	  Arg/N-­‐end	  rule	  substrates.	  Conversely,	  Ubr1	  can	  function	  as	  a	  processivity-­‐increasing	  component	  of	  the	  Ubr1-­‐Ufd4	  complex	  in	  its	  polyubiquitylation	  of	  UFD	  substrates.	  Moreover,	  Ubr1	  recognizes	  the	  N-­‐terminal	  Ub	  moiety	  of	  UFD	  substrates	  (Fig.	  6c).	  Thus	  Ubr1	  can	  bind	  to	  such	  substrates	  independently	  of	  Ufd4.	  Because	  Ubr1	  is	  ~10-­‐fold	  less	  abundant	  than	  Ufd4	  in	  wild-­‐type	  cells	  (see	  Results),	  the	  Ubr1/Rad6-­‐Ufd4/Ubc4	  complex	  is	  expected	  to	  mediate	  the	  bulk	  of	  the	  Arg/N-­‐end	  rule	  pathway,	  whereas	  the	  same	  complex	  mediates	  only	  a	  subset	  of	  the	  UFD	  pathway	  (Fig.	  1).	  Given	  the	  existence	  of	  the	  Ubr1-­‐Ufd4	  complex,	  it	  is	  possible	  that	  some	  functions	  of	  Ubr1	  might	  be	  mediated	  by	  its	  functionally	  relevant	  associations	  with	  other,	  non-­‐Ufd4	  E3s	  as	  well,	  for	  example	  with	  San1,	  a	  nuclear	  E3	  Ub	  ligase	  that	  recognizes	  misfolded	  proteins	  (67).	  In	  addition,	  the	  molar	  excess	  of	  Ufd4	  relative	  to	  Ubr1	  in	  vivo	  suggests	  that	  Ufd4	  might	  also	  interact	  with	  other	  E3s.	  One	  possibility	  is	  that	  the	  UFD	  pathway	  comprises	  a	  dynamic	  ‘mosaic’	  of	  reversible	  binary	  Ufd4	  complexes	  with	  several	  E3s,	  including	  Ubr1.	  These	  are	  just	  some	  of	  the	  ramifications	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suggested	  by	  results	  of	  the	  present	  study,	  which	  unified,	  in	  a	  novel	  way,	  two	  multifunctional	  proteolytic	  systems	  (Fig.	  1).	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Methods	  
Yeast	  strains,	  media,	  genetic	  techniques,	  and	  β-­‐galactosidase	  assay.	  
S.	  cerevisiae	  strains	  are	  described	  in	  Table	  S1.	  Standard	  techniques	  were	  employed	  for	  strain	  construction	  and	  transformation.	  The	  strains	  CHY233	  and	  CHY251	  (Table	  S1)	  were	  constructed	  by	  PCR-­‐mediated	  gene	  disruption	  of	  UFD4	  in	  S.	  
cerevisiae	  RJD347,	  using	  the	  pFA6a-­‐KanMX6	  plasmid	  (68).	  S.	  cerevisiae	  media	  included	  YPD	  medium	  (1%	  yeast	  extract,	  2%	  peptone,	  2%	  glucose;	  only	  most	  relevant	  media	  components	  are	  cited);	  SD	  medium	  (0.17%	  yeast	  nitrogen	  base,	  0.5%	  ammonium	  sulfate,	  2%	  glucose);	  SRGal	  medium	  (0.17%	  yeast	  nitrogen	  base,	  0.5%	  ammonium	  sulfate,	  2%	  raffinose,	  2%	  galactose);	  SHM	  medium	  (0.1%	  allantoin,	  2%	  glucose,	  0.17%	  yeast	  nitrogen	  base);	  and	  synthetic	  complete	  (SC)	  medium	  (0.17%	  yeast	  nitrogen	  base,	  0.5%	  ammonium	  sulfate,	  2%	  glucose,	  plus	  a	  drop-­‐out	  mixture	  of	  compounds	  required	  by	  a	  given	  auxotrophic	  strain).	  Assays	  for	  β-­‐galactosidase	  (β	  gal)	  activity	  in	  yeast	  extracts	  were	  carried	  out	  using	  Yeast	  β-­‐Galactosidase	  Assay	  Kit	  (Thermo	  scientific,	  Rockford,	  IL).	  S.	  cerevisiae	  strains	  that	  expressed	  His-­‐β	  gal	  or	  Tyr-­‐β	  gal	  were	  prototrophic	  for	  all	  20	  amino	  acids	  and	  were	  grown	  in	  a	  minimal	  medium	  in	  the	  absence	  of	  amino	  acids,	  to	  bypass	  the	  previously	  characterized	  activation	  of	  the	  Ubr1/Rad6	  Ub	  ligase	  by	  added	  amino	  acids	  (11,	  27).	  
Plasmids.	  
They	  are	  described	  in	  Table	  S2.	  In	  the	  high	  copy	  (2μ-­‐based)	  pCH522	  plasmid,	  
fUbr11-­‐510	  (N-­‐terminally	  tagged	  with	  flag)	  was	  expressed	  from	  the	  PADH1	  promoter.	  To	  construct	  pCH522,	  a	  region	  of	  the	  UBR1	  ORF	  was	  PCR-­‐amplified	  from	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pFlagUBR1SBX	  using	  the	  primers	  OCH820	  (ACACCATGGACTACAAGGACGAT	  GATGACAAGGGTTCTATGTCCGTTGCTGATGATGATTTA;	  the	  NcoI	  site	  is	  underlined)	  and	  OCH518	  (AAACTCGAGCTAATCAAAATAAAGAATATGTTGTAA;	  the	  XhoI	  site	  is	  underlined).	  The	  resulting	  DNA	  fragment	  was	  digested	  with	  NcoI/XhoI	  and	  subcloned	  into	  NcoI/XhoI-­‐cut	  pNTFlag717UBR1.	  The	  plasmids	  pCH230,	  pCH231,	  pCH232,	  which	  encoded	  His10-­‐Ub-­‐X-­‐DHFRha	  (X=Met,	  Arg,	  Leu),	  were	  constructed	  by	  ligating	  NdeI/HindIII-­‐digested	  pEJJ1-­‐M,	  pEJJ1-­‐R,	  and	  pEJJ1-­‐L,	  respectively	  (38),	  into	  the	  NdeI/HindIII-­‐cut	  pH10UE	  plasmid	  (10).	  Construction	  details	  for	  other	  plasmids	  (Table	  S2)	  are	  available	  upon	  request.	  All	  final	  constructs	  were	  verified	  by	  DNA	  sequencing.	  
Yeast-­‐based	  split-­‐ubiquitin	  assay.	  
A	  version	  of	  split-­‐Ub	  assay	  (52)	  used	  was	  described	  (53).	  The	  bait	  S.	  
cerevisiae	  proteins	  Ubr1	  and	  Ufd4	  were	  cloned	  via	  SfiI	  sites	  downstream	  of	  the	  OST4	  sequence	  into	  pDHB1.	  The	  prey	  proteins	  were	  cloned	  downstream	  of	  the	  NubG-­‐coding	  segment	  into	  prey	  vector	  pPR3-­‐N	  using	  full-­‐length	  UBR1	  and	  UFD4	  ORFs.	  All	  constructs	  were	  verified	  by	  sequencing.	  S.	  cerevisiae	  NMY51	  (MATa	  trp1	  leu2	  his3	  
ade2	  LYS2::lexA-­‐HIS3	  ade2::lexA-­‐ADE2	  URA3::lexA-­‐lacZ)	  (Dualsystems	  Biotech	  AG,	  Schlieren,	  Switzerland)	  was	  cotransformed	  with	  bait	  and	  prey	  plasmids	  using	  the	  lithium	  acetate	  method	  (69).	  Transformants	  were	  selected	  for	  the	  presence	  of	  bait	  and	  prey	  plasmids	  during	  3	  days	  of	  growth	  at	  30°C	  on	  SC(-­‐Trp,	  -­‐Leu)	  medium	  (minimal	  medium	  containing	  2%	  glucose,	  0.67%	  yeast	  nitrogen	  base,	  2%	  bacto-­‐agar,	  and	  complete	  amino	  acid	  mixture	  lacking	  Leu	  and	  Trp).	  Several	  colonies	  were	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transferred	  to	  liquid	  SC(-­‐Trp,	  -­‐Leu)	  and	  grown	  overnight	  to	  A600	  of	  ~1.	  Five-­‐fold	  serial	  dilutions	  were	  spotted	  onto	  SC(-­‐Trp,	  -­‐Leu)	  and	  SC(-­‐Trp,	  -­‐Leu,	  -­‐His,	  -­‐Ade)	  plates	  (53)	  and	  grown	  for	  2	  days	  at	  30°C.	  
Immunoblotting,	  coimmunoprecipitation,	  and	  GST-­‐pulldown	  assays.	  
Whole	  yeast	  cell	  extracts	  were	  prepared	  using	  a	  modification	  of	  Kushnirov’s	  method	  (11,	  18,	  70).	  Immunoblotting	  was	  performed	  as	  described	  (11,	  12,	  18).	  Co-­‐immunoprecipitation	  (co-­‐IP)	  assays	  with	  fUbr1	  and	  haUfd4	  were	  carried	  out	  as	  follows.	  Extracts	  (0.2	  mg)	  from	  JD52	  S.	  cerevisiae	  that	  co-­‐expressed,	  from	  indicated	  plasmids,	  the	  full-­‐length	  haUfd4	  and	  either	  full-­‐length	  fUbr1	  (pFlagUBR1SBX),	  fUbr11-­‐
1175	  (pFlagUBR1NT1-­‐1175),	  fUbr11-­‐717	  (pFlagUBR1NT1-­‐717),	  fUbr11-­‐510	  (pCH522),	  or	  
fUbr1454-­‐795	  (pCH487),	  were	  immunoprecipitated	  using	  anti-­‐ha	  antibody	  and	  protein	  G-­‐magnetic	  beads	  (Invitrogen)	  in	  lysis	  buffer	  (0.1	  M	  NaCl,	  0.1%	  NP40,	  0.5	  mM	  EDTA,	  5	  mM	  β-­‐mercaptoethanol,	  1	  mM	  phenylmethylsulfonyl	  fluoride	  (PMSF),	  25	  mM	  HEPES,	  pH	  7.5)	  containing	  the	  above-­‐cited	  protease-­‐inhibitor	  cocktail	  (Sigma).	  Bound	  proteins	  were	  eluted	  from	  thrice-­‐washed	  beads	  in	  0.5	  ml	  of	  lysis	  buffer,	  followed	  by	  SDS-­‐4-­‐12%	  NuPAGE,	  and	  immunoblotting	  with	  anti–ha	  or	  anti-­‐flag.	  In	  a	  different	  assay,	  purified	  fUbr1	  (0.125	  μg)	  and	  fUfd4	  (0.125	  μg)	  were	  incubated	  together	  for	  2	  h	  at	  4°C	  in	  0.25	  ml	  of	  reaction	  buffer	  (10%	  glycerol,	  0.1	  M	  NaCl,	  0.1%	  NP40,	  0.5	  mM	  EDTA	  25	  mM	  HEPES,	  pH	  7.5),	  followed	  by	  immunoprecipitation	  with	  affinity-­‐purified	  anti-­‐Ubr1	  antibody	  (1	  μg)	  (11)	  pre-­‐bound	  to	  Protein	  A	  immobilized	  on	  magnetic	  beads	  (Invitrogen).	  Bound	  proteins	  were	  washed	  4	  times	  in	  0.5	  ml	  of	  the	  same	  buffer,	  followed	  by	  SDS-­‐4-­‐12%	  NuPAGE	  and	  immunoblotting	  with	  anti-­‐
	   45	  
flag.	  In	  the	  assay	  for	  a	  direct	  interaction	  between	  purified	  fUbr1	  and	  fUfd4	  (see	  Fig.	  3c),	  immunoprecipitates	  were	  washed	  three	  times	  in	  the	  binding	  buffer,	  followed	  by	  elution	  of	  retained	  proteins,	  SDS-­‐PAGE,	  and	  immunoblotting	  with	  anti-­‐flag.	  
GST	  pulldown	  assays	  with	  purified	  fUbr1	  were	  carried	  out	  using	  a	  slight	  modification	  of	  the	  earlier	  procedure	  (22).	  Either	  GST	  alone	  or	  Ub-­‐GST	  fusion	  proteins	  (5	  μg)	  were	  incubated	  with	  glutathione-­‐Sepharose	  beads	  (15	  μl;	  50%	  slurry)	  in	  0.5	  ml	  of	  GST-­‐loading	  buffer	  (10%	  glycerol,	  0.5	  M	  NaCl,	  1%	  NP40,	  1	  mM	  EDTA,	  50	  mM	  Tris-­‐HCl,	  pH	  8.0)	  for	  20	  min	  at	  4°	  C.	  The	  beads	  were	  washed	  once	  with	  0.5	  ml	  of	  GST-­‐binding	  buffer	  (10	  %	  glycerol,	  0.05%	  NP40,	  50	  mM	  NaCl,	  50	  mM	  HEPES,	  pH	  7.8).	  Washed	  beads	  in	  0.25	  ml	  of	  GST-­‐binding	  buffer	  were	  incubated	  with	  1	  μl	  of	  purified	  fUbr1	  (1	  μg)	  in	  the	  absence	  or	  presence	  of	  1	  (or	  10)	  μM	  Ub,	  Ub-­‐ProtA,	  or	  Ub-­‐Met-­‐DHFRha	  at	  4°	  C	  for	  1	  h.	  Beads-­‐associated	  proteins	  were	  eluted	  and	  fractionated	  by	  SDS-­‐4-­‐12%	  NuPAGE,	  followed	  by	  immunoblotting	  with	  anti-­‐flag.	  Blots	  were	  also	  Coomassie-­‐stained,	  to	  verify	  the	  expected	  amounts	  of	  GST	  fusions	  pre-­‐bound	  to	  glutathione-­‐Sepharose	  beads.	  
Production	  and	  purification	  of	  X-­‐DHFRha	  test	  proteins.	  
The	  plasmids	  pCH230,	  pCH231,	  pCH232,	  which	  encoded	  His10-­‐Ub-­‐X-­‐DHFRha	  (X=Met,	  Arg,	  Leu)	  (54,	  55)	  (see	  also	  the	  legend	  to	  Fig.	  4)	  were	  transformed	  into	  KSP22	  (aatΔ)	  E.	  coli.	  Purification	  of	  these	  fusions	  and	  their	  in	  vitro	  deubiquitylation	  (55)	  were	  carried	  as	  described	  previously	  (15).	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Pulse-­‐chases.	  
35S-­‐pulse-­‐chase	  experiments,	  with	  5-­‐min	  pulses	  and	  chases	  of	  20	  and	  60	  min	  (Fig.	  5b,	  d)	  were	  performed	  as	  described	  (11,	  12,	  23),	  using	  S.	  cerevisiae	  JD52,	  JD55	  (ubr1Δ),	  CHY194	  (ufd4Δ)	  or	  CHY195	  (ubr1Δ	  ufd4Δ)	  that	  carried	  plasmids	  expressing	  either	  UbV76-­‐Val-­‐βgal,	  Ub-­‐His-­‐βgal,	  Ub-­‐Tyr-­‐βgal,	  or	  fDHFR-­‐UbK48R-­‐Cup9NSF	  (the	  latter	  from	  the	  plasmid	  p416fUPRCUPNSF;	  see	  the	  legend	  to	  Fig.	  S2).	  
In	  vitro	  ubiquitylation	  assay.	  
Unless	  indicated	  otherwise,	  in	  vitro	  ubiquitylation	  assays	  were	  carried	  out	  as	  described	  (12).	  Purified	  S.	  cerevisiae	  Uba1	  (E1	  enzyme)	  as	  well	  as	  Ub	  and	  its	  mutant	  derivatives	  were	  from	  Boston	  Biochem.	  The	  S35-­‐labelled	  Mgt1	  and	  Cup9	  test	  proteins	  were	  expressed	  as	  described	  (12)	  for	  Mgt1,	  using	  the	  in	  vitro	  transcription/translation	  TNT	  T7	  Quick	  for	  PCR	  DNA	  system,	  derived	  from	  rabbit	  reticulocyte	  extract	  (Promega).	  Thus	  far,	  we	  could	  not	  produce	  soluble	  Mgt1	  (a	  relatively	  hydrophobic	  protein)	  in	  E.	  coli.	  All	  experiments	  with	  Cup9	  utilized	  Cup9NSF,	  a	  previously	  characterized	  missense	  mutant	  that	  exhibited	  reduced	  specific	  binding	  to	  DNA,	  reduced	  toxicity	  in	  vivo,	  but	  no	  significant	  changes	  in	  the	  kinetics	  of	  in	  vivo	  degradation	  (5).	  The	  unlabeled	  Ub-­‐ProtA,	  Ub-­‐GST	  or	  Sic1PY	  test	  proteins,	  purified	  from	  E.	  coli	  (see	  above),	  were	  examined	  in	  ubiquitylation	  assays	  directly,	  whereas	  purified	  X-­‐DHFRha	  proteins	  (X=Met,	  Arg,	  Leu)	  were	  incubated,	  at	  first,	  with	  N-­‐ethylmaleimide	  (NEM;	  5	  mM)	  for	  5	  min	  at	  30°	  C	  to	  inactivate	  traces	  of	  the	  remaining	  Usp2-­‐cc	  DUB,	  followed	  by	  removal	  of	  NEM,	  using	  Zeba	  desalting	  columns	  (Thermo	  Scientific).	  2	  μl	  of	  either	  35S-­‐labeled	  Mgt1,	  35S-­‐labeled	  Cup9,	  unlabeled,	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purified	  X-­‐DHFRha	  (X=Met,	  Arg,	  Leu),	  Ub-­‐ProtA,	  Ub-­‐GST,	  or	  Sic1PY	  were	  incubated	  with	  purified	  fUbr1,	  fUfd4,	  Rad6,	  and/or	  Ubc4	  at	  30°	  C	  for	  15	  or	  30	  min	  in	  20	  μl	  of	  the	  final	  reaction	  sample	  (4	  mM	  ATP,	  0.15	  M	  NaCl,	  5	  mM	  MgCl2,	  1	  mM	  dithiothreitol	  (DTT),	  50	  mM	  HEPES,	  pH	  7.5)	  containing	  100	  nM	  Uba1	  and	  80	  μM	  Ub.	  The	  final	  concentrations	  of	  other	  purified	  proteins	  (if	  present	  in	  the	  assay)	  were	  as	  follows:	  125	  nM	  X-­‐DHFRha;	  125	  nM	  Ub-­‐ProtA;	  125	  nM	  Ub-­‐GST;	  125	  nM	  Sic1PY;	  200	  nM	  fUbr1;	  200	  nM	  fUfd4;	  1	  μM	  Rad6;	  1	  μM	  Ubc4.	  The	  reactions	  were	  terminated	  by	  adding	  8	  μl	  of	  4xSDS-­‐sample	  buffer.	  The	  samples	  were	  heated	  at	  95°C	  for	  5	  min,	  followed	  by	  SDS-­‐4–12%	  NuPAGE	  and	  either	  autoradiography	  or	  immunoblotting	  with	  antibodies	  to	  the	  ha	  epitope	  (1:2000;	  mouse	  monoclonal	  antibody;	  Sigma);	  to	  ProtA	  (polyclonal	  rabbit	  antibody;	  1:10000)	  (Sigma);	  to	  GST	  (polyclonal	  rabbit	  antibody;	  1:10000)	  (ZYMED	  Laboratories);	  and	  to	  the	  T7	  epitope	  (polyclonal	  rabbit	  antibody;	  1:10000)	  (Novagen).	  
Purification	  of	  the	  26S	  proteasome	  and	  degradation	  assay.	  
A	  slight	  modification	  of	  the	  earlier	  procedure	  (56)	  was	  employed.	  S.	  
cerevisiae	  YYS40,	  in	  which	  the	  Rpn11	  subunit	  of	  the	  26	  proteasome	  contained	  a	  triple-­‐flag	  tag,	  were	  grown	  to	  A600	  of	  3–4	  in	  2	  l	  of	  YPD	  medium.	  Cells	  were	  harvested	  by	  centrifugation	  at	  5000g	  for	  5	  min,	  washed	  in	  phosphate-­‐buffered	  saline	  (PBS)	  and	  stored	  at	  −80°	  C.	  Cell	  pellets	  were	  resuspended	  in	  10	  ml	  of	  the	  lysis	  buffer	  (10%	  glycerol,	  0.1	  M	  NaCl,	  10	  mM	  MgCl2,	  1	  mM	  DTT,	  4	  mM	  ATP,	  20	  mM	  creatine	  phosphate,	  creatine	  phosphokinase	  (20	  μg/ml),	  50	  mM	  Tris-­‐HCl,	  pH	  7.5).	  Cells	  were	  disrupted	  using	  a	  FastPrep-­‐24	  instrument	  (MP	  Biomedicals)	  at	  the	  speed	  setting	  of	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4.5,	  at	  20	  s/cycle	  for	  10	  cycles.	  After	  removal	  of	  glass	  beads,	  extract	  was	  cleared	  by	  centrifugation	  at	  11200g	  for	  30	  min,	  followed	  by	  incubation	  with	  0.2	  ml	  of	  anti-­‐flag	  M2	  agarose	  beads	  (Sigma)	  for	  2	  h	  at	  4°C.	  The	  beads	  were	  washed	  twice	  in	  10	  ml	  of	  storage	  buffer	  (10%	  glycerol,	  2	  mM	  ATP,	  5	  mM	  MgCl2,	  1	  mM	  DTT,	  50	  mM	  Tris-­‐HCl,	  pH	  7.5),	  then	  once	  with	  5	  ml	  of	  the	  same	  buffer	  containing	  also	  0.2%	  Triton	  X-­‐100,	  and	  thereafter	  again	  once	  with	  5	  ml	  of	  the	  storage	  buffer.	  The	  proteasomes	  were	  eluted	  with	  the	  triple-­‐flag	  peptide	  (0.1	  mg/ml;	  Sigma)	  in	  storage	  buffer	  and	  dialyzed	  against	  1	  l	  of	  storage	  buffer	  overnight	  at	  4°	  C.	  Polyubiquitylated	  Leu-­‐DHFRha,	  the	  N-­‐end	  rule	  substrate	  for	  degradation	  assay,	  was	  prepared	  by	  incubating	  the	  above	  in	  vitro	  ubiquitylation	  assay	  at	  30°	  C	  for	  18	  h.	  The	  reaction	  mixture	  was	  prepared	  by	  adding	  1	  μl	  of	  the	  purified	  26S	  proteasome	  (~500	  nM;	  its	  final	  concentration	  was	  ~50	  nM)	  to	  8	  μl	  of	  reaction	  buffer	  (2	  mM	  ATP,	  10%	  glycerol,	  0.1	  M	  NaCl,	  1	  mM	  DTT,	  5	  mM	  MgCl2,	  50	  mM	  Tris-­‐HCl,	  pH	  7.5),	  and	  thereafter	  adding	  1	  μl	  of	  polyubiquitylated	  Leu-­‐DHFRha	  (1.25	  μM;	  its	  final	  concentration	  was	  125	  nM).	  The	  reaction	  was	  performed	  at	  30°C	  for	  10	  and	  20	  min,	  followed	  by	  the	  addition	  of	  3	  μl	  of	  the	  4xSDS-­‐sample	  buffer,	  heating	  the	  samples	  at	  95°C	  for	  5	  min,	  and	  carrying	  out	  SDS-­‐4-­‐12%	  NuPAGE,	  following	  by	  immunoblotting	  with	  anti-­‐ha.	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Figure	  2.1.	  Ubiquitylation	  of	  Mgt1	  by	  Ubr1-­‐Ufd4.	  The	  in	  vitro	  ubiquitylation	  assay	  (12)	  is	  described	  in	  Methods.	  Reaction	  mixtures	  were	  incubated	  at	  30°	  C	  for	  15	  min,	  followed	  by	  SDS-­‐PAGE	  and	  autoradiography.	  35S-­‐Mgt1f3	  and	  its	  polyubiquitylated	  derivatives	  are	  indicated	  on	  the	  right.	  Lane	  1,	  Mgt1f3	  in	  the	  complete	  reaction	  but	  without	  added	  Ub	  and	  with	  Ubr1	  as	  the	  sole	  E3.	  Lane	  2,	  same	  as	  lane	  1	  but	  with	  wild-­‐type	  Ub.	  Lane	  3,	  same	  as	  lane	  1	  but	  with	  UbK29R.	  Lane	  4,	  same	  as	  lane	  1	  but	  with	  UbK48R.	  Lane	  5,	  same	  as	  lane	  1	  but	  with	  UbK63R.	  Lane	  6,	  35S-­‐Mgt1f3	  in	  the	  complete	  reaction	  (containing	  both	  Ubr1	  and	  Ufd4)	  but	  without	  added	  Ub.	  Lane	  7,	  same	  as	  lane	  6	  but	  with	  wild-­‐type	  Ub.	  Lane	  8,	  same	  as	  lane	  6	  but	  with	  UbK29R.	  Lane	  9,	  same	  as	  lane	  6	  but	  with	  UbK48R.	  Lane	  10,	  same	  as	  lane	  6	  but	  with	  UbK63R.	  Lane	  11,	  Mgt1f3	  in	  the	  complete	  reaction	  but	  without	  added	  Ub	  and	  with	  Ufd4.	  Lane	  12,	  same	  as	  lane	  11	  but	  with	  wild-­‐type	  Ub.	  Lane	  13,	  same	  as	  lane	  11	  but	  with	  UbK29R.	  Lane	  14,	  samas	  lane	  1	  but	  with	  UbK48R.	  Lane	  15,	  same	  as	  lane	  11	  but	  with	  UbK63R.	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  Figure	  2.2.	  Physical	  interaction	  between	  Ubr1	  and	  Ufd4.	  (a)	  Coimmunoprecipitation	  of	  fUbr1	  and	  haUfd4	  with	  anti-­‐flag	  antibody.	  JD52	  S.	  cerevisiae	  expressed	  N-­‐terminally	  flag-­‐tagged	  Ubr1	  (fUbr1),	  either	  alone	  (lane	  2)	  or	  together	  with	  N-­‐
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terminally	  ha-­‐tagged	  Ufd4	  (haUfd4)	  (lanes	  3	  and	  4).	  Cell	  extracts	  were	  immunoprecipitated	  with	  anti-­‐flag	  (lanes	  2	  and	  4)	  or	  with	  antibody-­‐free	  beads	  (lane	  3).	  The	  upper	  and	  lower	  panels	  show	  the	  results	  of	  immunoblotting	  with	  anti-­‐flag	  (detection	  of	  fUbr1)	  and	  with	  anti-­‐ha	  (detection	  of	  haUfd4),	  respectively.	  Lane	  1,	  1%	  input	  of	  extract	  from	  cells	  expressing	  both	  fUbr1	  and	  haUfd4.	  Lane	  2,	  extract	  from	  cells	  expressing	  only	  fUbr1	  was	  incubated	  with	  anti-­‐flag	  pre-­‐bound	  to	  beads.	  Immunoblotting	  with	  anti-­‐flag	  and	  anti-­‐ha	  (upper	  and	  lower	  panels,	  respectively).	  Lane	  3,	  extract	  from	  cells	  expressing	  both	  fUbr1	  and	  haUfd4,	  but	  with	  beads	  lacking	  antibody.	  Lane	  4,	  same	  as	  lane	  3	  but	  immunoprecipitation	  with	  anti-­‐flag.	  (b)	  Same	  as	  in	  a	  but	  extracts	  were	  immunoprecipitated	  with	  anti-­‐ha	  pre-­‐bound	  to	  beads	  (lanes	  2	  and	  4)	  or	  with	  beads	  lacking	  antibody	  (lane	  3),	  followed	  by	  SDS-­‐PAGE	  of	  immunoprecipitates	  and	  immunoblotting	  with	  anti-­‐flag	  and	  anti-­‐ha.	  (c)	  Direct	  interaction	  of	  fUbr1	  and	  fUfd4.	  Lane	  1,	  10%	  inputs	  of	  fUbr1	  and	  fUfd4	  (purified	  as	  described	  in	  ref.	  12;	  see	  also	  Fig.	  S1a).	  fUbr1	  (125	  ng)	  and	  fUfd4	  (125	  ng)	  were	  mixed	  and	  incubated	  with	  beads	  lacking	  antibody	  (lane	  2)	  or	  with	  previously	  characterized	  (11)	  affinity-­‐purified	  anti-­‐Ubr1	  antibody	  pre-­‐bound	  to	  beads	  (lane	  3),	  for	  1	  hr	  at	  4°	  C	  in	  0.25	  ml	  of	  binding	  buffer,	  followed	  by	  SDS-­‐PAGE	  and	  immunoblotting	  with	  anti-­‐flag.	  (d)	  In	  vivo	  detection	  of	  Ubr1-­‐Ufd4	  interactions	  using	  split-­‐Ub	  assay	  (53).	  S.	  cerevisiae	  coexpressing	  bait	  (pDHB1,	  pDHB1-­‐UBR1,	  or	  pDHB1-­‐UFD4)	  and	  prey	  (pPR3-­‐N*,	  pPR3-­‐N-­‐UFD4,	  or	  pPR3-­‐N-­‐UBR1)	  plasmids	  were	  grown	  to	  A600	  of	  ~1,	  serially	  diluted	  (5-­‐fold),	  and	  plated	  on	  either	  ‘permissive’	  SC(-­‐Leu,	  -­‐Trp)	  (left	  column)	  or	  SC(-­‐Leu,	  -­‐Trp,	  -­‐Ade,	  -­‐His)	  medium	  (right	  column).	  pDHB1	  and	  pPR3-­‐N	  are	  the	  initial	  (vector)	  plasmids.	  pPR3-­‐N*	  contained	  a	  stop	  codon	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immediately	  after	  the	  ORF	  encoding	  the	  mutant	  N-­‐terminal	  half	  of	  Ub	  (NUb)	  in	  pPR3-­‐N.	  (e)	  The	  UBR	  box,	  the	  BRR	  region,	  the	  RING	  domain,	  and	  the	  AI	  (autoinhibitory)	  domain	  of	  the	  S.	  cerevisiae	  Ubr1	  N-­‐recognin	  (11,	  17,	  23).	  Fragments	  of	  Ubr1	  employed	  to	  map	  its	  Ufd4-­‐interacting	  region	  are	  below	  the	  diagram.	  (f)	  Extracts	  from	  JD52	  S.	  cerevisiae	  that	  expressed	  haUfd4	  and	  either	  full-­‐length	  fUbr1	  or	  its	  flag-­‐tagged	  fragments	  were	  incubated	  with	  antibody-­‐lacking	  beads	  (lanes	  2,	  5,	  8,	  11	  and	  14)	  or	  with	  anti-­‐ha	  pre-­‐bound	  to	  beads	  (lanes	  3,	  6,	  9,	  12	  and	  15).	  Bound	  proteins	  were	  eluted	  from	  washed	  beads,	  followed	  by	  SDS-­‐PAGE	  and	  immunoblotting	  with	  anti-­‐flag.	  Input	  lanes,	  samples	  of	  extracts	  that	  corresponded	  to	  1%	  of	  initial	  extracts.	  (g)	  Coimmunoprecipitation	  of	  fUbr1454-­‐795	  and	  haUfd4	  with	  anti-­‐ha.	  Lane	  1,	  1%	  input	  of	  the	  initial	  extract.	  Lane	  2,	  extracts	  from	  cells	  that	  expressed	  the	  fUbr1454-­‐795	  fragment	  and	  full-­‐length	  haUfd4	  were	  incubated	  with	  antibody-­‐free	  beads	  (lanes	  2).	  Bound	  proteins	  were	  eluted	  from	  washed	  beads	  and	  fractionated	  by	  SDS-­‐PAGE,	  followed	  by	  immunoblotting	  with	  anti-­‐flag.	  Lane	  3,	  same	  as	  lane	  2	  but	  immunoprecipitation	  with	  anti-­‐ha	  pre-­‐bound	  to	  beads.	  (h)	  Lanes	  1-­‐3,	  same	  as	  lanes	  1-­‐3	  in	  g,	  but	  immunoprecipitation	  with	  anti-­‐flag	  (instead	  of	  anti-­‐ha),	  followed	  by	  immunoblotting	  with	  anti-­‐ha.	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  Figure	  2.3.	  Enhancement	  of	  ubiquitylation	  and	  degradation	  of	  Arg/N-­‐end	  rule	  substrates	  by	  Ufd4.	  (a)	  X-­‐eK-­‐DHFRha	  (X=Met,	  Arg,	  Leu),	  denoted	  as	  X-­‐DHFRha,	  are	  C-­‐terminally	  ha-­‐tagged	  Arg/N-­‐end	  rule	  reporters	  (54)	  produced	  from	  Ub-­‐X-­‐DHFRha	  using	  in	  vitro	  deubiquitylation	  (55)	  (Fig.	  S1b).	  X-­‐DHFRha	  contained	  the	  mouse	  dihydrofolate	  reductase	  (DHFR)	  moiety	  and	  the	  ~40-­‐residue	  N-­‐terminal	  extension	  called	  eK	  [extension	  (e)	  containing	  lysine	  (K)]	  (18).	  Purified	  X-­‐DHFRha	  (X=Met,	  Arg,	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Leu)	  (1.25	  μM;	  2	  μl)	  were	  incubated	  in	  20	  μl	  of	  a	  ubiquitylation	  assay	  (12)	  for	  15	  min	  at	  30°	  C,	  followed	  by	  SDS-­‐PAGE	  and	  immunoblotting	  with	  anti-­‐ha.	  Lanes	  1,	  7,	  13:	  X-­‐DHFRha	  in	  the	  absence	  of	  indicated	  assay’s	  components.	  Lanes	  2,	  8,	  14:	  same	  as	  lanes	  l,	  7,	  13	  but	  with	  Rad6	  E2.	  Lane	  3,	  9,	  15,	  same	  as	  lanes	  1,	  7,	  13	  but	  with	  Ubr1	  and	  Rad6.	  Lanes	  4,	  10,	  16	  same	  as	  lanes	  1,	  7,	  13	  but	  with	  Ubc4	  E2.	  Lane	  5,	  11,	  17	  same	  as	  lane	  1,	  7,	  13	  but	  with	  Ufd4	  and	  Ubc4.	  Lane	  6,	  12,	  18	  same	  as	  lane	  1	  but	  with	  Ubr1,	  Rad6,	  Ufd4	  and	  Ubc4.	  Asterisk	  on	  the	  right	  denotes	  a	  protein	  that	  crossreacted	  with	  anti-­‐ha	  antibody.	  (b)	  Same	  as	  in	  a	  but	  the	  assay	  was	  carried	  out	  with	  Arg-­‐DHFRha	  and	  indicated	  Ub	  mutants.	  Detection	  of	  immunoblotted	  proteins	  in	  this	  experiment	  was	  performed	  using	  Odyssey	  (Li-­‐Cor,	  Lincoln,	  NE,	  USA).	  Asterisks	  on	  the	  left	  indicate	  two	  bands	  of	  proteins	  (e.g.,	  lanes	  1,	  4)	  that	  crossreacted	  with	  anti-­‐ha,	  and	  were	  also	  present	  in	  samples	  lacking	  E2s	  and	  E3s.	  Lanes	  1,	  4,	  7,	  10,	  13,	  16,	  ubiquitylation	  of	  Arg-­‐DHFRha	  with	  Ufd4/Ubc4	  in	  the	  presence	  of	  either	  UbK29	  (lane	  1),	  UbK48	  (lane	  4),	  a	  50-­‐50	  mixture	  of	  UbK29	  and	  UbK48	  (lane	  7),	  UbK29R	  (lane	  10),	  UbK48R	  (lane	  13),	  or	  a	  50-­‐50	  mixture	  of	  UbK29R	  and	  UbK48R	  (lane	  16).	  Lanes	  2,	  5,	  8,	  11,	  14,	  17,	  same	  as	  lanes	  1,	  4,	  7,	  10,	  13,	  16,	  respectively,	  but	  with	  Ubr1/Rad6	  instead	  of	  Ufd4/Ubc4.	  Lanes	  3,	  6,	  9,	  12,	  15,	  18,	  same	  as	  lanes	  1,	  4,	  7,	  10,	  13,	  16,	  respectively,	  but	  with	  Ubr1/Rad6	  plus	  Ufd4/Ubc4.	  (c)	  Lanes	  1	  and	  2,	  molecular	  mass	  markers	  and	  Coomassie-­‐stained	  proteins	  of	  the	  affinity-­‐purified	  S.	  cerevisiae	  26S	  proteasome,	  respectively.	  (d)	  Lanes	  1–3,	  assay	  with	  26S	  proteasome	  and	  polyubiquitylated	  Leu-­‐DHFRha	  that	  had	  been	  prepared	  using	  Ubr1/Rad6	  alone,	  with	  chase	  times	  of	  10	  and	  20	  min.	  Lanes	  4–6,	  same	  as	  lanes	  1–3,	  but	  with	  polyubiquitylated	  Leu-­‐DHFRha	  that	  had	  been	  prepared	  with	  Ubr1/Rad6	  plus	  and	  Ufd4/Ubc4.	  (e)	  Quantitation	  of	  data	  in	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d,	  using	  ImageJ	  (http://rsb.info.nih.gov/ij/index.html).	  In	  plotting	  the	  levels	  of	  Leu-­‐DHFRha	  for	  each	  data	  set	  (lanes	  1–3	  and	  4–6	  in	  d),	  the	  levels	  at	  time	  zero	  were	  taken	  as	  100%.	  Open	  and	  closed	  circles,	  Leu-­‐DHFRha	  that	  had	  been	  ubiquitylated	  by	  Ubr1/Rad6	  and	  by	  Ubr1/Rad6	  plus	  Ufd4/Ubc4,	  respectively.	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  Figure	  2.4.	  Ufd4	  augments	  the	  Arg/N-­‐end	  rule	  pathway.	  (a)	  β	  gal	  activity	  in	  extracts	  from	  S.	  cerevisiae	  RJD347	  (wild-­‐type;	  white	  bars),	  AVY26	  (ubr1Δ;	  dotted	  bars),	  and	  CHY251	  (ufd4Δ;	  black	  bars)	  that	  expressed	  His-­‐β	  gal	  or	  Tyr-­‐β	  gal.	  (b	  ,c	  )	  Quantitation	  of	  data	  (using	  PhosphorImager)	  in	  a	  pulse-­‐chase	  assay	  (d)	  for	  His-­‐β	  gal	  (b)	  and	  Tyr-­‐β	  gal	  (c).	  Open	  and	  closed	  circles,	  wild-­‐type	  (RJD347)	  and	  ufd4Δ	  (CHY251)	  cells,	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respectively.	  In	  d,	  S.	  cerevisiae	  expressing	  Ub-­‐His-­‐β	  gal	  or	  Ub-­‐Tyr-­‐β	  gal	  were	  labeled	  for	  5	  min	  with	  35S-­‐methionine/cysteine,	  followed	  by	  a	  chase	  for	  20	  and	  60	  min,	  immunoprecipitation	  with	  anti-­‐β	  gal,	  SDS-­‐PAGE	  and	  autoradiography	  (1,	  54).	  Lanes	  1–3,	  His-­‐β	  gal	  in	  wild-­‐type	  cells.	  Lanes	  4–6,	  His-­‐β	  gal	  in	  ufd4Δ	  cells.	  Lanes	  7–9,	  Tyr-­‐β	  gal	  in	  wild-­‐type	  cells.	  Lanes	  10–12,	  Tyr-­‐β	  gal	  in	  ufd4Δ	  cells.	  (e)	  Ubr1/Rad6-­‐mediated	  polyubiquitylation	  of	  Cup9.	  In	  vitro	  ubiquitylation	  assay	  (12)	  was	  performed	  with	  
35S-­‐labeled	  Cup9NSF	  (see	  Methods).	  Lane	  1,	  35S-­‐Cup9	  in	  an	  otherwise	  complete	  assay	  but	  without	  E3s.	  Lanes	  2–8,	  same	  as	  lane	  1	  but	  with	  Ubr1/Rad6,	  in	  the	  presence	  of	  Arg-­‐Ala	  (R-­‐A)/Leu-­‐Ala	  (L-­‐A).	  Lane	  9,	  same	  as	  lane	  1	  but	  a	  separate	  assay.	  Lanes	  10–16,	  same	  as	  lanes	  2–8,	  but	  with	  Ubr1	  plus	  Ufd4.	  (f)	  Maximal	  stimulation	  of	  Cup9	  ubiquitylation	  by	  Ubr1-­‐Ufd4	  requires	  both	  type-­‐1	  and	  type-­‐2	  dipeptides.	  Lane	  1,	  35S-­‐Cup9,	  with	  Ufd4	  and	  wild-­‐type	  Ub,	  but	  in	  the	  absence	  of	  both	  Ubr1	  and	  type-­‐1/2	  dipeptides.	  Lane	  2,	  same	  as	  lane	  1	  but	  with	  Ubr1.	  Lane	  3,	  same	  as	  lane	  2,	  but	  with	  1	  μM	  R-­‐A.	  Lane	  4,	  same	  as	  lane	  2	  but	  in	  the	  presence	  of	  1	  μM	  L-­‐A.	  Lane	  5,	  same	  as	  lane	  2,	  but	  in	  the	  presence	  of	  R-­‐A	  and	  L-­‐A,	  each	  at	  1	  μM.	  Lane	  6,	  same	  as	  lane	  2	  but	  in	  the	  presence	  of	  Ala-­‐Arg/Ala-­‐Leu,	  each	  at	  1	  μM.	  Lanes	  7,	  same	  as	  lane	  6,	  but	  with	  UbK29R,	  instead	  of	  wild-­‐type	  Ub.	  Lane	  8,	  same	  as	  lane	  7,	  but	  in	  the	  presence	  of	  R-­‐A/L-­‐A,	  each	  at	  1	  μM.	  (g)	  Dipeptide-­‐mediated	  induction	  of	  the	  PTR2	  transporter	  in	  the	  absence	  or	  presence	  of	  Ufd4.	  S.	  cerevisiae	  RJD347	  (wild-­‐type;	  closed	  circles)	  and	  CHY251	  (ufd4Δ;	  open	  circles)	  expressed	  E.	  coli	  lacZ	  (β-­‐galactosidase)	  from	  the	  PPTR2	  promoter.	  Cells	  were	  grown	  to	  A600	  of	  ~0.8	  in	  the	  SHM	  medium	  at	  30°	  C	  in	  the	  presence	  of	  indicated	  concentrations	  of	  R-­‐A/L-­‐A,	  followed	  by	  measurements	  in	  triplicate,	  of	  β	  gal	  activity	  in	  cell	  extracts,	  with	  standard	  deviations	  shown.	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  Figure	  2.5.	  Recognition	  and	  synergistic	  polyubiquitylation	  of	  UFD	  substrates	  by	  Ufd4	  and	  Ubr1.	  (a)	  Ubiquitylation	  assay12,	  for	  15	  min	  at	  30°	  C,	  with	  Ub-­‐ProtA,	  a	  UFD	  substrate	  (0.125	  μM)	  (Fig.	  S1c),	  followed	  by	  SDS-­‐PAGE	  and	  immunoblotting	  with	  anti-­‐ProtA	  antibody.	  Lane	  1,	  without	  E3s.	  Lane	  2,	  same	  as	  lane	  1	  but	  with	  Ubr1/Rad6.	  Lane	  3,	  same	  as	  lane	  1	  but	  with	  Ufd4/Ubc4.	  Lane	  4,	  same	  as	  lane	  1	  but	  with	  Ubr1/Rad6	  plus	  Ufd4/Ubc4.	  Lane	  6,	  same	  as	  lane	  1	  but	  with	  Ufd2/Ubc4	  plus	  Ubr1/Rad6.	  Lane	  7,	  same	  as	  lane	  1	  but	  with	  Ufd2/Ubc4	  plus	  Ufd4/Ubc4.	  Lane	  8,	  same	  as	  lane	  1	  but	  with	  Ufd2/Ubc4,	  Ubr1/Rad6	  and	  Ufd4/Ubc4.	  (b)	  Ubiquitylation	  assay	  with	  Ub-­‐GST	  (0.125	  μM).	  Lane	  1,	  Ub-­‐GST	  without	  E3s.	  Lane	  2,	  same	  as	  lane	  1	  but	  with	  Ubr1/Rad6.	  Lane	  3,	  same	  as	  lane	  1	  but	  with	  Ufd4/Ubc4.	  Lane	  4,	  same	  as	  lane	  1	  but	  with	  Ubr1/Rad6	  plus	  Ufd4/Ubc4.	  Lane	  5,	  same	  as	  lane	  1	  but	  with	  Ufd2/Ubc4.	  Lane	  6,	  same	  as	  lane	  1	  but	  with	  Ufd2/Ubc4	  plus	  Ubr1/Rad6.	  Lane	  7,	  same	  as	  lane	  1	  but	  with	  Ufd2/Ubc4	  plus	  Ufd4/Ubc4.	  Lane	  8,	  same	  as	  lane	  1	  but	  with	  Ufd2/Ubc4,	  Ubr1/Rad6	  and	  Ufd4/Ubc4.	  (c)	  Interaction	  of	  Ubr1	  with	  immobilized	  UFD	  substrates	  could	  be	  competed	  out	  by	  UFD	  substrates	  but	  not	  by	  free	  Ub.	  Equal	  amounts	  of	  purified	  fUbr1	  (1	  μg)	  were	  incubated	  (in	  either	  the	  presence	  or	  absence	  of	  free	  Ub,	  Ub-­‐DHFRha	  (Ub-­‐Met-­‐DHFRha)	  or	  Ub-­‐ProtA,	  each	  of	  them	  at	  1	  or	  10	  μM))	  with	  GST	  alone	  or	  Ub-­‐GST	  (~5	  μg)	  that	  had	  been	  linked	  to	  glutathione-­‐Sepharose	  beads.	  Bound	  proteins	  were	  eluted	  from	  the	  beads,	  followed	  by	  SDS-­‐PAGE	  and	  immunoblotting	  with	  anti-­‐flag	  (upper	  panel),	  with	  subsequent	  Coomassie	  staining	  of	  the	  blotted	  PVDF	  membrane	  (lower	  panel).	  Lane	  1,	  GST	  alone.	  Lane	  2,	  Ub-­‐GST.	  Lane	  3,	  same	  as	  lane	  2	  but	  in	  the	  presence	  of	  1	  μM	  free	  Ub.	  Lane	  4,	  same	  as	  lane	  2	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but	  with	  10	  μM	  free	  Ub.	  Lane	  5,	  same	  as	  lane	  2	  but	  in	  with	  1	  μM	  Ub-­‐DHFRha.	  Lane	  6,	  same	  as	  lane	  2	  but	  with	  10	  μM	  Ub-­‐DHFRha.	  Lane	  7,	  same	  as	  lane	  2	  but	  with	  1	  μM	  Ub-­‐ProtA.	  Lane	  8,	  same	  as	  lane	  2	  but	  with	  10	  μM	  Ub-­‐ProtA.	  (d)	  In	  vivo	  levels	  of	  endogenous	  Ubr1.	  Lanes	  1–6,	  a	  dilution	  series	  with	  the	  indicated	  amounts	  of	  purified	  fUbr1	  was	  fractionated	  by	  SDS-­‐PAGE,	  followed	  by	  immunoblotting	  with	  affinity-­‐purified	  anti-­‐Ubr1	  antibody	  (11).	  Lane	  7,	  extract	  (50	  μg)	  from	  wild-­‐type	  S.	  
cerevisiae	  (JD52)	  that	  grew	  exponentially	  (A600	  of	  ~1)	  in	  YPD	  medium.	  Lane	  8,	  same	  as	  lane	  7	  but	  extract	  from	  ubr1Δ	  cells	  (JD55).	  These	  data	  and	  straightforward	  calculations	  indicated	  that	  ‘wild-­‐type’,	  haploid,	  exponentially	  growing	  S.	  cerevisiae	  contained	  500	  to	  1000	  Ubr1	  molecules	  per	  cell.	  (e)Ubr1	  and	  Ufd4	  did	  not	  affect	  the	  Rsp5-­‐mediated	  polyubiquitylation	  of	  T7	  epitope-­‐tagged	  Sic1PY.	  The	  PY	  motif	  is	  the	  sequence	  Pro-­‐Pro-­‐X-­‐Tyr,	  which	  binds	  to	  the	  WW	  domain	  of	  Rsp5	  (see	  Methods).	  Purified	  Sic1PY	  (Fig.	  S1c)	  was	  incubated	  in	  the	  above	  ubiquitylation	  assay,	  followed	  by	  SDS-­‐PAGE	  and	  immunoblotting	  with	  anti-­‐T7	  antibody.	  Lane	  1,	  Sic1PY	  without	  E3s.	  Lane	  2,	  same	  as	  lane	  1	  but	  with	  Ubr1/Rad6.	  Lane	  3,	  same	  as	  lane	  1	  but	  with	  Ufd4/Ubc4.	  Lane	  4,	  same	  as	  lane	  1	  but	  with	  Ubr1/rad6	  plus	  Ufd4/Ubc4.	  Lane	  5,	  same	  as	  lane	  1	  but	  with	  Rsp5/Ubc4.	  Lane	  6,	  same	  as	  lane	  1	  but	  with	  Rsp5/Ubc4	  and	  Ubr1/Rad6.	  Lane	  7,	  same	  as	  lane	  1	  but	  with	  Rsp5/Ubc4	  plus	  Ufd4/Ubc4.	  Lane	  8,	  same	  as	  lane	  1	  but	  with	  Rsp5/Ubc4,	  Ubr1/Rad6	  and	  Ufd4/Ubc4.	  (f,	  g)	  Equal	  amounts	  of	  cells	  from	  wild-­‐type	  (JD52),	  ubr1Δ	  (JD55),	  ufd4Δ	  (CHY194)	  or	  ubr1Δufd4	  
Δ	  (CHY195)	  strains	  were	  5-­‐fold	  serially	  diluted,	  plated	  on	  YPD	  plates	  containing	  6%	  ethanol	  (6%)	  (f)	  or	  canavanine	  at	  0.4	  mg/ml	  (g),	  and	  incubated	  at	  30°	  C	  for	  3	  days	  and	  1	  day,	  respectively.	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CHAPTER	  3:	  
CHARACTERIZATION	  OF	  THE	  UBR1-­‐UFD4	  E3-­‐E3	  COMPLEX	  
(Unpublished	  data	  in	  follow-­‐up	  to	  Chapter	  2)	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Abstract	  
This	  chapter	  describes	  unpublished	  follow-­‐up	  experiments	  for	  our	  paper	  entitled	  “The	  N-­‐End	  Rule	  Pathway	  is	  Mediated	  by	  a	  Complex	  of	  the	  RING-­‐type	  Ubr1	  
and	  HECT-­‐type	  Ufd4	  Ubiquitin	  Ligases”	  (1).	  These	  previously	  published	  results	  (see	  Chapter	  2)	  demonstrate	  that	  the	  RING-­‐type	  Ubr1	  E3	  and	  the	  HECT-­‐type	  Ufd4	  E3	  interact,	  both	  physically	  and	  functionally.	  The	  experiments	  in	  this	  chapter	  address	  the	  interaction	  of	  the	  Ubr1-­‐Ufd4	  complex	  with	  Mgt1	  (a	  DNA	  repair	  protein)	  and	  the	  formation	  of	  the	  E3-­‐E3	  complex	  itself.	  We	  found	  that	  the	  presence	  of	  MNNG,	  an	  alkylating	  agent	  that	  causes	  DNA	  damage,	  in	  the	  yeast	  growth	  media	  contributes	  to	  the	  formation	  of	  a	  complex	  of	  Ubr1-­‐Ufd4	  with	  Mgt1	  and	  also,	  remarkably,	  to	  the	  formation	  of	  the	  Ubr1-­‐Ufd4	  complex	  itself.	  	  Conversely,	  type-­‐1	  and	  type-­‐2	  dipeptides	  apparently	  interfere	  with	  the	  complex	  formation.	  
	  
Introduction	  and	  Results	  
In	  S.	  cerevisiae,	  the	  Arg/N-­‐end	  rule	  pathway	  is	  mediated	  by	  a	  physical	  complex	  of	  the	  RING-­‐type	  Ubr1	  E3	  (N-­‐recognin)	  and	  the	  HECT-­‐type	  Ufd4	  E3,	  in	  association	  with	  their	  cognate	  E2s	  Rad6	  and	  Ubc4/Ubc5,	  respectively	  (1)	  (Chapter	  2).	  The	  physical	  interaction	  between	  Ufd4	  and	  Ubr1	  was	  previously	  demonstrated	  both	  in	  vitro	  and	  in	  vivo	  (Fig.	  2.2).	  We	  further	  characterized	  this	  interaction	  using	  gel	  filtration	  of	  purified	  N-­‐terminally	  flag-­‐tagged	  Ufd4	  (fUfd4)	  and	  Ubr1	  (fUbr1).	  We	  showed	  that	  purified	  fUbr1	  and	  fUfd4	  elute	  differently	  when	  the	  proteins	  were	  preincubated	  together	  (Fig.	  3.1	  lower	  panel)	  rather	  than	  separately	  run	  on	  the	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column	  (Fig.	  3.1	  upper	  panel).	  	  When	  Ubr1	  and	  Ufd4	  are	  incubated	  together	  before	  running	  on	  the	  column,	  the	  two	  proteins	  elute	  in	  the	  same	  fractions	  (fractions	  20-­‐22).	  According	  to	  molecular	  weight	  standards,	  the	  size	  of	  the	  Ubr1-­‐Ufd4	  complex	  is	  400-­‐500	  kDa,	  which	  would	  indicate	  a	  1:1	  stoichiometry	  of	  Ubr1	  to	  Ufd4.	  Although	  Ubr1	  is	  larger	  than	  Ufd4,	  225	  kDa	  versus	  168	  kDa,	  Ufd4	  alone	  eluted	  earlier	  (fractions	  17-­‐18)	  than	  Ubr1	  (fractions	  22-­‐23),	  suggesting	  that	  Ufd4	  forms	  a	  homo-­‐oligomer	  complex	  in	  the	  absence	  of	  Ubr1.	  	  
In	  contrast	  to	  Ubr1,	  Ufd4	  is	  not	  an	  N-­‐recognin, that	  is,	  it	  does	  not,	  by	  itself,	  recognize	  N-­‐degrons.	  However,	  through	  its	  physical	  interaction	  with	  the	  Ubr1	  E3,	  the	  Ufd4	  E3	  functions	  as	  a	  novel	  component	  of	  the	  Arg/N-­‐end	  rule	  pathway	  that	  increases	  the	  overall	  efficacy	  of	  degradation	  of	  Arg/N-­‐end	  rule	  substrates,	  at	  least	  in	  part	  by	  augmenting	  the	  processivity	  of	  their	  polyubiquitylation	  by	  the	  Ubr1/Rad6-­‐Ufd4/Ubc4	  double	  E3-­‐E2	  complex.	  Interestingly,	  the	  function	  of	  Ufd4	  in	  the	  Arg/N-­‐end	  rule	  pathway	  is	  not	  confined	  to	  processivity	  of	  polyubiquitylation,	  as	  Ufd4	  was	  also	  shown	  to	  recognize	  the	  internal	  degron	  of	  the	  Mgt1	  DNA	  repair	  protein	  (a	  substrate	  of	  the	  Arg/N-­‐end	  rule	  pathway	  targeted	  through	  an	  internal	  degron)	  even	  in	  the	  absence	  of	  Ubr1,	  i.e.,	  ubr1Δ	  cells,	  that	  is,	  in	  the	  absence	  of	  Ubr1.	  Thus,	  the	  sets	  of	  internal	  degrons	  recognized	  by	  Ubr1	  and	  Ufd4	  are	  at	  least	  partially	  overlapping.	  In	  a	  coimmunoprecipitation	  experiment,	  we	  found	  that	  Ubr1	  and	  Ufd4	  compete	  for	  binding	  to	  Mgt1.	  Specifically,	  we	  overexpressed	  fUfd4	  alone	  from	  the	  PCUP1	  promoter,	  untagged	  Ubr1	  alone	  from	  the	  PGAL1	  promoter	  or	  fUfd4	  and	  Ubr1	  together.	  We	  used	  purified	  N-­‐terminally	  GST-­‐tagged	  Mgt1	  to	  pull	  down	  proteins	  that	  interacted	  with	  this	  fusion	  from	  a	  protein	  extract.	  We	  found	  that	  when	  both	  Ufd4	  and	  Ubr1	  were	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overexpressed	  together,	  the	  amount	  of	  the	  target	  protein	  (i.e.	  Ubr1	  or	  Ufd4)	  pulled	  down	  was	  less	  than	  when	  either	  was	  expressed	  alone	  (Fig.	  3.2	  compare	  lanes	  3	  and	  9	  for	  Ubr1;	  lanes	  3	  and	  6	  for	  Ufd4).	  A	  parsimonious	  interpretation	  of	  this	  result	  is	  that	  Ubr1	  and	  Ufd4	  each	  contain	  a	  substrate	  binding	  site	  specific	  for	  Mgt1.	  It	  is	  also	  possible	  but	  less	  likely	  (this	  ambiguity	  can	  be	  experimentally	  resolved)	  that	  the	  interaction	  between	  Ubr1	  and	  Ufd4	  weakens	  or	  abrogates	  their	  affinity	  for	  Mgt1,	  at	  least	  in	  vitro.	  	  
Earlier	  studies	  introduced	  the	  operationally	  defined	  concept	  of	  an	  E4	  as	  an	  E3-­‐like	  enzyme	  that	  cooperates	  with	  substrate-­‐specific	  ubiquitylation	  machinery	  to	  increase	  the	  efficacy	  (including	  processivity)	  of	  polyubiquitylation.	  Ufd2,	  an	  E4-­‐type	  enzyme	  of	  the	  UFD	  pathway,	  increased	  the	  processivity	  of	  ubiquitylation	  of	  the	  Ufd4	  E3	  (1).	  In	  contrast	  to	  Ufd4,	  Ufd2	  had	  only	  a	  weak	  effect	  on	  ubiquitylation	  by	  Ubr1	  (Fig.	  2.4).	  Owing	  to	  these	  results,	  we	  also	  tested	  the	  in	  vivo	  stability	  of	  Mgt1	  in	  the	  absence	  of	  Ufd2.	  MNNG,	  a	  DNA	  alkylating	  agent,	  was	  previously	  shown	  to	  accelerate	  the	  degradation	  of	  Mgt1	  (4).	  Using	  a	  cycloheximide	  chase	  (CHX)	  experiment,	  we	  found	  that	  both	  in	  the	  presence	  and	  absence	  of	  the	  MNNG,	  Mgt1	  became	  more	  unstable	  in	  ufd2Δ	  cells	  (lacking	  Ufd2)	  (Fig.	  3.3).	  Similar	  results	  were	  observed	  with	  ubr2Δ	  mutants,	  cells	  lacking	  Ubr2,	  an	  E3	  and	  sequelog	  of	  Ubr1	  that	  does	  not	  function	  as	  an	  N-­‐recognin	  (Fig.	  A1.2D).	  Ramifications	  of	  these	  results	  remain	  to	  be	  understood.	  
Since	  the	  DNA	  damaging	  agent	  MNNG	  accelerates	  the	  degradation	  of	  Mgt1,	  we	  decided	  to	  test	  how	  the	  presence	  of	  MNNG	  in	  the	  growth	  media	  affects	  the	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interaction	  of	  the	  Ubr1-­‐Ufd4	  complex	  with	  Mgt1	  and	  the	  interaction	  between	  Ufd4	  and	  Ubr1.	  The	  presence	  of	  MNNG	  in	  the	  media	  had	  no	  effect	  on	  the	  binding	  of	  Ubr1	  and	  Ufd4	  to	  Mgt1	  when	  they	  were	  expressed	  independently	  (Fig.	  3.4A	  compare	  lanes	  3	  and	  6).	  However,	  if	  Ubr1	  and	  Ufd4	  were	  co-­‐overexpressed,	  the	  presence	  of	  MNNG	  in	  the	  growth	  media	  decreased	  the	  binding	  of	  either	  Ubr1	  or	  Ufd4	  to	  Mgt1	  (Fig.	  3.4B	  compare	  lanes	  3	  and	  6).	  We	  also	  found	  that	  when	  cells	  overexpressing	  both	  Ubr1	  and	  Ufd4	  were	  grown	  in	  the	  presence	  of	  MNNG,	  the	  in	  vitro	  interaction	  observed	  between	  Ubr1	  and	  Ufd4	  became	  stronger	  (Fig.	  3.5A	  and	  B	  compare	  lanes	  3	  and	  6	  in	  the	  top	  panel).	  It	  is	  possible	  (these	  issues	  remain	  to	  be	  addressed	  experimentally)	  that	  the	  formation	  of	  the	  Ubr1-­‐Ufd4	  complex	  inhibits	  the	  binding	  of	  its	  components	  to	  Mgt1.	  It	  is	  also	  possible	  that	  in	  vivo,	  MNNG	  might	  be	  a	  signal	  for	  Ubr1	  to	  initiate	  the	  binding	  and	  ubiquitylation	  of	  Mgt1,	  followed	  by	  the	  binding	  of	  Ufd4	  that	  increases	  the	  processivity	  of	  polyubiquitylation.	  This	  circuit,	  interesting	  both	  functionally	  and	  mechanistically,	  remains	  to	  be	  deciphered	  in	  detail.	  
The	  binding	  of	  short	  peptides	  with	  destabilizing	  N-­‐terminal	  residues	  to	  the	  type-­‐1/2	  sites	  of	  Ubr1	  allosterically	  activates	  the	  third	  substrate-­‐binding	  site	  of	  Ubr1	  that	  recognizes	  an	  internal	  degron	  of	  Cup9,	  a	  transcriptional	  repressor	  (5).	  The	  in	  vitro	  binding	  of	  fUbr1	  to	  GST-­‐Cup9	  required	  the	  presence	  of	  cognate	  dipeptides	  such	  as	  Arg-­‐Ala	  (type-­‐1	  dipeptide)	  and	  Leu-­‐Ala	  (type-­‐2	  dipeptide)	  (Fig.	  A2.S4B,	  lanes	  11	  and	  12).	  Interestingly,	  however,	  the	  interaction	  between	  fUbr1	  and	  GST-­‐Mgt1	  was	  inhibited	  by	  the	  type	  1/2	  dipeptides	  (Fig.	  A2.S4B,	  lanes	  3-­‐8).	  On	  the	  other	  hand,	  the	  binding	  of	  haUfd4	  to	  GST-­‐Mgt1	  occurred	  irrespective	  of	  the	  presence	  or	  absence	  of	  type-­‐1/2	  or	  other	  tested	  dipeptides	  (Fig.	  A2.S4C).	  Given	  these	  results,	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we	  decided	  to	  examine	  the	  effect	  of	  type-­‐1/2	  dipeptides	  (Arg/Ala	  and	  Leu/Ala)	  on	  the	  interaction	  between	  Ubr1	  and	  Ufd4	  as	  assayed	  by	  gel	  filtration.	  In	  the	  control	  experiment,	  with	  dipeptides	  Ala-­‐Leu	  and	  Ala-­‐Arg,	  the	  elution	  of	  both	  Ubr1	  and	  Ufd4	  was	  unchanged	  from	  the	  elution	  pattern	  observed	  in	  the	  absence	  of	  dipeptides	  (compare	  Fig.	  3.1	  and	  3.5	  top	  panel).	  However,	  when	  Ubr1	  and	  Ufd4	  were	  separately	  incubated	  with	  type-­‐1/2	  dipeptides	  (Arg-­‐Ala	  and	  Leu-­‐Ala)	  and	  ran	  independently	  on	  the	  gel	  filtration	  column,	  Ubr1	  and	  Ufd4	  eluted	  differently.	  Specifically,	  an	  increased	  signal	  for	  Ubr1	  was	  observed	  in	  the	  same	  fractions	  as	  with	  non-­‐type-­‐1/2	  dipeptides,	  whereas	  Ufd4	  eluted	  later	  when	  there	  were	  no	  dipeptides	  present	  or	  non-­‐type-­‐1/2	  dipeptides.	  We	  also	  examined	  gel-­‐filtration	  properties	  of	  the	  Ubr1-­‐Ufd4	  complex	  in	  the	  presence	  of	  type-­‐1/2	  dipeptides.	  Remarkably,	  the	  Ubr1-­‐Ufd4	  complex	  apparently	  dissociates	  in	  the	  presence	  of	  Arg-­‐Ala	  and	  Leu-­‐Ala,	  the	  complex	  of	  Ubr1	  and	  Ufd4	  dissociates,	  with	  Ubr1	  eluting	  later	  and	  Ufd4	  eluting	  earlier	  than	  in	  the	  presence	  of	  the	  control	  dipeptides	  Ala-­‐Arg	  and	  Ala-­‐Leu.	  As	  mentioned	  above,	  these	  results	  are	  fascinating	  in	  more	  ways	  than	  one	  but	  remain	  to	  be	  made	  more	  detailed	  and	  interpretable	  more	  unambiguously	  through	  additional	  experimentation.	  	  
Discussion	  
	   In	  this	  chapter,	  the	  previously	  discovered	  Ubr1-­‐Ufd4	  complex	  was	  explored	  further.	  Our	  previous	  studies	  showed	  that	  Ufd4	  and	  Ubr1	  interact,	  both	  physically	  and	  functionally.	  We	  employed	  both	  in	  vivo	  and	  in	  vitro	  methods	  to	  begin	  examining	  conditions	  for	  the	  formation	  of	  this	  complex.	  Gel	  filtration	  was	  used	  to	  examine	  the	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complex	  using	  purified	  Ufd4	  and	  Ubr1.	  Interestingly,	  when	  Ufd4	  was	  present	  by	  itself,	  its	  elution	  patterns	  suggested	  that	  Ufd4	  formed	  a	  homo-­‐oligomer	  complex.	  When	  Ufd4	  and	  Ubr1	  were	  preincubated	  together,	  gel	  filtration	  patterns	  indicated	  that	  the	  two	  proteins	  formed	  what	  appeared	  to	  be	  a	  1:1	  complex	  (Fig.	  3.1).	  Our	  previous	  study	  found	  that	  Ufd4	  binds	  to	  a	  short	  segment	  of	  Ubr1	  (Fig.	  2.2).	  However,	  the	  Ubr1-­‐binding	  site	  of	  Ufd4	  remains	  unknown,	  and	  the	  interaction	  itself	  (let	  alone	  the	  crystal	  structures	  of	  these	  full-­‐length	  E3s)	  remains	  to	  be	  studied	  in	  greater	  detail.	  (The	  crystal	  structure	  of	  the	  80-­‐residue	  UBR	  box	  of	  the	  225	  kDa	  Ubr1	  was	  solved	  in	  2010	  (6,	  7)).	  It	  is	  possible	  that	  difficulties	  in	  crystallizing	  Ubr1,	  experienced	  over	  many	  years	  by	  more	  than	  one	  group,	  might	  stem,	  in	  part,	  from	  a	  higher	  flexibility	  of	  Ubr1	  in	  the	  absence	  of	  Ufd4,	  implying	  that	  the	  Ubr1-­‐Ufd4	  complex	  might	  be	  prove	  easier	  to	  crystallize.	  	  
	   Ufd4	  and	  Ubr1	  apparently	  compete	  for	  their	  binding	  to	  Mgt1	  (Fig.	  3.2),	  suggesting	  that	  in	  the	  Mgt1-­‐bound	  Ubr1-­‐Ufd4	  complex,	  only	  one	  of	  these	  E3s	  occupies	  the	  degron	  of	  Mgt1	  at	  a	  time.	  We	  also	  found	  that	  the	  presence	  of	  the	  MNNG	  alkylating	  agent	  in	  the	  growth	  media	  facilitates	  the	  formation	  of	  the	  Ufd4-­‐Ubr1	  complex	  (Fig.	  3.5).	  Thus,	  there	  might	  be	  an	  intracellular	  signal,	  elicited	  by	  MNNG,	  that	  induces	  this	  complex	  to	  form,	  either	  through	  a	  structural	  change	  or	  a	  posttranslational	  modification.	  (Another,	  less	  likely	  but	  not	  precluded	  possibility	  is	  that	  the	  cell-­‐penetrating	  MNNG	  might	  alkylate	  either	  Ubr1	  or	  Ufd4,	  or	  both	  of	  them,	  thereby	  altering	  their	  interactions.)	  Previous	  work	  has	  shown	  that	  Ubr1	  is	  allosterically	  activated	  to	  bind	  the	  internal	  degron	  of	  Cup9	  by	  the	  presence	  of	  type-­‐1/2	  dipeptides.	  In	  the	  previous	  study,	  we	  found	  that	  Ufd4,	  in	  the	  presence	  of	  type-­‐
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1/2	  dipeptides,	  enhances	  the	  processivity	  of	  ubiquitylation	  of	  Cup9	  (Fig.	  2.4).	  Interestingly,	  we	  found,	  in	  this	  follow-­‐up	  study,	  that	  the	  presence	  of	  type-­‐1/2	  dipeptides	  inhibits	  the	  formation	  of	  the	  Ubr1-­‐Ufd4	  complex	  (Fig.	  3.6).	  Thus,	  the	  binding	  of	  type-­‐1/2	  dipeptides	  may	  cause	  a	  structural	  change	  in	  Ubr1	  that	  prevents	  Ufd4	  from	  binding.	  In	  sum,	  the	  results	  in	  Figs.	  3.2,	  5,	  and	  6,	  while	  technically	  clear,	  are	  conceptually	  incomplete	  in	  that	  further	  studies	  will	  be	  required	  to	  decipher	  the	  Mgt1-­‐Ubr1/Rad6-­‐Ufd4/Ubc4/5	  circuit	  comprehensively,	  both	  in	  vitro	  and	  in	  vivo.	  
	   When	  cells	  are	  exposed	  to	  the	  DNA-­‐alkylating	  agent	  MNNG,	  Mgt1	  becomes	  particularly	  unstable.	  We	  found	  that	  also	  found	  that	  Mgt1	  is	  made	  more	  unstable	  (in	  the	  absence	  of	  MNNG)	  by	  the	  absence	  of	  Ufd2,	  a	  previously	  identified	  E4-­‐type	  enhancer	  of	  poly-­‐ubiquitylation	  (Fig.	  3.3).	  This	  destabilizing	  effect	  on	  Mgt1	  was	  also	  observed	  in	  the	  absence	  of	  Ubr2,	  a	  sequelog	  of	  Ubr1	  that	  does	  not	  function	  as	  an	  N-­‐recognin	  (Fig.	  2.2).	  Possible	  explanations	  of	  this	  effect	  (which	  suggests	  the	  involvement	  of	  Ufd2	  and	  Ubr2	  in	  processes	  under	  discussion)	  include	  upregulation	  of	  Ubr1	  or	  the	  proteasome.	  Again,	  given	  the	  complexity	  of	  new	  phenomena	  revealed	  by	  experiments	  in	  this	  chapter,	  the	  operation	  of	  the	  recently	  discovered	  Mgt1-­‐Ubr1-­‐Ufd4	  circuit	  remains	  to	  be	  investigated	  more	  comprehensively.	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  FIGURES	  	  A.	  fUbr1	  and	  fUfd4	  independently	  fractionated	  
	  
B.	  fUbr1	  and	  fUfd4	  preincubated	  together	  
	  
	  Figure	  3.1.	  Gel-­‐filtration	  of	  purified	  flag-­‐Ubr1	  (fUbr1)	  and	  flag-­‐Ufd4	  (fUfd4).	  	  A.	  fUbr1	  and	  fUfd4	  were	  run	  independently	  on	  the	  gel	  filtration	  column,	  using	  an	  equal	  molar	  amount	  for	  each	  protein.	  The	  bulk	  of	  fUbr1	  eluted	  in	  fraction	  22,	  which	  corresponds	  to	  about	  300	  kDa,	  according	  to	  molecular	  weight	  standards	  run	  on	  the	  same	  column.	  fUfd4	  eluted	  earlier,	  at	  fractions	  17	  and	  18,	  which	  is	  about	  600	  kDa.	  Since	  Ufd4	  is	  smaller	  than	  Ubr1,	  this	  shift	  in	  elution	  (i.e.	  fUfd4	  eluting	  earlier	  than	  
fUbr1)	  indicated	  the	  formation	  of	  a	  Ufd4	  homo-­‐oligomer	  complex.	  	  B.	  fUbr1	  and	  fUfd4	  were	  preincubated	  together	  and	  fractionated	  over	  the	  column	  at	  the	  same	  time.	  fUfd4	  and	  fUbr1	  eluted	  in	  the	  same	  fractions,	  20	  through	  22,	  as	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indicated	  by	  the	  box.	  This	  elution	  range	  would	  suggest	  a	  complex	  size	  between	  400	  and	  500	  kDa,	  which	  would	  be	  equivalent	  to	  a	  1:1	  complex	  of	  Ubr1	  to	  Ufd4.	  The	  elution	  patterns	  of	  the	  molecular	  weight	  standards	  are	  indicated	  beneath	  the	  panels.	  The	  two	  stars	  on	  the	  right	  of	  each	  panel	  denote	  molecular	  mass	  markers	  of	  250	  kDa	  and	  150	  kDa.	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Figure	  3.2.	  Ubr1	  and	  Ufd4	  compete	  for	  binding	  to	  Mgt1.	  Ubr1	  is	  overexpressed	  from	  the	  integrated	  PGAL1	  promoter	  at	  the	  UBR1	  locus.	  fUfd4	  is	  overexpressed	  on	  a	  plasmid	  from	  the	  PCUP1	  promoter.	  Cells	  either	  overexpressing	  Ubr1	  alone,	  fUfd4	  alone	  or	  both	  Ubr1	  and	  fUfd4	  were	  grown	  to	  an	  A600	  of	  ~1.0.	  5	  μg	  of	  purified	  GST-­‐Mgt1	  was	  incubated	  with	  extracts	  from	  cells	  expressing	  Ubr1	  and/or	  Ufd4.	  Mgt1	  was	  pulled	  down	  with	  glutathione	  agarose	  and	  the	  interacting	  proteins	  were	  detected	  by	  immunoblotting	  with	  either	  anti-­‐Ubr1	  (top	  panel)	  or	  anti-­‐flag	  (bottom	  panel)	  antibodies.	  As	  a	  control,	  protein	  extracts	  were	  incubated	  with	  purified	  GST	  (2.5	  μg).	  	  The	  co-­‐expression	  of	  Ubr1	  and	  Ufd4	  decreased	  each	  of	  their	  binding	  to	  Mgt1	  (compare	  lanes	  3	  and	  9	  for	  Ubr1	  and	  lanes	  3	  and	  6	  for	  Ufd4).	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  Figure	  3.3.	  Deletion	  of	  Ufd2	  destabilizes	  Mgt1.	  fMgt1	  was	  expressed	  from	  the	  PCUP1	  promoter	  in	  wildtype	  (wt),	  in	  cells	  lacking	  Ufd2	  (Δufd2),	  or	  in	  cells	  lacking	  Ufd4	  (Δufd4).	  Cells	  were	  grown	  either	  in	  the	  presence	  or	  absence	  of	  MNNG.	  Cycloheximide	  (CHX)	  was	  added	  to	  the	  cells	  and	  chased	  for	  the	  indicated	  times.	  Protein	  extracts	  were	  fractionated	  by	  SDS-­‐PAGE	  and	  then	  immunoblotted	  with	  either	  anti-­‐flag	  or	  anti-­‐tubulin	  antibodies.	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  A.	  Ubr1	  and	  fUfd4	  overexpressed	  independently	  	  
	  	  Figure	  3.4A.	  Expression	  of	  Ubr1	  or	  Ufd4	  independently	  in	  the	  presence	  or	  absence	  of	  MNNG	  does	  not	  affect	  binding	  to	  Mgt1.	  Ubr1	  was	  expressed	  from	  the	  PGAL1	  promoter	  in	  the	  absence	  of	  overexpressed	  Ufd4.	  fUfd4	  was	  overexpressed	  from	  the	  PCUP1	  promoter	  in	  the	  absence	  of	  Ubr1	  (Δubr1).	  Cells	  were	  grown	  either	  in	  the	  presence	  or	  absence	  of	  MNNG.	  Proteins	  extracs	  were	  made	  and	  incubated	  with	  purified	  GST-­‐Mgt1	  or	  GST	  alone.	  Mgt1	  was	  pulled	  down	  with	  glutathione	  sepharose	  and	  the	  coprecipitated	  proteins	  were	  fractionated	  by	  SDS-­‐PAGE,	  followed	  by	  immunoblotting	  with	  either	  anti-­‐Ubr1	  (top	  panel)	  or	  anti-­‐flag	  antibodies	  (bottom	  panel).	  The	  relative	  amounts	  of	  Ubr1	  or	  Ufd4	  pulled	  down	  with	  Mgt1	  did	  not	  change	  with	  the	  addition	  of	  MNNG.	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B.	  Ubr1	  and	  fUfd4	  overexpressed	  together	  
	   	  	  Figure	  3.4B.	  Coexpression	  of	  Ubr1	  and	  Ufd4	  in	  the	  presence	  of	  MNNG	  decreases	  their	  binding	  to	  Mgt1.	  Ubr1	  was	  overexpressed	  from	  the	  PGAL1	  promoter	  and	  fUfd4	  was	  overexpressed	  in	  the	  same	  cells	  from	  the	  PCUP1	  promoter.	  Cells	  coexpressing	  both	  proteins	  were	  grown	  either	  in	  the	  presence	  or	  absence	  of	  MNNG.	  Protein	  extracts	  were	  incubated	  with	  either	  purified	  GST-­‐Mgt1	  or	  GST	  alone.	  Coprecipitated	  proteins	  were	  eluted	  and	  fractionated	  by	  SDS-­‐PAGE,	  followed	  by	  immunoblotting	  with	  either	  anti-­‐Ubr1	  (top	  panel)	  or	  anti-­‐Flag	  (bottom	  panel)	  antibodies.	  The	  amount	  of	  Ubr1	  and	  Ufd4	  pulled	  down	  with	  Mgt1	  decreased	  when	  the	  cells	  were	  grown	  in	  the	  presence	  of	  MNNG	  (compare	  lanes	  3	  and	  6).	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A.	  IP	  with	  anti-­‐flag	  
	   	  	  B.	  IP	  with	  anti-­‐Ubr1	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either	  in	  the	  presence	  or	  absence	  of	  MNNG	  were	  grown	  to	  an	  A600	  of	  ~1.0.	  Protein	  extracts	  were	  either	  immunoprecipitated	  with	  anti-­‐flag	  (A)	  or	  anti-­‐Ubr1	  (B)	  antibodies.	  The	  antibodies	  were	  either	  bound	  to	  IgG	  or	  Ig	  magnetic	  beads.	  The	  coimmunoprecipitated	  proteins	  were	  eluted	  and	  fractionated	  by	  SDS-­‐PAGE,	  followed	  by	  immunoblotting	  	  with	  either	  anti-­‐Ubr1	  or	  anti-­‐flag	  antibodies.	  The	  amounts	  of	  coimmunoprecipitated	  proteins	  increased	  in	  the	  presence	  of	  MNNG	  in	  the	  growth	  media	  (compare	  lanes	  3	  and	  6,	  top	  panels	  in	  A	  and	  B).	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  A.	  fUbr1	  and	  fUbr1	  independently	  fractionated	  with	  dipeptides	  	  
	  	  	  B.	  fUbr1	  and	  fUbr1	  preincubated	  together	  with	  dipeptides	  	  
	  	  Figure	  3.6.	  The	  presence	  of	  type-­‐1/2	  dipeptides	  decreases	  the	  formation	  of	  the	  Ubr1-­‐Ufd4	  complex.	  A.	  Purified	  fUbr1	  or	  purified	  fUdf4	  were	  fractionated	  separately	  by	  gel	  filtration	  in	  the	  presence	  of	  either	  1mM	  Ala/Leu	  and	  Ala/Arg	  (control	  dipeptides;	  top	  panel)	  or	  1	  mM	  Leu/Ala	  and	  Arg/Ala	  (type-­‐1/2	  dipeptides;	  lower	  panel).	  Protein	  was	  precipitated	  by	  trichloroacetic	  acid	  (TCA),	  fractionated	  by	  SDS-­‐PAGE,	  and	  immunoblotted	  with	  anti-­‐flag.	  	  B.	  Purified	  fUbr1	  and	  fUfd4	  were	  preincubated	  together	  in	  a	  1:1	  molar	  ratio	  (left	  panels)	  or	  4:1	  molar	  ratio,	  with	  Ubr1	  in	  excess	  (right	  panels).	  The	  Ubr1-­‐Ufd4	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complex	  in	  the	  top	  panel	  is	  indicated	  by	  the	  box	  (upper	  panels).	  The	  Ubr1-­‐Ufd4	  complex	  apparently	  dissociated	  in	  the	  presence	  of	  type-­‐1/2	  dipeptides,	  as	  indicated	  by	  the	  absence	  of	  overlapping	  Ubr1	  and	  Ufd4	  bands	  in	  the	  elution	  profile	  (lower	  panels).	  The	  elution	  patterns	  of	  the	  molecular	  weight	  standards	  are	  indicated	  beneath	  the	  panels.	  The	  two	  stars	  on	  the	  left	  of	  each	  panel	  denote	  the	  molecular	  weight	  ladder	  at	  250	  kDa	  and	  150	  kDa.	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TABLES	  	  
Yeast	  strains	  used	  in	  this	  study	  	  Strain	   Relevant	  Genotype	   Source	  JD52	   MATa	  trp1-­‐	  63	  ura3-­‐52	  
his3-­‐	  200	  leu2-­‐3112.	  
lys2-­‐801	   Lab	  collection	  JD54	   PGAL1::UBR1	  in	  JD52	   Lab	  Collection	  JD55	   Δubr1::HIS3	  in	  JD52	   Lab	  Collection	  BY4741	   MATa	  his3Δ1	  leu2Δ0	  met15Δ0	  ura3Δ0	  	   Open	  Biosystems	  BY4425	   Δufd2::KANMX6	  in	  BY4741	   Open	  Biosystems	  BY3216	   Δufd4::KANMX6	  in	  BY4741	   Open	  Biosystems	  	  	  
Plasmids	  used	  in	  this	  study	  	  Plasmid	   Description	   Source	  p314CUP1FlagUfd4	   Ufd4	  with	  N-­‐terminal	  Flag	  tag	  in	  pRS314	  with	  PCUP1	  promoter	   Lab	  Collection	  pCH285	   pGEX4T3	  Mgt1HIS10	   ref.	  (4)	  pFlagUbr1SBX	   fUbr1	  in	  YEplac181,	  with	  PADH1	  promoter	   ref.	  (4)	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MATERIALS	  AND	  METHODS	  	  
Purification	  of	  Ufd4	  and	  Ubr1	  N-­‐terminally	  flag-­‐tagged	  Ubr1	  (fUbr1)	  was	  overexpressed	  in	  S.	  cerevisiae	  SC295	  and	  purified	  by	  fractionation	  over	  anti-­‐flag	  M2	  antibody	  agarose	  resin	  as	  described	  in	  Chapter	  2	  and	  Appendix	  1.	  The	  S.	  cerevisiae	  JD52	  that	  carried	  p314CUP1FlagUFD4	  and	  expressed	  the	  N-­‐terminally	  flag-­‐tagged	  Ufd4	  (fUfd4).	  fUfd4	  was	  purified	  using	  anti-­‐flag	  M2	  antibody	  agarose	  as	  described	  in	  (4).	  	  
Gel-­‐filtration	  Samples	  were	  run	  on	  a	  Superose	  6,	  10/300	  column	  connected	  to	  an	  FPLC	  system.	  Fractions	  were	  collected	  at	  0.25	  ml/min.	  The	  gel-­‐filtration	  buffer	  was	  0.1	  M	  NaCl,	  25	  mM	  Na-­‐HEPES	  pH	  7.5.	  Samples	  were	  incubated	  at	  room	  temperature	  for	  30	  min,	  centrifuged	  at	  10,000g	  and	  then	  loaded	  onto	  the	  column.	  If	  dipeptides	  were	  used,	  they	  were	  incubated	  with	  the	  sample	  at	  a	  concentration	  of	  1	  mM	  at	  this	  time.	  In	  these	  experiments,	  the	  gel-­‐filtration	  buffer	  also	  contained	  the	  appropriate	  dipeptides.	  Ovalbumin	  at	  a	  concentration	  of	  0.1	  mg/ml	  was	  used	  in	  the	  sample	  buffer	  to	  stabilize	  the	  proteins	  and	  prevent	  aggregation.	  0.5	  mL	  fractions	  were	  collected	  and	  the	  proteins	  were	  precipitated	  with	  trichloroacetic	  acid	  (TCA).	  The	  proteins	  were	  fractionated	  by	  SDS-­‐PAGE,	  followed	  by	  immunoblotting	  with	  anti-­‐flag	  antibody	  (Stratagene).	  Molecular	  weight	  markers	  (Sigma)	  were	  run	  on	  the	  column	  as	  described	  by	  the	  manufacturer’s	  instructions.	  	  	  
	  
	   91	  
GST	  Pulldowns	  GST-­‐Mgt1-­‐His10	  was	  purified	  from	  BL21-­‐Codon	  Plus	  (DE3)-­‐RIL	  E.	  coli	  strain	  (Stratagene),	  as	  described	  previously	  in	  Appendix	  1	  using	  Ni-­‐NTA	  resin	  (Qiagen).	  The	  S.	  cerevisiae	  strain	  JD54	  (JD52	  background	  strain	  overexpressing	  Ubr1	  from	  the	  PGAL1	  promoter)	  was	  transformed	  with	  either	  pRS313Cup1FlagUfd4	  or	  the	  empty	  pRS313Cup1	  vector.	  The	  S.	  cerevisiae	  yeast	  strain	  JD55	  (JD52	  background	  with	  a	  deletion	  of	  the	  UBR1	  coding	  region)	  was	  also	  transformed	  with	  the	  pRS313Cup1FlagUfd4	  vector.	  A	  50	  mL	  culture	  was	  grown	  to	  an	  A600	  of	  ~1	  in	  SC	  (-­‐His)	  medium	  containing	  0.2	  M	  CuSO4	  (to	  induce	  the	  PCUP1	  promoter)	  and	  either	  in	  2%	  glucose	  or	  galactose	  (to	  induce	  the	  PGAL1	  promoter).	  Cells	  were	  then	  grown	  either	  in	  the	  presence	  or	  absence	  of	  68	  μM	  MNNG	  for	  1	  h.	  The	  cells	  were	  spun	  down,	  washed	  once	  with	  PBS	  and	  stored	  at	  -­‐80°C.	  Cells	  were	  thawed	  and	  lysed	  by	  bead	  beating	  in	  GST	  binding	  buffer	  (10%	  glycerol,	  0.05%	  Nonidet	  P-­‐40,	  50	  mM	  NaCl,	  50	  mM	  Na-­‐HEPES,	  pH	  7.8).	  Purified	  GST-­‐Mgt1	  or	  GST	  alone	  was	  bound	  to	  GST-­‐sepharose	  and	  GST	  pulldowns	  were	  performed	  as	  described	  previously,	  using	  equal	  amounts	  of	  protein	  extracts,	  followed	  by	  SDS-­‐PAGE	  and	  immunoblotting	  with	  either	  anti-­‐Ubr1	  or	  anti-­‐flag	  antibodies.	  	  
Co-­‐immunoprecipitation	  Assay	  Cells	  overexpressing	  fUfd4	  and/or	  untagged	  Ubr1	  were	  grown	  as	  described	  in	  the	  section	  describing	  the	  GST-­‐pulldown	  assay.	  The	  coimmunoprecipitation	  experiments	  were	  performed	  as	  described	  previously,	  except	  that	  the	  previously	  described,	  affinity	  purified	  anti-­‐Ubr1	  antibody	  was	  used	  to	  immunoprecipitate	  Ubr1	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and	  anti-­‐flag	  antibody	  was	  used	  immunoprecipitate	  Ufd4.	  These	  antibodies	  were	  also	  used	  for	  immunoblotting.	  	  
	  
Cycloheximide	  Chase	  Experiment	  
S.	  cerevisiae	  were	  grown	  to	  A600	  of	  0.8	  to	  1.0	  in	  selective	  (plasmid-­‐maintaining)	  liquid	  media	  at	  30°C,	  followed	  by	  treatment	  with	  cycloheximide	  (CHX),	  at	  the	  final	  concentration	  of	  0.1	  mg/ml.	  At	  indicated	  times,	  cell	  samples	  (corresponding	  to	  1	  ml	  of	  cell	  suspension	  at	  A600	  of	  1)	  were	  harvested	  by	  centrifugation	  for	  1	  min	  at	  11,200g,	  and	  resuspended	  in	  1	  ml	  of	  0.2	  M	  NaOH.	  The	  samples	  were	  incubated	  for	  20	  min	  on	  ice,	  or	  for	  5	  min	  at	  room	  temperature,	  followed	  by	  centrifugation	  for	  1	  min	  at	  11,200g.	  Pelleted	  cells	  were	  resuspended	  in	  50	  μl	  of	  1X	  LDS	  buffer	  (Invitrogen,	  Carlsbad,	  CA)	  containing	  1X	  reducing	  agent	  and	  1X	  protease	  inhibitor	  cocktail	  “for	  use	  with	  fungal	  and	  yeast	  extracts”	  (Sigma),	  and	  heated	  for	  10	  min	  at	  70°C.	  After	  centrifugation	  at	  5	  min	  at	  11,200g,	  10	  μl	  of	  supernatant	  was	  fractionated	  by	  SDS-­‐4-­‐12%	  NuPAGE,	  followed	  by	  immunoblotting	  with	  the	  appropriate	  antibody.	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Abstract	  The	  retained	  N-­‐terminal	  methionine	  (Met)	  residue	  of	  a	  nascent	  protein	  is	  often	  N-­‐terminally	  acetylated	  (Nt-­‐acetylated).	  Removal	  of	  N-­‐terminal	  Met	  by	  Met-­‐aminopeptidases	  frequently	  leads	  to	  Nt-­‐acetylation	  of	  the	  resulting	  N-­‐terminal	  alanine	  (Ala),	  valine	  (Val),	  serine	  (Ser),	  threonine	  (Thr),	  and	  cysteine	  (Cys)	  residues.	  Although	  a	  majority	  of	  eukaryotic	  proteins	  (for	  example,	  more	  than	  80%	  of	  human	  proteins)	  are	  cotranslationally	  Nt-­‐acetylated,	  the	  function	  of	  this	  extensively	  studied	  modification	  is	  largely	  unknown.	  Using	  the	  yeast	  Saccharomyces	  cerevisiae,	  we	  found	  that	  the	  Nt-­‐acetylated	  Met	  residue	  could	  act	  as	  a	  degradation	  signal	  (degron),	  targeted	  by	  the	  Doa10	  ubiquitin	  ligase.	  Moreover,	  Doa10	  also	  recognized	  the	  Nt-­‐acetylated	  Ala,	  Val,	  Ser,	  Thr,	  and	  Cys	  residues.	  Several	  examined	  proteins	  of	  diverse	  functions	  contained	  these	  N-­‐terminal	  degrons,	  termed	  AcN-­‐degrons,	  which	  are	  a	  prevalent	  class	  of	  degradation	  signals	  in	  cellular	  proteins.	  	  
Introduction	  and	  Results	  Many	  eukaryotic	  proteins	  are	  acetylated	  at	  the	  α-­‐amino	  group	  of	  their	  N-­‐terminal	  residues	  (fig.	  S1A)	  (1).	  Previous	  studies	  of	  Nα-­‐terminal	  acetylation	  (Nt-­‐acetylation)	  have	  characterized	  Nt-­‐acetylated	  proteins	  and	  Nα-­‐terminal	  acetyltransferases	  (Nt-­‐acetylases)	  that	  catalyze	  this	  cotranslational	  modification	  (2–7).	  Owing	  to	  the	  design	  of	  the	  genetic	  code,	  nascent	  proteins	  contain	  N-­‐terminal	  Met.	  A	  retained	  N-­‐terminal	  Met	  that	  is	  followed	  by	  “acetylation-­‐permissive”	  residues	  is	  usually	  Nt-­‐acetylated	  (fig.	  S1A)	  (5–7).	  Met-­‐aminopeptidases	  cleave	  off	  the	  N-­‐terminal	  Met	  if	  the	  residue	  at	  position	  2	  has	  a	  small	  enough	  side	  chain,	  resulting	  in	  N-­‐terminal	  Ala,	  Val,	  Ser,	  Thr,	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Cys,	  Gly,	  or	  Pro	  (fig.	  S1B)	  (8).	  With	  the	  near-­‐exception	  of	  Gly	  and	  Pro,	  these	  N-­‐terminal	  residues	  are	  often	  Nt-­‐acetylated,	  similarly	  to	  N-­‐terminal	  Met	  (5–7).	  In	  cell	  extracts,	  some	  Nt-­‐acetylated	  proteins	  can	  be	  degraded	  by	  the	  ubiquitin	  (Ub)	  system	  (9).	  However,	  no	  cognate	  Ub	  ligases	  have	  been	  identified,	  and	  it	  has	  been	  assumed	  that	  the	  relevant	  degradation	  signals	  were	  internal	  (not	  N-­‐terminal)	  (9).	  Currently,	  the	  prevalent	  view	  of	  Nt-­‐acetylation	  is	  that	  this	  modification	  protects	  proteins	  from	  degradation.	  To	  the	  contrary,	  we	  report	  here	  that	  Nt-­‐acetylation	  creates	  specific	  degradation	  signals	  (degrons)	  that	  are	  targeted	  by	  a	  branch	  of	  the	  Ub-­‐dependent	  N-­‐end	  rule	  pathway.	  Destabilizing	  N-­‐terminal	  sequences.	  The	  N-­‐end	  rule	  relates	  the	  in	  vivo	  half-­‐life	  of	  a	  protein	  to	  the	  identity	  of	  its	  N-­‐terminal	  residue	  (10–20).	  N-­‐terminal	  degradation	  signals	  of	  the	  N-­‐end–rule	  pathway	  are	  called	  N-­‐degrons.	  Their	  main	  determinant	  is	  a	  destabilizing	  N-­‐terminal	  residue	  of	  a	  protein	  (fig.	  S1C).	  Recognition	  components	  of	  the	  N-­‐end–rule	  pathway	  are	  called	  N-­‐recognins.	  An	  N-­‐recognin	  is	  an	  E3	  Ub	  ligase	  that	  can	  target	  for	  polyubiquitylation	  at	  least	  a	  subset	  of	  N-­‐degrons	  (13,	  15,	  18,	  19).	  The	  N-­‐end	  rule	  of	  the	  yeast	  S.	  cerevisiae	  comprises	  12	  destabilizing,	  unacetylated	  N-­‐terminal	  residues	  (out	  of	  the	  fundamental	  set	  of	  20	  amino	  acids)	  (12–15,	  18,	  19).	  Among	  these	  residues,	  eight	  are	  primary	  destabilizing	  residues;	  that	  is,	  recognized	  directly	  by	  the	  Ubr1	  N-­‐recognin,	  whereas	  the	  other	  four	  N-­‐terminal	  residues,	  called	  secondary	  or	  tertiary	  destabilizing	  residues,	  must	  be	  modified	  through	  deamidation	  and/or	  arginylation	  before	  the	  corresponding	  proteins	  can	  be	  targeted	  by	  Ubr1	  (fig.	  S1C).	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In	  mammalian	  cells,	  the	  N-­‐terminal	  Cys	  of	  N-­‐end–rule	  substrates	  can	  be	  oxidized,	  by	  nitric	  oxide	  (NO)	  and	  oxygen,	  and	  thereafter	  arginylated	  by	  an	  arginyl-­‐transferase.	  The	  resulting	  N-­‐terminal	  Arg	  is	  recognized	  by	  Ubr1-­‐type	  N-­‐recognins	  (15,	  16).	  In	  contrast,	  N-­‐terminal	  Cys	  appeared	  to	  be	  a	  stabilizing	  residue	  in	  S.	  
cerevisiae,	  which	  lacks	  NO	  synthases	  (11).	  That	  study	  also	  classified	  N-­‐terminal	  Met,	  Ala,	  Val,	  Ser,	  and	  Thr	  as	  stabilizing	  residues	  in	  S.	  cerevisiae	  (11).	  One	  caveat	  in	  these	  assignments	  is	  the	  possible	  influence	  of	  sequences	  downstream	  of	  the	  reporter’s	  N	  terminus.	  To	  determine	  whether	  N-­‐terminal	  Cys	  can	  be	  destabilizing	  in	  yeast,	  we	  performed	  a	  screen	  in	  ura3	  S.	  cerevisiae	  with	  Cys-­‐Z-­‐eK-­‐Ura3	  reporters,	  produced	  by	  deubiquitylation	  (10,	  21)	  of	  Ub-­‐Cys-­‐Z-­‐eK-­‐Ura3.	  Z	  denotes	  a	  varied	  residue	  at	  position	  2,	  and	  eK	  [extension	  (e)	  containing	  lysine	  (K)]	  denotes	  a	  ~40-­‐residue	  sequence	  upstream	  of	  Ura3.	  The	  eK	  extension	  (fig.	  S1D)	  has	  the	  technically	  valuable	  property	  of	  lacking	  internal	  degrons	  while	  containing	  “ubiquitylatable”	  Lys	  residues	  (10–12).	  This	  screen	  identified	  Cys-­‐Z-­‐eK-­‐Ura3	  fusions	  (Z	  =	  Leu,	  Val,	  or	  Pro)	  with	  low	  Ura3	  activity.	  We	  examined	  these	  fusions	  using	  a	  cycloheximide	  (CHX)–chase	  assay,	  in	  which	  a	  protein	  is	  analyzed	  by	  immunoblotting	  as	  a	  function	  of	  time	  after	  the	  inhibition	  of	  translation	  by	  CHX	  (18,	  19).	  The	  above	  three	  reporters	  were	  short-­‐lived	  in	  vivo	  [half-­‐life	  (t1/2)	  <	  1	  hour],	  in	  contrast	  to	  GL-­‐eK-­‐Ura3	  (N-­‐terminal	  Gly)	  and	  CK-­‐eK-­‐Ura3	  (Lys	  at	  position	  2),	  which	  were	  long-­‐lived	  (Fig.	  1,	  A,	  B,	  and	  D;	  fig.	  S2B;	  and	  fig.	  S3,	  A	  and	  D).	  Other	  nonbasic	  residues	  at	  position	  2	  also	  yielded	  short-­‐lived	  CZ-­‐	  eK	  -­‐Ura3	  (Z	  =	  Trp,	  Glu,	  Gly,	  or	  Ile)	  (Fig.	  1B	  and	  fig.	  S3A).	  Several	  other	  XL-­‐eK-­‐Ura3	  reporters	  (X	  =	  Met,	  Ser,	  Val,	  Ala,	  or	  Thr)	  were	  also	  short-­‐lived	  in	  vivo,	  like	  CL-­‐eK-­‐Ura3	  and	  in	  contrast	  to	  long-­‐lived	  MK-­‐eK-­‐Ura3	  (Lys	  at	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position	  2),	  MR-­‐eK-­‐Ura3	  (Arg	  at	  position	  2),	  GL-­‐eK-­‐Ura3	  (N-­‐terminal	  Gly),	  and	  PL-­‐eK-­‐Ura3	  (N-­‐terminal	  Pro)	  (Fig.	  1,	  A	  to	  D;	  fig.	  S2,	  A	  and	  B;	  and	  fig.	  S3,	  B,	  C,	  and	  E).	  We	  also	  performed	  35S-­‐pulse	  chases	  (18,	  19)	  with	  CL-­‐eK-­‐Ura3	  and	  ML-­‐eK-­‐Ura3	  versus	  CK-­‐eK-­‐Ura3	  and	  MK-­‐eK-­‐Ura3	  (fig.	  S4,	  A	  to	  C).	  The	  techniques	  of	  CHX	  chases	  and	  35S-­‐pulse	  chases	  are	  complementary,	  because	  the	  former	  method	  monitors	  the	  degradation	  of	  all	  molecules	  of	  a	  specific	  protein,	  whereas	  the	  latter	  assay	  measures	  the	  degradation	  of	  newly	  formed	  (pulse-­‐labeled)	  molecules.	  35S-­‐pulse	  chases	  confirmed	  the	  instability	  of	  XL-­‐eK-­‐Ura3	  (X	  =	  Cys	  or	  Met)	  and	  stability	  of	  XK-­‐eK-­‐Ura3	  (X	  =	  Cys	  or	  Met)	  (Fig.	  1,	  A	  and	  C;	  fig.	  S2,	  A	  and	  B;	  and	  fig.	  S4,	  A	  to	  C).	  The	  degradation	  of	  ML-­‐eK-­‐Ura3	  was	  proteasome-­‐dependent,	  because	  the	  MG132	  proteasome	  inhibitor	  significantly	  increased	  the	  level	  of	  the	  normally	  short-­‐lived	  ML-­‐eK-­‐Ura3	  but	  not	  of	  the	  long-­‐lived	  MK-­‐eK-­‐Ura3,	  whose	  levels	  were	  high	  both	  in	  the	  presence	  and	  absence	  of	  MG132	  (Fig.	  1G).	  The	  Doa10	  ubiquitin	  ligase	  recognizes	  acetylated	  N-­‐terminal	  residues.	  To	  search	  for	  a	  Ub	  ligase	  or	  ligases	  that	  mediate	  the	  degradation	  of	  XL-­‐	  eK	  -­‐Ura3	  (X	  =	  Met,	  Ala,	  Val,	  Ser,	  Thr,	  or	  Cys),	  we	  expressed	  CL-­‐	  eK	  -­‐Ura3	  in	  S.	  cerevisiae	  mutants	  that	  lacked	  specific	  E3	  or	  E2	  enzymes	  (fig.	  S4D).	  CL-­‐	  eK	  -­‐Ura3	  became	  long-­‐lived	  in	  the	  absence	  of	  Doa10	  (Fig.	  1E	  and	  fig.	  S4,	  D	  and	  E).	  Moreover,	  other	  short-­‐lived	  XL-­‐	  eK	  -­‐Ura3	  proteins	  (Z	  =	  Met,	  Ser,	  or	  Val)	  were	  also	  stable	  in	  doa10∆	  cells	  (Fig.	  1F	  and	  fig.	  S4,	  F	  and	  G).	  Doa10	  is	  a	  transmembrane	  E3	  Ub	  ligase	  that	  functions	  with	  the	  Ubc6/Ubc7	  E2s	  and	  resides	  in	  the	  endoplasmic	  reticulum	  (ER)	  and	  inner	  nuclear	  membrane	  (INM)	  (22–24).	  To	  address	  the	  above	  results,	  we	  focused	  on	  MATα2,	  a	  physiological	  substrate	  of	  Doa10.	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The	  24-­‐kD	  MATα2	  contains	  more	  than	  one	  degradation	  signal	  and	  has	  an	  in	  vivo	  half-­‐life	  of	  5	  to	  10	  min	  (13,	  25,	  26).	  MATα2	  represses	  transcription	  of	  a-­‐specific	  genes	  in	  α-­‐cells,	  whereas	  in	  a/α	  diploids	  the	  MATα2-­‐MATa1	  complex	  represses	  haploid-­‐specific	  genes	  (27,	  28).	  The	  67-­‐residue	  N-­‐terminal	  region	  of	  MATα2,	  termed	  Deg1,	  has	  been	  shown	  to	  harbor	  a	  Doa10-­‐dependent	  degron	  (22–24).	  MATα2	  is	  absent	  from	  databases	  of	  Nt-­‐acetylated	  proteins	  (5,	  6),	  possibly	  because	  of	  its	  short	  in	  vivo	  half-­‐life.	  We	  expressed	  full-­‐length	  MATα2	  in	  doa10Δ	  ubc4Δ	  yeast	  and	  analyzed	  purified	  MATα2	  using	  liquid	  chromatography–tandem	  mass	  spectrometry	  (LC-­‐MS/MS).	  The	  results	  (fig.	  S5A)	  indicated	  virtually	  complete	  Nt-­‐acetylation	  of	  MATα2	  (no	  MATα2	  that	  lacked	  Nt-­‐acetylation	  could	  be	  detected),	  in	  agreement	  with	  Nt-­‐acetylation	  of	  other	  proteins	  containing	  the	  N-­‐terminal	  Met-­‐Asn	  (5–7).	  Similar	  LC-­‐MS/MS	  of	  the	  Doa10-­‐targeted,	  purified	  ML-­‐	  eK	  -­‐Ura3	  (fig.	  S5,	  B	  and	  C)	  indicated	  the	  Nt-­‐acetylation	  of	  this	  reporter,	  in	  agreement	  with	  Nt-­‐acetylation	  of	  other	  proteins	  containing	  the	  N-­‐terminal	  Met-­‐Leu	  (5–7).	  We	  also	  observed	  Nt-­‐acetylation	  of	  a	  Deg1-­‐bearing	  reporter	  that	  was	  purified	  from	  E.	  coli	  and	  incubated	  with	  S.	  
cerevisiae	  extracts	  (fig.	  S6A).	  In	  addition,	  we	  produced	  an	  antibody,	  termed	  anti-­‐AcNtMATα2,	  that	  recognized	  the	  Nt-­‐acetylated	  N-­‐terminal	  sequence	  of	  MATα2	  (Fig.	  2C)	  and	  was	  specific	  for	  the	  Nt-­‐acetylated,	  hemagglutinin	  (HA)–tagged,	  MATα2-­‐derived,	  MN-­‐α23-­‐
67-­‐	  eK	  -­‐Ura3	  reporter,	  denoted	  MNα2	  (Fig.	  2,	  A	  and	  B).	  Anti-­‐AcNtMATα2	  and	  anti-­‐Ha	  (the	  latter	  antibody	  recognized	  both	  Nt-­‐acetylated	  and	  unacetylated	  MNα2)	  were	  used	  to	  immunoblot	  extracts	  of	  cells	  that	  expressed	  MNα2.	  Wild-­‐type	  cells	  contained	  barely	  detectable	  steady-­‐state	  levels	  of	  either	  total	  or	  Nt-­‐acetylated	  MNα2	  (Fig.	  2A),	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owing	  to	  its	  rapid	  degradation.	  In	  contrast,	  nat3Δ	  cells,	  which	  lacked	  the	  cognate	  NatB	  Nt-­‐acetylase,	  contained	  high	  levels	  of	  unacetylated	  MNα2	  (detected	  by	  anti-­‐Ha)	  and	  almost	  no	  Nt-­‐acetylated	  MNα2	  (Fig.	  2A).	  Similar	  patterns	  were	  observed	  in	  wild-­‐type	  cells	  that	  expressed	  MKα2	  (Lys	  at	  position	  2)	  or	  GNα2	  (N-­‐terminal	  Gly)	  (Fig.	  2A).	  As	  shown	  by	  proteome-­‐scale	  analyses,	  S.	  cerevisiae	  proteins	  containing	  Lys	  at	  position	  2	  are	  virtually	  never	  Nt-­‐acetylated,	  and	  few	  proteins	  that	  bear	  N-­‐terminal	  Gly	  are	  Nt-­‐acetylated	  (5–7).	  Most	  importantly,	  high	  levels	  of	  Nt-­‐acetylated	  MNα2	  were	  present	  in	  doa10Δ	  cells	  (Fig.	  2A),	  owing	  to	  metabolic	  stabilization	  of	  Nt-­‐acetylated	  MNα2	  in	  the	  absence	  of	  Doa10.	  These	  data	  (Fig.	  2A)	  were	  in	  agreement	  with	  the	  LC-­‐MS/MS	  results	  showing	  that	  MATα2	  was	  Nt-­‐acetylated	  (fig.	  S5A).	  To	  determine	  whether	  the	  Doa10	  Ub	  ligase	  recognizes	  the	  Nt-­‐acetylated	  Met	  (AcNtMet),	  we	  used	  the	  X-­‐peptide	  assay	  (15)	  with	  synthetic	  peptides	  XNKIPIKDLLNC	  (X	  =	  Met,	  AcMet,	  or	  Gly)	  (29).	  Except	  for	  C-­‐terminal	  Cys	  and	  the	  varied	  N-­‐terminal	  residues,	  these	  peptides	  were	  identical	  to	  the	  N-­‐terminal	  region	  of	  MATα2.	  Immobilized	  peptides	  were	  incubated	  with	  extract	  from	  yeast	  that	  expressed	  myc13-­‐tagged	  Doa10,	  followed	  by	  elution	  of	  the	  bound	  proteins	  and	  immunoblotting	  with	  antibody	  to	  myc.	  Doa10myc13	  bound	  to	  the	  MATα2	  peptide	  with	  N-­‐terminal	  AcNtMet	  but	  not	  to	  the	  otherwise	  identical	  peptides	  with	  unmodified	  N-­‐terminal	  Met	  or	  with	  N-­‐terminal	  Gly	  (Fig.	  2D).	  Additional	  controls,	  which	  did	  not	  bind	  to	  Doa10myc13,	  were	  peptides	  XIFSTDTGPGGC	  (X	  =	  Gly,	  Met,	  Arg,	  or	  Phe)	  derived	  from	  the	  N	  terminus	  of	  nsP4,	  a	  Sindbis	  viral	  protein	  (13)	  (Fig.	  2D).	  Thus,	  Doa10	  recognizes	  the	  AcNtMet	  residue	  and	  does	  not	  have	  a	  significant	  affinity	  for	  downstream	  sequences	  of	  MATα2	  or	  nsP4.	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Doa10	  specificity	  was	  also	  analyzed	  with	  the	  synthetic	  peptide	  arrays	  on	  membrane	  support	  (SPOT)	  technique,	  in	  which	  synthetic	  XZ-­‐	  eK(3-­‐11)	  peptides	  and	  their	  Nt-­‐acetylated	  AcXZ-­‐	  eK(3-­‐11)	  counterparts	  were	  C-­‐terminally	  linked	  to	  a	  membrane	  as	  “dots”	  in	  equal	  molar	  amounts.	  SPOT	  peptides	  were	  identical	  to	  the	  N-­‐terminal	  region	  of	  eK	  (fig.	  S1D),	  with	  varied	  residues	  at	  positions	  1	  and	  2.	  A	  SPOT	  assay	  with	  C-­‐terminally	  flag-­‐tagged	  Doa10f	  indicated	  the	  recognition	  of	  AcNtMet	  by	  Doa10,	  in	  agreement	  with	  the	  results	  of	  the	  X-­‐peptide	  assay	  (Fig.	  2,	  D	  and	  E).	  SPOT	  also	  indicated	  a	  highly	  preferential	  binding	  of	  Doa10f	  to	  other	  Nt-­‐acetylated	  (versus	  unacetylated)	  AcXZ-­‐	  eK(3-­‐11)	  peptides	  (X	  =	  Gly,	  Ala,	  Val,	  Pro,	  Ser,	  Thr,	  or	  Cys),	  including	  Nt-­‐acetylated	  Gly	  and	  Pro	  (Fig.	  2E).	  Thus,	  Gly	  and	  Pro	  are	  (largely)	  stabilizing	  in	  the	  N-­‐end	  rule	  (Fig.	  1D	  and	  fig.	  S3E)	  because	  N-­‐terminal	  Gly	  and	  Pro	  are	  Nt-­‐acetylated	  in	  relatively	  few	  proteins	  (5–7).	  Doa10	  did	  not	  bind	  to	  N-­‐terminal	  AcNtMet	  if	  it	  was	  followed	  by	  Lys	  at	  position	  2	  (Fig.	  2E).	  Thus,	  the	  metabolic	  stability	  of	  XK-­‐	  eK	  -­‐Ura3	  (X	  =	  Met	  or	  Cys)	  containing	  Lys	  at	  position	  2	  (Fig.	  1,	  A	  and	  C)	  stems	  not	  only	  from	  the	  absence	  of	  Nt-­‐acetylation	  (5–7)	  but	  also	  from	  the	  rejection,	  by	  Doa10,	  of	  Lys	  at	  position	  2	  (Fig.	  2E).	  The	  Doa10-­‐dependent	  AcN-­‐degron	  of	  MATα2.	  Taking	  advantage	  of	  the	  specificity	  of	  anti-­‐AcNtMATα2	  for	  Nt-­‐acetylated	  MNα2,	  we	  performed	  CHX	  chases	  as	  well,	  in	  addition	  to	  steady-­‐state	  assays	  (Fig.	  2,	  A	  and	  B).	  MNα2	  was	  short-­‐lived	  in	  wild-­‐type	  cells.	  Even	  “time-­‐zero”	  samples,	  at	  the	  time	  of	  addition	  of	  CHX,	  contained	  barely	  detectable	  levels	  of	  either	  Nt-­‐acetylated	  or	  total	  MNα2	  (Fig.	  2B).	  In	  contrast,	  MNα2	  was	  a	  long-­‐lived	  protein	  in	  doa10Δ	  and	  nat3Δ	  cells,	  but	  for	  different	  reasons:	  In	  doa10Δ	  cells,	  which	  lacked	  the	  cognate	  Ub	  ligase,	  MNα2	  was	  long-­‐lived	  despite	  its	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Nt-­‐acetylation;	  whereas	  in	  nat3Δ	  cells,	  which	  lacked	  the	  cognate	  Nt-­‐acetylase,	  the	  largely	  unacetylated	  MNα2	  was	  long-­‐lived	  because	  the	  targeting	  by	  Doa10	  required	  Nt-­‐acetylation	  (Fig.	  2B).	  MATα2	  contains	  yet	  another	  degradation	  signal,	  targeted	  by	  an	  unknown	  E3	  in	  conjunction	  with	  the	  Ubc4	  and	  (to	  a	  minor	  extent)	  Ubc5	  E2s	  (25,	  26).	  This	  degron	  is	  nearly	  inactive	  in	  ubc4∆	  cells	  (23,	  26).	  In	  contrast,	  the	  Doa10	  Ub	  ligase	  functions	  with	  the	  Ubc6/Ubc7	  E2s	  and	  remains	  active	  in	  ubc4∆	  cells	  (22).	  In	  35S-­‐pulse	  chases	  with	  C-­‐terminally	  flag-­‐tagged	  full-­‐length	  MATα2f,	  the	  rapid	  degradation	  of	  wild-­‐type	  MNMATα2f	  in	  ubc4∆	  cells	  (t1/2	  ≈	  9	  min)	  was	  substantially	  decreased	  in	  doa10∆	  ubc4∆	  cells	  (t1/2	  ≈	  35	  min)	  (Fig.	  2F	  and	  fig.	  S6,	  B	  and	  C).	  A	  Lys	  residue	  at	  position	  2	  in	  a	  polypeptide	  chain	  is	  known	  to	  preclude	  Nt-­‐acetylation	  in	  S.	  cerevisiae,	  and	  few	  proteins	  that	  bear	  N-­‐terminal	  Gly	  are	  Nt-­‐acetylated	  (5,	  6).	  The	  absence	  of	  Nt-­‐acetylation	  in	  MKMATα2f	  (Lys	  at	  position	  2)	  or	  GNMATα2f	  (Gly	  at	  position	  1)	  decreased	  the	  rate	  of	  MATα2	  degradation	  in	  wild-­‐type	  cells	  (Fig.	  2F	  and	  fig.	  S6,	  B	  and	  C).	  The	  extent	  of	  this	  decrease,	  in	  comparison	  to	  degradation	  of	  Nt-­‐acetylated	  
MNMATα2f	  in	  wild-­‐type	  cells,	  was	  indistinguishable	  from	  the	  decrease	  of	  MNMATα2f	  degradation	  in	  doa10∆	  cells,	  which	  lacked	  the	  Doa10	  Ub	  ligase	  (Fig.	  2F	  and	  fig.	  S6,	  B	  to	  E).	  In	  addition	  to	  indicating	  that	  the	  sole	  degron	  targeted	  by	  Doa10	  in	  MATα2	  is	  its	  AcN-­‐degron,	  these	  results	  were	  also	  in	  agreement	  with	  technically	  independent	  evidence	  that	  used	  the	  anti-­‐AcNtMATα2	  to	  prove	  that	  the	  Nt-­‐acetylation	  of	  MNα2	  was	  required	  for	  its	  targeting	  by	  Doa10	  (Fig.	  2,	  A	  to	  C).	  
AcN-­‐degrons	  in	  cellular	  proteins.	  As	  expected,	  given	  the	  presence	  of	  the	  AcN-­‐degron	  in	  MATα2,	  both	  full-­‐length	  MATα2f	  and	  MNα2	  were	  strongly	  stabilized	  in	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nat3∆	  cells,	  which	  lacked	  the	  cognate	  NatB	  Nt-­‐acetylase	  (Fig.	  2,	  A	  and	  B,	  and	  fig.	  S6,	  D	  and	  E).	  Besides	  MATα2,	  our	  survey	  of	  S.	  cerevisiae	  proteins	  has	  encompassed,	  thus	  far,	  Tbf1,	  a	  regulator	  of	  telomeres;	  Slk19,	  a	  regulator	  of	  chromosome	  segregation;	  Ymr090w,	  a	  cytosolic	  protein	  of	  unknown	  function;	  His3,	  an	  enzyme	  of	  histidine	  biosynthesis;	  Pop2,	  a	  subunit	  of	  mRNA-­‐deadenylating	  complexes;	  Hsp104,	  a	  chaperone;	  Tho1,	  an	  RNA-­‐binding	  regulator;	  Ubp6,	  a	  deubiquitylating	  enzyme;	  and	  Aro8,	  an	  aromatic	  aminotransferase	  (Fig.	  3;	  fig.	  S2,	  C	  and	  D;	  and	  fig.	  S7)	  (30).	  Wild-­‐type	  Tbf1,	  Slk19,	  Pop2,	  Hsp104,	  Tho1,	  Ubp6,	  and	  Aro8	  are	  known	  to	  be	  Nt-­‐acetylated	  (5,	  6).	  In	  contrast,	  the	  testing	  of	  His3	  and	  Ymr090w	  stemmed	  from	  our	  two-­‐dimensional	  electrophoretic	  analyses,	  including	  35S-­‐pulse	  chases.	  The	  resulting	  patterns	  contained	  a	  number	  of	  protein	  spots	  with	  significantly	  higher	  levels	  of	  35S	  in	  samples	  from	  doa10∆	  versus	  wild-­‐type	  cells	  (fig.	  S8).	  We	  examined	  three	  of	  these	  spots	  using	  matrix-­‐assisted	  laser	  desorption/ionization–MS	  fingerprinting	  techniques	  and	  identified	  His3,	  Ymr090w,	  and	  Aro8	  as	  putative	  substrates	  of	  Doa10	  (fig.	  S8).	  The	  testing	  for	  AcN-­‐degrons	  in	  Tbf1,	  Slk19,	  Ymr090w,	  His3,	  Pop2,	  Hsp104,	  Tho1,	  Ubp6,	  and	  Aro8	  (this	  analysis	  included	  second-­‐residue	  mutants	  of	  some	  of	  these	  proteins)	  involved	  CHX	  chases	  in	  the	  presence	  or	  absence	  of	  a	  cognate	  Nt-­‐acetylase	  or	  the	  Doa10	  Ub	  ligase.	  As	  shown	  in	  Fig.	  3;	  fig.	  S2,	  C	  and	  D;	  and	  fig.	  S7,	  we	  identified	  AcN-­‐degrons	  in	  all	  of	  these	  proteins	  (in	  addition	  to	  MATα2),	  except	  Pop2	  and	  Tho1	  [see	  also	  (30)].	  
Discussion	  Our	  results,	  summarized	  in	  Fig.	  4,	  revealed	  the	  function	  of	  Nt-­‐acetylation,	  producing	  the	  largest	  increase	  in	  the	  scope	  of	  the	  N-­‐end–rule	  pathway	  since	  its	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discovery	  more	  than	  two	  decades	  ago	  (10–13).	  At	  present,	  only	  ~10	  proteins	  in	  all	  eukaryotes	  have	  been	  identified	  that	  require,	  or	  are	  inferred	  to	  require,	  Nt-­‐acetylation	  for	  their	  in	  vivo	  roles,	  which	  are	  unrelated	  to	  protein	  degradation	  [(30)	  and	  references	  therein].	  In	  contrast,	  the	  creation	  of	  degradation	  signals	  by	  Nt-­‐acetylation	  (Fig.	  4)	  is	  relevant,	  in	  principle,	  to	  all	  Nt-­‐acetylated	  proteins.	  N-­‐terminal	  Met,	  Ala,	  Val,	  Ser,	  Thr,	  and	  Cys	  are	  shown	  here	  to	  function	  as	  secondary	  destabilizing	  residues	  in	  the	  N-­‐end	  rule	  pathway,	  in	  that	  they	  must	  be	  Nt-­‐acetylated	  before	  their	  recognition	  by	  the	  S.	  cerevisiae	  Doa10	  Ub	  ligase	  as	  N-­‐degrons,	  termed	  AcN-­‐degrons,	  that	  require	  Nt-­‐acetylation	  (Fig.	  4).	  Out	  of	  20	  amino	  acids	  in	  the	  genetic	  code,	  18	  are	  now	  known	  to	  function	  as	  destabilizing	  N-­‐terminal	  residues	  in	  the	  N-­‐end	  rule	  pathway	  (Fig.	  4	  and	  fig.	  S1C).	  More	  than	  50%	  of	  proteins	  in	  S.	  cerevisiae	  and	  more	  than	  80%	  of	  proteins	  in	  human	  cells	  are	  Nt-­‐acetylated	  (5–7).	  Thus,	  remarkably,	  the	  majority	  of	  eukaryotic	  proteins	  harbor	  a	  specific	  degradation	  signal	  from	  the	  moment	  of	  their	  birth.	  Putative	  metazoan	  counterparts	  of	  the	  yeast	  Doa10	  Ub	  ligase	  (22–24)	  include	  human	  TEB4	  (31),	  indicating	  the	  likely	  relevance	  of	  our	  results	  to	  all	  eukaryotes.	  The	  Nt-­‐acetylation	  is	  largely	  cotranslational,	  apparently	  irreversible,	  and	  involves	  a	  majority	  of	  cellular	  proteins.	  What	  functions	  are	  subserved	  by	  such	  a	  massive	  production	  of	  degradation	  signals	  (AcN-­‐degrons)	  in	  nascent	  proteins	  if	  many	  of	  these	  proteins	  are	  destined	  for	  long	  half-­‐lives?	  We	  suggest	  that	  a	  major	  role	  of	  these	  degradation	  signals	  involves	  quality-­‐control	  mechanisms	  and	  the	  regulation	  of	  protein	  stoichiometries	  in	  a	  cell.	  A	  key	  feature	  of	  such	  mechanisms	  would	  be	  conditionality	  of	  AcN-­‐degrons.	  If	  a	  nascent	  Nt-­‐acetylated	  protein	  can	  fold	  its	  N-­‐
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terminal	  domain	  rapidly	  enough,	  or	  if	  this	  protein	  either	  interacts	  with	  a	  “protective”	  chaperone	  such	  as	  Hsp90	  or	  becomes	  assembled	  into	  a	  cognate	  multisubunit	  complex,	  the	  cotranslationally	  created	  AcN-­‐degron	  of	  this	  protein	  may	  become	  inaccessible	  to	  the	  Doa10	  Ub	  ligase.	  Consequently,	  the	  degradation	  of	  this	  protein	  would	  be	  decreased	  or	  precluded.	  In	  contrast,	  delayed	  or	  defective	  folding	  of	  a	  protein’s	  N-­‐terminal	  domain	  (because	  of	  oxidative,	  heat,	  or	  other	  stresses;	  or	  a	  conformation-­‐perturbing	  mutation;	  or	  nonstoichiometric	  levels	  of	  cognate	  protein	  ligands)	  would	  keep	  an	  AcN-­‐degron	  exposed	  (active)	  and	  thereby	  increase	  the	  probability	  of	  the	  protein’s	  destruction.	  The	  discovery	  that	  Nt-­‐acetylation	  is	  a	  part	  of	  the	  N-­‐end	  rule	  pathway	  (Fig.	  4)	  has	  also	  revealed	  the	  physiological	  functions	  of	  Nt-­‐acetylases	  and	  Met-­‐aminopeptidases.	  Nt-­‐acetylases	  produce	  AcN-­‐degrons,	  whereas	  the	  upstream	  Met-­‐aminopeptidases	  make	  possible	  these	  degradation	  signals,	  all	  of	  them	  except	  the	  one	  mediated	  by	  Nt-­‐acetylated	  Met	  (Fig.	  4).	  Nt-­‐acetylases	  and	  Met-­‐aminopeptidases	  are	  universally	  present,	  extensively	  characterized,	  and	  essential	  enzymes	  whose	  physiological	  roles	  were	  largely	  unknown.	  These	  enzymes	  are	  now	  functionally	  understood	  components	  of	  the	  N-­‐end	  rule	  pathway	  (Fig.	  4	  and	  fig.	  S1C).	  Although	  the	  bulk	  of	  Nt-­‐acetylation	  is	  cotranslational	  (4),	  posttranslational	  Nt-­‐acetylation	  is	  likely	  to	  be	  extensive	  as	  well.	  A	  number	  of	  proteases	  can	  specifically	  cleave	  a	  variety	  of	  intracellular	  proteins,	  resulting	  in	  C-­‐terminal	  fragments	  that	  often	  bear	  destabilizing	  N-­‐terminal	  residues	  of	  the	  Ubr1-­‐mediated	  branch	  of	  the	  N-­‐end–rule	  pathway	  (fig.	  S1C).	  Such	  fragments	  are	  often	  short-­‐lived	  in	  vivo,	  thereby	  regulating	  specific	  circuits	  [reviewed	  in	  (13)].	  Given	  the	  major	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expansion	  of	  the	  N-­‐end	  rule	  in	  the	  present	  work	  (Fig.	  4),	  most	  in	  vivo	  produced	  C-­‐terminal	  fragments	  of	  intracellular	  proteins	  should	  now	  be	  viewed,	  a	  priori,	  as	  putative	  targets	  of	  the	  Doa10	  or	  Ubr1	  branches	  of	  the	  N-­‐end	  rule	  pathway.	  The	  topologically	  unique	  location	  of	  N-­‐terminal	  residues,	  their	  massive	  involvement	  in	  proteolysis,	  and	  their	  extensive	  modifications	  make	  N-­‐degrons	  a	  particularly	  striking	  example	  of	  the	  scope	  and	  subtlety	  of	  regulated	  protein	  degradation	  (Fig.	  4	  and	  fig.	  S1C).	  
Materials	  and	  Methods	  Yeast	  strains,	  media	  and	  genetic	  techniques	  
S.	  cerevisiae	  strains	  used	  in	  this	  study	  are	  described	  in	  Table	  S1.	  Standard	  techniques	  (1,	  2)	  were	  employed	  for	  strain	  construction	  and	  transformation.	  The	  strains	  CHY248,	  CHY223,	  or	  CHY229	  were	  produced	  using	  PCR-­‐derived	  KanMX6	  modules	  (3).	  The	  strains	  CH287	  and	  CHY288	  were	  constructed	  by	  disrupting	  UBC4	  in	  BY4742	  and	  BY17299	  (Table	  S1)	  through	  a	  PCR-­‐mediated	  gene	  targeting	  that	  employed	  the	  pRS315	  plasmid	  (4),	  similarly	  to	  a	  previously	  described	  procedure	  (5).	  E2,	  E3	  and	  N-­‐acetyltransferase	  (Nt-­‐acetylase)	  mutant	  strains	  used	  in	  this	  study	  were	  from	  the	  Varshavsky	  laboratory’s	  strain	  collection	  or	  from	  Open	  Biosystems	  (Huntsville,	  AL).	  S.	  cerevisiae	  media	  included	  YPD	  (1%	  yeast	  extract,	  2%	  peptone,	  2%	  glucose;	  only	  most	  relevant	  components	  are	  cited);	  SD	  medium	  (0.17%	  yeast	  nitrogen	  base,	  0.5%	  ammonium	  sulfate,	  2%	  glucose);	  and	  synthetic	  complete	  (SC)	  medium	  (0.17%	  yeast	  nitrogen	  base,	  0.5%	  ammonium	  sulfate,	  2%	  glucose),	  plus	  a	  drop-­‐out	  mixture	  of	  compounds	  required	  by	  a	  given	  auxotrophic	  strain.	  Test	  proteins	  and	  construction	  of	  plasmids	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The	  plasmids	  used	  in	  this	  study	  are	  described	  in	  Table	  S2.	  The	  low	  copy	  (CEN)	  plasmid	  pCH178,	  which	  expressed	  Ub-­‐CK-­‐	  eK	  -­‐Ura3	  (Ub-­‐Cys-­‐Lys-­‐	  eK	  -­‐ha-­‐Ura3)	  from	  the	  PCUP1	  promoter	  was	  derived	  from	  the	  pRS314	  vector	  (4).	  To	  construct	  pCH178,	  a	  ubiquitin	  (Ub)-­‐gene	  fragment	  from	  the	  pMET416FUPRCUP9NSF	  plasmid	  (6)	  was	  PCR-­‐amplified	  (using	  primers	  OCH201	  and	  OCH214	  (Table	  S3)),	  digested	  with	  
EcoRI/BamHI	  and	  thereafter	  subcloned	  into	  EcoRI/BamHI-­‐cut	  pBAM	  (Table	  S2).	  pCH669,	  pCH508	  or	  pCH509	  were	  constructed	  by	  subcloning	  relevant	  DNA	  fragments	  from	  SacI/XhoI-­‐cut	  pCH504,	  pCH505	  or	  pCH506	  that	  expressed	  ML-­‐	  eK	  -­‐Ura3,	  SL-­‐	  eK	  -­‐Ura3	  or	  TL-­‐	  eK	  -­‐Ura3,	  respectively,	  into	  SacI/XhoI-­‐cut	  pRS313	  vector	  (4).	  To	  produce	  other	  plasmids	  that	  expressed	  XZ-­‐	  eK-­‐Ura3	  proteins,	  the	  corresponding	  EcoRI/BamHI-­‐digested	  PCR-­‐produced	  fragments	  encoding	  Ub-­‐XZ-­‐	  eK-­‐Ura3	  (X	  and	  Z	  denote	  varied	  residues)	  were	  subcloned	  into	  EcoRI/BamHI-­‐cut	  pBAM	  vector	  or	  pCH508	  (Table	  S2).	  S.	  cerevisiae	  Tbf1	  is	  a	  63	  kDa	  (N-­‐terminal	  Met-­‐Asp)	  transcriptional	  activator	  and	  regulator	  of	  telomere	  length	  (refs.	  (7-­‐9)	  and	  refs.	  therein).	  The	  95	  kDa	  Slk19	  (N-­‐terminal	  Met-­‐Asn)	  is	  a	  kinetochore-­‐associated	  regulator	  of	  chromosome	  segregation	  (10,	  11).	  The	  25	  kDa	  Ymr090w	  (N-­‐terminal	  Ser-­‐Pro)	  is	  a	  cytosolic	  protein	  of	  unknown	  function,	  with	  sequence	  similarities	  to	  DTDP-­‐glucose	  4,6-­‐dehydratases.	  The	  24	  kDa	  His3	  (N-­‐terminal	  Thr-­‐Glu)	  is	  imidazole	  glycerol-­‐phosphate	  dehydratase	  (IGPD),	  an	  enzyme	  of	  histidine	  biosynthesis	  (12,	  
13).	  The	  50	  kDa	  Pop2	  (N-­‐terminal	  Met-­‐Gln)	  is	  a	  subunit	  of	  a	  complex	  that	  deadenylates	  mRNAs	  (14).	  The	  102-­‐kDa	  Hsp104	  (N-­‐terminal	  Met-­‐Asn)	  is	  a	  chaperone	  and	  heat	  stress	  protein	  (refs.	  (15,	  16)	  and	  refs.	  therein).	  The	  56	  kDa	  Aro8	  (N-­‐terminal	  Thr-­‐Leu)	  is	  an	  aromatic	  aminotransferase	  that	  participates	  in	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particular,	  in	  the	  biosynthesis	  of	  phenylalanine	  (17).	  The	  57	  kDa	  Ubp6	  (N-­‐terminal	  Ser-­‐Gly)	  is	  a	  deubiquitylating	  enzyme	  associated	  with	  the	  26S	  proteasome	  (18-­‐20).	  The	  24	  kDa	  Tho1	  (N-­‐terminal	  Ala-­‐Asp)	  is	  a	  nuclear	  RNA-­‐binding	  protein	  (21).	  The	  open	  reading	  frame	  (ORF)	  encoding	  TBF1ha	  with	  a	  C-­‐terminal	  ha	  tag	  was	  subcloned	  into	  the	  low-­‐copy	  (CEN)	  pRS316	  vector	  (4),	  and	  was	  expressed	  from	  the	  vector’s	  PCUP1	  promoter.	  The	  TBF1ha	  ORF	  was	  produced	  by	  PCR,	  using	  S.	  cerevisiae	  genomic	  DNA	  and	  specific	  primers	  for	  DNA	  fragments	  encoding	  wild-­‐type	  MDTbf1ha	  (with	  N-­‐terminal	  Met-­‐Asp),	  the	  mutant	  MKTbf1ha,	  (with	  Lys	  at	  position	  2),	  and	  the	  mutant	  
MGTbf1ha	  (with	  N-­‐terminal	  Gly,	  after	  removal	  of	  N-­‐terminal	  Met	  by	  MetAPs).	  Similar	  procedures	  were	  used	  to	  construct	  and	  amplify	  DNA	  fragments	  encoding	  wild-­‐type	  
MNSlk19ha	  (with	  N-­‐terminal	  Met-­‐Asn);	  mutant	  MKSlk19ha	  (with	  Lys	  at	  position	  2);	  mutant	  MGSlk19ha	  (with	  N-­‐terminal	  Gly);	  wild-­‐type	  MSYmr090wha	  (with	  N-­‐terminal	  Met-­‐Ser);	  mutant	  MKYmr090wha	  (with	  Lys	  at	  position	  2);	  mutant	  MGYmr090wha	  (with	  N-­‐terminal	  Gly);	  wild-­‐type	  MTHis3ha	  (with	  N-­‐terminal	  Met-­‐Thr);	  wild-­‐type	  MQPop2ha	  (with	  N-­‐terminal	  Met-­‐Gln);	  wild-­‐type	  MNHsp104ha	  (with	  N-­‐terminal	  Met-­‐Asn);	  mutant	  MKHsp104ha	  (with	  Lys	  at	  position	  2);	  and	  also	  wild-­‐type	  Aro8ha,	  Ubp6ha,	  and	  Tho1ha.	  These	  DNA	  fragments	  were	  digested	  with	  BamHI/NotI	  or	  EcoRI/XhoI	  and	  subcloned	  into	  BamHI/NotI-­‐cut	  pRS316-­‐CUP1	  or	  EcoRI/XhoI-­‐cut	  pCH508.	  To	  construct	  a	  library	  of	  plasmids	  encoding	  Ub-­‐CZ-­‐	  eK-­‐Ura3	  (Z=any	  residue	  except	  Trp,	  Gln,	  Glu,	  Lys),	  EcoRI/BamHI-­‐digested,	  PCR-­‐amplified	  Ub	  gene	  fragment	  from	  pBAM	  (Table	  S2)	  were	  subcloned	  into	  EcoRI/BamHI-­‐cut	  pCH178	  (Table	  S2),	  followed	  by	  transformation	  of	  E.	  coli	  DH5α.	  PCR	  primers	  used	  for	  the	  above	  amplification	  were	  OCH201	  (GGG	  GAA	  TTC	  ATG	  CAG	  ATT	  TTC	  GTC	  AAG	  ACT	  TTG	  GTC,	  EcoRI	  site	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underlined)	  and	  OCH202	  (AAA	  GGA	  TCC	  RNN	  ACA	  ACC	  ACC	  TCT	  TAG	  CCT	  TAG	  CAC	  AAG,	  R=A,	  G;	  N=A,	  C,	  G,	  T;	  BamHI	  site	  underlined).	  EcoRI/BamHI-­‐digestion	  of	  20	  randomly	  retrieved	  plasmids	  from	  transformants	  suggested	  correct	  insertions	  in	  more	  than	  90%	  of	  plasmids	  in	  this	  library.	  After	  pooling	  ~1,000	  E.	  coli	  transformants,	  a	  plasmid	  DNA	  preparation	  was	  made	  and	  thereafter	  used	  as	  the	  CZ-­‐	  eK-­‐Ura3	  library.	  pCH535,	  which	  expressed	  MNMATα23-­‐67-­‐	  eK-­‐Ura3,	  was	  constructed	  by	  subcloning	  a	  SacII/BamHI-­‐digested	  DNA	  fragment	  (produced	  by	  PCR	  from	  S.	  
cerevisiae	  genomic	  DNA	  and	  the	  primer	  pairs	  OCH817	  and	  OCH833	  (Table	  S3))	  into	  
SacII/BamHI-­‐cut	  pCH178.	  pCH641	  (Table	  S2)	  was	  produced	  by	  inserting	  SacI/XhoI-­‐
cut	  pCH535	  into	  SacI/XhoI-­‐cut	  p416MET25.	  To	  construct	  pCH645,	  SacII/KpnI-­‐
digested	  pCH535	  (Table	  S2)	  was	  subcloned	  into	  SacII/KpnI-­‐cut	  pH10UE,	  yielding	  pCH622.	  Thereafter	  BamHI/HindIII-­‐cut	  pEJJ-­‐M	  was	  subcloned	  into	  pCH622	  (Table	  S2),	  yielding	  pCH645.	  To	  construct	  pCH595,	  a	  DNA	  fragment	  containing	  a	  5’-­‐proximal	  part	  of	  the	  S.	  cerevisiae	  DOA10	  ORF,	  a	  SmaI	  site	  and	  a	  3-­‐proximal	  part	  of	  the	  DOA10f	  fragment	  was	  PCR-­‐amplified	  using	  the	  primers	  OCH901	  and	  OCH902	  (Table	  S3).	  The	  resulting	  DNA	  fragment	  was	  subcloned	  into	  BamHI/XhoI-­‐cut	  p425GAL1	  vector	  (22),	  yielding	  pCH581.	  That	  plasmid	  was	  digested	  with	  SmaI	  and	  transformed	  into	  the	  SC295	  S.	  cerevisiae	  strain	  to	  clone	  C-­‐terminally	  flag-­‐tagged	  
DOA10	  using	  gap	  repair.	  The	  resulting	  pCH595	  plasmid	  (Table	  S2)	  expressed	  Doa10f	  from	  the	  PGAL1	  promoter	  of	  the	  high	  copy	  pRS425GAL1	  plasmid.	  pCH704,	  pCH705,	  or	  pCH706,	  which	  expressed	  XZ-­‐MATα23-­‐210f	  from	  the	  PMET25	  promoter	  on	  a	  low	  copy	  plasmid,	  were	  constructed	  by	  inserting	  the	  BamHI/XhoI-­‐digested,	  C-­‐terminally	  flag-­‐tagged	  MATα2f	  ORF	  (produced	  by	  PCR	  from	  S.	  cerevisiae	  genomic	  DNA	  and	  the	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primer	  pairs	  OCH989/OCH819,	  OCH990/OCH819	  or	  OCH991/OCH819	  (Table	  S3))	  into	  the	  p416MET25	  vector	  (Table	  S2).	  pCH719,	  expressing	  MATα2f	  	  as	  Ub-­‐reference	  fusions	  (see	  fig.	  S5D,	  E),	  were	  constructed	  by	  subcloning	  SacII/XhoI-­‐cut	  MATα2f	  ORF	  (PCR-­‐produced	  using	  the	  primer	  pairs	  OCH817/OCH819	  (Table	  S3))	  into	  
SacII/XhoI-­‐cut	  pMET416FUPRCUP9NSF	  (Table	  S2).	  Construction	  details	  for	  other	  plasmids	  (Table	  S2)	  are	  available	  upon	  request.	  All	  final	  constructs	  were	  verified	  by	  DNA	  sequencing.	  Screening	  a	  library	  of	  CZ-­‐eK-­‐Ura3	  fusions	  	  CZ-­‐eK-­‐Ura3	  library	  plasmids	  were	  transformed	  into	  S.	  cerevisiae	  JD52	  (Table	  S1)	  and	  thereafter	  plated	  on	  SC(-­‐Trp;	  -­‐Ura;	  +FOA	  (1	  mg/ml);	  +CuSO4	  (10	  μM)).	  Among	  ~6,200	  transformants,	  ~165	  colonies	  were	  formed	  on	  these	  FOA-­‐based	  plates,	  with	  selection	  for	  low	  levels	  of	  Ura3.	  After	  streaking	  and	  re-­‐growing	  FOA-­‐resistant	  transformants	  on	  the	  same	  medium	  for	  2	  days	  at	  30°C,	  80	  colonies	  were	  re-­‐isolated.	  Plasmids	  were	  retrieved	  from	  these	  colonies	  and	  initially	  analyzed	  using	  
BamHI/EcoRI	  digestion	  and	  gel	  electrophoresis,	  followed	  by	  a	  partial	  sequencing	  of	  51	  plasmids.	  Although	  most	  CZ-­‐eK-­‐Ura3	  fusions	  that	  yielded	  low	  levels	  of	  Ura3	  activity	  resulted	  from	  truncating	  mutations	  in	  the	  Ub	  or	  Ura3	  moieties,	  three	  low-­‐Ura3	  isolates	  (Z=Leu,	  Val,	  Pro)	  encoded	  intact	  Ub	  and	  Ura3.	  These	  fusions	  were	  analyzed	  using	  degradation	  assays	  (see	  the	  main	  text).	  Purification	  of	  Ub-­‐XZ-­‐MATα23-­‐67-­‐eK-­‐DHFRha	  and	  in	  vitro	  deubiquitylation	  	  The	  plasmids	  pCH645,	  pCH646,	  pCH647,	  and	  pCH648,	  which	  encoded	  His10Ub-­‐XZ-­‐α23-­‐67-­‐eK-­‐DHFRha	  (X=Met,	  Gly,	  Arg;	  Z=Asn,	  Lys),	  were	  transformed	  into	  BL21(DE3)	  CodonPlus	  E.	  coli	  cells	  (Stratagene,	  La	  Jolla,	  CA).	  50-­‐ml	  overnight	  culture	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of	  transformed	  cells	  was	  inoculated	  into	  800	  ml	  of	  LB	  medium	  containing	  100	  μg/ml	  ampicilin	  and	  34	  μg/ml	  chloramphenicol,	  followed	  by	  growth	  at	  37°C	  to	  A600	  of	  ~0.6.	  Expression	  of	  His10Ub-­‐XZ-­‐Matα23-­‐67-­‐eK-­‐DHFRha	  was	  induced	  with	  isopropyl	  β-­‐D-­‐thiogalactoside	  (IPTG)	  at	  0.2	  mM	  for	  4	  hr	  at	  30°C.	  His10Ub-­‐XZ-­‐Matα23-­‐67-­‐eK-­‐DHFRha	  fusion	  proteins	  were	  purified	  by	  affinity	  chromatography	  with	  Ni-­‐NTA	  resin	  (Qiagen,	  Valencia,	  CA).	  Briefly,	  E.	  coli	  cells	  were	  harvested	  by	  centrifugation	  and	  frozen	  at	  -­‐80°C.	  Cell	  pellets	  were	  thawed	  and	  resuspended	  in	  Ni-­‐NTA	  binding	  buffer	  (10%	  glycerol,	  20	  mM	  imidazole,	  0.3	  M	  NaCl,	  10	  mM	  β-­‐mercaptoethanol,	  1	  mM	  PMSF,	  50	  mM	  NaH2PO4/Na2HPO4	  (pH	  7.5))	  containing	  1x	  Protease	  Inhibitor	  Cocktail	  “for	  use	  in	  purification	  of	  histidine-­‐tagged	  proteins”	  (Sigma-­‐Aldrich,	  St.	  Louis,	  MO).	  Cells	  were	  disrupted	  by	  sonication,	  5	  times	  for	  1	  min	  each	  at	  1-­‐min	  intervals,	  followed	  by	  the	  addition	  of	  NP40	  to	  the	  final	  concentration	  of	  0.1%.	  After	  centrifugation	  of	  the	  extract	  at	  11,200g	  for	  30	  min,	  the	  supernatant	  was	  added	  to	  2	  ml	  of	  Ni-­‐NTA	  resin	  (Qiagen,	  50%	  slurry),	  and	  incubated	  for	  2	  hr	  at	  4°C.	  The	  resin	  was	  transferred	  to	  a	  10-­‐ml	  column	  and	  washed	  4	  times	  with	  50	  ml	  of	  washing	  buffer	  (10%	  glycerol,	  50	  mM	  imidazole,	  0.3	  M	  NaCl,	  10	  mM	  β-­‐mercaptoethanol,	  50	  mM	  NaH2PO4/Na2HPO4,	  pH	  7.5).	  His10Ub-­‐XZ-­‐Matα23-­‐67-­‐eK-­‐DHFRha	  proteins	  were	  then	  stepwise	  eluted	  using	  2-­‐ml	  samples	  of	  the	  binding	  buffer	  that	  contained	  increasing	  concentrations	  of	  imidazole	  (100,	  150,	  200,	  250,	  300	  mM).	  Pooled	  eluted	  samples	  were	  dialyzed	  overnight	  at	  4°C	  against	  storage	  buffer	  (10%	  glycerol,	  0.15	  M	  NaCl,	  10	  mM	  β-­‐mercaptoethanol,	  50	  mM	  NaH2PO4/Na2HPO4,	  pH	  7.5).	  Thus	  purified	  His10Ub-­‐X-­‐eK-­‐DHFRha	  proteins	  (~1	  mg)	  were	  digested	  with	  purified	  Usp2-­‐cc	  deubiquitylating	  enzyme(23,	  24)	  (0.1	  mg	  overnight	  at	  4°C	  in	  1	  ml	  of	  cleavage	  buffer	  (10%	  glycerol,	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0.3	  M	  NaCl,	  2	  mM	  β-­‐mercaptoethanol	  50	  mM	  NaH2PO4/Na2HPO4,	  pH	  7.5).	  His10-­‐tagged	  ubiquitin	  and	  His6-­‐	  tagged	  Usp2-­‐cc	  were	  removed	  by	  incubation	  with	  Ni-­‐NTA	  (0.5	  ml)	  for	  1	  h	  at	  4°C.	  The	  unbound	  proteins	  were	  dialyzed	  against	  second	  storage	  buffer	  (10%	  glycerol,	  0.15	  M	  NaCl,	  5	  mM	  β-­‐mercaptoethanol,	  50	  mM	  HEPES,	  pH	  7.5)	  and	  frozen	  at	  -­‐80°C.	  In	  vitro	  acetylation	  assay	  	  A	  sample	  of	  purified	  XZ-­‐Matα3-­‐67-­‐eK-­‐DHFRhas	  (~15	  μg)	  was	  incubated	  in	  20	  μl	  of	  anti-­‐ha	  agarose	  (50%	  slurry)	  (Sigma-­‐Aldrich)	  on	  ice	  for	  30	  min,	  was	  further	  washed	  in	  0.25	  ml	  of	  lysis	  buffer	  (10%	  glycerol,	  0.15	  M	  NaCl,	  1	  mM	  PMSF,	  50	  mM	  HEPES	  (pH	  7.5))	  containing	  1x	  protease	  inhibitor	  cocktail	  “for	  use	  with	  fungal	  and	  
yeast	  extracts”	  (Sigma-­‐Aldrich).	  Whole-­‐cell	  extracts	  from	  wild-­‐type	  (BY4742;	  Table	  S1)	  S.	  cerevisiae	  were	  passed	  through	  the	  Protein	  Desalting	  Spin	  columns	  (Thermo	  Scientific,	  Rockford,	  IL).	  Samples	  of	  XZ-­‐α3-­‐67-­‐eK-­‐DHFRha	  bound	  to	  anti-­‐ha-­‐agarose	  beads	  were	  incubated	  in	  0.1	  ml	  of	  a	  reaction	  mixture	  (0.1	  mg	  crude	  extract,	  5	  mM	  Na-­‐butyrate	  (Sigma-­‐Aldrich),	  0.2	  μCi	  C14-­‐Acetyl-­‐Coenzyme	  A	  (Ac-­‐CoA)	  (1.85	  Mbq)	  (Perkin-­‐Elmer,	  Fremont,	  CA)	  for	  1	  hr	  at	  30°C.	  After	  washing	  the	  beads	  3	  times	  with	  0.4	  ml	  of	  lysis	  buffer,	  the	  bound	  proteins	  were	  eluted	  and	  fractionated	  by	  SDS-­‐12%	  PAGE	  (Tris-­‐glycine),	  followed	  by	  autoradiography	  with	  X-­‐ray	  films,	  at	  -­‐80°C	  for	  30	  days.	  Antibody	  specific	  for	  Nt-­‐acetylated	  N-­‐terminal	  sequence	  of	  MATα2	  	  The	  Nt-­‐acetylated	  synthetic	  peptide	  AcMNKIPIKDLLNC	  and	  its	  unacetylated	  counterpart	  MNKIPIKDLLNC	  were	  produced	  and	  purified	  by	  Abgent	  (San	  Diego,	  CA).	  Except	  for	  C-­‐terminal	  Cys	  (used	  for	  conjugation	  of	  peptides	  to	  keyhole	  limpet	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hemocyanin),	  the	  amino	  acid	  sequence	  of	  these	  peptides	  was	  identical	  to	  the	  N-­‐terminal	  region	  of	  MATα2.	  Standard	  procedures	  (2)	  were	  employed	  by	  Abgent	  to	  produce	  rabbit	  antisera	  to	  AcMNKIPIKDLLNC.	  Antibodies	  that	  bound	  to	  
AcMNKIPIKDLLNC	  were	  selected	  from	  immune	  sera	  by	  affinity	  chromatography	  on	  a	  resin	  derivatized	  with	  this	  Nt-­‐acetylated	  peptide.	  The	  resulting	  samples	  were	  then	  “negatively”	  selected	  by	  passing	  them	  through	  a	  resin	  derivatized	  with	  MNKIPIKDLLNC,	  the	  unacetylated	  counterpart	  of	  AcMNKIPIKDLLNC.	  The	  resulting	  antibody,	  termed	  anti-­‐AcNtMATα2,	  was	  highly	  specific	  for	  Nt-­‐acetylated	  Matα2,	  and	  was	  employed	  to	  directly	  detect	  Nt-­‐acetylated	  species	  of	  a	  Matα2-­‐derived	  reporter	  in	  S.	  cerevisiae	  extracts	  (see	  Results).	  Immunoblotting	  with	  anti-­‐AcNtMATα2	  (0.5	  μg/ml)	  were	  carried	  out	  for	  4	  h	  at	  room	  temperature	  (RT)	  in	  5%	  skin	  milk	  in	  PBST	  (PBS	  containing	  0.5%	  Tween-­‐20).	  The	  bound	  anti-­‐AcNtMATα2	  was	  detected	  using	  the	  Odyssey	  Imaging	  System	  (Li-­‐Cor,	  Lincoln,	  NE)	  and	  a	  goat	  anti-­‐rabbit	  antibody	  (at	  1:5,000	  dilutions)	  that	  was	  conjugated	  to	  IRDye-­‐680	  (Li-­‐Cor).	  Cycloheximide-­‐chase	  degradation	  assay	  
S.	  cerevisiae	  were	  grown	  to	  A600	  of	  0.8	  to	  1.0	  in	  plasmid-­‐maintaining	  (selective)	  liquid	  media	  at	  30°C,	  followed	  by	  treatment	  with	  cycloheximide	  (CHX),	  at	  the	  final	  concentration	  of	  0.1	  mg/ml).	  At	  indicated	  times,	  cell	  samples	  (corresponding	  to	  1	  ml	  of	  cell	  suspension	  at	  A600	  of	  1)	  were	  harvested	  by	  centrifugation	  for	  30	  sec	  at	  11,200g,	  and	  resuspended	  in	  1	  ml	  of	  0.2	  M	  NaOH,	  for	  20	  min	  on	  ice,	  or	  for	  5	  min	  at	  room	  temperature,	  followed	  by	  centrifugation	  for	  30	  sec	  at	  11,200g.	  Pelleted	  cells	  were	  resuspended	  in	  50	  μl	  of	  HU	  buffer	  (8	  M	  urea,	  5%	  SDS,	  1	  mM	  EDTA,	  0.1	  M	  dithiothreitol	  (DTT),	  0.005%	  bromophenol	  blue,	  0.2	  M	  Tris-­‐HCl,	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pH	  6.8)	  containing	  1x	  protease	  inhibitor	  cocktail	  “for	  use	  with	  fungal	  and	  yeast	  
extracts”	  (Sigma-­‐Aldrich),	  and	  heated	  for	  10	  min	  at	  70°C.	  After	  centrifugation	  at	  5	  min	  at	  11,200g,	  10	  μl	  of	  supernatant	  was	  fractionated	  by	  SDS-­‐4-­‐12%	  NuPAGE	  (Invitrogen,	  Carlsbad,	  CA),	  followed	  by	  immunoblotting	  with	  anti-­‐ha	  (1:2,000)	  and	  anti-­‐tubulin	  (1:4,000)	  antibodies	  (Sigma-­‐Aldrich).	  Quantitations	  of	  CHX-­‐chase	  immunoblotting	  patterns	  (see	  fig.	  S2)	  were	  carried	  out	  using	  the	  ImageJ	  software	  (http://rsb.info.nih.gov/ij/index.html).	  
35S-­‐pulse-­‐chase	  degradation	  assays	  
35S-­‐pulse-­‐chase	  experiments	  were	  performed	  essentially	  as	  described	  (5,	  6,	  
25),	  with	  slight	  modifications.	  S.	  cerevisiae	  BY4742	  (wild	  type),	  BY17299	  (doa10Δ)	  ,	  BY15546	  (nat3Δ),	  and	  CHY287	  (ubc4Δ),	  or	  CHY288	  (ubc4Δ	  doa10Δ)	  that	  carried	  either	  p416MET25,	  pCH704,	  pCH705,	  pCH706	  or	  pCH719	  were	  grown	  at	  30°C	  to	  A600	  of	  ~1	  in	  10	  ml	  of	  SD	  medium	  with	  required	  amino	  acids	  for	  auxotrophic	  growth.	  Cells	  were	  pelleted	  by	  centrifugation	  and	  washed	  with	  0.8	  ml	  of	  SD	  medium	  with	  required	  amino	  acids.	  Cell	  pellets	  were	  gently	  resuspended	  in	  0.4	  ml	  of	  the	  same	  medium	  and	  labeled	  for	  5	  min	  at	  30°C	  with	  0.16	  mCi	  of	  35S-­‐EXPRESS	  (Perkin-­‐Elmer).	  Cells	  were	  pelleted	  again	  and	  resuspended	  in	  0.3	  ml	  of	  SD	  medium	  containing	  cold	  10	  mM	  methionine	  and	  5	  mM	  cysteine	  and	  required	  amino	  acids.	  Samples	  (0.1	  ml)	  were	  taken	  at	  the	  indicated	  time	  points,	  followed	  by	  preparation	  of	  extracts,	  immunoprecipitation	  with	  anti-­‐flag	  agarose,	  SDS-­‐4-­‐12%	  NuPAGE,	  and	  autoradiography.	  In	  other,	  similar	  35S-­‐pulse-­‐chase	  experiments,	  S.	  cerevisiae	  JD53	  expressing	  either	  pCH178,	  pCH195,	  pCH504	  or	  pCH547	  were	  grown	  at	  30°C	  to	  A600	  of	  ~1	  in	  10	  ml	  of	  SC(-­‐Trp)	  medium	  containing	  10	  μM	  CuSO4	  and	  required	  amino	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acids.	  Pulse-­‐chases	  were	  then	  preformed	  as	  described	  above,	  in	  SD	  medium	  with	  10	  μM	  CuSO4	  and	  required	  amino	  acids.	  For	  35S-­‐pulse-­‐chase	  assays	  that	  involved	  2-­‐D	  electrophoresis	  (fig.	  S8	  and	  data	  not	  shown),	  S.	  cerevisiae	  BY4742	  (wild	  type)	  or	  BY17299	  (doa10Δ)	  that	  carried	  pCH641	  (Table	  S2)	  were	  grown	  at	  30°C	  to	  A600	  of	  ~0.8	  in	  200	  ml	  of	  SD	  medium	  with	  required	  amino	  acids	  and	  0.1	  mM	  CuSO4.	  Cells	  were	  pelleted	  by	  centrifugation	  and	  washed	  with	  10	  ml	  of	  SD	  medium	  with	  required	  amino	  acids	  and	  0.1	  mM	  CuSO4,	  followed	  by	  incubation	  for	  30	  min	  at	  30°C	  in	  the	  same	  medium	  that	  lacked	  methionine	  and	  cysteine.	  Cells	  were	  harvested	  by	  centrifugation.	  The	  pellets	  were	  gently	  resuspended	  in	  20	  ml	  of	  the	  same	  medium	  and	  labeled	  for	  15	  min	  at	  30°C	  with	  2	  mCi	  of	  35S-­‐EXPRESS	  (Perkin-­‐Elmer).	  Cells	  were	  pelleted	  again	  and	  resuspended	  in	  20	  ml	  of	  SD	  medium	  containing	  unlabeled	  10	  mM	  methionine	  and	  5	  mM	  cysteine,	  required	  amino	  acids,	  and	  0.1	  mM	  CuSO4.	  Samples	  (10	  ml)	  were	  taken	  at	  0	  and	  3-­‐hr	  time	  points,	  followed	  by	  preparation	  of	  extracts,	  using	  the	  Sample	  Buffer	  Mailing	  kit	  (Kendrick	  laboratories,	  Madison,	  WI).	  2D-­‐electrophoretic	  analyses	  and	  autoradiography	  of	  our	  samples	  were	  carried	  out	  by	  Kendrick	  Laboratories,	  Inc.	  The	  first-­‐dimension	  isoelectric	  focusing	  was	  performed	  using	  IEF	  tube	  gel	  containing	  2%	  pH	  4-­‐8	  mixed	  ampholines.	  The	  second	  dimension	  fractionation	  was	  by	  SDS-­‐10%	  PAGE,	  using	  22-­‐cm	  long	  slab	  gels.	  The	  latter	  were	  stained	  with	  Coomassie,	  vacuum-­‐dried,	  and	  subjected	  to	  autoradiography	  with	  Kodak	  BioMax	  X-­‐ray	  film	  for	  6	  hr	  at	  RT.	  Image	  matching	  of	  the	  autoradiograms	  to	  Coomassie-­‐	  stained	  gels	  was	  carried	  out	  manually.	  The	  relevant	  spots	  were	  excised	  from	  the	  gel,	  followed	  by	  their	  processing	  for	  in-­‐gel	  digestion	  with	  trypsin	  and	  mass	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spectrometry	  (MALDI-­‐TOF),	  which	  were	  performed	  by	  the	  Protein	  Analysis	  Facility	  at	  the	  Columbia	  University	  (New	  York,	  NY).	  Analysis	  of	  Nα-­‐terminal	  acetylation	  by	  mass	  spectrometry	  CHY288	  (doa10Δ	  ubc4Δ)	  S.	  cerevisiae	  expressing	  the	  C-­‐terminally	  flag-­‐tagged	  full-­‐length	  Matα2f	  from	  the	  PGAL1	  promoter	  were	  grown	  to	  A600	  of~	  0.6	  in	  2	  l	  of	  SC(-­‐Ura)	  medium	  containing	  0.1%	  glucose	  (instead	  of	  usual	  2%),	  and	  were	  incubated	  for	  a	  further	  24	  hr	  after	  the	  addition	  of	  30%	  galactose	  to	  the	  final	  concentration	  of	  2%.	  Cells	  were	  harvested	  by	  centrifugation	  at	  5,000g	  for	  5	  min,	  washed	  in	  phosphate-­‐buffered	  saline	  (PBS)	  and	  stored	  at	  -­‐80°C.	  The	  pellets	  were	  resuspended	  in	  10	  ml	  of	  lysis	  buffer	  (10%	  glycerol	  0.1%	  NP40,	  0.2	  M	  KCl,	  1	  mM	  EDTA,	  5	  mM	  β-­‐mercaptoethanol,	  1	  mM	  PMSF,	  50	  mM	  HEPES	  (pH	  7.5))	  containing	  1x	  protease	  inhibitor	  cocktail	  “for	  use	  with	  fungal	  and	  yeast	  extracts”	  (Sigma-­‐Aldrich).	  Cells	  were	  then	  disrupted	  using	  a	  FastPrep-­‐24	  instrument	  (MP	  Biomedicals,	  Solon	  OH)	  at	  the	  speed	  setting	  of	  6.5,	  at	  20	  sec/cycle,	  for	  10	  cycles.	  After	  removal	  of	  glass	  beads,	  the	  extracts	  were	  clarified	  by	  centrifugation	  at	  11,2000g	  for	  30	  min	  and	  incubated	  with	  0.2	  ml	  of	  anti-­‐flag	  M2	  agarose	  beads	  (50%	  slurry,	  Sigma-­‐Aldrich)	  for	  2	  hr	  at	  4°C.	  Beads	  were	  washed	  once	  in	  10	  ml	  of	  lysis	  buffer,	  then	  in	  10	  ml	  of	  the	  washing	  buffer	  (lysis	  buffer	  containing	  0.5	  M	  KCl)	  and	  finally	  in	  10	  ml	  of	  elution	  buffer	  (lysis	  buffer	  without	  NP40).	  Matα2f	  	  was	  eluted	  with	  0.2	  mg/ml	  of	  the	  flag	  peptide	  (Sigma-­‐Aldrich)	  in	  elution	  buffer.	  The	  eluted	  Matα2f	  was	  precipitated	  by	  20%	  CCl3COOH	  (TCA)	  (final	  concentration),	  and	  washed	  twice	  with	  cold	  acetone	  at	  -­‐20°C.	  Thus	  precipitated	  sample	  was	  solubilized	  in	  SDS-­‐sample	  buffer,	  heated	  at	  95°C	  for	  5	  min,	  and	  fractionated	  by	  SDS-­‐4-­‐12%	  NuPAGE.	  Proteins	  were	  stained	  with	  Novex	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Colloidal	  Blue	  Staining	  kit	  (Invitrogen).	  The	  band	  of	  Matα2f	  (~1	  μg)	  was	  excised	  and	  transferred	  to	  0.65	  ml	  of	  SafeSeal	  Microcentrifuge	  tube	  (Sorenson,	  Salk	  Lake	  City,	  UT).	  Gel	  slices	  were	  incubated	  2	  times	  for	  30	  min	  at	  37°C	  by	  shaking	  in	  0.2	  ml	  of	  destaining	  solution	  (25	  mM	  NH4HCO3	  in	  50%	  acetonitrile,	  pH	  8.0).	  After	  removing	  destaining	  solution,	  the	  samples	  were	  incubated	  at	  60°C	  for	  10	  min	  in	  30	  μl	  of	  reducing	  buffer	  (50	  mM	  Tris[2-­‐carboxyethyl]phosphine	  (TCEP)	  (Thermo	  Scientific)	  in	  25	  mM	  NH4HCO3,	  pH	  8.0).	  After	  cooling	  the	  sample	  to	  RT	  and	  removing	  the	  reducing	  buffer,	  gel	  slices	  were	  incubated	  in	  the	  dark	  at	  RT	  for	  1	  hr	  in	  30	  μl	  of	  alkylation	  buffer	  (0.1	  M	  iodoacetamide,	  25	  mM	  NH4HCO3,	  pH	  8.0).	  After	  removing	  the	  alkylation	  buffer,	  gel	  slices	  were	  shrank	  by	  incubating	  them	  twice	  for	  15	  min	  at	  37°C	  (with	  shaking)	  in	  50	  μl	  of	  acetonitrile	  at	  RT.	  After	  removing	  acetonitrile,	  gel	  slices	  were	  air-­‐dried	  for	  10	  min	  and	  swelled	  in	  25	  μl	  of	  25	  mM	  NH4HCO3,	  pH	  8.0.	  Thereafter	  Matα2f	  in	  gel	  slices	  was	  digested	  in	  situ	  with	  100	  ng	  of	  Asp-­‐N	  endoprotease	  (Roche,	  Indianapolis,	  IN)	  overnight	  at	  37°C,	  whereas	  ML-­‐eK-­‐Ura3	  (see	  below)	  was	  digested	  identically	  but	  with	  100	  ng	  of	  activated	  trypsin	  (Thermo	  Scientific).	  Nt-­‐acetylated	  peptides	  in	  the	  resulting	  samples	  were	  analyzed	  by	  nanoscale-­‐microcapillary	  reversed	  phase	  liquid	  chromatography	  and	  tandem	  mass	  spectrometry	  (cLC-­‐MS/MS),	  using	  the	  QSTAR	  XL	  quadrupole	  time	  of	  flight	  mass	  spectrometer	  (Applied	  Biosystems,	  Foster	  City,	  CA).	  Acetylation	  sites	  were	  assigned	  by	  manual	  inspection	  of	  MS/MS	  spectra	  and	  also	  by	  using	  the	  Mascot	  search	  engine	  (Matrix	  Science,	  Boston,	  MA).	  Similar	  procedures	  were	  used	  to	  analyze	  Nα-­‐terminal	  acetylation	  of	  the	  short-­‐lived	  ML-­‐eK-­‐Ura3	  (ML-­‐eK-­‐ha-­‐Ura3)	  (fig.	  S5B,	  C)	  and	  SL-­‐eK-­‐Ura3	  (SL-­‐eK-­‐ha-­‐Ura3).	  CHY223	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(doa10Δ)	  S.	  cerevisiae	  expressing	  pCH504	  or	  pCH505	  (Table	  S1)	  were	  grown	  to	  A600	  of	  3	  to	  4	  in	  1	  liter	  of	  SC(-­‐Trp)	  medium	  containing	  0.1	  mM	  CuSO4.	  The	  cells	  were	  harvested	  by	  centrifugation	  at	  5,000g	  for	  5	  min,	  washed	  in	  PBS,	  stored	  at	  -­‐80°C,	  and	  were	  processed	  for	  isolation	  of	  ML-­‐eK-­‐Ura3	  and	  SL-­‐eK-­‐Ura3	  identically	  to	  the	  steps	  above	  for	  Matα2f,	  except	  that	  a	  cell	  extract	  was	  incubated	  with	  0.4	  ml	  of	  anti-­‐ha	  agarose	  beads	  (50%	  slurry)	  for	  2	  hr	  at	  4°C.	  Beads	  were	  washed	  in	  50	  ml	  of	  the	  lysis	  buffer	  and	  thereafter	  in	  10	  ml	  of	  the	  elution	  buffer	  (lysis	  buffer	  without	  NP40).	  ML-­‐eK-­‐Ura3	  and	  SL-­‐eK-­‐Ura3	  were	  eluted	  with	  1	  ml	  of	  the	  ha	  peptide	  (0.25	  mg/ml;	  Sigma-­‐Aldrich)	  in	  the	  elution	  buffer,	  and	  thereafter	  by	  2	  ml	  of	  0.1	  M	  glycine	  (pH	  3.0).	  The	  eluted	  proteins	  were	  precipitated	  by	  20%	  TCA.	  The	  rest	  of	  the	  procedure	  was	  identical	  to	  the	  one	  with	  Matα2f,	  except	  that	  ML-­‐eK-­‐Ura3	  and	  SL-­‐eK-­‐Ura3	  were	  digested	  in	  situ	  with	  trypsin,	  without	  reduction/alkylation	  steps.	  X-­‐peptide	  pulldown	  assay	  with	  Doa10myc13	  The	  previously	  characterized	  X-­‐peptide	  pulldown	  assay	  (26,	  27)	  utilized,	  in	  the	  present	  study,	  a	  set	  of	  12-­‐residue	  synthetic	  peptides	  XNKIPIKDLLNC	  (X=Met,	  
AcMet,	  Gly).	  Except	  for	  C-­‐terminal	  Cys	  (added	  for	  crosslinking	  to	  beads)	  and	  the	  varied	  identity	  of	  N-­‐terminal	  residue,	  these	  peptides	  were	  identical	  to	  the	  11-­‐residue	  N-­‐terminal	  region	  of	  MATα2.	  We	  also	  employed	  12-­‐	  residue	  peptides	  XIFSTDTGPGGC	  (X=Gly,	  Met,	  Arg,	  Phe).	  Except	  for	  C-­‐terminal	  Gly-­‐Gly-­‐Cys	  and	  the	  varied	  identity	  of	  N-­‐terminal	  residue,	  these	  peptides	  were	  identical	  to	  the	  9-­‐residue	  N-­‐terminal	  region	  of	  Sindbis	  virus	  RNA	  polymerase	  (nsP4)	  (refs.	  (26,	  28),	  and	  refs.	  therein).	  Each	  peptide,	  synthesized	  by	  Abgent	  (San	  Diego,	  CA),	  was	  purified	  by	  HPLC	  to	  greater	  than	  95%	  purity,	  and	  verified	  by	  mass	  spectrometry.	  A	  peptide	  (1	  mg)	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was	  crosslinked,	  via	  its	  C-­‐terminal	  Cys	  residue,	  to	  2	  ml	  (50%	  slurry)	  of	  SulfoLink	  Immobilization	  Kit	  for	  Peptides	  (Thermo	  Scientific),	  as	  described	  in	  the	  manufacturer’s	  protocol.	  Extract	  from	  S.	  cerevisiae	  CHY248	  cells	  (Table	  S1)	  containing	  full-­‐length,	  C-­‐terminally	  myc13-­‐tagged	  Doa10myc13,	  was	  diluted	  by	  lysis	  buffer	  (10%	  glycerol,	  1%	  Triton	  X100,	  0.15	  M	  NaCl,	  5	  mM	  β-­‐mercaptoethanol,	  1	  mM	  PMSF,	  50	  mM	  HEPES,	  (pH	  7.5)	  containing	  1x	  protease	  inhibitor	  cocktail	  “for	  use	  with	  
fungal	  and	  yeast	  extracts”	  (Sigma-­‐	  Aldrich))	  to	  1	  mg/ml	  of	  total	  protein.	  These	  samples	  also	  contained	  50	  μM	  bestatin	  (Sigma-­‐	  Aldrich),	  an	  aminopeptidase	  inhibitor.	  A	  sample	  (1	  ml)	  was	  transferred	  to	  a	  tube	  containing	  20	  μl	  (packed	  volume)	  of	  a	  carrier-­‐linked	  12-­‐residue	  peptide,	  followed	  by	  gentle	  mixing	  for	  2	  hr	  at	  4°C.	  Beads	  were	  pelleted	  by	  a	  brief	  centrifugation	  in	  a	  microcentrifuge,	  followed	  by	  three	  washes,	  for	  5	  min	  each,	  with	  lysis	  buffer.	  The	  beads	  were	  then	  suspended	  in	  20	  μl	  of	  SDS/PAGE	  loading	  buffer,	  and	  heated	  at	  65°C	  for	  10	  min,	  followed	  by	  a	  brief	  spin	  in	  a	  microcentrifuge,	  SDS-­‐4-­‐12%	  NuPAGE,	  and	  detection	  of	  Doa10myc13	  by	  immunoblotting	  with	  anti-­‐myc	  antibody.	  Purification	  of	  Doa10f	  	  for	  SPOT	  binding	  assay	  
S.	  cerevisiae	  SC295	  that	  carried	  pCH595	  and	  expressed	  the	  C-­‐terminally	  flag-­‐tagged	  Doa10	  (Doa10f)	  from	  the	  PGAL1	  promoter	  and	  the	  high	  copy	  plasmid	  pRS425	  was	  grown	  at	  30°C	  to	  A600	  of	  ~1	  in	  4	  liters	  of	  SC(-­‐Leu)	  medium	  containing	  1%	  glucose	  and	  2%	  galactose.	  Cells	  were	  harvested	  by	  centrifugation,	  washed	  once	  with	  ice-­‐cold	  PBS,	  quick-­‐frozen	  in	  liquid	  nitrogen,	  and	  stored	  at	  -­‐80°C.	  Frozen	  pellets	  were	  resuspended	  in	  50	  ml	  of	  lysis	  buffer	  (0.1	  M	  sorbitol	  50	  mM	  K-­‐acetate,	  2	  mM	  EDTA,	  1	  mM	  DTT,	  1	  mM	  PMSF,	  20	  mM	  HEPES	  (pH	  7.5)	  plus	  1x	  protease	  inhibitor	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cocktail	  “for	  use	  with	  fungal	  and	  yeast	  extracts”	  (Sigma-­‐Aldrich).	  Cells	  were	  then	  disrupted	  using	  a	  FastPrep-­‐24	  instrument	  (MP	  Biomedicals,	  Solon	  OH)	  at	  the	  speed	  setting	  of	  6.5,	  at	  20	  sec/cycle,	  for	  6	  cycles.	  After	  removal	  of	  the	  glass	  beads,	  unbroken	  cells	  were	  removed	  by	  two	  rounds	  of	  centrifugation	  in	  the	  Sorvall	  RT-­‐600B	  centrifuge	  at	  3,000	  rpm	  for	  5	  min	  at	  4°C.	  The	  resulting	  supernatant	  was	  centrifuged	  at	  11,200g	  for	  10	  min	  at	  4°C.	  The	  pellets,	  which	  contained	  membrane-­‐	  embedded	  Doa10f,	  were	  washed	  twice	  in	  25	  ml	  of	  buffer	  88	  (0.25	  M	  sorbitol,	  0.15	  M	  K-­‐acetate,	  5	  mM	  Mg-­‐acetate,	  20	  mM	  HEPES	  (pH	  6.8))	  containing	  1x	  protease	  inhibitor	  cocktail	  “for	  use	  with	  fungal	  and	  yeast	  extracts”	  (Sigma-­‐Aldrich),	  using	  centrifugation	  at	  11,200g	  for	  10	  min.	  The	  resulting	  microsomes	  were	  resuspended	  and	  solubilized	  by	  incubating	  in	  20	  ml	  of	  extraction	  buffer	  (10%	  glycerol,	  1%	  Triton	  X-­‐100,	  0.2	  M	  KCl,	  1	  mM	  EDTA,	  5	  mM	  β-­‐mercaptoethanol,	  1	  mM	  PMSF,	  50	  mM	  HEPES	  (pH	  7.5))	  containing	  1x	  protease	  inhibitor	  cocktail	  “for	  use	  with	  fungal	  and	  yeast	  
extracts”	  (Sigma-­‐Aldrich)	  for	  2	  hr	  at	  4°C.	  The	  resulting	  suspension	  was	  centrifuged	  at	  11,200g	  for	  30	  min,	  and	  the	  supernatant	  was	  gently	  mixed	  with	  2	  ml	  of	  anti-­‐flag	  M2	  affinity	  beads	  (50%	  slurry)	  (Sigma-­‐Aldrich)	  for	  2	  h	  at	  4°C.	  The	  beads	  were	  then	  collected	  by	  centrifugation	  in	  the	  Sorvall	  RT-­‐600B	  centrifuge	  at	  1,000	  rpm	  for	  5	  min	  at	  4°C,	  and	  were	  washed,	  repeatedly,	  with	  100	  ml	  of	  extraction	  buffer.	  The	  anti-­‐flag	  antibody-­‐bound	  Doa10f	  was	  eluted	  with	  5	  ml	  of	  extraction	  buffer	  containing	  0.5	  mg/ml	  of	  the	  flag	  peptide	  (Sigma-­‐Aldrich),	  followed	  by	  dialysis	  at	  4°C	  overnight	  against	  storage	  buffer	  (10%	  glycerol,	  1%	  Triton	  X-­‐100,	  0.15	  M	  NaCl,	  5	  mM	  β-­‐mercaptoethanol,	  50	  mM	  HEPES,	  pH	  7.5).	  SPOT	  binding	  assay	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These	  experiments	  employed	  synthetic	  XZ-­‐eK(3-­‐11)	  peptides	  and	  their	  Nt-­‐acetylated	  AcXZ-­‐eK(3-­‐11)	  counterparts	  that	  were	  C-­‐terminally	  linked	  to	  a	  cellulose-­‐PEG	  membrane	  as	  “dots”,	  in	  equal	  molar	  amounts.	  Except	  for	  varied	  residues	  XZ	  at	  positions	  1	  and	  2	  (including	  Nt-­‐acetylated	  versus	  unacetylated	  residues	  at	  position	  1),	  the	  sequences	  of	  the	  11-­‐residue	  SPOT-­‐arrayed	  peptides	  were	  identical	  to	  the	  N-­‐terminal	  sequence	  of	  eK	  (fig.	  S1D).	  These	  PepSpot	  (PEG)	  peptides	  were	  synthesized	  using	  JPT	  Peptide	  Technology,	  GmbH	  (JPT)	  (Berlin,	  Germany)	  (29).	  Each	  peptide	  “spot”	  contained	  approximately	  5	  nmoles	  of	  identical	  peptides	  covalently	  conjugated,	  C-­‐terminally,	  to	  a	  cellulose-­‐PEG-­‐membrane.	  Before	  the	  binding	  assay,	  dry	  membranes	  were	  washed	  in	  methanol	  for	  10	  min,	  and	  3	  times	  for	  20	  min	  each	  in	  Tris-­‐buffered	  saline	  (TBS)	  (170	  mM	  NaCl,	  6.4	  mM	  KCl,	  31	  mM	  Tris-­‐HCl,	  pH	  7.6)	  at	  RT,	  and	  thereafter	  blocked	  by	  incubation	  in	  buffer	  A	  (10%	  glycerol,	  50	  μM	  bestatine,	  0.1	  M	  NaCl,	  5	  mM	  β-­‐mercaptoethanol,	  50	  mM	  HEPES,	  pH	  7.5)	  for	  30	  min	  at	  RT.	  Thereafter	  a	  SPOT	  membrane	  was	  incubated	  with	  2.5	  ml	  of	  the	  purified	  Doa10f	  (0.1	  mg/ml)	  in	  the	  storage	  buffer	  (10%	  glycerol,	  1%	  Triton	  X-­‐100,	  0.15	  M	  NaCl,	  5	  mM	  β-­‐mercaptoethanol,	  50	  mM	  HEPES,	  pH	  7.5)	  at	  RT	  for	  2	  hr.	  The	  membrane	  was	  then	  washed	  twice	  in	  buffer	  A	  for	  15	  min.	  The	  bound	  Doa10f	  was	  electroblotted	  onto	  polyvinylene	  difluoride	  (PVDF)	  membranes	  (Millipore)	  using	  a	  semi-­‐dry	  blotter	  (Bio-­‐Rad,	  Hercules,	  CA).	  During	  the	  transfer,	  PVDF	  membranes	  were	  sandwiched	  between	  blotting	  paper	  soaked	  with	  cathode	  buffer	  (25	  mM	  Tris-­‐base,	  40	  mM	  6-­‐aminohexane	  acid,	  0.01%	  SDS,	  20%	  MeOH)	  and	  one	  of	  the	  anode	  buffers	  (AI:	  30	  mM	  Tris	  base,	  20%	  MeOH;	  AII:	  300	  mM	  Tris	  base,	  20%	  MeOH).	  Electroblotting	  was	  performed	  twice	  for	  30	  min	  at	  the	  constant	  current	  of	  0.8	  mA	  per	  cm2	  of	  cellulose	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membrane.	  The	  transferred	  Doa10f	  were	  detected	  by	  immunoblotting	  with	  anti-­‐flag	  antibody,	  using	  a	  SuperSignal	  West	  Pico	  Chemiluminescent	  Substrate	  (Thermo	  Scientific).	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  Figure	  4.1.	  Destabilizing	  N-­‐terminal	  residues.	  (A)	  CHX	  chases,	  for	  0,	  1,	  and	  2	  hours	  in	  wild-­‐type	  S.	  cerevisiae	  expressing	  CK-­‐eK-­‐Ura3	  (lanes	  1	  to	  3)	  or	  CL-­‐eK-­‐Ura3	  (lanes	  4	  to	  6).	  Cell	  extracts	  were	  fractionated	  by	  SDS–polyacrylamide	  gel	  electrophoresis,	  followed	  by	  immunoblotting	  with	  anti-­‐Ha	  and	  anti-­‐tubulin,	  the	  latter	  a	  loading	  control.	  (B)	  As	  in	  (A)	  but	  chases	  for	  0	  and	  2	  hours	  with	  XZ-­‐eK-­‐Ura3	  (X	  =	  Cys,	  Met,	  or	  Ser;	  Z	  =	  Trp,	  Val,	  or	  Leu)	  in	  wild-­‐type	  versus	  ubr1Δ	  cells.	  (C)	  As	  in	  (A)	  but	  with	  MZ-­‐eK-­‐Ura3	  (Z	  =	  Leu	  or	  Lys)	  in	  wild-­‐type	  cells.	  (D)	  As	  in	  (A)	  but	  chases	  for	  0,	  0.5,	  and	  1.5	  hours	  with	  XL-­‐eK-­‐Ura3	  (X	  =	  Gly,	  Val,	  Ala,	  or	  Thr)	  in	  wild-­‐type	  cells.	  (E)	  As	  in	  (A)	  but	  with	  CL-­‐eK-­‐Ura3	  in	  wild-­‐type	  cells	  (lanes	  1	  to	  3)	  versus	  doa10Δ	  cells	  (lanes	  4	  to	  6).	  (F)	  As	  in	  (E)	  but	  chases	  for	  0,	  0.5,	  1,	  and	  2	  hours	  with	  ML-­‐eK-­‐Ura3.	  (G)	  Lanes	  1	  and	  2,	  short-­‐lived	  ML-­‐eK-­‐Ura	  in	  the	  MG132-­‐sensitive	  pdr5Δ	  S.	  cerevisiae,	  in	  the	  absence	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and	  presence	  of	  MG132,	  respectively.	  Lanes	  3	  and	  4,	  same	  as	  lanes	  1	  and	  2	  but	  with	  long-­‐lived	  MK-­‐eK-­‐Ura3.	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  Figure	  4.2.	  Doa10	  as	  an	  N-­‐recognin.	  (A)	  Extracts	  from	  wild-­‐type,	  doa10Δ,	  and	  nat3Δ	  
S.	  cerevisiae	  that	  expressed	  XZ-­‐α23-­‐67-­‐eK-­‐Ura3	  (XZα2)	  (X	  =	  Met,	  Arg,	  or	  Gly;	  Z	  =	  Asn	  or	  Lys)	  were	  immunoblotted	  with	  anti-­‐AcNtMATα2	  (which	  selectively	  recognized	  Nt-­‐acetylated	  MNα2)	  or	  (separately)	  with	  anti-­‐Ha,	  which	  recognized	  both	  Nt-­‐acetylated	  and	  unacetylated	  MNα2,	  or	  with	  anti-­‐tubulin.	  XZα2	  (“α2”),	  Nt-­‐acetylated	  XZα2	  (“Ac-­‐α2”),	  and	  tubulin	  are	  indicated.	  Asterisks	  denote	  a	  protein	  cross-­‐reacting	  with	  anti-­‐
AcNtMATα2.	  (B)	  As	  in	  (A)	  but	  CHX	  chases	  for	  0,	  0.5,	  1,	  and	  2	  hours	  with	  MNα2,	  in	  wild-­‐type,	  doa10Δ,	  and	  nat3Δ	  cells.	  (C)	  Indicated	  amounts	  of	  the	  Nt-­‐acetylated	  Ac-­‐MNKIPIKDLLNC	  peptide	  versus	  its	  unacetylated	  counterpart	  were	  spotted	  onto	  membrane	  and	  assayed	  for	  their	  binding	  to	  anti-­‐AcNtMATα2.	  (D)	  X-­‐peptide	  pulldown	  with	  peptides	  XNKIPIKDLLNC	  (X	  =	  Met,	  AcMet,	  or	  Gly)	  (lanes	  2	  to	  4)	  or	  
	   125	  
XIFSTDTGPGGC	  (X	  =	  Gly,	  Met,	  Arg,	  or	  Phe)	  (lanes	  5	  to	  8)	  and	  extract	  of	  S.	  cerevisiae	  that	  expressed	  Doa10myc13.	  Lane	  1,	  input	  extract	  (5%).	  (E)	  SPOT	  assay	  with	  purified,	  flag-­‐tagged	  Doa10f	  and	  spot-­‐arrayed	  synthetic	  peptides	  XZ-­‐eK(3-­‐11)	  (X	  =	  Gly,	  Ala,	  Val,	  Pro,	  Ser,	  Thr,	  or	  Cys;	  Z	  =	  Leu	  or	  Lys)	  and	  their	  Nt-­‐acetylated	  XZ-­‐eK(3-­‐11)	  counterparts.	  XZ	  residues	  are	  indicated	  at	  the	  top	  of	  the	  membrane.	  (F)	  Quantitation,	  using	  a	  PhosphorImager,	  of	  35S-­‐pulse	  chases	  with	  MATα2f	  and	  its	  mutant	  derivatives	  (fig.	  S6,	  B	  and	  C).	  Solid	  circles,	  MNMATα2f;	  open	  circles,	  MKMATα2f;	  upright	  triangles,	  
GNMATα2f	  (initially	  MGNMATα2f)	  in	  ubc4Δ	  cells;	  inverted	  triangles,	  MNMATα2f	  in	  
ubc4Δ	  doa10Δ	  cells.	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  Figure	  4.3.	  AcN-­‐degrons	  in	  yeast	  proteins.	  (A)	  Lanes	  1	  to	  3,	  CHX	  chase	  for	  0,	  1,	  and	  2	  hours	  in	  wild-­‐type	  S.	  cerevisiae	  expressing	  Tbf1ha.	  Lanes	  4	  to	  6,	  7	  to	  9,	  and	  10	  to	  12,	  analogous	  patterns	  but	  in	  doa10Δ	  cells	  with	  MKTbf1ha	  (Lys	  at	  position	  2),	  GTbf1ha	  (initially	  MGTbf1ha),	  and	  wild-­‐type	  Tbf1ha,	  respectively.	  (B)	  As	  in	  (A)	  but	  with	  wild-­‐type	  Slk19ha	  and	  its	  mutant	  derivatives	  in	  wild-­‐type	  versus	  doa10Δ	  cells.	  (C)	  As	  in	  (A)	  but	  with	  wild-­‐type	  Ymr090wha	  and	  its	  mutant	  derivatives	  in	  wild-­‐type	  versus	  
doa10Δ	  cells.	  (D)	  As	  in	  (C)	  but	  with	  wild-­‐type	  Ymr090wha	  in	  wild-­‐type	  versus	  
doa10Δ	  and	  ard1Δ	  cells.	  (E)	  As	  in	  (A)	  but	  with	  wild-­‐type	  His3ha	  in	  wild-­‐type	  versus	  
doa10Δ	  cells.	  (F)	  As	  in	  (E),	  with	  wild-­‐type	  His3ha	  in	  wild-­‐type	  versus	  doa10Δ	  and	  
ard1Δ	  cells.	  (G)	  As	  in	  (A)	  but	  CHX	  chases	  for	  0,	  0.5,	  1,	  and	  2	  hours	  with	  wild-­‐type	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Aro8ha	  in	  wild-­‐type	  versus	  doa10Δ	  and	  ard1Δ	  cells.	  (H)	  As	  in	  (A)	  but	  with	  wild-­‐type	  Hsp104ha	  and	  its	  mutant	  derivatives	  in	  wild-­‐type	  versus	  doa10Δ	  cells.	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  Figure	  4.4.	  Nα-­‐terminal	  acetylases,	  Met-­‐aminopeptidases,	  and	  the	  Doa10	  branch	  of	  the	  N-­‐end	  rule	  pathway.	  (A)	  The	  Doa10-­‐mediated	  branch	  of	  the	  S.	  cerevisiae	  N-­‐end	  rule	  pathway	  (see	  fig.	  S1C	  for	  the	  Ubr1-­‐mediated	  branch	  of	  this	  pathway).	  The	  red	  arrow	  on	  the	  left	  indicates	  the	  MetAP-­‐mediated	  removal	  of	  N-­‐terminal	  Met.	  This	  Met	  is	  retained	  if	  a	  residue	  at	  position	  2	  is	  nonpermissive	  (too	  large)	  for	  MetAPs.	  If	  the	  retained	  N-­‐terminal	  Met	  or	  N-­‐terminal	  Ala,	  Val,	  Ser,	  Thr,	  and	  Cys	  are	  followed	  by	  acetylation-­‐permissive	  residues,	  the	  above	  N-­‐terminal	  residues	  are	  usually	  Nt-­‐acetylated	  (5–7).	  The	  resulting	  N-­‐degrons	  are	  termed	  AcN-­‐degrons.	  The	  term	  “secondary”	  refers	  to	  the	  necessity	  of	  modification	  (Nt-­‐acetylation)	  of	  a	  destabilizing	  N-­‐terminal	  residue	  before	  a	  protein	  can	  be	  recognized	  by	  a	  cognate	  Ub	  ligase	  (fig.	  S1C).	  Proteins	  containing	  AcN-­‐degrons	  are	  targeted	  for	  ubiquitylation	  (and	  proteasome-­‐mediated	  degradation)	  by	  the	  Doa10	  E3	  Ub	  ligase.	  Although	  Gly	  or	  Pro	  can	  be	  made	  N-­‐terminal	  by	  MetAPs,	  and	  although	  Doa10	  can	  recognize	  Nt-­‐
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CHAPTER	  5:	  
CONTROL	  OF	  PROTEIN	  QUALITY	  AND	  STOICHIOMETRIES	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SUMMARY	  Nα-­‐terminal	  acetylation	  of	  cellular	  proteins	  was	  recently	  discovered	  to	  create	  specific	  degradation	  signals,	  termed	  Ac/N-­‐degrons	  and	  targeted	  by	  the	  Ac/N-­‐end	  rule	  pathway.	  We	  show	  that	  Hcn1,	  a	  subunit	  of	  the	  APC/C	  ubiquitin	  ligase,	  contains	  an	  Ac/N-­‐degron	  that	  is	  repressed	  by	  Cut9,	  another	  APC/C	  subunit	  and	  the	  ligand	  of	  Hcn1.	  Cog1,	  a	  subunit	  of	  the	  Golgi-­‐associated	  COG	  complex,	  is	  also	  shown	  to	  contain	  an	  Ac/N-­‐degron.	  Cog2	  and	  Cog3,	  direct	  ligands	  of	  Cog1,	  can	  repress	  this	  degron.	  Furthermore,	  the	  subunit	  decoy	  technique	  was	  developed	  and	  used	  to	  show	  that	  the	  endogenous,	  long-­‐lived	  Cog1	  is	  destabilized	  and	  destroyed	  via	  its	  Ac/N-­‐degron	  if	  the	  total	  level	  of	  Cog1	  is	  increased	  in	  a	  cell.	  Hcn1	  and	  Cog1	  are	  the	  first	  examples	  of	  regulation,	  through	  physiologically	  relevant	  steric	  shielding,	  of	  natural	  Ac/N-­‐degrons.	  This	  mechanistically	  straightforward	  circuit	  can	  employ	  the	  exceptional	  pervasiveness	  and	  conditionality	  of	  Ac/N-­‐degrons	  to	  regulate	  subunit	  stoichiometries	  and	  other	  aspects	  of	  protein	  quality	  control.	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INTRODUCTION	  Nearly	  90%	  of	  human	  proteins	  are	  Nα-­‐terminally	  acetylated	  (Nt-­‐acetylated)	  (86-­‐90).	  There	  is	  no	  evidence	  for	  Nt-­‐deacetylases,	  i.e.,	  Nt-­‐acetylation	  is	  apparently	  irreversible,	  in	  contrast	  to	  the	  dynamic	  acetylation-­‐deacetylation	  of	  internal	  lysines	  in	  cellular	  proteins	  (91).	  Nt-­‐acetylation	  can	  occur	  posttranslationally	  but	  the	  bulk	  of	  it	  is	  cotranslational,	  being	  mediated	  by	  ribosome-­‐associated	  Nt-­‐acetylases	  (92-­‐94).	  We	  discovered	  that	  a	  major	  biological	  function	  of	  Nt-­‐acetylation	  is	  the	  creation	  of	  specific	  degradation	  signals	  (degrons)	  in	  cellular	  proteins	  (95).	  These	  degrons,	  implemented	  by	  a	  novel	  branch	  of	  the	  N-­‐end	  rule	  pathway,	  are	  the	  largest	  class	  of	  degradation	  signals	  in	  the	  proteome,	  as	  Nt-­‐acetylation	  involves	  the	  majority	  of	  eukaryotic	  proteins	  (95,96).	  The	  N-­‐end	  rule	  pathway	  targets	  proteins	  containing	  N-­‐terminal	  degradation	  signals	  called	  N-­‐degrons,	  polyubiquitylates	  these	  proteins	  and	  thereby	  causes	  their	  processive	  degradation	  by	  the	  proteasome	  (Figure	  S1A,	  B).	  The	  main	  determinant	  of	  an	  N-­‐degron	  is	  a	  destabilizing	  N-­‐terminal	  residue	  of	  a	  protein.	  Recognition	  components	  of	  the	  N-­‐end	  rule	  pathway	  are	  called	  N-­‐recognins.	  In	  eukaryotes,	  N-­‐recognins	  are	  E3	  ubiquitin	  (Ub)	  ligases	  that	  can	  target	  N-­‐degrons.	  Regulated	  destruction	  of	  specific	  proteins	  by	  the	  N-­‐end	  rule	  pathway	  mediates	  a	  strikingly	  broad	  range	  of	  biological	  functions,	  cited	  in	  the	  legend	  to	  Figure	  S1	  (96-­‐101).	  In	  eukaryotes,	  the	  N-­‐end	  rule	  pathway	  comprises	  two	  branches,	  the	  Arg/N-­‐end	  rule	  pathway	  and	  the	  Ac/N-­‐end	  rule	  pathway	  (Figure	  S1A,	  B).	  The	  Arg/N-­‐end	  rule	  pathway	  recognizes	  specific	  unacetylated	  N-­‐terminal	  residues.	  N-­‐terminal	  Arg,	  Lys,	  His,	  Leu,	  Phe,	  Tyr,	  Trp,	  and	  Ile	  are	  directly	  recognized	  by	  E3	  N-­‐recognins.	  In	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contrast,	  N-­‐terminal	  Asn,	  Gln,	  Asp,	  and	  Glu	  (as	  well	  as	  Cys,	  under	  some	  metabolic	  conditions)	  are	  destabilizing	  owing	  to	  their	  preliminary	  enzymatic	  modifications,	  which	  include	  Nt-­‐deamidation	  and	  Nt-­‐arginylation	  (Figure	  S1B)	  (96,102-­‐105).	  In	  contrast	  to	  the	  Arg/N-­‐end	  rule	  pathway,	  the	  Ac/N-­‐end	  rule	  pathway	  targets	  proteins	  through	  their	  Nt-­‐acetylated	  residues,	  largely	  Nt-­‐acetylated	  Met,	  Ala,	  Val,	  Ser,	  Thr,	  or	  Cys.	  These	  N-­‐terminal	  degradation	  signals	  are	  called	  Ac/N-­‐degrons,	  to	  distinguish	  them	  from	  other	  N-­‐degrons.	  In	  the	  yeast	  Saccharomyces	  cerevisiae,	  the	  Ac/N-­‐end	  rule	  pathway	  is	  mediated	  by	  the	  Doa10	  E3	  Ub	  ligase	  and	  possibly	  by	  other	  N-­‐recognins	  as	  well	  (Figure	  S1A)	  (95,96).	  Nt-­‐acetylation	  is	  largely	  cotranslational,	  apparently	  irreversible,	  and	  involves	  a	  large	  majority	  of	  proteins.	  What	  functions	  are	  subserved	  by	  such	  a	  massive	  production	  of	  specific	  degradation	  signals,	  if	  proteins	  bearing	  Ac/N-­‐degrons	  are	  often	  destined	  for	  in	  vivo	  half-­‐lives	  of	  many	  hours	  or	  days?	  We	  suggested	  that	  the	  biological	  roles	  of	  Ac/N-­‐degrons	  include	  protein	  quality	  control,	  including	  the	  regulation	  of	  input	  stoichiometries	  of	  subunits	  in	  oligomeric	  proteins	  (95,96).	  In	  the	  latter	  process,	  a	  free	  subunit	  of	  a	  protein	  complex	  is	  short-­‐lived	  until	  the	  subunit	  becomes	  a	  part	  of	  the	  complex.	  Consider	  a	  multisubunit	  protein	  that	  sterically	  shields	  a	  cognate	  subunit’s	  Nt-­‐acetylated	  residue.	  The	  initial	  destruction,	  through	  an	  Ac/N-­‐degron,	  of	  some	  of	  this	  subunit’s	  newly	  formed	  molecules	  would	  be	  halted	  by	  the	  formation	  of	  the	  complex	  and	  the	  resulting	  sequestration	  of	  the	  Ac/N-­‐degron.	  If	  the	  shielding	  occurs	  through	  intramolecular	  folding	  or	  through	  homo-­‐oligomeric	  interactions,	  this	  Ac/N-­‐degron	  would	  be	  self-­‐regulated	  by	  default.	  If	  the	  shielding	  involves	  hetero-­‐oligomeric	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interactions,	  there	  is	  an	  upper	  boundary	  on	  the	  level	  of	  subunit	  expression	  that	  is	  compatible	  with	  self-­‐regulation.	  Above	  that	  boundary,	  some	  subunit	  molecules	  would	  remain	  short-­‐lived,	  owing	  to	  titration	  of	  protein	  ligands	  that	  would	  normally	  sequester	  the	  subunit’s	  Ac/N-­‐degron.	  	  In	  this	  model,	  the	  regulation	  of	  input	  stoichiometries	  of	  subunits	  in	  protein	  complexes	  involves	  the	  degradation	  of	  uncomplexed,	  e.g.,	  overproduced	  proteins	  in,	  for	  example,	  aneuploid	  cells.	  The	  same	  mechanism	  can	  mediate	  the	  degradation	  of	  misfolded	  or	  otherwise	  abnormal	  proteins	  that	  cannot	  sequester	  their	  Ac/N-­‐degrons	  through	  protein	  interactions.	  Because	  most	  Ac/N-­‐degrons	  are	  formed	  cotranslationally,	  the	  processive	  proteolysis	  of	  a	  protein	  by	  the	  Ac/N-­‐end	  rule	  pathway	  would	  occur,	  in	  part,	  concurrently	  with	  the	  synthesis	  of	  a	  nascent	  polypeptide	  or	  shortly	  after	  its	  completion,	  for	  example	  during	  the	  cotranslational	  assembly	  of	  protein	  complexes,	  or	  in	  the	  context	  of	  a	  polypeptide’s	  interaction	  with	  chaperones	  (106-­‐109).	  The	  same	  logic	  applies	  to	  any	  conditional	  degradation	  signal.	  In	  fact,	  specific	  internal	  degrons	  participate	  in	  degradation-­‐mediated	  protein	  homeostasis,	  including	  the	  destruction	  of	  abnormal	  proteins	  (96,110-­‐116).	  Note,	  however,	  that	  compared	  to	  other	  characterized	  degradation	  signals,	  Ac/N-­‐degrons	  are	  unique	  in	  their	  prevalence	  and	  mechanistic	  uniformity,	  as	  nearly	  90%	  of	  human	  proteins	  are	  Nt-­‐acetylated	  and	  Ac/N-­‐degrons	  are	  the	  earliest	  degradation	  signals	  to	  form	  in	  nascent	  polypeptide	  chains.	  Physiological	  functions	  of	  Ac/N-­‐degrons	  were	  suggested	  to	  involve	  the	  metabolic	  fates	  of	  most	  cellular	  proteins,	  from	  Nt-­‐
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acetylated	  subunits	  of	  protein	  dimers	  to	  Nt-­‐acetylated	  subunits	  of	  the	  largest	  intracellular	  complexes	  such	  as	  the	  proteasome	  and	  the	  ribosome	  (95,96).	  To	  begin	  addressing	  this	  model	  and	  the	  new	  field	  of	  the	  Ac/N-­‐end	  rule	  pathway,	  we	  focused	  on	  Cog1	  and	  Hcn1.	  S.	  cerevisiae	  Cog1	  is	  a	  48	  kDa	  subunit	  of	  the	  Conserved	  Oligomeric	  Golgi	  (COG)	  complex,	  which	  comprises	  the	  subunits	  Cog1-­‐Cog8,	  resides	  in	  the	  cytosol,	  associates	  with	  membranes,	  and	  participates	  in	  Golgi	  transport	  (117,118).	  Cog1	  is	  a	  bridging	  subunit	  between	  the	  lobes	  of	  the	  COG	  complex	  (119,120).	  Hcn1	  (Cdc26)	  is	  a	  9	  kDa	  subunit	  of	  the	  Anaphase-­‐Promoting	  Complex/Cyclosome	  (APC/C)	  Ub	  ligase,	  which	  mediates	  the	  degradation	  of	  mitotic	  regulators	  and	  other	  proteins	  (121-­‐123).	  We	  show	  here	  that	  both	  Cog1	  and	  Hcn1	  contain	  Ac/N-­‐degrons.	  We	  also	  show,	  using	  the	  subunit	  decoy	  technique,	  that	  the	  Ac/N-­‐degrons	  of	  Cog1	  and	  Hcn1	  are	  regulated	  through	  the	  formation	  of	  complexes	  between	  these	  proteins	  and	  their	  cognate	  protein	  ligands.	  These	  results	  constitute	  the	  first	  evidence	  for	  the	  physiologically	  relevant	  conditionality	  of	  Ac/N-­‐degrons	  and	  for	  the	  steric	  shielding	  basis	  of	  this	  conditionality.	  In	  addition,	  these	  advances	  clarify,	  in	  hindsight,	  the	  cause	  of	  the	  long-­‐held	  assumption	  (before	  the	  discovery	  of	  Ac/N-­‐degrons)	  that	  Nt-­‐acetylation	  protects	  intracellular	  proteins	  from	  degradation.	  Specifically,	  many	  Nt-­‐acetylated	  proteins	  appeared	  to	  be	  long-­‐lived,	  a	  correct	  but	  incomplete	  conclusion.	  The	  new	  understanding	  is	  two-­‐fold.	  First,	  the	  Nt-­‐acetylation	  of	  a	  protein	  creates	  an	  Ac/N-­‐degron	  while	  precluding	  the	  targeting	  of	  this	  protein	  by	  proteolytic	  systems	  (e.g.,	  the	  Arg/N-­‐end	  rule	  pathway)	  that	  require	  the	  unmodified	  N-­‐terminus.	  Second,	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those	  Nt-­‐acetylated	  proteins	  that	  become	  long-­‐lived	  enter	  this	  state	  after	  cessation	  of	  their	  initial	  degradation	  by	  the	  Ac/N-­‐end	  rule	  pathway.	  	  
RESULTS	  	  
The	  Ac/N-­‐Degron	  of	  Cog1,	  a	  Subunit	  of	  the	  COG	  Complex	  
S.	  cerevisiae	  Cog1	  is	  Nt-­‐acetylated	  (86).	  Independent	  evidence	  for	  Nt-­‐acetylation	  of	  Cog1	  is	  described	  below.	  The	  encoded	  Met-­‐Asp	  (MD)	  N-­‐terminal	  sequence	  of	  wild-­‐type	  (wt)	  Cog1,	  termed	  MD-­‐Cog1wt,	  implied	  that	  its	  (retained)	  N-­‐terminal	  Met	  is	  Nt-­‐acetylated	  by	  the	  NatB	  Nt-­‐acetylase	  (Figure	  S2B-­‐D).	  MD-­‐Cog1wt	  was	  expressed	  in	  S.	  cerevisiae	  using	  low	  copy	  plasmids,	  the	  PCUP1	  promoter,	  and	  C-­‐terminal	  epitope	  tagging.	  Cycloheximide	  (CHX)-­‐chases	  showed	  that	  MD-­‐Cog1wt	  was	  short-­‐lived	  in	  wt	  cells	  (t1/2	  <<	  1	  hr)	  (Figure	  1A,	  lanes	  1-­‐3).	  MD-­‐Cog1wt	  remained	  short-­‐lived	  in	  doa10Δ	  cells	  lacking	  the	  Doa10	  E3	  Ub	  ligase,	  one	  of	  the	  E3s	  (see	  below)	  that	  target	  Ac/N-­‐degrons	  (Figure	  1A,	  lanes	  1-­‐3,	  7-­‐9,	  Figure	  S3A,	  and	  Figure	  S5D,	  E).	  In	  agreement	  with	  the	  presence	  of	  an	  Ac/N-­‐degron	  in	  MD-­‐Cog1wt,	  it	  was	  stabilized,	  including	  its	  increased	  levels	  at	  time	  zero	  (the	  beginning	  of	  the	  chase)	  in	  naa20Δ	  (nat3Δ)	  cells,	  which	  lacked	  the	  catalytic	  subunit	  of	  the	  cognate	  NatB	  Nt-­‐acetylase	  (Figures	  S2D	  and	  S3A,	  lanes	  7-­‐9	  vs.	  lanes	  1-­‐3;	  Figure	  S3C,	  lanes	  7-­‐9	  vs.	  lanes	  1-­‐6,	  10-­‐15;	  and	  Figure	  S3G,	  lanes	  4-­‐6	  vs.	  lanes	  1-­‐3).	  In	  contrast,	  the	  instability	  of	  MD-­‐Cog1wt	  did	  not	  require	  the	  non-­‐cognate	  Nt-­‐acetylases	  NatA,	  NatC	  or	  NatD	  (Figures	  S2C,	  D	  and	  S3C,	  lanes	  7-­‐9	  vs.	  lanes	  1-­‐6,	  10-­‐15).	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A	  CHX-­‐chase	  monitors	  the	  degradation	  of	  both	  “young”	  and	  “old”	  protein	  molecules.	  35S-­‐pulse-­‐chases	  were	  used	  to	  analyze	  newly	  formed	  Cog1.	  In	  agreement	  with	  CHX-­‐chases,	  MD-­‐Cog1wt	  was	  short-­‐lived	  in	  wt	  and	  doa10Δ	  cells	  (t1/2	  ≈	  10	  min)	  but	  was	  nearly	  completely	  stabilized	  in	  naa20Δ	  cells	  lacking	  the	  NatB	  Nt-­‐acetylase	  (Figures	  S2D	  and	  1B,	  lanes	  1-­‐3,	  7-­‐9;	  Figure	  1C,	  lanes	  1-­‐4	  vs.	  lanes	  9-­‐12;	  and	  Figure	  1D).	   We	  also	  constructed	  the	  MK-­‐Cog1D2K	  and	  P-­‐Cog1	  mutants.	  In	  MK-­‐Cog1D2K,	  wt	  Asp2	  (Figure	  S2B)	  was	  replaced	  by	  Lys.	  In	  P-­‐Cog1,	  the	  Pro	  residue	  was	  inserted	  before	  Asp2.	  The	  N-­‐terminal	  sequences	  of	  mutant	  proteins	  were	  Met-­‐Lys	  (MK)	  and	  Pro-­‐Asp	  (PD),	  respectively,	  the	  latter	  after	  the	  cotranslational	  removal	  of	  N-­‐terminal	  Met.	  It	  has	  been	  shown	  that	  either	  N-­‐terminal	  Pro	  followed	  by	  any	  residue	  or	  N-­‐terminal	  Met	  followed	  by	  a	  basic	  residue	  are	  not	  Nt-­‐acetylated	  in	  S.	  cerevisiae	  (Figure	  S2C)	  (86,124).	  In	  agreement	  with	  the	  presence	  of	  an	  Ac/N-­‐degron	  in	  MD-­‐Cog1wt,	  the	  non-­‐Nt-­‐acetylatable	  MK-­‐Cog1D2K	  and	  P-­‐Cog1D2P	  were	  stabilized	  in	  CHX-­‐chases	  compared	  to	  MD-­‐Cog1wt,	  including	  their	  increased	  levels	  at	  time	  zero	  (the	  beginning	  of	  the	  chase)	  (Figure	  1A,	  lanes	  4-­‐6	  vs.	  lanes	  1-­‐3;	  and	  Figure	  S3B,	  lanes	  4-­‐6	  vs.	  lanes	  1-­‐3).	  The	  non-­‐Nt-­‐acetylatable	  P-­‐Cog1D2P	  was	  also	  stabilized	  in	  35S-­‐pulse-­‐chases,	  in	  comparison	  to	  MD-­‐Cog1wt	  (Figure	  1B,	  lanes	  4-­‐6	  vs.	  lanes	  1-­‐3,	  Figure	  1C,	  lanes	  5-­‐8,	  vs.	  lanes	  1-­‐4,	  and	  Figure	  1D).	  The	  bulk	  of	  MD-­‐Cog1wt	  degradation	  was	  mediated	  by	  the	  proteasome,	  as	  shown	  using	  either	  pdr5Δ	  S.	  cerevisiae,	  which	  allowed	  for	  the	  intracellular	  retention	  of	  MG132,	  a	  proteasome	  inhibitor	  (Figure	  S3D,	  lanes	  1	  vs.	  2,	  and	  Figure	  S3E),	  or	  through	  a	  CHX-­‐chase	  of	  MD-­‐Cog1wt	  in	  wt	  cells	  made	  permeable	  to	  MG132	  by	  low	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levels	  of	  SDS	  (Figure	  S3G).	  In	  contrast,	  phenylmethanesulfonyl	  fluoride	  (PMSF),	  a	  serine	  protease	  inhibitor,	  had	  no	  significant	  effect	  on	  the	  levels	  of	  MD-­‐Cog1wt	  (Figure	  S3D,	  lanes	  3	  vs.	  4,	  and	  Figure	  S3F).	  MD-­‐Cog1wt	  was	  also	  examined	  using	  the	  temperature-­‐sensitive	  uba1-­‐204	  allele	  of	  the	  Uba1	  Ub-­‐activating	  (E1)	  enzyme	  (125).	  MD-­‐Cog1wt	  was	  short-­‐lived	  in	  wt	  and	  uba1-­‐204	  cells	  at	  30°C	  and	  remained	  short-­‐lived	  in	  wt	  cells	  at	  the	  nonpermissive	  temperature	  of	  37°C	  (Figure	  S3H,	  lanes	  1-­‐9).	  In	  contrast,	  MD-­‐Cog1wt	  was	  stabilized	  at	  37°C	  in	  uba1-­‐204	  cells,	  including	  its	  increased	  levels	  at	  time	  zero	  (Figure	  S3H,	  lanes	  10-­‐12	  vs.	  lanes	  1-­‐9).	  Thus,	  the	  degradation	  of	  MD-­‐Cog1wt	  requires	  ubiquitylation,	  most	  likely	  of	  MD-­‐Cog1wt	  itself.	  	  
Antibody	  Specific	  for	  Nt-­‐Acetylated	  Cog1	  Ac-­‐MDEVLPLFRDS,	  the	  Nt-­‐acetylated	  N-­‐terminal	  peptide	  of	  MD-­‐Cog1wt,	  was	  used	  to	  produce	  a	  rabbit	  antibody,	  termed	  anti-­‐Cog1AcNt,	  that	  recognized	  Ac-­‐MDEVLPLFRDS	  but	  not	  the	  unacetylated	  peptide	  (Figure	  S4A-­‐C).	  This	  antibody	  detected	  Nt-­‐acetylated	  MD-­‐Cog1wt	  in	  extracts	  from	  wt	  cells	  either	  at	  the	  beginning	  of	  the	  CHX-­‐chase	  (Figure	  1E,	  lane	  1)	  or	  under	  steady-­‐state	  conditions	  (Figure	  S4B,	  lane	  1).	  In	  contrast,	  anti-­‐Cog1AcNt	  detected,	  at	  most,	  trace	  amounts	  of	  MD-­‐Cog1wt	  in	  otherwise	  identical	  extracts	  from	  naa20Δ	  (nat3Δ)	  cells	  lacking	  the	  cognate	  NatB	  Nt-­‐acetylase	  (Figure	  1E,	  lane	  1	  vs.	  lane	  7),	  thereby	  providing	  independent	  (immunological)	  confirmation	  of	  the	  earlier	  mass	  spectrometric	  evidence	  (86)	  for	  Nt-­‐acetylation	  of	  MD-­‐Cog1wt	  in	  wt	  cells.	  The	  same	  immunoblot	  re-­‐probed	  with	  anti-­‐flag	  antibody	  revealed	  comparable	  levels	  of	  MD-­‐Cog1wt	  (C-­‐terminally	  tagged	  with	  3	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flag	  epitopes)	  in	  both	  wt	  and	  naa20Δ	  cells	  at	  the	  beginning	  of	  CHX-­‐chase,	  thereby	  confirming	  the	  specificity	  of	  anti-­‐Cog1AcNt	  for	  Nt-­‐acetylated	  MD-­‐Cog1wt	  (Figure	  1F,	  lanes	  1,	  7	  vs.	  Figure	  1E,	  lanes	  1,	  7).	  In	  agreement	  with	  previously	  cited	  chases	  (Figures	  1A-­‐D	  and	  S3A-­‐C),	  MD-­‐Cog1wt	  was	  short-­‐lived	  in	  wt	  cells	  but	  was	  stabilized	  in	  naa20Δ	  cells	  (Figure	  1E,	  F,	  lanes	  1-­‐3	  vs.	  lanes	  7-­‐9,	  and	  Figure	  1G,	  H),	  whereas	  P-­‐Cog1	  was	  almost	  completely	  stable	  under	  all	  conditions	  (Figure	  1E,	  F,	  lanes	  4-­‐6	  vs.	  lanes	  1-­‐3,	  and	  Figure	  1H).	  Together,	  CHX-­‐chases,	  35S-­‐pulse-­‐chases,	  and	  anti-­‐Cog1AcNt	  results	  with	  wt	  versus	  mutant	  S.	  cerevisiae	  and	  with	  mutants	  of	  MD-­‐Cog1wt	  (Figures	  1,	  S3,	  and	  S4A-­‐C)	  identified	  this	  subunit	  of	  the	  COG	  complex	  as	  a	  short-­‐lived	  substrate	  of	  the	  Ac/N-­‐end	  rule	  pathway,	  which	  targets	  the	  Ac/N-­‐degron	  of	  MD-­‐Cog1wt.	  	  
Cog1	  Interactions	  with	  Other	  COG	  Subunits	  and	  Membranes	  In	  the	  Absence	  of	  
Nt-­‐Acetylation	  The	  targeting	  of	  some	  cytosolic	  proteins,	  such	  as	  Arl3,	  to	  the	  Golgi	  membrane	  requires	  their	  Nt-­‐acetyl	  group	  (126).	  Cog1	  contributes	  to	  interactions	  of	  the	  COG	  complex	  with	  the	  Golgi	  membrane	  (117,118).	  In	  a	  test	  that	  did	  not	  distinguish	  between	  Golgi	  and	  other	  membranes,	  cell	  extracts	  were	  fractionated	  into	  soluble	  (“cytosol”)	  and	  insoluble	  (“membrane”)	  parts.	  The	  absence	  of	  Nt-­‐acetylation	  of	  MD-­‐Cog1wt	  in	  naa20Δ	  cells	  did	  not	  affect	  its	  partitioning	  between	  membrane	  and	  soluble	  fractions	  (Figure	  S4D-­‐E).	  Schulman	  and	  colleagues	  showed	  that	  the	  Nt-­‐acetyl	  moiety	  can	  significantly	  contribute	  to	  the	  affinity	  between	  an	  Nt-­‐acetylated	  protein	  and	  its	  protein	  ligand	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(90,127).	  We	  used	  anti-­‐flag	  to	  immunoprecipitate	  the	  C-­‐terminally	  triple-­‐flagged	  MD-­‐Cog1wt	  from	  extracts	  of	  cells	  that	  co-­‐expressed	  the	  C-­‐terminally	  ha-­‐tagged	  Cog3ha	  or	  Cog4ha.	  Both	  Cog3ha	  and	  Cog4ha	  were	  coimmunoprecipitated	  with	  MD-­‐Cog1wt	  from	  wt	  and	  naa20Δ	  extracts	  (Figure	  S4G,	  H).	  We	  conclude	  that	  Nt-­‐acetylation	  of	  MD-­‐Cog1wt	  is	  not	  strictly	  required	  for	  its	  direct	  or	  indirect	  interactions	  with	  Cog3	  and	  Cog4,	  i.e.,	  a	  possibly	  lower	  affinity	  of	  unacetylated	  MD-­‐Cog1wt	  (in	  naa20Δ	  cells)	  for	  its	  protein	  ligands	  was	  still	  sufficient	  for	  coimmunoprecipitation.	  Interestingly,	  the	  apparent	  Mr	  of	  the	  93-­‐kDa	  Cog3	  was	  increased	  by	  ~8	  kDa	  either	  in	  naa20Δ	  cells	  lacking	  the	  NatB	  Nt-­‐acetylase	  or	  in	  the	  absence	  of	  overexpressed	  MD-­‐Cog1wt.	  The	  upshifted	  Cog3	  also	  coimmunoprecipitated	  with	  MD-­‐Cog1wt	  (Figure	  S4G,	  lane	  1	  vs.	  lane	  2,	  lane	  5	  vs.	  lane	  6).	  This	  increase	  in	  Mr	  is	  consistent	  with,	  e.g.,	  monoubiquitylation	  of	  Cog3	  under	  the	  above	  conditions.	  There	  are	  no	  data	  about	  Nt-­‐acetylation	  of	  COG	  subunits	  other	  than	  MD-­‐Cog1wt.	  All	  of	  these	  subunits,	  save	  for	  Cog3,	  are	  expected	  to	  be	  Nt-­‐acetylated	  in	  wt	  cells	  (Figure	  S2B,	  C).	  	  
Ac/N-­‐Degrons	  Are	  Recognized	  by	  More	  Than	  One	  Ubiquitin	  Ligase	  MD-­‐Cog1wt,	  whose	  degradation	  is	  Ub-­‐dependent	  (Figure	  S3H),	  was	  not	  stabilized	  in	  cells	  lacking	  the	  Doa10	  E3,	  an	  N-­‐recognin	  of	  the	  Ac/N-­‐end	  rule	  pathway	  (Figure	  1A,	  lanes	  1-­‐3,	  7-­‐9;	  Figure	  1B,	  lanes	  1-­‐3,	  7-­‐9;	  Figure	  S1A;	  Figure	  S3A,	  lanes	  1-­‐6;	  and	  Figure	  S5D,	  lanes	  1-­‐6).	  In	  agreement	  with	  these	  results,	  MD-­‐Cog1wt	  was	  also	  not	  stabilized	  in	  the	  ubc6Δ	  ubc7Δ	  double-­‐mutant	  cells	  lacking	  cognate	  E2s	  of	  the	  Doa10	  E3	  (Figure	  S5F,	  G).	  In	  addition,	  MD-­‐Cog1wt	  was	  not	  stabilized	  in	  null	  mutants	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of	  nine	  other	  E2s	  (Figure	  S5A-­‐C).	  Examination	  of	  ubr1Δ	  and	  san1Δ	  cells	  lacking,	  respectively,	  the	  E3	  N-­‐recognin	  of	  the	  Arg/N-­‐end	  rule	  pathway	  (Figure	  S1B)	  and	  a	  nuclear	  E3	  mediating	  the	  degradation	  of	  misfolded	  proteins	  (113),	  yielded	  similar	  results	  (Figure	  S5D,	  E).	  The	  affinity	  of	  the	  Doa10	  N-­‐recognin	  for	  Nt-­‐acetylated	  peptides	  involves	  largely	  their	  Nt-­‐acetyl	  moiety	  and	  is	  less	  dependent	  on	  the	  side	  chain	  of	  the	  N-­‐terminal	  residue	  (95).	  Therefore	  it	  is	  likely	  that	  Doa10	  can	  recognize	  Nt-­‐acetylated	  MD-­‐Cog1wt	  but	  may	  not	  be	  able	  to	  efficaciously	  target	  its	  Ac/N-­‐degron.	  Similarly	  to	  other	  N-­‐degrons,	  an	  Ac/N-­‐degron	  of	  a	  protein	  is	  expected	  to	  be	  at	  least	  tripartite,	  with	  its	  other	  determinants	  being	  a	  “ubiquitylatable”	  internal	  lysine	  and	  a	  disordered	  chain	  segment	  (96).	  In	  sum,	  an	  unknown	  E3	  N-­‐recognin	  (S.	  cerevisiae	  genome	  encodes	  more	  than	  150	  E3s)	  targets	  the	  Ac/N-­‐degron	  of	  MD-­‐Cog1wt	  either	  by	  itself	  or	  redundantly	  with	  Doa10.	  	  
Endogenous	  Cog1	  Is	  Long-­‐Lived	  In	  experiments	  described	  so	  far,	  MD-­‐Cog1wt	  was	  moderately	  overexpressed	  from	  a	  low	  copy	  plasmid	  and	  the	  PCUP1	  promoter	  (Figures	  1	  and	  S3-­‐S5).	  We	  also	  replaced,	  through	  in	  vivo	  recombination,	  the	  chromosomal	  COG1	  with	  an	  otherwise	  identical	  DNA	  segment	  that	  expressed	  the	  C-­‐terminally	  triply	  ha-­‐tagged	  MD-­‐Cog1wt	  (MD-­‐Cog1!"#!" )	  from	  the	  endogenous	  PCOG1	  promoter.	  Remarkably,	  in	  cells	  expressing	  solely	  the	  endogenous	  MD-­‐Cog1!"#!" 	  at	  its	  wt	  levels,	  it	  was	  much	  more	  stable	  than	  the	  triply	  flag-­‐tagged	  MD-­‐Cog1!"!"	  overexpressed	  from	  the	  PCUP1	  promoter.	  Specifically,	  less	  than	  10%	  of	  the	  endogenous	  MD-­‐Cog1!"#!" 	  was	  degraded	  during	  2	  hrs	  of	  CHX-­‐
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chase,	  in	  contrast	  to	  degradation	  of	  nearly	  all	  overexpressed	  MD-­‐Cog1!"!"	  (Figure	  2A	  vs.,	  for	  example,	  Figure	  1A,	  lanes	  1-­‐3,	  or	  Figure	  1F,	  lanes	  1-­‐3).	  In	  addition,	  the	  metabolic	  stability	  of	  endogenous	  MD-­‐Cog1!"#!" 	  remained	  unaltered	  in	  naa20Δ	  cells	  lacking	  the	  cognate	  NatB	  Nt-­‐acetylase,	  in	  contrast	  to	  a	  strong	  stabilization	  of	  the	  (short-­‐lived)	  overexpressed	  MD-­‐Cog1!"!"	  in	  the	  absence	  of	  NatB	  (Figure	  2A	  vs.	  Figures	  1C,	  S3A,	  and	  S3C).	  	  
Short-­‐Lived	  Cog1	  Is	  Stabilized	  by	  Coexpression	  of	  Cog2-­‐Cog4	  Both	  the	  conjectured	  conditionality	  of	  Ac/N-­‐degrons	  (95)	  and	  electron	  microscopy	  of	  the	  yeast	  Cog1-­‐Cog4	  subcomplex	  (Figure	  S1D)	  (120)	  suggested	  that	  the	  Ac/N-­‐degron	  of	  MD-­‐Cog1wt	  may	  be	  at	  least	  partially	  sequestered	  in	  the	  subcomplex.	  In	  agreement	  with	  this	  possibility,	  the	  striking	  dichotomy	  between	  the	  Ac/N-­‐degron-­‐mediated	  degradation	  of	  overexpressed	  MD-­‐Cog1wt	  and	  the	  stability	  of	  non-­‐overexpressed,	  endogenous	  MD-­‐Cog1wt	  (Figures	  1	  and	  S2A-­‐C	  vs.	  Figure	  2A)	  suggested	  an	  involvement,	  in	  the	  latter	  case,	  of	  other	  COG	  subunits.	  Cog2	  and	  Cog3	  are	  direct	  binding	  ligands	  of	  MD-­‐Cog1wt	  (117).	  We	  asked	  whether	  the	  short-­‐lived,	  moderately	  overexpressed	  (from	  the	  PCUP1	  promoter	  on	  a	  low	  copy	  plasmid)	  MD-­‐Cog1!"!"	  could	  be	  stabilized	  by	  expressing,	  from	  the	  galactose-­‐inducible	  PGAL1-­‐10	  promoter	  on	  a	  high	  copy	  plasmid,	  the	  COG	  subunits	  Cog2,	  Cog3	  and	  Cog4.	  Indeed,	  the	  short-­‐lived	  MD-­‐Cog1!"!"	  was	  strongly	  stabilized	  by	  coexpression	  of	  either	  Cog2	  and	  Cog3	  or	  of	  Cog2,	  Cog3	  and	  Cog4	  (Figure	  2B,	  lanes	  1-­‐3	  vs.	  lanes	  4-­‐6;	  Figure	  2C,	  lanes	  1-­‐3	  vs.	  lanes	  4-­‐6;	  and	  Figure	  2D,	  E).	  We	  conclude	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that	  the	  Ac/N-­‐degron	  of	  MD-­‐Cog1wt	  is	  conditional	  in	  a	  physiologically	  relevant	  manner	  (see	  Discussion).	  	  
Subunit	  Decoy	  Technique	  Reveals	  the	  Cause	  of	  Stability	  of	  Endogenous	  Cog1	  The	  above	  results	  suggested	  that	  the	  stability	  of	  endogenous	  MD-­‐Cog1wt	  (Figure	  2A)	  stems	  from	  sequestration	  of	  its	  Ac/N-­‐degron	  by	  other	  COG	  subunits	  during	  the	  assembly	  of	  the	  degradation-­‐resistant	  COG	  complex.	  We	  addressed	  this	  possibility	  by	  an	  approach	  termed	  the	  subunit	  decoy	  technique.	  First,	  a	  C-­‐terminally	  epitope-­‐tagged	  protein	  of	  interest	  is	  expressed	  at	  its	  endogenous	  level	  from	  its	  native	  chromosomal	  location	  and	  transcriptional	  promoter.	  Second,	  the	  same	  protein	  but	  C-­‐terminally	  tagged	  with	  an	  alternative	  epitope	  is	  also	  expressed	  in	  these	  cells	  (Figure	  3A).	  In	  one	  design	  of	  the	  subunit	  decoy	  experiment,	  cells	  expressing	  wt	  levels	  of	  MD-­‐Cog1!"#$%!" 	  (C-­‐terminally	  tagged	  with	  13	  myc	  epitopes)	  from	  the	  chromosomal	  
COG1	  locus	  were	  transformed	  either	  with	  a	  vector	  alone	  or	  with	  a	  plasmid	  expressing	  the	  otherwise	  identical	  MD-­‐Cog1!"!"	  (C-­‐terminally	  tagged	  with	  3	  flag	  epitopes)	  from	  the	  constitutive	  PADH1	  promoter	  (Figure	  3A).	  Remarkably,	  whereas	  the	  endogenous	  MD-­‐Cog1!"#$%!" 	  was	  stable	  in	  the	  absence	  of	  ectopically	  expressed	  MD-­‐Cog1!"!",	  the	  same	  endogenous	  MD-­‐Cog1!"#$%!" 	  became	  a	  short-­‐lived	  protein	  in	  the	  presence	  of	  the	  (also	  short-­‐lived)	  MD-­‐Cog1!"!"	  (Figure	  3A,	  B).	  In	  a	  different	  design	  of	  the	  subunit	  decoy	  experiment,	  cells	  expressing	  wt	  levels	  of	  MD-­‐Cog1!"#!" 	  (C-­‐terminally	  tagged	  with	  3	  ha	  epitopes)	  from	  the	  chromosomal	  COG1	  locus	  were	  transformed	  with	  a	  plasmid	  expressing	  the	  otherwise	  identical	  MD-­‐Cog1!"!"	  from	  the	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galactose-­‐inducible	  PGAL1	  promoter.	  In	  glucose	  medium,	  where	  MD-­‐Cog1!"!"	  was	  not	  expressed,	  the	  endogenous	  MD-­‐Cog1!"#!" 	  was	  long-­‐lived	  (t1/2	  >>	  1	  hr),	  as	  evidenced	  by	  its	  stability	  in	  a	  CHX-­‐chase	  and	  the	  absence	  of	  a	  significant	  change	  in	  naa20Δ	  cells	  lacking	  the	  cognate	  NatB	  Nt-­‐acetylase	  (Figure	  3C,	  F).	  In	  striking	  contrast,	  the	  same	  endogenous	  MD-­‐Cog1!"#!" 	  became	  short-­‐lived	  (t1/2	  <<	  30	  min)	  in	  the	  presence	  of	  galactose,	  which	  induced	  MD-­‐Cog1!"!"	  (Figure	  3C-­‐F).	  The	  conditional	  sequestration	  model	  of	  Ac/N-­‐degrons	  predicts	  the	  observed	  destabilization	  of	  endogenous	  MD-­‐Cog1wt	  under	  these	  conditions	  (see	  Discussion).	  	  
The	  Ac/N-­‐Degron	  of	  Hcn1,	  a	  Subunit	  of	  the	  APC/C	  Ubiquitin	  Ligase	  In	  the	  crystal	  structure,	  by	  Barford	  and	  colleagues,	  of	  the	  complex	  between	  the	  APC/C	  subunits	  Hcn1	  and	  Cut9	  of	  the	  yeast	  Schizosaccharomyces	  pombe	  (128),	  the	  Nt-­‐acetylated	  Met	  residue	  of	  Hcn1	  was	  found	  to	  be	  enclosed	  within	  a	  chamber	  of	  the	  folded	  Cut9	  subunit	  (Figure	  S1C).	  (128)	  interpreted	  this	  result	  as	  a	  possible	  example	  of	  the	  sequestration	  of	  Ac/N-­‐degrons	  proposed	  by	  (95).	  The	  encoded	  Met-­‐Leu	  (ML)	  N-­‐terminal	  sequence	  of	  the	  9-­‐kDa	  wt	  Hcn1,	  termed	  ML-­‐Hcn1wt,	  implied	  that	  its	  (retained)	  N-­‐terminal	  Met	  was	  Nt-­‐acetylated	  by	  the	  NatC	  Nt-­‐acetylase	  (Figure	  S2C).	  ML-­‐Hcn1wt	  was	  C-­‐terminally	  tagged	  with	  3	  flag	  epitopes	  and	  expressed	  in	  S.	  cerevisiae	  from	  the	  PCUP1	  promoter.	  As	  determined	  using	  both	  CHX-­‐chases	  and	  35S-­‐pulse-­‐chases,	  ML-­‐Hcn1wt	  was	  indeed	  short-­‐lived	  in	  wt	  cells,	  with	  t1/2	  <	  40	  min	  in	  the	  CHX-­‐chase	  (Figure	  4A,	  lanes	  1-­‐3)	  and	  t1/2	  of	  ~10	  min	  in	  the	  35S-­‐pulse-­‐chase	  (Figure	  4C,	  lanes	  1-­‐3,	  and	  Figure	  4D).	  In	  contrast,	  ML-­‐Hcn1wt	  was	  virtually	  completely	  stabilized	  in	  naa30Δ	  (mak3Δ)	  cells	  lacking	  the	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catalytic	  subunit	  of	  the	  cognate	  NatC	  Nt-­‐acetylase	  (Figure	  4A,	  lanes	  1-­‐3	  vs.	  lanes	  4-­‐6;	  Figure	  4C,	  lanes	  1-­‐3	  vs.	  lanes	  4-­‐6;	  and	  Figure	  4D).	  We	  conclude	  that	  the	  degradation	  of	  ML-­‐Hcn1wt	  is	  mediated	  by	  its	  Ac/N-­‐degron.	  We	  also	  asked	  whether	  Cdc26,	  the	  S.	  cerevisiae	  counterpart	  of	  S.	  pombe	  Hcn1,	  contained	  an	  Ac/N-­‐degron.	  Its	  N-­‐terminal	  sequence	  being	  Met-­‐Ile,	  Cdc26	  is	  a	  substrate	  of	  the	  NatC	  Nt-­‐acetylase	  (Figure	  S2C).	  Cdc26	  was	  indeed	  unstable	  in	  wt	  cells	  but	  was	  nearly	  completely	  stabilized	  in	  naa30Δ	  (mak3Δ)	  cells,	  in	  addition	  to	  an	  increase	  of	  its	  zero-­‐time	  level	  (Figure	  4B,	  lanes	  1-­‐3	  vs.	  lanes	  4-­‐6).	  	  
Coexpression	  of	  Cut9	  with	  Hcn1	  Represses	  the	  Ac/N-­‐degron	  of	  Hcn1	  Given	  the	  sequestration	  of	  the	  Nt-­‐acetylated	  Met	  of	  ML-­‐Hcn1wt	  in	  a	  cleft	  of	  Cut9	  (Figure	  S1C),	  and	  the	  demonstrated	  degradation	  of	  ML-­‐Hcn1wt	  (in	  the	  absence	  of	  Cut9)	  by	  the	  Ac/N-­‐end	  rule	  pathway	  (Figure	  4),	  we	  asked	  whether	  coexpression	  of	  Cut9	  would	  inhibit	  the	  degradation	  of	  ML-­‐Hcn1wt.	  Several	  independent	  CHX-­‐chase	  assays	  have	  shown	  that	  the	  short-­‐lived	  ML-­‐Hcn1wt	  was	  virtually	  completely	  stabilized	  by	  Cut9	  upon	  its	  overexpression	  from	  the	  galactose-­‐inducible	  PGAL1	  promoter	  (Figure	  4E,	  F).	  These	  results	  were	  analogous	  to	  the	  metabolic	  stabilization	  of	  the	  short-­‐lived	  MD-­‐Cog1wt	  by	  its	  coexpressed	  ligands	  Cog2-­‐Cog4	  (Figure	  2A-­‐E),	  except	  that	  the	  inhibition	  of	  the	  degradation	  of	  ML-­‐Hcn1wt	  by	  Cut9	  (Figure	  4E,	  F)	  can	  now	  be	  understood	  at	  near-­‐atomic	  resolution,	  owing	  to	  the	  crystal	  structure	  of	  the	  Hcn1-­‐Cut9	  complex	  (Figure	  S1C)	  (128).	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DISCUSSION	  The	  discovery	  of	  the	  Ac/N-­‐end	  rule	  pathway	  and	  Ac/N-­‐degrons	  (Figure	  S1A)	  (95)	  has	  revealed	  the	  largest	  class	  of	  degradation	  signals	  in	  the	  proteome,	  as	  nearly	  90%	  of	  human	  proteins	  are	  Nt-­‐acetylated.	  Because	  most	  proteins	  acquire	  Ac/N-­‐degrons	  cotranslationally,	  the	  bulk	  of	  these	  degradation	  signals	  would	  be	  expected	  to	  be	  rapidly	  (and	  reversibly)	  repressed,	  as	  many	  proteins	  are	  long-­‐lived	  in	  vivo.	  Given	  the	  exceptional	  prevalence	  of	  Ac/N-­‐degrons,	  they	  would	  be	  likely	  to	  underlie	  processes	  that	  encompass	  the	  bulk	  of	  the	  proteome,	  for	  example,	  the	  control	  of	  protein	  quality,	  including	  the	  regulation	  of	  input	  stoichiometries	  of	  subunits	  in	  oligomeric	  proteins.	  Until	  now,	  these	  were	  merely	  suggestions	  about	  possible	  biological	  roles	  of	  Ac/N-­‐degrons,	  made	  upon	  the	  discovery	  of	  the	  Ac/N-­‐end	  rule	  pathway	  (95).	  To	  address	  the	  functions	  of	  Ac/N-­‐degrons,	  we	  chose	  two	  unrelated	  natural	  Nt-­‐acetylated	  proteins,	  Cog1	  (MD-­‐Cog1wt)	  and	  Hcn1	  (ML-­‐Hcn1wt),	  described	  in	  Introduction.	  CHX-­‐chases	  and	  35S-­‐pulse-­‐chases	  with	  MD-­‐Cog1wt	  and	  its	  site-­‐directed	  mutants	  expressed	  in	  wt	  or	  mutant	  S.	  cerevisiae,	  as	  well	  as	  the	  development	  of	  an	  antibody,	  anti-­‐Cog1AcNt,	  that	  selectively	  recognized	  Nt-­‐acetylated	  MD-­‐Cog1wt,	  identified	  this	  subunit	  of	  the	  COG	  complex	  as	  a	  short-­‐lived	  substrate	  of	  the	  Ac/N-­‐end	  rule	  pathway	  (Figures	  1	  and	  S3-­‐S5).	  Analogous	  experiments	  with	  ML-­‐Hcn1wt	  also	  showed	  it	  to	  be	  an	  unstable	  protein	  targeted	  through	  its	  Ac/N-­‐degron	  (Figure	  4).	  As	  discussed	  below,	  further	  analyses	  of	  MD-­‐Cog1wt	  and	  ML-­‐Hcn1wt	  showed	  that	  their	  Ac/N-­‐degrons	  are	  regulated	  through	  the	  formation	  of	  complexes	  between	  these	  proteins	  and	  their	  cognate	  protein	  ligands.	  These	  mechanistically	  unambiguous	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results	  (Figures	  2-­‐5)	  constitute	  the	  first	  evidence	  for	  the	  physiologically	  relevant	  conditionality	  of	  Ac/N-­‐degrons	  and	  for	  the	  steric	  sequestration	  basis	  of	  this	  conditionality.	  Being	  an	  S.	  pombe	  protein,	  ML-­‐Hcn1wt	  was	  not	  expected	  to	  have	  ligands	  in	  S.	  
cerevisiae	  that	  might	  shield	  its	  Nt-­‐acetylated	  Met	  and	  thereby	  repress	  its	  Ac/N-­‐degron.	  The	  disposition	  was	  different	  with	  S.	  cerevisiae	  MD-­‐Cog1wt,	  in	  that	  some	  newly	  formed	  molecules	  of	  overexpressed	  MD-­‐Cog1wt	  were	  expected	  to	  associate	  with	  Cog1-­‐binding	  subunits	  of	  the	  COG	  complex	  and	  thereby	  possibly	  repress,	  through	  steric	  shielding,	  the	  Ac/N-­‐degron	  of	  MD-­‐Cog1wt.	  However,	  a	  majority	  of	  newly	  formed	  molecules	  of	  overexpressed	  MD-­‐Cog1wt	  would	  be	  unable	  to	  experience	  such	  a	  fate,	  as	  they	  would	  “run	  out”	  of	  cognate	  COG	  protein	  ligands	  to	  bind	  to.	  If	  so,	  overexpressed	  MD-­‐Cog1wt	  and	  ML-­‐Hcn1wt	  would	  be	  expected	  to	  be	  stabilized	  by	  coexpression	  of	  their	  cognate	  protein	  ligands.	  Indeed,	  a	  short-­‐lived,	  overexpressed	  MD-­‐Cog1wt	  became	  a	  long-­‐lived	  protein	  when	  Cog2	  and	  Cog3	  (direct	  ligands	  of	  Cog1)	  or	  Cog2,	  Cog3	  and	  Cog4	  were	  coexpressed	  (Figure	  2B-­‐E).	  Analogously,	  the	  short-­‐lived	  ML-­‐Hcn1wt	  was	  stabilized	  upon	  coexpression	  of	  its	  cognate	  ligand	  Cut9	  (Figure	  4E,	  F).	  Thus,	  the	  Ac/N-­‐degrons	  of	  MD-­‐Cog1wt	  and	  ML-­‐Hcn1wt	  are	  conditional	  in	  a	  physiologically	  relevant	  manner,	  as	  they	  can	  be	  repressed	  through	  the	  availability	  of	  the	  previously	  demonstrated	  physical	  interactions	  between	  these	  proteins	  and	  their	  protein	  ligands.	  	  When	  MD-­‐Cog1wt	  was	  expressed	  at	  wt	  levels	  and	  in	  the	  absence	  of	  other	  versions	  of	  Cog1	  in	  the	  cell,	  it	  was	  found	  to	  be	  long-­‐lived,	  in	  striking	  contrast	  to	  overexpressed	  MD-­‐Cog1wt,	  the	  bulk	  of	  which	  was	  degraded	  through	  the	  Ac/N-­‐
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degron	  (Figure	  1A,	  lanes	  1-­‐3	  vs.	  Figure	  2A).	  This	  finding,	  one	  of	  several	  key	  insights	  of	  the	  present	  work,	  provided	  a	  new	  explanation	  for	  earlier	  observations,	  by	  a	  number	  of	  studies	  over	  many	  years	  (for	  example,	  (129)),	  that	  most	  Nt-­‐acetylated	  proteins	  appeared	  to	  be	  long-­‐lived.	  These	  –	  correct	  but	  incomplete	  –	  observations	  were	  a	  major	  cause	  of	  the	  long-­‐held	  assumption	  (before	  the	  discovery	  of	  Ac/N-­‐degrons)	  that	  Nt-­‐acetylation	  protects	  intracellular	  proteins	  from	  degradation.	  To	  the	  contrary,	  the	  clear-­‐cut	  existence	  of	  Ac/N-­‐degrons,	  their	  exceptionally	  high	  prevalence	  in	  the	  proteome	  (95),	  and	  the	  results	  of	  this	  study	  (Figures	  1-­‐5,	  S1-­‐S5)	  indicated	  a	  different	  view	  of	  the	  observed	  stability	  of	  Nt-­‐acetylated	  proteins.	  Specifically,	  those	  Nt-­‐acetylated	  proteins	  that	  become	  long-­‐lived	  do	  so	  after	  cessation	  of	  their	  initial	  degradation	  by	  the	  Ac/N-­‐end	  rule	  pathway.	  The	  initial	  destruction	  of	  a	  fraction	  of	  a	  newly	  formed	  protein	  containing	  an	  Ac/N-­‐degron,	  before	  this	  degron	  is	  repressed	  through	  protein	  interactions,	  can	  be	  transient	  enough	  to	  be	  overlooked	  in	  conventional	  degradation	  assays.	  This	  understanding	  was	  further	  advanced	  by	  an	  approach	  we	  termed	  the	  subunit	  decoy	  technique,	  in	  which	  a	  C-­‐terminally	  epitope-­‐tagged	  protein	  is	  expressed	  at	  its	  wt	  level	  in	  the	  absence	  or	  presence	  of	  the	  same	  protein	  that	  is	  alternatively	  tagged	  and	  overexpressed	  (Figure	  3).	  A	  subunit	  decoy	  assay	  is	  employed	  when,	  for	  example,	  an	  epitope-­‐tagged	  protein	  is	  overexpressed	  in	  the	  presence	  of	  an	  endogenous	  (and	  experimentally	  distinguishable)	  version	  of	  the	  same	  protein.	  Over	  the	  last	  two	  decades,	  it	  was	  occasionally	  reported	  that	  an	  overexpressed	  protein	  diminishes	  the	  expression	  of	  its	  endogenous	  counterpart,	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and	  that	  this	  repression	  is	  often	  posttranscriptional,	  i.e.,	  it	  can	  involve	  protein	  degradation,	  through	  unknown	  degrons	  (e.g.,	  (130)).	  Our	  subunit	  decoy	  experiments	  provided	  a	  direct,	  mechanistically	  explicit	  explanation	  of	  this	  phenomenon	  in	  the	  context	  of	  Ac/N-­‐degrons	  and	  thereby	  completed	  the	  explanation	  of	  why	  a	  protein	  (e.g.,	  MD-­‐Cog1wt)	  expressed	  at	  wt	  levels	  can	  be	  long-­‐lived	  while	  the	  same	  but	  overexpressed	  protein	  is	  metabolically	  unstable	  (Figure	  1A,	  lanes	  1-­‐3	  vs.	  Figure	  2A).	  Specifically,	  when	  the	  C-­‐terminally	  ha-­‐tagged,	  long-­‐lived	  endogenous	  MD-­‐Cog1!"#!" 	  was	  expressed	  in	  the	  presence	  of	  the	  otherwise	  identical	  but	  flag-­‐tagged	  and	  overexpressed	  MD-­‐Cog1!"!"	  decoy,	  the	  previously	  stable	  MD-­‐Cog1!"#!" 	  became	  short-­‐lived	  (Figure	  3).	  The	  conditional	  sequestration	  model	  of	  Ac/N-­‐degrons	  predicts	  this	  outcome.	  Specifically,	  endogenous	  (i.e.,	  sufficiently	  low)	  expression	  levels	  of	  MD-­‐Cog1!"#!" 	  would	  be	  comparable	  to	  the	  endogenous	  levels	  of	  protective	  subunits	  of	  the	  COG	  complex	  such	  as	  Cog2	  and	  Cog3.	  As	  a	  result,	  most	  (though	  not	  necessarily	  all)	  molecules	  of	  newly	  formed	  MD-­‐Cog1!"#!" 	  escape	  the	  degradation	  by	  the	  Ac/N-­‐end	  rule	  pathway	  through	  the	  formation	  of	  complexes	  with	  other	  COG	  subunits	  that	  shield	  the	  Ac/N-­‐degron	  of	  MD-­‐Cog1!"#!" .	  In	  contrast,	  the	  “additional”	  expression	  of	  the	  MD-­‐Cog1!"!"	  decoy	  results	  in	  total	  levels	  of	  MD-­‐Cog1wt	  that	  outstrip	  the	  supply	  of	  endogenous	  Cog1-­‐binding	  subunits	  of	  the	  COG	  complex.	  Consequently,	  most	  newly	  formed	  molecules	  of	  MD-­‐Cog1!"#!" 	  are	  no	  longer	  forming	  protected	  COG-­‐based	  complexes	  and	  therefore	  remain	  short-­‐lived,	  alongside	  the	  also	  short-­‐lived	  molecules	  of	  the	  MD-­‐Cog1!"!"	  decoy	  (Figure	  3).	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The	  subunit	  decoy	  experiments	  produced	  yet	  another	  insight.	  Specifically,	  it	  was	  the	  bulk	  (not	  just	  a	  small	  subset)	  of	  the	  endogenous	  MD-­‐Cog1!"#!" 	  that	  was	  destabilized	  by	  the	  coexpression	  of	  the	  MD-­‐Cog1!"!"	  decoy	  (Figure	  3).	  In	  other	  words,	  this	  destabilization	  of	  MD-­‐Cog1!"#!" 	  included	  its	  older	  molecules	  that	  were	  the	  long-­‐lived	  components	  of	  the	  COG	  complex,	  before	  the	  expression	  of	  the	  MD-­‐Cog1!"!"	  decoy.	  While	  a	  detailed	  understanding	  of	  this	  effect	  must	  await	  further	  studies,	  these	  findings	  implied	  that	  the	  COG	  complex	  is	  dynamic	  in	  vivo,	  with	  dissociations-­‐reassociations	  of	  COG	  subunits	  (on	  the	  scale	  of	  minutes	  or	  less)	  that	  repeatedly	  “expose”	  the	  Ac/N-­‐degron	  of	  MD-­‐Cog1!"#!" .	  The	  fact	  that	  endogenous	  MD-­‐Cog1!"#!" 	  is	  relatively	  long-­‐lived	  in	  the	  absence	  of	  the	  MD-­‐Cog1!"!"	  decoy	  (Figure	  3)	  implies	  a	  physiologically	  significant	  but	  low	  (in	  absolute	  terms)	  probability	  of	  destruction	  of	  MD-­‐Cog1!"#!" 	  upon	  a	  single	  cycle	  of	  its	  transient	  (and	  rapidly	  reversed)	  dissociation	  from	  the	  COG	  complex.	  In	  contrast,	  dissociation	  of	  the	  COG	  complex	  in	  the	  presence	  of	  the	  coexpressed	  MD-­‐Cog1!"!"	  decoy	  would	  prevent,	  through	  competition,	  an	  efficacious	  re-­‐incorporation	  of	  MD-­‐Cog1!"#!" 	  into	  the	  reassembled	  COG	  complex,	  thereby	  greatly	  increasing	  the	  probability	  of	  destruction	  of	  the	  “orphaned”	  (competed	  out)	  MD-­‐Cog1!"#!" 	  by	  the	  Ac/N-­‐end	  rule	  pathway	  (Figure	  3).	  Expression	  levels	  of	  subunits	  that	  comprise	  a	  protein	  complex	  are	  adjusted,	  on	  evolutionary	  timescales,	  to	  be	  roughly	  stoichiometric.	  The	  additional,	  fine-­‐tuning	  and	  homeostatic	  control	  of	  subunit	  stoichiometries	  is	  mediated	  by	  selective	  and	  conditional	  protein	  degradation	  of	  the	  kind	  dissected	  in	  the	  present	  study	  using	  MD-­‐Cog1wt	  and	  ML-­‐Hcn1wt.	  For	  example,	  we	  showed	  that	  the	  Ac/N-­‐degron	  of	  ML-­‐Hcn1wt,	  a	  subunit	  of	  the	  APC/C	  Ub	  ligase,	  is	  repressed	  by	  Cut9,	  another	  subunit	  of	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APC/C	  that	  binds	  to	  ML-­‐Hcn1wt	  and	  sterically	  shields	  its	  Nt-­‐acetylated	  Met	  residue	  (Figures	  4	  and	  S1C)	  (128).	  The	  resulting	  regulatory	  circuit,	  summarized	  in	  Figure	  5	  and	  mediated	  by	  Ac/N-­‐degrons,	  is	  mechanistically	  straightforward.	  As	  discussed	  above	  in	  the	  context	  of	  Cog1	  and	  Hcn1,	  this	  mechanism	  can	  underlie	  the	  degradation-­‐mediated	  control	  of	  input	  stoichiometries	  of	  subunits	  in	  oligomeric	  proteins.	  This	  mechanism	  can	  also	  mediate	  the	  destruction	  of	  misfolded	  or	  otherwise	  abnormal	  proteins	  whose	  cotranslationally	  formed	  Ac/N-­‐degrons	  do	  not	  become	  shielded	  soon	  enough.	  One	  setting	  in	  which	  the	  control,	  by	  the	  Ac/N-­‐end	  rule	  pathway	  and	  Ac/N-­‐degrons,	  of	  the	  input	  stoichiometries	  of	  protein	  subunits	  may	  prove	  to	  be	  particularly	  significant	  physiologically	  is	  aneuploidy,	  in	  which	  the	  chromosome	  number	  in	  a	  cell	  is	  not	  an	  exact	  multiple	  of	  the	  haploid	  number.	  Aneuploidy	  is	  often	  encountered	  in	  natural	  cell	  populations,	  from	  S.	  cerevisiae	  to	  human	  cells,	  including	  human	  cancers	  and	  birth	  defects	  such	  as	  the	  Down	  syndrome.	  Physiological	  defects	  in	  aneuploid	  cells	  are	  caused,	  at	  least	  in	  part,	  by	  maladaptive	  molar	  ratios	  of	  newly	  formed	  proteins	  in	  such	  cells,	  given	  their	  deviations	  from	  normal	  gene	  dosages.	  Homeostatic	  responses	  in	  aneuploid	  cells	  would	  have	  to	  destroy	  a	  higher	  than	  normal	  load	  of	  unassembled	  protein	  subunits.	  This	  may	  account	  for	  the	  known	  hypersensitivity	  of	  these	  cells	  to	  proteasome	  inhibitors	  (131).	  Now	  that	  the	  conditionality	  of	  Ac/N-­‐degrons	  (Figure	  5)	  is	  no	  longer	  a	  conjecture,	  it	  should	  be	  possible	  to	  determine,	  using,	  for	  example,	  the	  in	  vivo	  dynamics	  of	  Cog1	  and	  other	  subunits	  of	  the	  COG	  complex	  as	  reporter	  proteins	  (Figures	  1-­‐3),	  whether	  the	  Ac/N-­‐
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end	  rule	  pathway	  plays	  a	  major	  role	  in	  homeostatic	  responses	  that	  compensate,	  through	  selective	  proteolysis,	  for	  protein	  subunit	  misbalances	  in	  aneuploid	  cells.	  The	  Nt-­‐acetyl	  group	  at	  protein	  N-­‐termini	  contributes	  to	  the	  physical	  affinities	  between	  specific	  subunits	  in	  oligomeric	  proteins	  (90,127,128).	  It	  would	  be	  important	  to	  determine,	  therefore,	  whether	  the	  striking	  prevalence	  of	  Ac/N-­‐degrons	  (nearly	  90%	  of	  human	  proteins	  are	  Nt-­‐acetylated	  (see	  Introduction))	  has	  resulted,	  on	  evolutionary	  timescales,	  largely	  from	  adaptive	  (fitness-­‐increasing)	  effects	  of	  these	  degrons,	  as	  distinguished,	  for	  example,	  from	  adaptive	  effects	  of	  Nt-­‐acetylation	  on	  the	  strengthening	  of	  specific	  protein-­‐protein	  interactions,	  irrespective	  of	  proteolysis.	  The	  function	  of	  the	  Nt-­‐acetyl	  group	  as	  a	  key	  determinant	  of	  Ac/N-­‐degrons	  is	  compatible	  with	  other	  aspects	  of	  Nt-­‐acetylation,	  including	  its	  contributions	  to	  protein-­‐membrane	  interactions,	  to	  physical	  affinities	  between	  specific	  proteins,	  and	  to	  the	  negative	  regulation	  of	  protein	  translocation	  into	  the	  endoplasmic	  reticulum	  ((90,126,132)	  and	  references	  therein).	  Some	  protein	  complexes	  are	  formed	  cotranslationally,	  i.e.,	  a	  specific	  subunit	  of	  a	  (future)	  complex	  can	  interact	  with	  its	  protein	  ligands	  while	  being	  a	  ribosome-­‐associated	  nascent	  polypeptide	  chain	  ((106,107),	  and	  references	  therein).	  The	  metabolic	  stability	  of	  such	  a	  subunit	  is	  strongly	  decreased	  in	  the	  absence	  of	  its	  protein	  ligand	  (106).	  Because	  most	  proteins	  acquire	  their	  Ac/N-­‐degrons	  cotranslationally	  (95),	  the	  conditional	  degradation	  of	  subunits	  in	  cotranslationally	  assembling	  complexes	  may	  involve	  Ac/N-­‐degrons.	  This	  proposition	  can	  now	  be	  addressed	  experimentally,	  either	  though	  analyses	  of	  Ac/N-­‐degrons	  in	  previously	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characterized	  complexes	  of	  this	  class	  (106)	  or	  by	  determining	  whether	  the	  assembly	  of	  the	  COG	  complex	  of	  the	  present	  work	  occurs	  cotranslationally.	  Either	  “soluble”	  or	  transmembrane	  proteins	  that	  enter	  the	  endoplasmic	  reticulum	  (ER)	  can	  be	  retrotranslocated	  to	  the	  cytosol	  and	  destroyed	  if	  these	  proteins	  are	  recognized	  as	  abnormal	  and	  acted	  upon	  by	  a	  quality	  control	  system	  termed	  the	  ER-­‐associated	  degradation	  (ERAD)	  (110,111).	  The	  ER-­‐embedded	  transmembrane	  Doa10	  E3	  Ub	  ligase	  is	  one	  N-­‐recognin	  of	  the	  Ac/N-­‐end	  rule	  pathway	  and	  also,	  at	  the	  same	  time,	  an	  E3	  that	  mediates	  ERAD.	  Given	  this	  remarkable	  dichotomy,	  it	  is	  possible	  and	  indeed	  likely	  that	  Ac/N-­‐degrons	  and	  the	  Ac/N-­‐end	  rule	  pathway	  are	  a	  part	  of	  ERAD	  as	  well,	  a	  verifiable	  proposition.	  In	  conjunction	  with	  the	  initial	  discovery	  of	  the	  Ac/N-­‐degrons	  (95),	  the	  present	  study	  of	  Cog1	  and	  Hcn1	  opened	  up	  a	  number	  of	  experimental	  strategies	  for	  further	  advances	  in	  the	  functional	  understanding	  of	  the	  Ac/N-­‐end	  rule	  pathway.	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EXPERIMENTAL	  PROCEDURES	  	  
Yeast	  Strains,	  Plasmids,	  and	  Genetic	  Techniques	  Tables	  S1	  and	  S2	  describe	  S.	  cerevisiae	  strains	  and	  plasmids	  used	  in	  this	  study.	  Standard	  techniques	  were	  employed	  for	  strain	  and	  plasmid	  construction.	  	  
Cycloheximide-­‐Chase	  and	  35S-­‐Pulse-­‐Chase	  Degradation	  Assays	  These	  assays	  were	  carried	  out	  largely	  as	  described	  (95,133).	  The	  Odyssey	  near-­‐infrared	  scanner	  (Li-­‐Cor)	  was	  used	  for	  visualizing	  secondary	  antibodies	  and	  for	  quantifying	  specific	  protein	  bands.	  Quantification	  of	  35S-­‐pulse-­‐chases	  was	  carried	  out	  using	  Storm	  PhosphorImager	  and	  ImageQuant	  (GE	  Healthcare).	  
	  
Antibody	  Specific	  for	  N-­‐Terminally	  Acetylated	  Cog1	  The	  Nt-­‐acetylated	  synthetic	  peptide	  AcMDEVLPLFRDSC	  and	  its	  unacetylated	  counterpart	  MDEVLPLFRDSC	  were	  produced	  by	  Abgent	  (San	  Diego,	  CA).	  Details	  of	  the	  production	  and	  characterization	  of	  the	  anti-­‐Cog1AcNt	  antibody	  are	  described	  in	  the	  legend	  to	  Figure	  S4A-­‐C	  and	  in	  Extended	  Experimental	  Procedures.	  	  
Coimmunoprecipitation	  of	  Cog1	  with	  Cog2-­‐Cog4	  
S.	  cerevisiae	  coexpressing	  flag-­‐tagged	  MD-­‐Cog1wt	  and	  either	  Cog3	  or	  Cog4	  (ha-­‐tagged)	  were	  lysed,	  and	  clarified	  extracts	  were	  subjected	  to	  immunoprecipitation	  using	  anti-­‐flag	  magnetic	  beads.	  The	  immunoprecipitates	  were	  analyzed	  by	  SDS-­‐PAGE	  and	  immunoblotting.	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SUPPLEMENTAL	  INFORMATION	  Supplemental	  Information	  includes	  Extended	  Experimental	  Procedures,	  five	  figures,	  and	  two	  tables.	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Figure	  5.1
 
Figure	  5.1.	  The	  Ac/N-­‐degron	  of	  Cog1.	  (A)	  Cycloheximide	  (CHX)-­‐chases	  were	  carried	  out	  at	  30°C	  with	  wild-­‐type	  (wt)	  or	  doa10Δ	  S.	  cerevisiae	  that	  expressed	  either	  wt	  Cog1,	  termed	  MD-­‐Cog1wt,	  or	  its	  MK-­‐Cog1	  derivative	  in	  which	  Asp2	  was	  replaced	  with	  Lys2.	  Both	  proteins	  were	  C-­‐terminally	  ha-­‐tagged.	  At	  the	  indicated	  times	  of	  chase,	  proteins	  in	  cell	  extracts	  were	  fractionated	  by	  SDS-­‐PAGE	  and	  assayed	  by	  immunoblotting	  with	  anti-­‐ha	  antibody.	  (B)	  35S-­‐pulse-­‐chase	  with	  MD-­‐Cog1wt	  or	  P-­‐Cog1	  in	  wt,	  doa10Δ,	  or	  naa10Δ	  (ard1Δ)	  S.	  cerevisiae,	  the	  latter	  lacking	  the	  catalytic	  subunit	  of	  the	  non-­‐cognate	  (for	  MD-­‐Cog1wt)	  NatA	  Nt-­‐acetylase	  (Figure	  S2).	  Cog1	  proteins	  were	  C-­‐terminally	  tagged	  
Figure 1, Shemorry et al.
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with	  3	  flag	  epitopes	  modified	  to	  contain	  a	  Met	  residue	  in	  each	  epitope,	  to	  increase	  
35S-­‐Met	  in	  Cog1.	  (C)	  Same	  as	  in	  B	  but	  another	  35S-­‐pulse-­‐chase.	  It	  included	  naa20Δ	  (nat3Δ)	  S.	  
cerevisiae	  lacking	  the	  catalytic	  subunit	  of	  the	  cognate	  (for	  MD-­‐Cog1wt)	  NatB	  Nt-­‐acetylase	  (Figure	  S2).	  (D)	  Quantification	  of	  data	  in	  C.	  u,	  MD-­‐Cog1wt	  in	  wt	  cells.	  p,	  MD-­‐Cog1wt	  in	  
naa20Δ	  cells.	  n,	  P-­‐Cog1	  in	  wt	  cells.	  (E)	  Anti-­‐Cog1AcNt	  antibody	  specific	  for	  Nt-­‐acetylated	  MD-­‐Cog1wt	  (see	  Figure	  S4A-­‐C)	  was	  used	  for	  immunoblotting	  in	  CHX-­‐chase	  assays	  with	  MD-­‐Cog1wt	  and	  P-­‐Cog1	  (C-­‐terminally	  tagged	  with	  3	  flag	  epitopes)	  in	  either	  wt	  or	  naa20Δ	  (nat3Δ)	  S.	  
cerevisiae	  (see	  the	  main	  text).	  (F)	  Same	  as	  in	  E,	  except	  that	  the	  same	  membrane	  was	  reprobed	  with	  anti-­‐flag	  antibody.	  (G)	  Quantification	  of	  anti-­‐Cog1AcNt-­‐specific	  immunoblotting	  patterns	  in	  E	  using	  Odyssey	  (Li-­‐Cor)	  and	  a	  linear	  scale,	  with	  the	  level	  of	  MD-­‐Cog1wt	  at	  time	  zero	  in	  wt	  cells	  taken	  as	  100%.	  u,	  MD-­‐Cog1wt	  in	  wt	  cells.	  p,	  MD-­‐Cog1wt	  in	  naa20Δ	  cells.	  n,	  P-­‐Cog1	  in	  wt	  cells.	  (H)	  Same	  as	  in	  G	  but	  quantification	  of	  the	  flag-­‐specific	  Cog1	  immunoblotting	  patterns	  in	  F.	  Same	  designations	  as	  in	  G.	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Figure	  5.2
 
Figure	  5.2.	  Metabolic	  Stability	  of	  Endogenous	  Cog1	  and	  Stabilization	  of	  Overexpressed	  Cog1	  by	  Coexpressed	  Cog2-­‐Cog4.	  (A)	  CHX-­‐chases	  with	  MD-­‐Cog1wt	  (C-­‐terminally	  tagged	  with	  3	  ha	  epitopes)	  expressed	  from	  the	  chromosomal	  COG1	  locus	  and	  the	  native	  PCOG1	  promoter	  in	  wt,	  
doa10Δ,	  and	  naa20Δ	  (nat3Δ)	  cells.	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Figure 2, Shemorry et al.
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(B)	  Stabilization	  of	  overexpressed	  MD-­‐Cog1wt	  by	  coexpressed	  Cog2	  and	  Cog3.	  Lane	  M	  and	  red	  stars,	  molecular	  mass	  markers	  of	  37,	  50,	  and	  100	  kDa,	  respectively.	  Lanes	  1-­‐3,	  wt	  S.	  cerevisiae	  grown	  in	  2%	  glucose,	  expressing	  MD-­‐Cog1wt	  (C-­‐terminally	  tagged	  with	  3	  flag	  epitopes)	  from	  the	  PCUP1	  promoter	  on	  a	  low	  copy	  plasmid,	  and	  carrying	  a	  high	  copy	  plasmid	  that	  expressed,	  only	  in	  galactose,	  both	  Cog2	  and	  Cog3	  (C-­‐terminally	  tagged	  with	  ha)	  from	  the	  bidirectional	  PGAL1/10	  promoter.	  A	  CHX-­‐chase	  was	  carried	  out	  for	  30	  and	  60	  min.	  Lanes	  4-­‐6,	  same	  as	  lanes	  1-­‐3	  but	  with	  cells	  in	  2%	  galactose.	  Asterisk	  on	  the	  right	  indicates	  a	  protein	  crossreacting	  with	  anti-­‐ha.	  (C)	  Same	  as	  in	  B	  but	  cells	  also	  carried	  a	  second	  high	  copy	  plasmid	  expressing	  Cog4	  (C-­‐terminally	  tagged	  with	  ha)	  from	  the	  PGAL1/10	  promoter.	  (D)	  Quantification	  of	  data	  in	  B	  for	  MD-­‐Cog1wt.	  u,	  MD-­‐Cog1wt	  in	  cells	  that	  did	  not	  coexpress	  other	  COG	  subunits.	  n,	  MD-­‐Cog1wt	  in	  cells	  that	  coexpressed	  (in	  galactose)	  Cog2	  and	  Cog3.	  (E)	  Quantification	  of	  data	  in	  C	  for	  MD-­‐Cog1wt.	  u,	  MD-­‐Cog1wt	  in	  cells	  that	  did	  not	  coexpress	  other	  COG	  subunits.	  n,	  MD-­‐Cog1wt	  in	  cells	  that	  coexpressed	  (in	  galactose)	  Cog2-­‐Cog4.	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Figure	  5.3	  
Figure	  5.3.	  Subunit	  Decoy	  Technique	  and	  the	  Cause	  of	  Stability	  of	  Endogenous	  Cog1.	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(A)	  Lane	  M	  and	  red	  stars,	  molecular	  mass	  markers	  of	  37,	  50,	  and	  100	  kDa,	  respectively.	  Lanes	  1-­‐4,	  stability	  of	  endogenous	  MD-­‐Cog1!"#$%!" 	  (C-­‐terminally	  tagged	  with	  13	  myc	  epitopes)	  in	  the	  absence	  of	  the	  MD-­‐Cog1!"!"	  decoy	  (C-­‐terminally	  tagged	  with	  3	  flag	  epitopes).	  CHX-­‐chase	  with	  MD-­‐Cog1!"#$%!" 	  expressed	  from	  the	  chromosomal	  COG1	  locus	  and	  the	  native	  PCOG1	  promoter	  in	  wt	  cells	  in	  the	  presence	  of	  a	  plasmid	  vector	  alone.	  Lanes	  5-­‐8,	  same	  as	  lanes	  1-­‐4	  but	  cells	  carried	  a	  plasmid	  that	  expressed	  the	  MD-­‐Cog1!"!"	  decoy	  from	  the	  PADH1	  promoter.	  An	  asterisk	  denotes	  a	  protein	  crossreacting	  with	  anti-­‐flag	  antibody.	  (B)	  Quantification	  of	  data	  in	  A.	  u,	  endogenous	  MD-­‐Cog1!"#$%!" 	  in	  wt	  cells	  that	  did	  not	  express	  the	  MD-­‐Cog1!"!"	  decoy.	  n,	  endogenous	  MD-­‐Cog1!"#$%!" 	  in	  wt	  cells	  that	  also	  expressed	  MD-­‐Cog1!"!".	  (C)	  Lanes	  1-­‐3,	  stability	  of	  endogenous	  MD-­‐Cog1!"#!" 	  (C-­‐terminally	  tagged	  with	  3	  ha	  epitopes).	  CHX-­‐chase	  with	  cells	  in	  2%	  glucose	  expressing	  the	  endogenous	  MD-­‐Cog1!"#!" 	  in	  the	  absence	  of	  the	  MD-­‐Cog1!"!"	  decoy.	  The	  latter	  was	  encoded	  by	  a	  plasmid	  that	  could	  express	  MD-­‐Cog1!"!"	  from	  the	  galactose-­‐inducible	  PGAL1	  promoter.	  Lanes	  4-­‐6,	  same	  as	  lanes	  1-­‐3	  but	  in	  naa20Δ	  cells.	  (D)	  Same	  as	  in	  C	  but	  with	  wt	  and	  naa20Δ	  cells	  expressing	  the	  endogenous	  MD-­‐Cog1!"#!" 	  in	  2%	  galactose,	  i.e.,	  in	  the	  presence	  of	  the	  coexpressed	  MD-­‐Cog1!"!"	  decoy.	  Immunoblotting	  was	  performed	  using	  anti-­‐ha	  antibody,	  specific	  for	  MD-­‐Cog1!"#!" .	  (E)	  Same	  as	  in	  D	  but	  also	  probed	  (in	  a	  parallel	  immunoblot)	  with	  anti-­‐flag	  antibody,	  specific	  for	  MD-­‐Cog1!"!".	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Figure	  5.4.	  The	  Ac/N-­‐degron	  of	  Hcn1	  and	  Repression	  of	  This	  Degron	  by	  Cut9.	  (A)	  CHX-­‐chases	  for	  30	  and	  60	  min	  in	  wt	  or	  naa30Δ	  (mak3Δ)	  S.	  cerevisiae	  that	  expressed	  the	  wt	  S.	  pombe	  Hcn1,	  termed	  ML-­‐Hcn1wt,	  C-­‐terminally	  tagged	  with	  3	  flag	  epitopes.	  naa30Δ	  cells	  lack	  the	  catalytic	  subunit	  of	  the	  cognate	  NatC	  Nt-­‐acetylase	  (Figure	  S2).	  Lane	  1	  and	  red	  stars,	  molecular	  mass	  markers	  of	  10,	  15,	  20,	  37,	  and	  50	  kDa,	  respectively.	  (B)	  Same	  as	  in	  A	  but	  with	  Cdc26,	  termed	  MI-­‐Cdc26wt,	  the	  S.	  cerevisiae	  counterpart	  of	  S.	  pombe	  ML-­‐Hcn1wt.	  Lane	  1	  and	  red	  stars,	  molecular	  mass	  markers	  of	  20,	  37,	  and	  50	  kDa,	  respectively.	  (C)	  35S-­‐pulse-­‐chase,	  for	  20	  and	  40	  min,	  of	  ML-­‐Hcn1wt	  in	  wt	  and	  naa30Δ	  (mak3Δ)	  S.	  cerevisiae.	  Lane	  7,	  vector	  alone	  (negative	  control).	  (D)	  Quantification	  of	  data	  in	  C.	  u,	  ML-­‐Hcn1wt	  in	  wt	  cells.	  n,	  ML-­‐Hcn1wt	  in	  
naa30Δ	  cells.	  (E)	  Lanes	  1-­‐4,	  CHX-­‐chases	  for	  30,	  60	  and	  90	  min	  with	  wt	  cells	  in	  2%	  galactose	  (and	  without	  methionine)	  that	  expressed	  ML-­‐Hcn1wt	  from	  the	  methionine-­‐repressible	  PMET25	  promoter	  on	  a	  low	  copy	  plasmid	  and	  carried	  a	  vector	  alone	  (no	  Cut9	  expression).	  Note	  the	  metabolic	  instability	  of	  ML-­‐Hcn1wt	  (lower	  panel).	  Lanes	  5-­‐8,	  same	  as	  lanes	  1-­‐4	  but	  with	  a	  low	  copy	  plasmid	  (instead	  of	  control	  vector)	  expressing	  Cut9	  from	  the	  galactose-­‐inducible	  PGAL1	  promoter,	  with	  both	  ML-­‐Hcn1wt	  and	  Cut9	  C-­‐terminally	  tagged	  with	  3	  flag	  epitopes.	  Note	  the	  metabolic	  stabilization	  of	  ML-­‐Hcn1wt	  (lower	  panel),	  including	  a	  strong	  increase	  of	  its	  level	  at	  the	  beginning	  of	  the	  chase.	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Figure	  5.5	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APPENDIX	  1:	  
TWO	  PROTEOLYTIC	  PATHWAYS	  REGULATE	  DNA	  REPAIR	  BY	  
COTARGETING	  THE	  MGT1	  ALKYLGUANINE	  TRANSFERASE	  From	  Hwang,	  C.	  S.,	  Shemorry,	  A.,	  and	  Varshavsky,	  A.	  (2009)	  Proceedings	  of	  the	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Abstract	  O6-­‐methylguanine	  (O6meG)	  and	  related	  modifications	  of	  guanine	  in	  double-­‐stranded	  DNA	  are	  functionally	  severe	  lesions	  that	  can	  be	  produced	  by	  many	  alkylating	  agents,	  including	  N-­‐methyl-­‐N-­‐nitro-­‐N-­‐nitrosoguanidine	  (MNNG),	  a	  potent	  carcinogen.	  O6meG	  is	  repaired	  through	  its	  demethylation	  by	  the	  O6-­‐alkylguanine-­‐DNA	  alkyltransferase	  (AGT).	  This	  protein	  is	  called	  Mgmt	  (or	  MGMT)	  in	  mammals	  and	  Mgt1	  in	  the	  yeast	  Saccharomyces	  cerevisiae.	  AGT	  proteins	  remove	  methyl	  and	  other	  alkyl	  groups	  from	  an	  alkylated	  O6	  in	  guanine	  by	  transferring	  the	  adduct	  to	  an	  active-­‐site	  cysteine	  residue.	  The	  resulting	  S-­‐alkyl-­‐Cys	  of	  AGT	  is	  not	  restored	  back	  to	  Cys,	  so	  repair	  proteins	  of	  this	  kind	  can	  act	  only	  once.	  We	  report	  here	  that	  S.	  cerevisiae	  Mgt1	  is	  cotargeted	  for	  degradation,	  through	  a	  degron	  near	  its	  N	  terminus,	  by	  2	  ubiquitin-­‐mediated	  proteolytic	  systems,	  the	  Ubr1/Rad6-­‐dependent	  N-­‐end	  rule	  pathway	  and	  the	  Ufd4/Ubc4-­‐dependent	  ubiquitin	  fusion	  degradation	  (UFD)	  pathway.	  The	  cotargeting	  of	  Mgt1	  by	  these	  pathways	  is	  synergistic,	  in	  that	  it	  increases	  not	  only	  the	  yield	  of	  polyubiquitylated	  Mgt1,	  but	  also	  the	  processivity	  of	  polyubiquitylation.	  The	  N-­‐end	  rule	  and	  UFD	  pathways	  comediate	  both	  the	  constitutive	  and	  MNNG-­‐accelerated	  degradation	  of	  Mgt1.	  Yeast	  cells	  lacking	  the	  Ubr1	  and	  Ufd4	  ubiquitin	  ligases	  were	  hyperresistant	  to	  MNNG	  but	  hypersensitive	  to	  the	  toxicity	  of	  overexpressed	  Mgt1.	  We	  consider	  ramifications	  of	  this	  discovery	  for	  the	  control	  of	  DNA	  repair	  and	  mechanisms	  of	  substrate	  targeting	  by	  the	  ubiquitin	  system.	  
	  
Introduction	  Since	  the	  1987	  discovery	  that	  a	  key	  DNA	  repair	  protein,	  Rad6,	  was	  a	  ubiquitin	  (Ub)-­‐conjugating	  enzyme	  (1,	  2),	  there	  have	  been	  great	  strides	  in	  understanding	  the	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massive,	  multilevel	  involvement	  of	  the	  Ub–proteasome	  system	  in	  the	  DNA	  damage	  response	  (reviewed	  in	  refs.	  3	  and	  4).	  A	  major	  aspect	  of	  this	  response	  is	  the	  repair	  of	  damage	  caused	  by	  alkylating	  agents	  such	  as	  N-­‐methyl-­‐N’-­‐nitro-­‐N-­‐nitrosoguanidine	  (MNNG)	  and	  methyl	  methane	  sulfonate	  (MMS),	  which	  produce	  both	  mutagenic	  and	  cytotoxic	  lesions	  in	  DNA	  (4,	  5).	  One	  functionally	  severe	  lesion	  in	  double-­‐stranded	  DNA	  is	  O6-­‐methylguanine	  (O6meG),	  which	  is	  demethylated	  by	  the	  O6-­‐alkylguanine-­‐DNA	  alkyltransferase	  (AGT).	  This	  protein	  is	  called	  Mgmt	  (or	  MGMT)	  in	  mammals	  and	  Mgt1	  in	  the	  yeast	  Saccharomyces	  cerevisiae	  (5–8).	  Compounds	  that	  produce	  O6meG	  in	  DNA	  are	  common	  environmental	  carcinogens.	  Some	  of	  these	  compounds	  are	  also	  formed	  as	  a	  part	  of	  normal	  cellular	  metabolism.	  The	  repair	  of	  O6meG	  in	  DNA	  is	  down-­‐regulated	  in	  many	  cancers,	  usually	  because	  of	  lower	  than	  normal	  levels	  of	  Mgmt	  in	  cancer	  cells.	  Consequently,	  some	  anticancer	  drugs	  are	  DNA	  alkylating	  agents	  whose	  targets	  include	  O6	  in	  guanine.	  An	  acquired	  or	  preexisting	  resistance	  of	  cancer	  cells	  to	  such	  drugs	  often	  involves	  an	  up-­‐regulation	  of	  Mgmt	  (4,	  5).	  AGT	  proteins	  remove	  methyl	  and	  other	  alkyl	  groups	  from	  alkylated	  O6	  in	  guanine	  by	  transferring	  an	  adduct	  to	  an	  active-­‐site	  Cys	  residue	  (5,	  6).	  The	  resulting	  S-­‐alkyl-­‐Cys	  residue	  of	  AGT	  is	  not	  restored	  back	  to	  Cys,	  so	  repair	  proteins	  of	  this	  kind	  can	  act	  only	  once.	  In	  mammals,	  the	  alkylated	  (inactive)	  Mgmt	  and	  possibly	  the	  unmodified	  Mgmt	  are	  short-­‐lived	  proteins,	  degraded	  by	  an	  unknown	  pathway	  (9).	  In	  human	  cells	  that	  express	  the	  E6	  protein	  of	  the	  human	  papilloma	  virus	  (HPV),	  MGMT	  is	  also	  targeted	  for	  degradation	  by	  a	  complex	  of	  the	  viral	  E6	  protein	  and	  E6AP,	  one	  of	  mammalian	  HECT-­‐domain	  E3	  Ub	  ligases	  (8,	  10).	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In	  this	  study,	  we	  discovered	  that	  Mgt1,	  the	  O6meG-­‐DNA	  alkyltransferase	  of	  S.	  cerevisiae,	  is	  a	  physiological	  substrate	  of	  both	  the	  Ubr1-­‐dependent	  N-­‐end	  rule	  pathway	  and	  the	  Ufd4-­‐dependent	  Ub	  fusion	  degradation	  (UFD)	  pathway	  (Fig.	  1).	  S.	  cerevisiae	  Mgt1	  is	  a	  188-­‐residue	  protein	  that	  is	  sequelogous	  (similar	  in	  sequence)	  (11)	  to	  mammalian	  Mgmt	  (7,	  12,	  13).	  The	  N-­‐end	  rule	  relates	  the	  in	  vivo	  half-­‐life	  of	  a	  protein	  to	  the	  identity	  of	  its	  N-­‐terminal	  residue	  (2,	  14–17).	  Degradation	  signals	  (degrons)	  that	  are	  targeted	  by	  the	  N-­‐end	  rule	  pathway	  include	  a	  set	  called	  N-­‐degrons	  (2,	  15).	  The	  main	  determinant	  of	  an	  N-­‐degron	  is	  a	  destabilizing	  N-­‐terminal	  residue	  of	  a	  substrate	  protein.	  The	  N-­‐end	  rule	  has	  a	  hierarchic	  structure	  that	  involves	  the	  primary,	  secondary,	  and	  tertiary	  destabilizing	  N-­‐terminal	  residues	  (Fig.	  1A).	  Destabilizing	  activities	  of	  these	  residues	  differ	  by	  their	  requirements	  for	  a	  preliminary	  enzymatic	  modification	  (refs.	  2	  and	  15–18	  and	  references	  therein).	  E3	  Ub	  ligases	  of	  the	  N-­‐end	  rule	  pathway	  are	  called	  N-­‐recognins	  (15,	  17,	  19–21).	  They	  bind	  to	  primary	  destabilizing	  N-­‐terminal	  residues	  of	  N-­‐end	  rule	  substrates.	  The	  S.	  
cerevisiae	  N-­‐end	  rule	  pathway	  contains	  a	  single	  N-­‐recognin,	  Ubr1,	  a	  225-­‐kDa	  sequelog	  (11)	  of	  mammalian	  Ubr1	  and	  Ubr2	  (Fig.	  1A)	  (19–23).	  The	  functions	  of	  the	  N-­‐end	  rule	  pathway	  (Fig.	  1A)	  include	  the	  sensing	  of	  nitric	  oxide	  (NO),	  oxygen,	  heme,	  and	  short	  peptides;	  the	  maintenance	  of	  the	  high	  fidelity	  of	  chromosome	  segregation;	  the	  control	  of	  peptide	  import;	  regulation	  of	  signaling	  by	  transmembrane	  receptors,	  through	  the	  NO/O2-­‐dependent	  degradation	  of	  regulators	  of	  G	  protein	  signaling	  (RGS)	  proteins	  that	  downregulate	  G	  proteins;	  specific	  functions	  of	  the	  pancreas;	  regulation	  of	  apoptosis,	  meiosis,	  spermatogenesis,	  neurogenesis,	  and	  cardiovascular	  development	  in	  mammals;	  and	  regulation	  of	  leaf	  senescence	  in	  plants	  (refs.	  2,	  17,	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18,	  and	  21–25	  and	  references	  therein).	  The	  UFD	  pathway	  was	  discovered	  through	  the	  use	  of	  engineered	  Ub	  fusions	  in	  which	  the	  structure	  of	  either	  the	  N-­‐terminal	  Ub	  moiety	  or	  its	  junction	  with	  a	  downstream	  polypeptide	  inhibited	  the	  cleavage	  of	  a	  Ub	  fusion	  by	  deubiquitylating	  enzymes	  (DUBs)	  (14,	  26,	  27).	  Genetic	  dissection	  of	  the	  UFD	  pathway	  in	  S.	  cerevisiae	  identified	  Ufd1–Ufd5	  as	  proteins	  that	  were	  required,	  either	  strictly	  or	  in	  part,	  for	  the	  degradation	  of	  engineered	  UFD	  substrates	  (27,	  28).	  Ufd4	  is	  the	  168-­‐kDa	  HECT-­‐domain	  E3	  enzyme	  of	  the	  UFD	  pathway,	  which	  functions	  together	  with	  the	  E2	  enzymes	  Ubc4	  or	  Ubc5.	  Distinct	  domains	  of	  Ufd4	  were	  shown	  to	  recognize	  the	  N-­‐terminal	  Ub	  moiety	  of	  UFD	  substrates	  (29)	  and	  also	  specific	  subunits	  of	  the	  26S	  proteasome	  (30,	  31).	  Ufd4	  plays	  a	  role	  in	  the	  conditional	  autoubiquitylation	  and	  degradation	  of	  the	  Ubc7	  E2	  enzyme	  (32).	  Rad4,	  a	  nucleotide	  excision	  repair	  protein,	  is	  partially	  stabilized	  in	  ufd4Δ	  cells,	  suggesting	  that	  Rad4	  may	  be	  a	  substrate	  of	  the	  UFD	  pathway	  (33).	  Besides	  its	  relevance	  to	  DNA	  repair,	  the	  identification	  of	  S.	  cerevisiae	  Mgt1	  DNA	  alkyltransferase	  as	  a	  physiological	  substrate	  of	  both	  the	  N-­‐end	  rule	  and	  UFD	  pathways	  (Fig.	  1)	  brings	  together	  2	  mechanistically	  distinct	  targeting	  systems,	  in	  that	  Ubr1	  is	  a	  RING-­‐type	  E3,	  whereas	  Ufd4	  is	  a	  HECT-­‐type	  E3.	  The	  N-­‐end	  rule	  and	  UFD	  pathways	  were	  the	  first	  specific	  pathways	  of	  the	  Ub	  system	  to	  be	  discovered	  (14).	  Studies	  of	  these	  pathways	  have	  been	  proceeding	  largely	  in	  parallel	  (2,	  14,	  15,	  26–29,	  31,	  33),	  until	  the	  present	  discovery	  of	  their	  functional	  and	  mechanistic	  connection,	  as	  described	  below.	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Results	  and	  Discussion	  N-­‐End	  Rule	  Pathway	  Targets	  Mgt1	  for	  Degradation	  	  Large-­‐scale	  identification	  of	  S.	  cerevisiae	  protein	  complexes	  through	  coimmunoprecipitation	  and	  other	  assays	  suggested	  that	  the	  225-­‐kDa	  Ubr1	  E3	  Ub	  ligase	  (Fig.	  1A)	  may	  physically	  interact	  with	  Ygl081w,	  Pex7,	  Yak1,	  Mgt1,	  Ccr4,	  Gal80,	  and	  Srs2	  [see	  supporting	  information	  (SI)	  Materials	  and	  Methods	  and	  the	  legend	  to	  Fig.	  S1].	  We	  asked	  whether	  any	  of	  these	  putative	  Ubr1	  ligands	  were	  short-­‐lived	  in	  vivo,	  and,	  if	  so,	  whether	  they	  were	  degraded	  at	  least	  in	  part	  by	  the	  N-­‐end	  rule	  pathway.	  We	  used	  a	  ‘‘cycloheximide-­‐chase’’	  assay	  with	  wild	  type	  (wt)	  versus	  
ubr1Δ	  S.	  cerevisiae.	  In	  this	  method,	  the	  in	  vivo	  levels	  of	  a	  protein	  of	  interest	  are	  determined	  by	  SDS/PAGE	  and	  immunoblotting	  (IB)	  of	  cell	  extracts	  as	  a	  function	  of	  time	  after	  the	  inhibition	  of	  translation	  by	  cycloheximide.	  A	  majority	  of	  the	  above	  proteins	  were	  found	  to	  metabolically	  unstable.	  However,	  the	  absence	  of	  Ubr1	  stabilized	  just	  one	  of	  these	  proteins,	  Mgt1	  (Fig.	  S1A),	  the	  sole	  O6-­‐methylguanine	  DNA-­‐alkyltransferase	  in	  S.	  cerevisiae	  (see	  Introduction).	  Although	  the	  inferred	  ORF	  of	  S.	  cerevisiae	  Mgt1	  contains	  2	  in-­‐frame	  start	  codons,	  18	  codons	  apart	  (7),	  only	  the	  smaller,	  188-­‐residue	  Mgt1	  is	  produced	  in	  vivo	  (13).	  We	  replaced	  the	  chromosomal	  MGT1	  gene	  with	  an	  otherwise	  identical	  ORF	  expressing	  Mgt1m13	  (C-­‐terminally	  tagged	  with	  13	  copies	  of	  the	  10-­‐residue	  myc	  epitope)	  from	  the	  endogenous	  PMGT1	  promoter.	  Mgt1m13	  was	  indistinguishable	  from	  wt	  MGT1	  in	  its	  ability	  to	  protect	  cells	  from	  MNNG,	  a	  DNA-­‐alkylating	  agent	  (Fig.	  S1C).	  The	  instability	  of	  Mgt1m13	  could	  be	  restored	  by	  reintroducing	  UBR1	  into	  ubr1Δ	  cells	  (Fig.	  2A).	  Importantly,	  this	  rescue	  did	  not	  occur	  with	  Ubr1C1220S,	  an	  inactive	  Ubr1	  mutant	  (20)	  (Fig.	  2A).	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A	  cycloheximide-­‐chase	  assay	  monitors	  the	  in	  vivo	  decay	  of	  both	  ‘‘young’’	  and	  ‘‘old’’	  molecules	  of	  a	  test	  protein.	  To	  assess	  the	  metabolic	  fate	  of	  newly	  formed	  Mgt1,	  we	  carried	  out	  pulse–chase	  assays	  with	  fDHFR-­‐UbK48R-­‐Mgt1f	  [‘‘f’’	  denotes	  the	  flag	  epitope	  linked	  to	  the	  N	  terminus	  and	  C	  terminus	  of	  the	  dihydrofolate	  reductase	  (DHFR)	  and	  Mgt1	  moieties,	  respectively].	  DUBs	  cotranslationally	  cleave	  this	  Ub	  fusion	  at	  the	  UbK48R-­‐Mgt1f	  junction,	  yielding	  the	  long-­‐lived	  reference	  fDHFR-­‐UbK48R	  and	  the	  test	  protein	  Mgt1f.	  In	  this	  Ub-­‐reference	  technique	  (refs.	  23	  and	  25	  and	  references	  therein),	  the	  free	  fDHFR-­‐UbK48R	  serves	  as	  a	  ‘‘built-­‐in’’	  reference	  protein	  to	  compensate	  for	  scatter	  of	  expression	  levels	  and	  immunoprecipitation	  efficiency,	  thereby	  increasing	  the	  accuracy	  of	  pulse–chase	  assays.	  The	  in	  vivo	  half-­‐life	  (t1/2)	  of	  Mgt1f	  at	  30	  °C	  was	  19	  min	  in	  wt	  cells	  and	  32	  min	  in	  ubr1Δ	  cells	  (Fig.	  S2A),	  consistent	  with	  the	  results	  of	  cycloheximide-­‐chase	  assays	  (Fig.	  S1A),	  including	  the	  residual	  instability	  of	  Mgt1	  in	  ubr1Δ	  cells.	  We	  also	  used	  the	  pdr5Δ	  S.	  cerevisiae	  strain,	  in	  which	  the	  absence	  of	  the	  Pdr5	  transporter	  allows	  the	  intracellular	  accumulation	  of	  MG132,	  a	  proteasome	  inhibitor.	  No	  Mgt1m13-­‐linked	  polyUb	  ‘‘ladders’’	  were	  detected	  in	  wt	  cells	  in	  the	  absence	  of	  MG132	  (Fig.	  S1B,	  lanes	  1	  and	  2),	  suggesting	  that	  polyubiquitylation	  of	  Mgt1	  (in	  contrast	  to	  its	  subsequent	  destruction	  by	  the	  proteasome)	  was	  rate-­‐limiting	  under	  these	  conditions.	  Consistent	  with	  this	  interpretation,	  larger,	  presumably	  polyubiquitylated	  forms	  of	  Mgt1m13	  appeared	  after	  the	  treatment	  of	  cells	  for	  1	  h	  with	  MG132	  (Fig.	  S1B,	  lanes	  1	  and	  2	  versus	  lanes	  3	  and	  4).	  The	  levels	  of	  MG132-­‐induced	  Mgt1m13	  derivatives	  were	  much	  lower	  in	  ubr1Δ	  cells	  but	  were	  still	  detectable	  (Fig.	  S1B,	  lane	  4	  versus	  lane	  6),	  suggesting	  that	  another	  Ub	  ligase	  may	  also	  target	  Mgt1.	  In	  a	  different	  assay,	  Mgt1ha	  
	   192	  
(C-­‐terminally	  ha-­‐tagged)	  was	  coexpressed	  in	  wt	  S.	  cerevisiae	  with	  His6-­‐tagged	  UbK48R,G76A,	  a	  double-­‐mutant	  Ub	  that	  can	  become	  a	  part	  of	  polyUb	  chains	  but	  would	  inhibit	  their	  disassembly	  by	  DUBs	  (ref.	  2	  and	  references	  therein).	  S.	  cerevisiae	  was	  treated	  with	  MNNG,	  and	  polyubiquitylated	  proteins	  were	  isolated	  from	  cell	  extracts	  by	  using	  His6-­‐specific	  chromatography,	  followed	  by	  SDS/PAGE	  and	  IB	  with	  anti-­‐ha	  antibody.	  A	  smear	  of	  high-­‐Mr,	  Mgt1ha	  containing	  proteins	  was	  observed	  near	  the	  top	  of	  the	  gel,	  whereas	  such	  proteins	  were	  virtually	  absent	  in	  a	  test	  with	  His6-­‐lacking	  UbK48R,G76A	  (Fig.	  2B).	  The	  Ub	  ligase	  holoenzyme	  of	  the	  N-­‐end	  rule	  pathway	  is	  Ubr1-­‐Rad6,	  in	  which	  the	  20-­‐kDa	  Rad6	  is	  the	  Ub-­‐conjugating	  enzyme	  (E2)	  (15,	  20).	  To	  determine	  whether	  other	  E2s	  might	  also	  play	  a	  role,	  we	  carried	  out	  cycloheximide-­‐chase	  assays	  with	  a	  collection	  of	  E2-­‐null	  mutants	  that	  expressed	  Mgt1f3	  (wt	  Mgt1	  C-­‐terminally	  tagged	  with	  3	  copies	  of	  the	  flag	  epitope).	  Mgt1f3	  was	  strongly	  stabilized	  only	  in	  rad6Δ	  cells	  (Fig.	  S1D,	  lanes	  5	  and	  6).	  In	  addition	  to	  being	  the	  E2	  of	  the	  Ubr1	  E3,	  Rad6	  also	  functions	  as	  a	  part	  of	  Ub	  ligases	  that	  contain,	  in	  particular,	  the	  Bre1,	  Ubr2,	  or	  Rad18	  E3s	  (34).	  In	  cycloheximide-­‐chase	  assays	  with	  null	  mutants	  in	  these	  E3s,	  Mgt1	  was	  significantly	  stabilized	  only	  in	  ubr1Δ	  cells	  (Fig.	  2D).	  Interestingly,	  the	  degradation	  of	  Mgt1	  was	  accelerated	  in	  a	  ubr2Δ	  strain,	  compared	  with	  its	  wt	  counterpart	  (Fig.	  2D,	  lanes	  5	  and	  6;	  compare	  with	  lanes	  1	  and	  2).	  Ubr2	  is	  a	  sequelog	  of	  Ubr1	  that	  also	  functions	  in	  a	  complex	  with	  Rad6.	  However,	  in	  contrast	  to	  Ubr1,	  Ubr2	  does	  not	  recognize	  N-­‐degrons	  (35).	  The	  enhancement	  of	  Mgt1	  degradation	  in	  ubr2Δ	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cells	  (Fig.	  2D	  and	  Fig.	  S2B)	  could	  be	  caused	  by	  an	  increased	  level	  of	  Ubr1-­‐accessible	  Rad6,	  and	  also,	  nonalternatively,	  by	  an	  up-­‐regulation	  of	  the	  proteasome,	  owing	  to	  an	  increase	  in	  Rpn4,	  which	  is	  partially	  stabilized	  in	  ubr2Δ	  cells	  (35,	  36).	  Either	  MNNG	  or	  High	  Temperature	  Accelerate	  Mgt1	  Degradation	  	  At	  approximately	  200	  molecules	  per	  haploid	  cell	  in	  exponential	  cultures,	  the	  endogenous	  Mgt1	  is	  a	  scarce	  protein	  in	  S.	  cerevisiae	  (12).	  Mgt1-­‐dependent	  DNA-­‐alkyltransferase	  activity	  in	  S.	  cerevisiae	  extracts	  was	  strongly	  decreased	  after	  a	  treatment	  of	  cells	  with	  MNNG	  or	  shifting	  them	  from	  30°C	  to	  37°C	  (12).	  Our	  results	  account	  for	  these	  effects,	  as	  the	  in	  vivo	  degradation	  of	  Mgt1	  was	  accelerated	  by	  these	  treatments	  (Fig.	  2E	  and	  Fig.	  S2C).	  Strong	  effects	  of	  increased	  temperature	  on	  Mgt1	  degradation	  could	  be	  detected	  by	  either	  cycloheximide-­‐chase	  or	  conventional	  pulse–chase	  assays	  (Fig.	  2	  C	  and	  F	  and	  Figs.	  S1E	  and	  S2C).	  In	  contrast,	  oxidizing	  agents	  such	  as	  H2O2	  (Fig.	  S2C)	  or	  t-­‐butyl	  hydroxide	  (data	  not	  shown)	  did	  not	  increase	  the	  rate	  of	  Mgt1	  degradation.	  The	  acceleration	  of	  yeast	  Mgt1	  degradation	  by	  MNNG	  (Fig.	  2E)	  was	  analogous	  to	  the	  previously	  observed	  effects	  of	  either	  MNNG	  or	  O6-­‐benzylguanine	  (the	  latter	  alkylates	  the	  active-­‐site	  Cys	  of	  Mgmt)	  on	  the	  degradation,	  by	  an	  unknown	  pathway,	  of	  Mgmt,	  the	  mammalian	  counterpart	  of	  Mgt1	  (9).	  We	  also	  examined	  mgt1Δ	  cells	  that	  expressed	  either	  Mgt1f3,	  Mgt1C151M,f3,	  or	  Mgt1C151S,f3.	  In	  the	  latter	  derivatives	  of	  Mgt1,	  the	  active-­‐site	  Cys151	  was	  replaced	  either	  by	  Met,	  a	  mimic	  of	  methylated	  Cys,	  or	  by	  Ser,	  a	  substitution	  that	  also	  inactivates	  Mgt1.	  S.	  cerevisiae	  expressing	  Mgt1C151M,f3	  or	  Mgt1C151S,f3	  were	  hypersensitive	  to	  MNNG	  (Fig.	  2G).	  In	  the	  absence	  of	  MNNG,	  Mgt1C151M,f3	  was	  much	  shorter-­‐lived	  than	  wt	  Mgt1f3	  (data	  not	  shown).	  By	  contrast,	  and	  in	  agreement	  with	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the	  inability	  of	  the	  Ser-­‐mutant	  Mgt1C151S,f3	  	  to	  be	  alkylated	  at	  position	  151,	  this	  mutant	  was	  longer-­‐lived	  than	  wt	  Mgt1f3	  in	  cells	  that	  were	  treated	  with	  MNNG	  (Fig.	  3A).	   The	  3D	  structure	  of	  the	  22-­‐kDa	  human	  MGMT	  (6),	  a	  counterpart	  of	  the	  21-­‐kDa	  S.	  cerevisiae	  Mgt1,	  showed	  that	  MGMT	  consists	  of	  a	  ‘‘ribonuclease-­‐like’’	  N-­‐terminal	  domain	  (residues	  6–92)	  and	  a	  C-­‐terminal	  DNA-­‐binding	  domain	  (residues	  96–176)	  (Fig.	  S3	  A,	  B,	  and	  D).	  A	  putative	  3D	  structure	  of	  S.	  cerevisiae	  Mgt1	  was	  modeled	  on	  human	  MGMT	  and	  took	  into	  account	  its	  sequelogy	  to	  Mgt1	  (Fig.	  S4C).	  The	  active-­‐site	  Cys	  of	  human	  MGMT	  resides	  between	  the	  C-­‐terminal	  DNA-­‐binding	  domain	  and	  the	  N-­‐terminal	  lobe	  that	  faces	  away	  from	  DNA	  (6)	  (Fig.	  S3B).	  Our	  findings	  (see	  Fig.	  S4A)	  indicate	  that	  the	  degron	  of	  S.	  cerevisiae	  Mgt1	  is	  close	  to	  its	  N	  terminus.	  Thus,	  the	  active-­‐site	  Cys151	  of	  Mgt1	  is	  not	  a	  part	  of	  its	  degron	  per	  se.	  Instead,	  the	  alkylation	  of	  Cys151	  that	  accompanies	  the	  repair	  of	  alkylated	  DNA	  by	  Mgt1	  may	  change	  its	  conformation	  and/or	  conformational	  mobility	  and	  thereby	  increase	  the	  accessibility	  of	  its	  degron	  (which	  would	  be	  expected	  to	  ‘‘face	  away’’	  from	  DNA)	  to	  cognate	  Ub	  ligases.	  This	  model	  is	  consistent	  with	  the	  above-­‐mentioned	  faster	  degradation	  of	  Mgt1C151M,f3,	  which	  contains	  Met151,	  a	  mimic	  of	  methylated	  Cys,	  instead	  of	  wt	  Cys151.	  The	  absence	  of	  Ubr1	  made	  S.	  cerevisiae	  10-­‐fold	  more	  resistant	  to	  MNNG,	  compared	  with	  wt	  cells	  (Fig.	  2H	  and	  Fig.	  S2E).	  These	  results	  suggested	  that	  Ubr1	  targets	  not	  only	  alkylated	  (inactive)	  Mgt1	  but	  also	  unmodified	  Mgt1.	  This	  interpretation	  would	  account	  for	  the	  higher	  MNNG	  resistance	  of	  ubr1Δ	  cells,	  as	  the	  absence	  of	  degradation	  of	  unmodified	  Mgt1	  would	  result	  in	  more	  of	  it	  available	  for	  DNA	  repair.	  In	  agreement	  with	  the	  hyperresistance	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of	  ubr1Δ	  cells	  to	  MNNG,	  they	  were	  also	  found	  to	  exhibit	  a	  lower	  frequency	  of	  MNNG-­‐induced	  mutations	  (Fig.	  S2D).	  Ubr1	  Targets	  Mgt1	  Via	  a	  Degron	  Near	  Its	  N	  Terminus.	  	  C-­‐terminally	  truncated	  fragments	  of	  Mgt1f3	  were	  expressed	  in	  either	  ubr1Δ	  or	  wt	  S.	  cerevisiae,	  followed	  by	  SDS/PAGE	  of	  cell	  extracts	  and	  IB	  with	  anti-­‐flag	  antibody	  (Fig.	  S4A).	  Mgt11–100,f3,	  which	  contained	  the	  ribonuclease-­‐like	  N-­‐terminal	  domain	  of	  Mgt1	  but	  lacked	  the	  activesite	  Cys151,	  was	  undetectable	  in	  wt	  cells	  but	  readily	  detectable	  in	  ubr1Δ	  cells	  (Fig.	  S4A,	  lanes	  5	  and	  6),	  indicating	  the	  presence	  of	  a	  Ubr1-­‐specific	  degron	  in	  the	  N-­‐terminal	  half	  of	  Mgt1.	  The	  results	  with	  Mgt11–144,f3	  (Fig.	  S4A,	  lanes	  3	  and	  4)	  were	  similar	  to	  those	  with	  Mgt11–100,f3.	  Mgt184–188,f3,	  an	  N-­‐terminally	  truncated	  Mgt1,	  could	  not	  be	  expressed	  at	  detectable	  levels	  in	  either	  wt	  or	  ubr1Δ	  cells	  (Fig.	  S4A,	  lanes	  7	  and	  8).	  	  UFD	  and	  N-­‐End	  Rule	  Pathways	  Cotarget	  Mgt1	  for	  Degradation	  	  Given	  the	  residual	  instability	  of	  Mgt1	  in	  the	  absence	  of	  Ubr1	  (Fig.	  2	  A,	  D,	  and	  E),	  we	  attempted	  to	  identify	  another	  E3	  that	  may	  target	  Mgt1.	  This	  search	  involved	  expression	  of	  the	  Mgt11–100,f3	  fragment	  from	  the	  PMGT1	  promoter	  (Fig.	  S4A)	  and	  a	  set	  of	  S.	  cerevisiae	  mutants	  in	  several	  E3s	  (ubr1Δ,	  ubr2Δ,	  hrd1Δ,	  hrd3Δ,	  doa10Δ,	  ufd2Δ,	  
tul1Δ,	  hul4Δ,	  hul5Δ,	  ufd4Δ,	  tom1Δ,	  rps5-­‐1ts).	  Among	  these	  mutants,	  the	  Mgt11–100,f3	  fragment	  was	  significantly	  stabilized	  in	  ubr1Δ	  cells	  (as	  expected),	  and	  also,	  remarkably,	  in	  ufd4Δ	  cells	  (Fig.	  3B,	  lane	  3).	  Ufd4	  is	  a	  168-­‐kDa	  HECT-­‐domain	  E3	  Ub	  ligase	  that	  mediates	  the	  UFD	  pathway	  (see	  Introduction	  and	  Fig.	  1B).	  Given	  this	  result,	  we	  carried	  out	  cycloheximide	  chase	  assays	  with	  wt,	  ubr1Δ,	  and	  ubr1Δufd4Δ	  double-­‐mutant	  S.	  cerevisiae	  strains	  that	  expressed	  full-­‐length	  Mgt1m13.	  The	  absence	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of	  both	  Ubr1	  and	  Ufd4	  stabilized	  Mgt1	  much	  more	  than	  the	  absence	  of	  Ubr1	  alone	  (Fig.	  3C	  and	  Fig.	  S2F).	  The	  synergistically	  enhanced	  stabilization	  of	  Mgt1m13	  in	  
ubr1Δufd4Δ	  cells	  was	  observed	  either	  at	  37°C	  (Fig.	  S2F)	  or	  upon	  a	  treatment	  with	  MNNG	  (Fig.	  3C).	  Moreover,	  a	  conventional	  pulse–chase	  assay	  at	  37°C	  with	  Mgt1f3	  and	  either	  wt,	  ubr1Δ,	  or	  ubr1Δufd4Δ	  cells	  has	  demonstrated	  a	  virtually	  complete	  stabilization	  of	  newly	  formed	  Mgt1	  in	  ubr1Δufd4Δ	  cells	  (Fig.	  3	  D	  and	  E).	  As	  would	  be	  expected	  (given	  the	  results	  above),	  the	  absence	  of	  Ufd4	  alone	  partially	  stabilized	  Mgt1,	  especially	  in	  ufd4Δ	  versus	  wt	  cells	  that	  were	  treated	  with	  MNNG	  (Fig.	  S2	  G	  and	  H).	  S.	  cerevisiae	  lacking	  Ufd4	  were	  2.5-­‐fold	  more	  resistant	  to	  MNNG	  than	  their	  wt	  counterparts	  (Fig.	  3F	  and	  Fig.	  S4F).	  Double	  mutant	  ubr1Δufd4Δ	  cells,	  in	  which	  Mgt1	  was	  particularly	  long-­‐lived	  (Fig.	  3	  C–E),	  grew	  slightly	  slower	  than	  congenic	  wt	  cells	  (Fig.	  S4	  F	  and	  G	  and	  data	  not	  shown).	  Moreover,	  overexpressing	  of	  Mgt1f3	  in	  either	  wt,	  ubr1Δ,	  or	  ufd4Δ	  cells	  did	  not	  significantly	  impair	  their	  growth	  (data	  not	  shown)	  but	  led	  to	  a	  severe	  growth	  defect	  in	  ubr1Δufd4Δ	  cells	  (Fig.	  S4	  G	  and	  H).	  Thus,	  the	  inability	  to	  destroy	  Mgt1	  is	  near-­‐lethal	  upon	  overexpression	  of	  Mgt1	  and	  is	  also	  likely	  to	  be	  deleterious,	  to	  a	  lower	  extent,	  at	  physiological	  levels	  of	  Mgt1.	  In	  Vitro	  Binding	  of	  Ubr1	  and	  Ufd4	  to	  Mgt1	  and	  Cup9	  	  The	  type	  1	  and	  type	  2	  substrate-­‐binding	  sites	  of	  Ubr1	  are	  specific	  for	  basic	  N-­‐terminal	  residues	  (Arg,	  Lys,	  His)	  and	  bulky	  hydrophobic	  N-­‐terminal	  residues	  (Trp,	  Phe,	  Tyr,	  Leu,	  Ile),	  respectively.	  The	  third	  binding	  site	  of	  Ubr1	  recognizes	  an	  internal	  (non-­‐N-­‐degron)	  degradation	  signal	  of	  Cup9,	  a	  transcriptional	  repressor	  of	  a	  regulon	  that	  includes	  the	  Ptr2	  transporter	  of	  di-­‐	  and	  tripeptides	  (19,	  22,	  25).	  This	  binding	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site	  of	  Ubr1	  is	  autoinhibited	  but	  can	  be	  allosterically	  activated	  by	  the	  binding	  of	  cognate	  peptides	  (including	  those	  imported	  into	  cells	  by	  Ptr2)	  to	  the	  type	  1/2	  sites	  of	  Ubr1.	  The	  resulting	  down-­‐regulation	  of	  the	  Cup9	  repressor,	  through	  its	  accelerated	  degradation	  by	  the	  N-­‐end	  rule	  pathway,	  up-­‐regulates	  the	  expression	  of	  the	  Ptr2	  transporter.	  This	  positive-­‐feedback	  circuit	  allows	  S.	  cerevisiae	  to	  detect	  the	  presence	  of	  extracellular	  peptides	  and	  to	  react	  by	  increasing	  their	  uptake	  (22,	  23,	  25).	  We	  used	  cup9Δ,	  ubr1Δ,	  and	  cup9Δubr1Δ	  mutants	  to	  determine	  whether	  the	  observed	  effect	  of	  Ubr1	  on	  the	  in	  vivo	  degradation	  of	  Mgt1	  (e.g.,	  Fig.	  2	  A,	  B,	  D,	  and	  F)	  might	  be	  influenced	  by	  a	  circuit	  controlled	  by	  Cup9,	  and	  found	  no	  such	  influence	  (Fig.	  S4E).	  In	  agreement	  with	  previous	  work,	  which	  used	  GST-­‐pulldown	  assays	  to	  demonstrate	  the	  dependence	  of	  interactions	  between	  Ubr1	  and	  GST-­‐Cup9	  on	  the	  presence	  of	  cognate	  (type	  1/2)	  dipeptides	  (19,	  22),	  the	  in	  vitro	  binding	  of	  
fUbr1	  to	  GST-­‐Cup9	  required	  the	  presence	  of	  cognate	  dipeptides	  such	  as	  Arg-­‐Ala	  (type	  1	  dipeptide)	  and	  Leu-­‐Ala	  (type	  2	  dipeptide)	  (Fig.	  S4B,	  lane	  11;	  compare	  with	  lane	  12).	  Analogous	  GST	  pulldowns	  were	  used	  to	  detect	  a	  specific	  interaction	  between	  fUbr1	  and	  GST-­‐Mgt1	  (Fig.	  S4B,	  lanes	  3–9).	  Interestingly,	  this	  interaction	  did	  not	  require	  the	  presence	  of	  cognate	  dipeptides.	  Moreover,	  it	  was	  inhibited	  by	  the	  same	  (cognate)	  dipeptides	  at	  concentrations	  that	  activated	  the	  interaction	  of	  fUbr1	  with	  GST-­‐Cup9	  (Fig.	  S4B,	  lane	  8,	  compare	  with	  lanes	  3	  and	  9).	  The	  comparably	  robust	  but	  opposite	  effect	  of	  cognate	  peptides	  on	  the	  Ubr1-­‐Mgt1	  interaction	  remains	  to	  be	  understood	  in	  physiological	  terms.	  As	  would	  be	  expected	  from	  the	  Ufd4-­‐dependent	  degradation	  of	  Mgt1	  in	  vivo	  (Fig.	  3	  B–E	  and	  Fig.	  S2	  G	  and	  H),	  a	  GST-­‐Mgt1	  
	   198	  
pulldown	  with	  haUfd4	  (instead	  of	  fUbr1)	  confirmed	  the	  binding	  of	  Ufd4	  to	  Mgt1	  (Fig.	  S4C).	  In	  contrast	  to	  Mgt1-­‐Ubr1	  interactions,	  which	  were	  inhibited	  by	  cognate	  type	  1/2	  dipeptides	  (Fig.	  S4B),	  the	  binding	  of	  haUfd4	  to	  GST-­‐Mgt1	  occurred	  irrespective	  of	  type	  1/2	  or	  other	  tested	  dipeptides	  (Fig.	  S4C).	  The	  same	  results	  were	  obtained	  with	  Mgt1-­‐GST,	  in	  which	  the	  GST	  moiety	  was	  C-­‐terminal	  rather	  than	  N-­‐terminal	  (data	  not	  shown).	  The	  Ufd4-­‐Mgt1interaction	  could	  also	  be	  detected	  by	  using	  a	  coimmunoprecipitation	  assay	  (Fig.	  S4D).	  Synergistic	  Enhancement	  of	  the	  Extent	  and	  Processivity	  of	  Mgt1	  Polyubiquitylation	  by	  Ubr1	  and	  Ufd4	  	  We	  developed	  an	  in	  vitro	  system	  that	  consisted	  of	  the	  following	  purified	  components:	  Ub;	  Uba1	  (Ub-­‐activating	  enzyme,	  E1);	  Rad6	  and/or	  Ubc4	  (E2	  enzymes	  specific	  for	  Ubr1	  and	  Ufd4,	  respectively);	  Ubr1	  and/or	  Ufd4	  (E3s	  that	  target	  Mgt1);	  and	  ATP.	  This	  system	  also	  contained	  35S-­‐labeled	  Mgt1f3,	  which	  was	  produced	  in	  reticulocyte	  lysate	  (see	  SI	  Materials	  and	  Methods).	  In	  the	  final	  reaction	  mix,	  10%	  of	  the	  total	  volume	  was	  contributed	  by	  the	  35S-­‐Mgt1-­‐containing	  reticulocyte	  lysate.	  Either	  the	  Ubr1-­‐Rad6	  Ub	  ligase	  alone	  or	  the	  Ufd4-­‐Ubc4	  Ub	  ligase	  alone	  polyubiquitylated	  Mgt1	  in	  vitro	  (Fig.	  4,	  lanes	  3	  and	  5;	  compare	  with	  lane	  1).	  Whereas	  the	  yield	  of	  polyubiquitylated	  Mgt1	  was	  higher	  with	  Ubr1-­‐Rad6	  alone	  than	  with	  Ufd4-­‐Ubc4	  alone,	  the	  latter	  Ub	  ligase	  was	  more	  processive.	  Specifically,	  Mgt1	  that	  was	  polyubiquitylated	  by	  Ufd4-­‐Ubc4	  alone	  migrated	  as	  a	  set	  of	  derivatives	  in	  a	  relatively	  narrow	  size	  range,	  180	  kDa.	  This	  molecular	  mass	  implied	  the	  presence	  of	  a	  polyUb	  chain	  linked	  to	  the	  21-­‐kDa	  Mgt1	  and	  containing	  19	  Ub	  moieties	  (Fig.	  4,	  lane	  5).	  In	  contrast,	  the	  polyubiquitylated	  Mgt1	  produced	  by	  Ubr1-­‐Rad6	  alone	  migrated	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as	  a	  more	  diffuse	  set	  of	  derivatives,	  and	  at	  a	  significantly	  lower	  size	  range,	  up	  to	  150	  kDa	  (Fig.	  4,	  lanes	  3	  and	  5;	  compare	  with	  lane	  1).	  Strikingly,	  the	  polyubiquitylation	  of	  Mgt1	  in	  the	  presence	  of	  Ubr1-­‐Rad6	  and	  Ufd4-­‐Ubc4	  together	  exhibited	  both	  a	  higher	  overall	  yield	  and	  higher	  processivity.	  Specifically,	  Mgt1	  that	  was	  polyubiquitylated	  in	  the	  presence	  of	  both	  the	  N-­‐end	  rule’s	  and	  UFD’s	  Ub	  ligases	  migrated	  as	  a	  set	  of	  higher-­‐yield	  derivatives	  in	  a	  relatively	  narrow	  size	  range,	  200	  kDa	  on	  average	  (Fig.	  4,	  lane	  6;	  compare	  with	  lanes	  3	  and	  5).	  This	  size	  was	  higher	  than	  the	  one	  with	  Mgt1	  with	  Ufd4-­‐Ubc4	  alone	  (Fig.	  4,	  lane	  5)	  and	  much	  higher	  than	  the	  one	  with	  Mgt1	  with	  Ubr1-­‐Rad6	  alone	  (Fig.	  4,	  lane	  3;	  compare	  with	  lane	  1).	  This	  reproducible	  result	  (Fig.	  4,	  lane	  6,	  and	  data	  not	  shown)	  indicated	  that	  the	  targeting	  mechanisms	  of	  the	  N-­‐end	  rule	  and	  UFD	  pathways	  are	  not	  simply	  ‘‘additive’’	  in	  regard	  to	  Mgt1.	  Specifically,	  this	  cotargeting	  of	  Mgt1,	  reconstituted	  in	  the	  in	  vitro	  system,	  is	  synergistic	  both	  in	  regard	  to	  yields	  of	  polyubiquitylated	  Mgt1	  and	  in	  regard	  to	  the	  processivity	  of	  polyubiquitylation	  (Fig.	  4,	  lanes	  1,	  3,	  5,	  and	  6).	  Operationally,	  the	  Ufd4-­‐Ubc4	  Ub	  ligase	  appears	  to	  function,	  in	  part,	  as	  an	  enhancer	  of	  the	  processivity	  of	  Mgt1	  polyubiquitylation	  by	  Ubr1-­‐Rad6	  (Fig.	  4).	  Such	  a	  role	  of	  Ufd4-­‐Ubc4	  may	  be	  analogous	  to	  the	  function	  of	  Ufd2,	  a	  component	  of	  the	  UFD	  pathway	  that	  Jentsch	  and	  colleagues	  showed	  to	  act	  by	  increasing	  the	  processivity	  of	  polyubiquitylation	  of	  UFD	  substrates	  that	  contain	  the	  N-­‐terminal	  Ub	  moiety	  (28).	  Concluding	  Remarks	  	  The	  discovery	  that	  Mgt1,	  the	  DNA	  alkyltransferase	  of	  S.	  cerevisiae,	  is	  a	  physiological	  substrate	  of	  both	  the	  N-­‐end	  rule	  pathway	  and	  the	  UFD	  pathway	  (Fig.	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1C)	  has	  ramifications	  for	  the	  control	  of	  DNA	  repair	  not	  only	  in	  fungi	  but	  in	  other	  eukaryotes	  as	  well.	  The	  AGT	  proteins	  (see	  Introduction),	  including	  yeast	  Mgt1	  and	  mammalian	  Mgmt	  (MGMT),	  are	  highly	  sequelogous	  (Fig.	  S3D).	  In	  addition,	  the	  N-­‐end	  rule	  and	  UFD	  pathways	  are	  present	  in	  all	  eukaryotes	  examined	  (2,	  14,	  26–29,	  33).	  Using	  a	  split-­‐Ub	  assay,	  we	  found	  that	  mouse	  Ubr1	  and	  Ubr2,	  2	  sequelogous	  N-­‐recognins	  of	  the	  mammalian	  N-­‐end	  rule	  pathway,	  interact	  with	  mouse	  Mgmt	  in	  vivo	  (J.	  Sheng,	  C.-­‐S.	  H.,	  and	  A.	  V.,	  unpublished	  data),	  strongly	  suggesting	  that	  (at	  least)	  the	  N-­‐end	  rule	  pathway	  mediates	  the	  degradation	  of	  mammalian	  Mgmt.	  Mouse	  Ubr2/	  fibroblasts,	  which	  lack	  Ubr2	  and	  therefore	  contain	  a	  partially	  impaired	  N-­‐end	  rule	  pathway,	  were	  found	  to	  be	  hypersensitive	  to	  mitomycin	  C,	  a	  DNA	  cross-­‐linking	  agent	  (37).	  Melanoma	  cells	  that	  overexpress	  Mgmt	  are	  also	  hypersensitive	  to	  mitomycin	  C	  (38).	  Taken	  together	  with	  our	  results	  (Fig.	  1C),	  these	  findings	  suggest	  that	  the	  degradation	  of	  mammalian	  Mgmt,	  presumably	  by	  both	  the	  N-­‐end	  rule	  and	  UFD	  pathways,	  plays	  a	  role	  in	  determining	  the	  sensitivity	  of	  mammalian	  cells	  to	  alkylating	  agents,	  including	  some	  DNA	  crosslinking	  agents	  as	  well.	  The	  striking	  effect	  of	  simultaneous	  presence	  of	  the	  Ubr1-­‐Rad6	  and	  Ufd4-­‐Ubc4	  Ub	  ligases	  on	  both	  the	  yield	  and	  processivity	  of	  Mgt1	  polyubiquitylation	  makes	  the	  in	  vitro	  system	  described	  in	  Fig.	  4	  a	  promising	  tool	  for	  further	  analyses	  of	  Mgt1	  targeting.	  It	  should	  be	  possible	  to	  make	  this	  assay	  better	  defined	  through	  the	  provision	  of	  purified	  Mgt1,	  currently	  the	  system’s	  sole	  unpurified	  component	  (Fig.	  4).	  Questions	  that	  can	  be	  addressed	  by	  this	  approach	  include	  specific	  location(s)	  and	  topology	  of	  Mgt1-­‐linked	  polyUb	  chains	  that	  are	  produced	  by	  the	  Ubr1-­‐Rad6	  versus	  Ufd4-­‐Ubc4	  Ub	  ligases.	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The	  in	  vivo	  destruction	  of	  Mgt1	  that	  had	  become	  alkylated	  (through	  the	  repair	  of	  alkylated	  DNA	  by	  Mgt1)	  may	  occur	  at	  or	  near	  the	  sites	  of	  repaired	  DNA	  lesions.	  A	  priori,	  it	  is	  likely	  (nothing	  is	  known	  about	  this	  at	  present)	  that	  Mgt1	  functions	  as	  a	  part	  of	  chromosome-­‐associated	  protein	  complexes.	  If	  so,	  the	  subunit	  selectivity	  of	  the	  N-­‐end	  rule	  pathway,	  i.e.,	  its	  ability	  to	  remodel	  a	  protein	  complex	  by	  destroying	  a	  subset	  of	  its	  subunits	  while	  sparing	  the	  rest	  of	  them	  (39),	  might	  play	  a	  role	  in	  the	  in	  vivo	  degradation	  of	  Mgt1.	  This	  process	  may	  be	  analogous	  to	  the	  previously	  discovered	  selective	  degradation,	  by	  the	  N-­‐end	  rule	  pathway,	  of	  the	  separase-­‐produced	  fragment	  of	  Scc1,	  a	  subunit	  of	  chromosome	  associated	  cohesin	  complexes	  (40).	  This	  degradation	  of	  the	  Scc1	  fragment	  is	  essential	  for	  the	  high	  fidelity	  of	  chromosome	  segregation	  (40).	  Both	  the	  alkylated	  (inactive)	  Mgt1	  protein	  (Fig.	  1C)	  and	  the	  separase-­‐produced	  fragment	  of	  the	  Scc1	  cohesin	  subunit	  (40)	  are	  obligatory	  
in	  vivo	  products	  of	  the	  corresponding	  circuits.	  These	  proteins	  are	  also	  ‘‘dead-­‐end’’	  structures.	  Under	  conditions	  where	  the	  Scc1	  fragment	  cannot	  be	  eliminated	  by	  the	  N-­‐end	  rule	  pathway,	  this	  protein	  can	  be	  shown	  to	  perturb	  chromosome	  mechanics	  (40).	  A	  chromosome-­‐bound,	  alkylated	  but	  unremoved	  Mgt1	  may	  present	  an	  analogous	  problem.	  Thus,	  the	  N-­‐end	  rule	  and	  UFD	  pathways	  operate,	  in	  these	  contexts,	  as	  homeostasis-­‐maintaining	  devices	  that	  employ	  their	  capacity	  for	  subunit-­‐selective	  protein	  remodeling	  (39)	  to	  reset	  the	  states	  of	  relevant	  circuits.	  Because	  ubr1Δ,	  ufd4Δ,	  and	  particularly	  ubr1Δufd4Δ	  cells	  were	  hyperresistant	  (rather	  than	  hypersensitive)	  to	  the	  toxicity	  of	  MNNG	  (Fig.	  3F),	  a	  precise	  role	  of	  the	  N-­‐end	  rule	  and	  UFD	  pathways	  vis-­‐a-­‐vis	  DNA	  repair	  and	  other	  cellular	  functions	  remains	  to	  be	  understood.	  For	  example,	  a	  homeostatic	  role	  of	  these	  pathways	  in	  removing,	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through	  degradation,	  the	  alkylated	  (chromosome-­‐bound?)	  Mgt1	  may	  be	  important	  not	  for	  the	  repair	  of	  alkylated	  DNA	  per	  se	  but	  for	  another	  chromosome-­‐associated	  process(es)	  that	  would	  be	  either	  halted	  or	  function	  suboptimally	  in	  the	  presence	  of	  unremoved	  Mgt1.	  This	  interpretation	  is	  consistent	  with	  a	  strong	  toxicity	  of	  overexpressed	  Mgt1	  in	  ubr1Δufd4Δ	  cells	  but	  not	  in	  wt	  cells	  (Fig.	  S4	  G	  and	  H).	  The	  discovery	  that	  Mgt1	  is	  cotargeted	  by	  2	  otherwise	  dissimilar	  Ub-­‐dependent	  pathways	  (Fig.	  1)	  opens	  up	  new	  questions.	  For	  example:	  Might	  the	  cotargeting	  of	  Mgt1	  by	  Ubr1	  and	  Ufd4	  (Fig.	  1C)	  signify	  a	  physical	  interaction	  between	  these	  E3s?	  Our	  preliminary	  data	  suggest	  that	  Ubr1	  and	  Ufd4	  indeed	  interact,	  possibly	  in	  a	  conditional	  manner	  (unpublished	  data).	  Furthermore,	  previous	  work	  indicated	  that	  the	  both	  the	  Ubr1	  and	  Ufd4	  E3s	  interact	  with	  specific	  subunits	  of	  the	  26S	  proteasome	  (30,	  31).	  Thus,	  the	  demonstrated	  cotargeting	  of	  Mgt1	  by	  the	  N-­‐end	  rule	  and	  UFD	  pathways	  (Fig.	  1C)	  may	  involve	  not	  only	  copolyubiquitylation	  of	  Mgt1	  (Fig.	  4)	  but	  proteasome-­‐docking	  steps	  as	  well.	  	  
SI	  Materials	  and	  Methods	  Yeast	  Strains,	  Media,	  and	  Genetic	  Techniques.	  The	  S.	  cerevisiae	  strains	  used	  in	  this	  work	  are	  described	  in	  Table	  S1.	  Standard	  techniques	  (1)	  were	  used	  for	  strain	  construction	  and	  transformation.	  The	  strains	  CHY107,	  CHY108,	  CHY115,	  CHY116,	  and	  CHY169	  were	  produced	  by	  extending	  the	  endogenous	  MGT1	  ORF	  in	  the	  S.	  
cerevisiae	  strains	  JD52,	  JD55,	  CHY49,	  or	  CHY50	  (Table	  S1)	  with	  a	  sequence	  encoding	  13	  head-­‐to-­‐tail	  repeats	  of	  the	  myc	  epitope	  tag	  (1).	  This	  was	  done	  using	  a	  PCR-­‐mediated	  gene	  targeting	  that	  used	  pFA6a-­‐13MYC-­‐TRP1	  (2),	  similarly	  to	  a	  previously	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described	  procedure	  that	  was	  used	  for	  gene	  disruption	  (3).	  S.	  cerevisiae	  CHY121,	  CHY122,	  CHY169,	  CHY194,	  CHY195,	  and	  CHY219	  were	  constructed	  through	  disruptions	  of	  MGT1	  or	  UFD4	  in	  JD52,	  JD55,	  and	  CHY108	  strains	  (Table	  S1),	  using	  a	  PCR-­‐mediated	  gene	  disruption	  that	  used	  pFA6aKanMX6	  or	  pFA6a-­‐TRP1	  (2)	  similarly	  to	  a	  previously	  described	  procedure	  (3).	  S.	  cerevisiae	  that	  were	  null	  mutants	  in	  specific	  E2	  or	  E3	  genes	  were	  either	  from	  the	  Varshavsky	  laboratory’s	  strain	  collection,	  or	  obtained	  from	  Dr.	  Youming	  Xie	  (Wayne	  State	  University,	  Detroit,	  MI),	  or	  purchased	  from	  Open	  Biosystems.	  S.	  cerevisiae	  media	  included	  YPD	  (1%	  yeast	  extract,	  2%	  peptone,	  2%	  glucose;	  only	  most	  relevant	  media	  components	  are	  cited);	  SD	  medium	  (0.17%	  yeast	  nitrogen	  base,	  0.5%	  ammonium	  sulfate,	  2%	  glucose);	  and	  synthetic	  complete	  (SC)	  medium	  (0.17%	  yeast	  nitrogen	  base,	  0.5%	  ammonium	  sulfate,	  2%	  glucose,	  plus	  a	  drop-­‐out	  mixture	  of	  compounds	  required	  by	  a	  given	  auxotrophic	  strain).	  Plasmids	  and	  Site-­‐Directed	  Mutagenesis.	  The	  plasmids	  used	  in	  this	  study	  are	  cited	  in	  Table	  S2.	  The	  low	  copy	  (CEN-­‐based)	  pCH336	  plasmid	  expressed	  Mgt1f3	  (C-­‐terminally	  tagged	  with	  flag3)	  from	  the	  native	  PMGT1	  promoter.	  To	  construct	  pCH336,	  the	  promoter	  region	  and	  the	  MGT1	  ORF	  were	  PCR-­‐amplified	  from	  S.	  cerevisiae	  genomic	  DNA	  using	  OCH576/OCH450	  and	  OCH492/OCH577	  primers	  (Table	  S3).	  The	  resulting	  DNA	  fragments	  was	  digested	  with	  BamHI/HindIII	  and	  HindIII/XhoI,	  respectively,	  and	  triply	  ligated	  into	  BamHI/XhoI-­‐cut	  pRS416	  (4).	  Overlap	  extension	  PCR	  (5)	  was	  used	  to	  introduce	  codons	  encoding	  Ser151	  or	  Met151	  instead	  of	  wild-­‐type	  (WT)	  active-­‐site	  Cys151	  into	  the	  ORF	  of	  MGT1.	  A	  pair	  of	  the	  above	  PCR	  primers	  (OCH576/OCH577)	  was	  used,	  in	  conjunction	  with	  primers	  OCH540/OCH541	  or	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OCH553/OCH554	  (Table	  S3),	  for	  the	  cloning	  of	  pCH337or	  pCH338,	  respectively	  (Table	  S2).	  For	  example,	  to	  construct	  pCH337,	  which	  expressed	  Mgt1C151S,	  two	  overlapping	  DNA	  fragments	  with	  a	  requisite	  missense	  mutation	  were	  produced	  initially,	  using	  PCR	  with	  the	  primer	  pairs	  OCH576/OCH541	  and	  OCH540/OCH577	  (Table	  S3).	  These	  fragments	  were	  then	  denatured	  and	  reannealed,	  so	  that	  they	  formed	  a	  partially	  duplex	  DNA	  that	  encompassed	  the	  site	  of	  mutation	  contained	  3	  overhangs	  that	  enabled	  another	  PCR,	  with	  the	  primers	  OCH576	  and	  OCH577	  (Table	  S3),	  that	  yielded	  both	  the	  MGT1C151S	  ORF	  and	  its	  promoter.	  DNA	  fragments	  produced	  by	  this	  procedure	  (which	  encoded	  either	  Mgt1C151S	  or	  Mgt1C151M)	  were	  digested	  with	  BamHI/XhoI	  and	  subcloned	  into	  BamHI/XhoI-­‐cut	  pRS416	  vector,	  yielding,	  respectively,	  pCH337	  and	  pCH338	  (Table	  S2).	  The	  ubiquitin	  (Ub)	  reference	  (UR)	  (6)	  plasmids	  pCH280	  and	  pCH281	  were	  constructed	  by	  inserting	  the	  SacII/EcoRI-­‐digested,	  PCR-­‐amplified	  MGT1	  ORF	  (using	  the	  primer	  pair	  OCH494/OCH495)	  into	  SacII/EcoR	  I-­‐cut	  pMET416FUPRCUP9NSF	  (7).	  To	  construct	  pCH285,	  which	  expressed	  GST-­‐Mgt1-­‐His10,	  the	  MGT1-­‐His10	  ORF,	  encoding	  also	  the	  C-­‐terminal	  His10	  tag,	  was	  produced	  by	  PCR	  and	  the	  primer	  pair	  OCH492/OCH498	  (Table	  S3).	  The	  resulting	  DNA	  fragment	  was	  cloned	  into	  BamHI/XhoI-­‐cut	  pGEX-­‐4T3	  (GE	  Healthcare).	  Construction	  details	  for	  other	  plasmids	  (Table	  S2)	  are	  available	  upon	  request.	  All	  of	  the	  final	  plasmid	  constructs	  were	  verified	  by	  DNA	  sequencing.	  	  Preparation	  of	  Cell	  Extracts	  for	  Immunoblot	  Analysis.	  	  Yeast	  extracts	  were	  prepared	  using	  a	  modification	  of	  Kushnirov’s	  method	  (8).	  After	  yeast	  cells	  were	  grown	  to	  exponential	  phase	  in	  selective	  medium,	  1	  mL	  of	  a	  culture	  with	  A600	  of	  1	  was	  centrifuged	  for	  30	  sec	  at	  11,200g.	  Cells	  were	  
	   205	  
resuspended	  in	  1	  mL	  of	  0.2	  M	  NaOH,	  and	  incubated	  for	  20	  min	  on	  ice	  or	  for	  5	  min	  at	  room	  temperature,	  followed	  by	  centrifugation	  for	  30	  sec	  at	  11,200g.	  The	  pelleted	  cells	  were	  resuspended	  in	  50	  μL	  of	  HU	  buffer	  (8	  M	  urea,	  5%	  SDS,	  1	  mM	  EDTA,	  100	  mM	  DTT,	  0.005%	  bromophenol	  blue,	  0.2	  M	  TrisHCl,	  pH	  6.8)	  containing	  protease	  inhibitor	  mixture	  (Sigma–Aldrich),	  and	  heated	  for	  10	  min	  at	  70°C.	  After	  centrifugation	  for	  5	  min	  at	  11,200g,	  10	  μL	  of	  supernatant	  was	  subjected	  to	  SDS/4–12%	  NuPAGE	  (Invitrogen)	  and	  immunoblotted	  with	  either	  anti-­‐flag	  (Stratagene),	  anti-­‐myc,	  anti-­‐ha,	  or	  anti-­‐tubulin	  antibodies	  (Sigma–Aldrich).	  In	  vivo	  Mgt1	  polyubiquitylation	  assays	  (Fig.	  2B	  and	  the	  main	  text)	  used	  the	  plasmids	  pUB204	  (UbK48R,G76A),	  pUB223	  (His6-­‐UbK48R,G76A),	  and	  pCH277	  (Mgt1ha)	  (Table	  S2).	  S.	  cerevisiae	  expressing	  Mgt1ha	  and	  overexpressing	  either	  UbK48R,G76A	  (lane	  1)	  or	  His6-­‐UbK48R,G76A	  (lane	  2)	  were	  grown	  to	  A600	  of	  0.5	  in	  SD	  medium	  with	  required	  amino	  acids	  containing	  0.2	  mM	  CuSO4	  (to	  induce	  the	  PCUP1	  promoter)	  for	  3	  h	  before	  the	  addition	  of	  MG132	  to	  the	  final	  concentration	  of	  50	  μM	  for	  30	  min,	  followed	  by	  a	  further	  incubation	  in	  the	  presence	  of	  68	  μM	  MNNG	  for	  1	  h.	  Cell	  extracts	  were	  subjected	  to	  Ni-­‐NTA	  chromatography	  under	  denaturing	  conditions;	  the	  retained	  proteins	  were	  fractionated	  by	  SDS/4–12%	  NuPAGE,	  followed	  by	  IB	  with	  anti-­‐ha	  antibody	  (Fig.	  2C	  and	  the	  main	  text).	  GST	  Fusions	  and	  Pulldown	  Assay,	  and	  Purification	  of	  GST-­‐Mgt1-­‐His10	  from	  E.	  
coli.	  The	  plasmid	  pCH285	  (Table	  S2),	  which	  encoded	  GST-­‐Mgt1-­‐His10,	  was	  transformed	  into	  the	  E.	  coli	  BL21-­‐Codon	  Plus	  (DE3)-­‐RIL	  strain	  (Stratagene).	  A	  total	  of	  50	  mL	  of	  overnight	  culture	  of	  transformed	  cells	  was	  inoculated	  into	  1	  L	  of	  LB	  medium	  containing	  0.1	  mg/ml	  ampicilin	  and	  34	  g/ml	  chloramphenicol,	  followed	  by	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growth	  at	  37	  °C	  for	  1	  h	  to	  A600	  of	  0.8.	  The	  expression	  of	  GST-­‐Mgt1-­‐His10	  was	  induced	  with	  0.2	  mM	  isopropyl	  -­‐D-­‐thiogalactoside	  (IPTG)	  at	  30	  °C	  for	  4	  h.	  GST-­‐Mgt1-­‐His10,	  was	  purified	  from	  cell	  extracts	  by	  affinity	  chromatography	  with	  Ni-­‐NTA	  resin	  (Qiagen).	  Specifically,	  E.	  coli	  cells	  were	  harvested	  by	  centrifugation	  and	  frozen	  at	  -­‐80	  °C.	  Cell	  pellets	  were	  thawed	  and	  resuspended	  in	  the	  Ni-­‐NTA	  binding	  buffer	  (0.3	  M	  NaCl,	  10	  mM	  imidazole,	  10	  mM	  -­‐mercaptoethanol,	  50	  mM	  NaH2PO4/Na2HPO4,	  pH	  8.0)	  containing	  chicken	  egg	  white	  lysozyme	  (1	  mg/ml;	  Sigma–Aldrich).	  The	  cells	  were	  incubated	  at	  4	  °C	  for	  30	  min	  and	  thereafter	  disrupted	  by	  sonication,	  3	  times	  for	  1	  min	  each	  at	  1-­‐min	  intervals,	  followed	  by	  the	  addition	  of	  Nonidet	  P-­‐40	  to	  the	  final	  concentration	  of	  0.1%.	  After	  centrifugation	  at	  11,200g	  for	  30	  min,	  the	  supernatant	  was	  added	  to	  a	  2-­‐ml	  Ni-­‐NTA	  resin	  (Qiagen,	  50%	  slurry),	  and	  incubated	  for	  1	  h	  at	  4	  °C.	  The	  resin	  was	  transferred	  to	  a	  10-­‐mL	  column	  and	  washed	  4	  times	  in	  10	  mL	  of	  washing	  buffer	  (0.5	  M	  NaCl,	  20	  mM	  imidazole,	  10	  mM	  -­‐mercaptoethanol,	  0.1%	  Nonidet	  P-­‐40,	  50	  mM	  NaH2PO4/Na2HPO4,	  pH	  8.0).	  GST-­‐Mgt1-­‐His10	  was	  then	  eluted	  with	  1-­‐mL	  samples	  of	  the	  binding	  buffer	  containing	  increasing	  levels	  of	  imidazole	  (25,	  50,	  100,	  150,	  200,	  250,	  300	  mM),	  followed	  by	  overnight	  dialysis	  against	  storage	  buffer	  (10%	  glycerol,	  0.15	  M	  NaCl,	  10	  mM	  -­‐mercaptoethanol,	  50	  mM	  Hepes,	  pH	  7.5).	  GST-­‐pulldown	  assays	  with	  extracts	  from	  S.	  cerevisiae	  containing	  fUbr1	  were	  carried	  out	  essentially	  as	  described	  in	  ref.	  9,	  with	  a	  slight	  modification.	  Either	  a	  GST-­‐fusion	  protein	  or	  GST	  alone	  (5	  g)	  was	  incubated	  with	  10	  μL	  GST-­‐Sepharose	  (50%	  slurry)	  in	  50	  μL	  of	  50	  mM	  NaH2PO4/Na2HPO4	  (pH	  8.0)	  for	  20	  min	  on	  ice.	  The	  beads	  were	  washed	  once	  with	  0.5	  mL	  of	  GST-­‐loading	  buffer	  (10%	  glycerol,	  1%	  Nonidet	  P-­‐40,	  0.5	  M	  NaCl,	  1	  mM	  EDTA,	  50	  mM	  TrisHCl,	  pH	  8.0)	  and	  once	  with	  0.5	  mL	  of	  GST-­‐binding	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buffer	  (10%	  glycerol,	  0.05%	  Nonidet	  P-­‐40,	  50	  mM	  NaCl,	  50	  mM	  Hepes,	  pH	  7.8).	  Samples	  of	  washed	  beads	  in	  0.1	  mL	  of	  GST-­‐binding	  buffer	  were	  incubated	  with	  0.16-­‐mL	  samples	  of	  yeast	  extracts	  containing	  fUbr1	  in	  the	  absence	  or	  presence	  of	  indicated	  dipeptides,	  at	  1	  mM	  each.	  The	  beads	  were	  washed	  3	  times	  with	  0.25	  mL	  of	  GST-­‐binding	  buffer	  containing	  dipeptides	  at	  1	  mM,	  and	  the	  bound	  proteins	  were	  eluted	  by	  adding	  12.5	  μL	  of	  2X	  	  SDS	  loading	  buffer	  and	  incubating	  the	  sample	  at	  95	  °C	  for	  5	  min,	  followed	  by	  SDS/4–12%	  NuPAGE	  and	  immunoblotting	  with	  anti-­‐flag	  antibody.	  Pulse–Chase	  Assays.	  Pulse–chase	  experiments	  were	  performed	  essentially	  as	  described	  (7,	  10),	  with	  slight	  modifications.	  S.	  cerevisiae	  JD52	  (WT),	  JD55	  (ubr1Δ),	  and	  CHY195	  (ubr1Δufd4Δ)	  (Table	  S1)	  that	  carried	  the	  plasmids	  pCH280,	  pCH437,	  pCH438,	  or	  pCH439	  (Table	  S2)	  were	  grown	  at	  30	  °C	  to	  A600	  of	  1	  in	  10	  mL	  of	  SD	  medium	  with	  required	  amino	  acids.	  Cells	  were	  pelleted	  by	  centrifugation	  and	  washed	  with	  0.8	  mL	  of	  the	  medium.	  Cell	  pellets	  were	  gently	  resuspended	  in	  0.4	  mL	  of	  the	  same	  medium	  and	  labeled	  for	  5	  or	  10	  min	  at	  30	  °C	  with	  0.16	  mCi	  of	  35S-­‐EXPRESS	  (Perkin-­‐Elmer).	  Cells	  were	  pelleted	  again	  and	  resuspended	  in	  0.4	  mL	  of	  SD	  medium	  containing	  unlabeled	  L-­‐methionine	  (10	  mM)	  and	  L-­‐cysteine	  (5	  mM),	  in	  addition	  to	  required	  amino	  acids.	  Samples	  (0.1	  mL)	  were	  taken	  at	  the	  indicated	  time	  points,	  followed	  by	  preparation	  of	  extracts,	  immunoprecipitation	  with	  anti-­‐flag	  antibody	  cross-­‐linked	  to	  agarose	  beads	  (Sigma–Aldrich),	  SDS/4–12%	  NuPAGE	  in	  Mes	  buffer,	  and	  autoradiography.	  Mutation	  Frequency	  and	  Sensitivity	  of	  Cells	  to	  MNNG	  Treatment.	  To	  measure	  increases	  in	  mutation	  rate	  that	  were	  caused	  by	  MNNG,	  the	  JD52	  (UBR1),	  JD55	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(ubr1Δ),	  CHY121	  (mgt1Δ)	  or	  CHY122	  (mgt1Δubr1Δ)	  S.	  cerevisiae	  were	  grown	  in	  YPD	  medium	  (from	  200	  cells	  per	  ml)	  for	  2	  days	  (38	  h)	  to	  A600	  of	  5.	  The	  cells	  in	  YPD	  were	  incubated	  in	  the	  absence	  or	  presence	  of	  34	  μM	  MNNG	  for	  30	  min	  at	  30	  °C.	  Cells	  in	  1	  mL	  of	  culture	  (A600	  of	  5)	  were	  pelleted	  by	  centrifugation,	  then	  washed	  once	  in	  1	  mL	  of	  phosphate	  buffered	  saline	  (PBS),	  then	  pelleted	  again,	  and	  resuspended	  in	  1	  mL	  of	  PBS.	  To	  determine	  the	  frequency	  of	  mutations	  that	  conferred	  canavanine	  resistance,	  0.1-­‐mL	  samples	  of	  cells	  were	  spread	  onto	  SC-­‐Arg	  plates	  containing	  canavanine	  (60	  μg/ml)	  and	  incubated	  for	  3	  days	  at	  30°C.	  To	  determine	  the	  fraction	  of	  viable	  cells,	  these	  cell	  suspensions	  were	  diluted	  250,000-­‐fold	  in	  PBS,	  and	  0.1-­‐mL	  samples	  were	  spread	  on	  YPD	  medium,	  followed	  by	  incubation	  for	  3	  days	  at	  30	  °C.	  To	  determine	  whether	  the	  C-­‐terminal	  13-­‐myc	  epitope	  of	  Mgt1m13	  affects	  MNNG	  sensitivity	  of	  cells	  expressing	  Mgt1m13	  instead	  of	  WT	  Mgt1,	  the	  corresponding	  S.	  cerevisiae	  strains	  were	  grown	  to	  A600	  of	  0.5	  in	  YPD	  medium,	  followed	  by	  the	  addition	  MNNG	  (to	  the	  final	  concentration	  of	  30	  M)	  for	  3	  h.	  The	  cultures	  were	  5-­‐fold	  serially	  diluted,	  spotted	  onto	  YPD	  medium,	  and	  incubated	  for	  2	  days	  at	  30°C.	  To	  determine	  the	  fraction	  of	  surviving	  cells	  after	  treatments	  with	  MNNG,	  the	  YPH277	  (UBR1)	  or	  YPH277	  HR1	  (ubr1Δ)	  S.	  cerevisiae	  strains	  (Table	  S1)	  were	  grown	  in	  YPD	  medium	  at	  30°C	  to	  A600	  of	  1.	  Stock	  MNNG	  solution	  (6.8	  mM	  in	  50	  mM	  Na-­‐acetate,	  pH	  5.0)	  was	  added	  to	  1-­‐ml	  cell	  suspensions,	  to	  the	  indicated	  final	  concentrations	  of	  MNNG.	  Samples	  were	  incubated	  with	  vigorous	  shaking	  for	  1	  h	  at	  30	  °C,	  followed	  by	  appropriate	  dilutions	  in	  PBS,	  spreading	  on	  YPD	  plates,	  incubation	  for	  3	  days	  at	  30°C,	  and	  measurements	  of	  colony	  numbers.	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In	  Vivo	  Ubiquitylation	  Assay.	  S.	  cerevisiae	  JD52	  that	  expressed	  Mgt1ha	  (from	  pCH279)	  and	  overexpressed	  either	  UbK48R,G76A	  (from	  pUB204)	  or	  His6-­‐UbK48R,G76A	  (from	  pUB223)	  were	  grown	  at	  30	  °C	  to	  A600	  of	  0.4	  in	  SC(-­‐Trp,	  -­‐Ura)	  medium.	  Cells	  were	  then	  treated	  with	  0.2	  mM	  CuSO4	  (to	  induce	  the	  expression	  of	  His6-­‐UbK48R,G76A)	  for	  2.5	  h	  at	  30°C,	  and	  thereafter	  with	  68	  μM	  MNNG	  for	  1	  h.	  Pelleted	  and	  washed	  cells	  were	  resuspended	  and	  placed	  in	  the	  bead-­‐beater	  in	  the	  denaturing	  lysis	  buffer	  [6	  M	  guanidine	  hydrochloride,	  1	  mM	  PMSF,	  0.1	  M	  NaH2PO4,	  10	  mM	  N-­‐ethylmaleimide,	  20	  mM	  TrisHCl	  (pH	  8.0)	  and	  protease	  inhibitor	  mixture].	  The	  suspension	  was	  centrifuged	  at	  11,200g	  for	  20	  min,	  and	  the	  supernatant	  was	  incubated	  with	  Ni-­‐NTA	  agarose	  beads	  (Qiagen)	  for	  2	  h	  at	  4	  °C.	  The	  beads	  were	  washed	  4	  times	  in	  denaturing	  lysis	  buffer,	  followed	  by	  4	  times	  in	  wash	  buffer	  (0.5	  M	  NaCl	  50	  mM	  Tris,	  pH	  8.0).	  Bound	  proteins	  were	  eluted	  in	  elution	  buffer	  (1%	  SDS,	  0.1	  M	  EDTA,	  0.1	  mM	  DTT,	  0.1	  M	  Tris,	  pH	  6.8)	  and	  fractionated	  by	  SDS/4–12%	  NuPAGE,	  followed	  by	  immunoblotting	  with	  anti-­‐ha	  antibody	  (Sigma–Aldrich).	  Expression	  and	  Purification	  of	  Ufd4,	  Ubr1,	  Rad6	  and	  Ubc4.	  The	  S.	  cerevisiae	  JD52	  (Table	  S1)	  that	  carried	  p314CUP1FlagUFD4	  (Table	  S2)	  and	  expressed	  the	  N-­‐terminally	  flag-­‐tagged	  Ufd4	  (fUfd4)	  was	  grown	  at	  30°C	  to	  A600	  of	  4	  in	  4-­‐L	  of	  SC(-­‐Trp)	  medium	  containing	  0.2	  mM	  CuSO4.	  The	  cells	  were	  harvested	  by	  centrifugation,	  washed	  once	  with	  PBS,	  and	  frozen	  in	  liquid	  N2.	  Cells	  in	  a	  frozen	  pellet	  (20	  g)	  were	  broken	  using	  glass	  beads	  for	  5	  X40	  sec	  at	  the	  power	  setting	  of	  6.5	  in	  FastPrep-­‐24	  (MP	  Biomedicals)	  in	  40	  mL	  of	  lysis	  buffer	  (10%	  glycerol,	  0.5%	  Nonidet	  P-­‐40,	  0.2	  M	  KCl,	  1	  mM	  PMSF,	  5	  mM	  -­‐glycerol	  phosphate,	  50	  mM	  Hepes,	  pH	  7.5)	  containing	  protease	  inhibitor	  mixture	  ‘‘for	  use	  with	  fungal	  and	  yeast	  extracts’’	  (Sigma–Aldrich).	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The	  suspension	  was	  centrifuged	  at	  11,200g	  for	  30	  min,	  and	  the	  supernatant	  was	  mixed	  with	  2	  mL	  of	  anti-­‐flag	  M2	  affinity	  beads	  (Sigma–Aldrich)	  at	  4	  °C	  for	  1	  h.	  The	  beads	  were	  collected	  by	  centrifugation	  in	  Sorvall	  RT-­‐600B	  at	  1,000	  rpm	  for	  5	  min	  at	  4	  °C,	  and	  were	  washed,	  sequentially,	  with	  10	  mL	  of	  lysis	  buffer,	  10	  mL	  of	  buffer	  A	  [10%	  glycerol,	  0.5%	  Nonidet	  P-­‐40,	  1	  M	  KCl,	  1	  mM	  EDTA,	  50	  mM	  Hepes	  (pH	  7.5),	  5	  mM	  -­‐mercaptoethanol],	  and	  10	  mL	  of	  buffer	  B	  (lysis	  buffer	  without	  Nonidet	  P-­‐40).	  
fUfd4	  that	  was	  bound	  by	  the	  anti-­‐flag	  antibody	  was	  eluted	  from	  the	  beads	  with	  buffer	  C	  (buffer	  B	  containing	  flag	  peptide	  at	  0.5	  mg/ml),	  and	  thereafter	  dialyzed	  at	  4	  °C	  overnight	  against	  dialysis	  buffer	  (10%	  glycerol,	  0.15	  M	  NaCl,	  5	  mM	  -­‐mercaptoethanol,	  50	  mM	  Hepes,	  pH	  7.5).	  N-­‐terminally	  flag-­‐tagged	  Ubr1	  (fUbr1)	  was	  overexpressed	  in	  S.	  cerevisiae	  SC295	  (Table	  S1)	  and	  purified	  by	  fractionation	  over	  anti-­‐flag	  M2	  antibody	  agarose	  resin	  as	  described	  in	  ref.	  3.	  S.	  cerevisiae	  Rad6	  or	  Ubc4	  were	  overexpressed	  in	  the	  E.	  coli	  BL21-­‐Codon	  Plus	  (DE3)-­‐RIL	  strain	  and	  purified	  as	  described	  previously	  (7,	  9).	  In	  Vitro	  Ubiquitylation	  Assay.	  Purified	  S.	  cerevisiae	  Uba1	  (Ub	  activating	  enzyme,	  E1)	  and	  human	  Ub	  were	  from	  Boston	  Biochem.	  35S-­‐labeled	  Mgt1f3	  was	  expressed	  in	  the	  reticulocytebased	  in	  vitro	  transcription/translation	  TNT	  T7	  Quick	  for	  PCR	  DNA	  kit	  (Promega),	  using	  a	  PCR-­‐derived	  DNA	  fragment	  that	  was	  produced	  with	  pCH437	  (Table	  S2)	  as	  a	  template	  and	  the	  primer	  pair	  OCH834/OCH438	  (Table	  S3).	  A	  total	  of	  2	  μl	  of	  35S-­‐labeled	  Mgt1	  was	  incubated	  with	  purified	  fUbr1	  (0.2	  μM),	  
fUfd4	  (0.2	  μM),	  Rad6	  (1	  μM),	  and/or	  Ubc4	  (1	  μM)	  (see	  Fig.	  4)	  at	  30	  °C	  for	  15	  min	  in	  20	  μL	  of	  reaction	  samples	  (4	  mM	  ATP,	  0.15	  M	  NaCl,	  5	  mM	  MgCl2,	  1	  mM	  DTT,	  50	  mM	  Hepes,	  pH	  7.5)	  containing	  100	  nM	  Uba1	  and	  80	  μM	  Ub.	  The	  reactions	  were	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terminated	  by	  adding	  8	  μL	  of	  4X	  SDS/PAGE	  loading	  buffer.	  Samples	  of	  14	  μL	  were	  heated	  at	  95	  °C	  for	  5	  min,	  followed	  by	  SDS/4–12%	  NuPAGE	  in	  Mops	  buffer,	  and	  autoradiography.	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Table	  2.S1	  Some	  of	  the	  S.	  cerevisiae	  strains	  used	  in	  this	  study	  	  
	   	  
Table S1. Some of the S. cerevisiae strains used in this study
Strains Genotypes and characteristics Source or ref.
JD52 MATa trp1-! 63 ura3–52 his3-! 200 leu2–3112. lys2–801 1
JD55 ubr1!::HIS3 in JD52 1
SC295 MATa ura3–52 leu2–3,112 regl-501 gal1 pep4–3 2
AVY4 ubr1!::LEU2 in JD52 Laboratory collection
AVY16 leu2–3,112::LEU2 in JD52 Laboratory collection
AVY50 cup9!::LEU2 in JD52 Laboratory collection
AVY51 cup9!::LEU2 in JD55 Laboratory collection
AVY105 ubr2!::HIS3 in JD52 Laboratory collection
CHY49 pdr5!::KanMX6 in JD52 3
CHY50 pdr5!::KanMX6 in JD55 3
CHY92 GAL80::3HA::KanMX6 in JD52 This study
CHY93 GAL80::3HA::KanMX6 in JD52 This study
CHY94 KnaMX6::PGAL1::3HA-SRS2 This study
CHY95 KnaMX6::PGAL1::3HA-SRS2 This study
CHY101 SGS1::13MYC::TRP1 in JD52 This study
CHY102 SGS::13MYC::TRP1 in JD55 This study
CHY107 MGT1::13MYC::TRP1 in JD52 This study
CHY108 MGT1::13MYC::TRP1 in JD55 This study
CHY109 CCR4::3HA::TRP1 in JD52 This study
CHY110 CCR4::3HA::TRP1 in JD55 This study
CHY115 MGT1::13MYC::TRP1 pdr5!::KanMX6 in JD52 This study
CHY116 MGT1::13MYC::TRP1 pdr5!::KanMX6 in JD55 This study
CHY121 mgt1!::KanMX6 in JD52 This study
CHY122 mgt1!::KanMX6 in JD55 This study
CHY134 ubr1!::LEU2 ubr2!::HIS3 in JD52 This study
CHY161 PEX7::3HA in JD52 This study
CHY162 PEX7::3HA::TRP1 in JD55 This study
CHY163 YGL081W::13MYC::TRP1 in JD52 This study
CHY164 YGL081W::13MYC::TRP1 in JD55 This study
CHY169 MGT1::13MYC::TRP1 ufd4!::KanMX6 in JD55 This study
CHY107 MGT1::13MYC::TRP1 in JD52 This study
CHY108 MGT1::13MCY::TRP1 in JD55 This study
CHY194 ufd4!::KanMX6 in JD52 This study
CHY195 ubr1!::HIS3 ufd4!::KanMX6 in JD52 This study
CHY219 ufd4!:: TRP1 MGT1–13MYC::KanMX6 in JD52 This study
YPH277 MATa ura3–52 ade2–101 trp1-D1 leu2-D1 CFVII (RAD2.d) URA3 SUP11 4
YPH277HR1 ubr1!::LEU2 in YPH277 5
BY4425 ubc2!:: KanMX4 in BY4741 Open Biosystems
BY3216 ubc4!:: KanMX4 in BY4741 Open Biosystems
BY3994 ubc5!::KanMX4 in BY4741 Open Biosystems
BBY67.3 ubc6!::HIS3 in JD52 Laboratory collection
BY597 ubc7!::KanMX4 in BY4741 Open Biosystems
BY6577 ubc8!:: KanMX4 in BY4741 Open Biosystems
BY4763 ubc10!:: KanMX4 in BY4741 Open Biosystems
BY1636 ubc11!:: KanMX4 in BY4741 Open Biosystems
BY5214 ubc12!:: KanMX4 in BY4741 Open Biosystems
BY4027 ubc13!:: KanMX4 in BY4741 Open Biosystems
BY4454 mms2!:: KanMX4 in BY4741 Open Biosystems
BY3771 bre1!:: KanMX4 in BY4741 Open Biosystems
BY6430 rad5!:: KanMX4 in BY4741 Open Biosystems
BY5787 rad18!:: KanMX4 in BY4741 Open Biosystems
BY4425 ufd2!:: KanMX4 in BY4741 Open Biosystems
BY3216 ufd4!:: KanMX4 in BY4741 Open Biosystems
BY3994 hul4!::KanMX4 in BY4741 Open Biosystems
BY597 hul5!::KanMX4 in BY4741 Open Biosystems
BY6577 tom1!:: KanMX4 in BY4741 Open Biosystems
BY4763 hrd1!:: KanMX4 in BY4741 Open Biosystems
BY4156 hrd3!:: KanMX4 in BY4741 Open Biosystems
BY4883 tul1!:: KanMX4 in BY4741 Open Biosystems
BY7299 doa10!::KanMX4 in BY4741 Open Biosystems
BY4814 ubr1!:: KanMX4 in BY4741 Open Biosystems
BY1579 ubr2!:: KanMX4 in BY4741 Open Biosystems
BY3771 bre1!:: KanMX4 in BY4741 Open Biosystems
BY6430 rad5!:: KanMX4 in BY4741 Open Biosystems
BY5787 rad18!:: KanMX4 in BY4741 Open Biosystems
MGG15 ura3–52 cdc34–2 6
FW1808 MAT !his4–912 R5 !lys2–128 !ura3–52 rps5–1 7
Hwang et al. www.pnas.org/cgi/content/short/0812316106 8 of 11
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  Figure	  A1.1.	  The	  N-­‐end	  rule	  pathway,	  the	  UFD	  pathway,	  and	  cotargeting	  of	  the	  Mgt1	  DNA	  alkyltransferase	  by	  these	  proteolytic	  systems.	  (A)	  The	  S.	  cerevisiae	  N-­‐end	  rule	  pathway.	  N-­‐terminal	  residues	  are	  indicated	  by	  single-­‐letter	  abbreviations	  for	  amino	  acids.	  Yellow	  ovals	  denote	  the	  rest	  of	  a	  protein	  substrate.	  Primary,	  secondary,	  and	  tertiary	  denote	  mechanistically	  distinct	  subsets	  of	  destabilizing	  N-­‐terminal	  residues.	  Hemin	  (Fe3+-­‐heme)	  inhibits	  the	  arginylation	  activity	  of	  the	  ATE1-­‐encoded	  Arg-­‐tRNA-­‐protein	  transferase	  (R-­‐	  transferase),	  and	  also	  inhibits	  a	  subset	  of	  Ubr1	  functions	  (24).	  Reactions	  in	  the	  shaded	  rectangle	  are	  a	  part	  of	  the	  pathway	  that	  is	  active	  in	  multicellular	  eukaryotes,	  which	  produce	  NO	  (18),	  and	  is	  also	  relevant	  to	  eukaryotes	  such	  as	  S.	  cerevisiae,	  which	  lack	  NO	  synthases	  but	  can	  produce	  NO	  by	  other	  routes	  and	  can	  also	  be	  influenced	  by	  NO	  from	  extracellular	  sources.	  C*	  
strate of both the N-end rule and UFD pathways (Fig. 1) brings
together 2 mechanistically distinct targeting systems, in that
Ubr1 is a RING-type E3, whereas Ufd4 is a HECT-type E3. The
N-end rule and UFD pathways were the first specific pathways
of the Ub system to be discovered (14). Studies of these pathways
have been proceeding largely i parallel (2, 14, 15, 26–29, 31, 33),
until the present discovery of their functional and mechanistic
connection, as described below.
Results and Discussion
N-End Rule Pathway Targets Mgt1 for Degradation. Large-scale
identification of S. cerevisiae protein complexes through coimmu-
noprecipitation and other assays suggested that the 225-kDa Ubr1
E3 Ub ligase (Fig. 1A) may physically interact with Ygl081w, Pex7,
Yak1,Mgt1, Ccr4,Gal80, and Srs2 [see supporting information (SI)
Materials andMethods and the legend to Fig. S1].We askedwhether
any of these putative Ubr1 ligands were short-lived in vivo, and, if
so, whether they were degraded at least in part by the N-end rule
pathway. We used a ‘‘cycloheximide-chase’’ assay with wild type
(wt) versus ubr1! S. cerevisiae. In this method, the in vivo levels of
a protein of interest are determined by SDS/PAGE and immuno-
blotting (IB) of cell extracts as a function of time after the inhibition
of translation by cycloheximide. A majority of the above proteins
were found to metabolically unstable. However, the absence of
Ubr1 stabilized just one of these proteins,Mgt1 (Fig. S1A), the sole
O6-methylguanine DNA-alkyltransferase in S. cerevisiae (see
Introduction).
Although the inferred ORF of S. cerevisiae Mgt1 contains 2
in-frame start codons, 18 codons apart (7), only the smaller,
188-residue Mgt1 is produced in vivo (13). We replaced the
chromosomal MGT1 gene with an otherwise identical ORF ex-
pressing Mgt1m13 (C-terminally tagged with 13 copies of the 10-
residue myc epitope) from the endogenous PMGT1 promoter.
Mgt1m13 was indistinguishable from wt MGT1 in its ability to
protect cells fromMNNG, a DNA-alkylating agent (Fig. S1C). The
instability ofMgt1m13 could be restored by reintroducingUBR1 into
ubr1! cells (Fig. 2A). Importantly, this rescue did not occur with
Ubr1C1220S, an inactive Ubr1 mutant (20) (Fig. 2A).
A cycloheximide-chase assay monitors the in vivo decay of both
‘‘young’’ and ‘‘old’’ molecules of a test protein. To assess the
metabolic fate of newly formed Mgt1, we carried out pulse–chase
assays with fDHFR-UbK48R-Mgt1f [‘‘f’’ denotes the flag epitope
linked to the N terminus and C terminus of the dihydrofolate
reductase (DHFR) and Mgt1 moieties, respectively]. DUBs co-
translationally cleave this Ub fusion at the UbK48R-Mgt1f junction,
yielding the long-lived reference fDHFR-UbK48R and the test
protein Mgt1f. In this Ub-reference technique (refs. 23 and 25 and
references therein), the free fDHFR-UbK48R serves as a ‘‘built-in’’
reference protein to compensate for scatter of expression levels and
immunoprecipitation efficiency, thereby increasing the accuracy of
pulse–chase assays. The in vivo half-life (t1/2) of Mgt1f at 30 °C was
"19 min in wt cells and "32 min in ubr1! cells (Fig. S2A),
consistent with th results of cycloheximide-chase assays (Fig.
S1A), including the residual instability of Mgt1 in ubr1! cells.
We also used the pdr5! S. cerevisiae strain, in which the absence
of the Pdr5 transporter allows the intracellular accumulation of
MG132, a proteasome inhibitor. No Mgt1m13-linked polyUb ‘‘lad-
ders’’ were detected in wt cells in the absence of MG132 (Fig. S1B,
lanes 1 and 2), suggesting that polyubiquitylation of Mgt1 (in
contrast to its subsequent destruction by the proteasome) was
rate-limiting under these conditions. Consistent with this interpre-
tation, larger, presumably polyubiquitylated forms of Mgt1m13
appeared after the treatment of cells for 1 h withMG132 (Fig. S1B,
lanes 1 and 2 versus lanes 3 and 4). The levels of MG132-induced
Mgt1m13 derivatives were much lower in ubr1! cells but were still
detectable (Fig. S1B, lane 4 versus lane 6), suggesting that another
Ub ligase may also target Mgt1. In a different assay, Mgt1ha
(C-terminally ha-tagged) was coexpressed in wt S. cerevisiae with
His6-tagg d UbK48R,G76A, a double-mutant Ub that can become a
part of polyUb chains but would inhibit their disassembly by DUBs
(ref. 2 and references therein). S. cerevisiae was treated with
MNNG, and polyubiquitylated proteins were isolated from cell
extracts by using His6-specific chromatography, followed by SDS/
PAGE and IB with anti-ha antibody. A smear of high-Mr, Mgt1ha-
containing proteins was observed near the top of the gel, whereas
such proteins were virtually absent in a test with His6-lacking
UbK48R,G76A (Fig. 2B).
The Ub ligase holoenzyme of the N-end rule pathway is
Ubr1-Rad6, in which the 20-kDa Rad6 is the Ub-conjugating
enzyme (E2) (15, 20). To determine whether other E2s might
also play a role, we carried out cycloheximide-chase assays with
a collection of E2-null mutants that expressed Mgt1f3 (wt Mgt1
C-terminally tagged with 3 copies of the flag epitope). Mgt1f3
was strongly stabilized only in rad6! cells (Fig. S1D, lanes 5 and
6). In addition to being the E2 of the Ubr1 E3, Rad6 also
functions as a part of Ub ligases that contain, in particular, the
Bre1, Ubr2, or Rad18 E3s (34). In cycloheximide-chase assays
with null mutants in these E3s, Mgt1 was significantly stabilized
only in ubr1! cells (Fig. 2D). Interestingly, the degradation of
Mgt1 was accelerated in a ubr2! strain, compared with its wt
counterpart (Fig. 2D, lanes 5 and 6; compare with lanes 1 and 2).
Ubr2 is a sequelog of Ubr1 that also functions in a complex with
Fig. 1. The N-end rule pathway, the UFD pathway, and cotargeting of the
Mgt1 DNA alkyltransferase by these proteolytic systems. (A) The S. cerevisiae
N-end rule pathway. N-terminal residues are indicated by single-letter abbre-
viations for amino acids. Yellow ovals denote the rest of a protein substrate.
Primary, secondary, and tertiary denote m chanistically distinct subsets of
destabilizing N-terminal residues. Hemin (Fe3#-heme) inhibits the arginyla-
tion activity of the ATE1-encoded Arg-tRNA-protein transferase (R-
transferase), and also inhibits a subset of Ubr1 functions (24). Reactions in the
shaded rectangle are a part of the pathway that is active in multicellular
eukaryotes, which produce NO (18), and is also relevant to eukaryotes such as
S. cerevisiae, which lackNO synthases but can produceNOby other routes and
can also be influenced by NO from extracellular sources. C* denotes oxidized
Cys, either Cys-sulfinate or Cys-sulfonate. (B) The S. cerevisiae UFD pathway.
Previously known artificial (engineered) UFD substrates have in common a
‘‘nonremovable’’ N-t rminal Ub moiety, which functions as a degron in the
UFD pathway (14, 26, 27). Mgt1 is the first physiological UFD substrate that
lacks an N-terminal Ub moiety and is not a component of the Ub system (see
Introduction). A question mark denotes the expectation of other UFD sub-
strates. (C) Cotargeting of Mgt1 by the N-end rule and UFD pathways.
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denotes	  oxidized	  Cys,	  either	  Cys-­‐sulfinate	  or	  Cys-­‐sulfonate.	  (B)	  The	  S.	  cerevisiae	  UFD	  pathway.	  Previously	  known	  artificial	  (engineered)	  UFD	  substrates	  have	  in	  common	  a	  ‘‘nonremovable’’	  N-­‐terminal	  Ub	  moiety,	  which	  functions	  as	  a	  degron	  in	  the	  UFD	  pathway	  (14,	  26,	  27).	  Mgt1	  is	  the	  first	  physiological	  UFD	  substrate	  that	  lacks	  an	  N-­‐terminal	  Ub	  moiety	  and	  is	  not	  a	  component	  of	  the	  Ub	  system	  (see	  Introduction).	  A	  question	  mark	  denotes	  the	  expectation	  of	  other	  UFD	  substrates.	  (C)	  Cotargeting	  of	  Mgt1	  by	  the	  N-­‐end	  rule	  and	  UFD	  pathways.	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  Figure	  A1.2.	  Mgt1	  as	  a	  physiological	  substrate	  of	  the	  N-­‐end	  rule	  pathway.	  (A)	  CHY108,	  a	  ubr1Δ	  strain	  of	  S.	  cerevisiae	  that	  expressed	  Mgt1m13	  (Mgt1	  C-­‐terminally	  tagged	  with	  13	  myc	  epitopes)	  (see	  SI	  Materials	  and	  Methods	  and	  Table	  S1)	  was	  transformed	  with	  pRS315	  (vector	  alone),	  with	  pCH100	  (expressing	  wt	  Ubr1),	  or	  with	  pCH159	  (expressing	  inactive	  Ubr1C1220S)	  (20).	  Cultures	  were	  grown	  to	  an	  A600	  of	  ~1	  in	  SD	  medium,	  followed	  by	  a	  ‘‘chase’’	  with	  cycloheximide	  for	  1	  h	  and	  IB	  of	  cell	  extracts	  with	  either	  anti-­‐myc	  or	  anti-­‐tubulin	  antibodies	  (the	  latter	  antibody	  was	  used	  to	  verify	  the	  uniformity	  of	  total	  protein	  loads).	  (B)	  Polyubiquitylated	  Mgt1ha,	  detected	  by	  IB	  with	  anti-­‐ha	  antibody,	  in	  MNNG-­‐treated	  cells	  that	  expressed	  untagged	  Ub	  (lane	  1)	  or	  His6-­‐Ub	  (lane	  2).	  Dots	  on	  the	  left	  refer	  to	  positions	  of	  molecular	  mass	  markers,	  at	  75,	  100,	  150,	  and	  250	  kDa,	  respectively.	  (C)	  S.	  cerevisiae	  expressing	  Mgt1f3	  (pCH437)	  or	  Mgt1C151S,f3	  (pCH438)	  (Table	  S2)	  were	  grown	  in	  SD	  
Rad6. However, in contrast to Ubr1, Ubr2 does not recognize
N-degrons (35). The enhancement of Mgt1 degradation in ubr2!
cells (Fig. 2D and Fig. S2B) could be caused by an increased level
of Ubr1-accessible Rad6, and also, nonalternatively, by an
up-regulation of the proteasome, owing to an increase in Rpn4,
which is partially stabilized in ubr2! cells (35, 36).
Either MNNG or High Temperature Accelerate Mgt1 Degradation. At
approximately 200 molecules per haploid cell in exponential cul-
tures, the endogenous Mgt1 is a scarce protein in S. cerevisiae (12).
Mgt1-dependent DNA-alkyltransferase activity in S. cerevisiae ex-
tracts was strongly decreased after a treatment of cells withMNNG
or shifting them from 30 °C to 37 °C (12). Our results account for
these effects, as the in vivo degradation of Mgt1 was accelerated by
these treatments (Fig. 2E and Fig. S2C). Strong effects of increased
temperature on Mgt1 degradation could be detected by either
cycloheximide-chase or conventional pulse–chase assays (Fig. 2 C
and F and Figs. S1E and S2C). In contrast, oxidizing agents such as
H2O2 (Fig. S2C) or t-butyl hydroxide (data not shown) did not
increase the rate of Mgt1 degradation. The acceleration of yeast
Mgt1 degradation by MNNG (Fig. 2E) was analogous to the
previously observed effects of either MNNG or O6-benzylguanine
(the latter alkylates the active-siteCys ofMgmt) on the degradation,
by an unknown pathway, of Mgmt, the mammalian counterpart of
Mgt1 (9). We also examined mgt1! cells that expressed either
Mgt1f3, Mgt1C151M,f3, or Mgt1C151S,f3. In the latter derivatives of
Mgt1, the active-site Cys151 was replaced either by Met, a mimic of
methylated Cys, or by Ser, a substitution that also inactivates Mgt1.
S. cerevisiae expressing Mgt1C151M,f3 or Mgt1C151S,f3 were hypersen-
sitive to MNNG (Fig. 2G). In the absence of MNNG, Mgt1C151M,f3
was much shorter-lived than wt Mgt1f3 (data not shown). By
contrast, and in agreement with the inability of the Ser-mutant
Mgt1C151S,f3 to be alkylated at position 151, this mutant was
longer-lived than wt Mgt1f3 in cells that were treated with MNNG
(Fig. 3A).
The 3D structure of the 22-kDa human MGMT (6), a counter-
part of the 21-kDa S. cerevisiaeMgt1, showed that MGMT consists
of a ‘‘r bonuclease-like’’ N-terminal domain (residues 6–92) and a
C-terminal DNA-binding domain (residues 96–176) (Fig. S3 A, B,
and D). A putative 3D structure of S. cerevisiaeMgt1 was modeled
on human MGMT and took into account its sequelogy to Mgt1
(Fig. S4C). The active-site Cys of human MGMT resides between
the C-terminal DNA-binding domain and the N-terminal lobe that
faces away from DNA (6) (Fig. S3B). Our findings (see Fig. S4A)
indicate that the degron of S. cerevisiae Mgt1 is close to its N
terminus. Thus, the active-site Cys151 of Mgt1 is not a part of its
degron per se. Instead, the alkylation of Cys151 that accompanies
the repair of alkylated DNA by Mgt1 may change its conformation
and/or conformational mobility and thereby increase the accessi-
bility of its degron (which would be expected to ‘‘face away’’ from
DNA) to cognate Ub ligases This model is consistent with the
above-mentioned faster degradation of Mgt1C151M,f3, which con-
tains Met151, a mimic of methylated Cys, instead of wt Cys151.
The absence of Ubr1 made S. cerevisiae"10-fold more resistant
to MNNG, compared with wt cells (Fig. 2H and Fig. S2E). These
results suggested that Ubr1 targets not only alkylated (inactive)
Mgt1 but also unmodifiedMgt1. This interpretation would account
for the higher MNNG resistance of ubr1! cells, as the absence of
degradation of unmodifiedMgt1would result inmore of it available
for DNA repair. In agreement with the hyperresistance of ubr1!
cells to MNNG, they were also found to exhibit a lower frequency
of MNNG-induced mutations (Fig. S2D).
Ubr1 Targets Mgt1 Via a Degron Near Its N Terminus. C-terminally
truncated fragments ofMgt1f3 were expressed in either ubr1! or wt
S. cerevisiae, followed by SDS/PAGE of cell extracts and IB with
Fig. 2. Mgt1 as a physiological substrate of the N-end
rule pathway. (A) CHY108, a ubr1! strain of S. cerevisiae
that expressedMgt1m13 (Mgt1 C-terminally taggedwith
13 myc epitopes) (see SI Materials and Methods and
Table S1) was transformed with pRS315 (vector alone),
with pCH100 (expressing wt Ubr1), or with pCH159 (ex-
pressing inactiveUbr1C1220S) (20).Culturesweregrownto
an A600 of"1 in SDmedium, followed by a ‘‘chase’’ with
cycloheximide for 1 h and IB of cell extracts with either
anti-myc or anti-tubulin antibodies (the latter antibody
was used to verify the uniformity of total protein loads).
(B) PolyubiquitylatedMgt1ha,detectedby IBwithanti-ha
antibody, in MNNG-treated cells that expressed un-
tagged Ub (lane 1) or His6-Ub (lane 2). Dots on the left
refer to positions of molecular mass markers, at 75, 100,
150,and250kDa, respectively. (C)S. cerevisiaeexpressing
Mgt1f3 (pCH437)orMgt1C151S,f3 (pCH438) (TableS2)were
grown in SDmedium to an A600 of"0.8, then incubated
further for 1 h at 30 °Cor 37 °C and labeledwith [35S]me-
thionine/cysteine for 5min, followedbya chase for 0, 20,
and 40 min at 30 °C or 37 °C, respectively. Cell extracts
were precipitated with anti-flag antibody, followed by
SDS–4–12% NuPAGE and autoradiography. (D) Cyclo-
heximide ‘‘chase’’ assayswithMgt1 and S. cerevisiae null
mutants in genes encoding the indicated E3 Ub ligases.
(E) Wt and ubr1! S. cerevisiae expressing Mgt1m13
(Mgt1myc13) from the PMGT1 promoter were grown to an
A600 of"0.6 and incubated further in the presence of 68
!MMNNG for 1 h, followed by a ‘‘chase’’ with cyclohex-
imide for20and40min, SDS–4–12%NuPAGEofcell extracts, and IBwithanti-mycandanti-tubulinantibodies. (F)Quantitationof thedata inC, usingPhosphorImager.
Openand solid circles indicateMgt1f3 at 37 °Candat 30 °C, respectively; open triangles indicateMgt1C151S,f3 at 37 °C. (G) CHY21 (mgt1!) S. cerevisiaeexpressingMgt1f3
(pCH336),Mgt1C151S,f3 (pCH337), orMgt1C151M,f3 (pCH338)were g own to anA600 of"0.8 at 30 °C in SDmedium, followedby further incubation for 1 h, in ither t e
presence or absence of 68!MMNNG. The cultures were serially diluted, spotted on YPD plates, and incubated for 3 days at 30 °C. (H) Colony assay forMNNG toxicity.
S. cerevisiae YPH277 (wt) (solid circles) and YPH277HR1 (ubr1!) (open circles) were grown in YPDmedium at 30 °C to an A600 of"1.0 andwere further incubated for
1 h in the presence of MNNG at indicated concentrations. ell suspensions were diluted in PBS, spread on YPD plates, and incubated for 3 ays at 30 °C, followed by
determination of colony numbers.
2144 ! www.pnas.org"cgi"doi"10.1073"pnas.0812316106 Hwang et al.
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medium	  to	  an	  A600	  of	  ~0.8,	  then	  incubated	  further	  for	  1	  h	  at	  30°C	  or	  37°C	  and	  labeled	  with	  [35S]methionine/cysteine	  for	  5	  min,	  followed	  by	  a	  chase	  for	  0,	  20,	  and	  40	  min	  at	  30°C	  or	  37°C,	  respectively.	  Cell	  extracts	  were	  precipitated	  with	  anti-­‐flag	  antibody,	  followed	  by	  SDS–4–12%	  NuPAGE	  and	  autoradiography.	  (D)	  Cycloheximide	  ‘‘chase’’	  assays	  with	  Mgt1	  and	  S.	  cerevisiae	  null	  mutants	  in	  genes	  encoding	  the	  indicated	  E3	  Ub	  ligases.	  (E)	  Wt	  and	  ubr1Δ	  S.	  cerevisiae	  expressing	  Mgt1m13	  (Mgt1myc13)	  from	  the	  PMGT1	  promoter	  were	  grown	  to	  an	  A600	  of	  ~0.6	  and	  incubated	  further	  in	  the	  presence	  of	  68	  μM	  MNNG	  for	  1	  h,	  followed	  by	  a	  ‘‘chase’’	  with	  cycloheximide	  for	  20	  and	  40	  min,	  SDS–	  4	  –12%	  NuPAGE	  of	  cell	  extracts,	  and	  IB	  with	  anti-­‐myc	  and	  anti-­‐tubulin	  antibodies.	  (F)	  Quantitation	  of	  the	  data	  in	  C,	  using	  PhosphorImager.	  Open	  and	  solid	  circles	  indicate	  Mgt1f3	  at	  37°C	  and	  at	  30°C,	  respectively;	  open	  triangles	  indicate	  Mgt1C151S,f3	  at	  37	  °C.	  (G)	  CHY21	  (mgt1Δ)	  S.	  
cerevisiae	  expressing	  Mgt1f3	  (pCH336),	  Mgt1C151S,f3	  (pCH337),	  or	  Mgt1C151M,f3	  (pCH338)	  were	  grown	  to	  an	  A600	  of	  ~0.8	  at	  30°C	  in	  SD	  medium,	  followed	  by	  a	  further	  incubation	  for	  1	  h,	  in	  either	  the	  presence	  or	  absence	  of	  68	  μM	  MNNG.	  The	  cultures	  were	  serially	  diluted,	  spotted	  on	  YPD	  plates,	  and	  incubated	  for	  3	  days	  at	  30	  °C.	  (H)	  Colony	  assay	  for	  MNNG	  toxicity.	  S.	  cerevisiae	  YPH277	  (wt)	  (solid	  circles)	  and	  YPH277HR1	  (ubr1Δ)	  (open	  circles)	  were	  grown	  in	  YPD	  medium	  at	  30	  °C	  to	  an	  A600	  of	  ~1.0	  and	  were	  further	  incubated	  for	  1	  h	  in	  the	  presence	  of	  MNNG	  at	  indicated	  concentrations.	  Cell	  suspensions	  were	  diluted	  in	  PBS,	  spread	  on	  YPD	  plates,	  and	  incubated	  for	  3	  days	  at	  30	  °C,	  followed	  by	  determination	  of	  colony	  numbers.	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  Figure	  A1.3.	  The	  UFD	  pathway	  plays	  a	  role	  in	  degradation	  of	  Mgt1.	  (A)	  CHY21	  (mgt1Δ)	  S.	  cerevisiae	  expressing	  Mgt1f3	  (pCH336),	  Mgt1C151S,f3	  (pCH337),	  or	  Mgt1C151M,f3	  (pCH338)	  were	  grown	  to	  an	  A600	  of	  ~0.8	  at	  30	  °C,	  then	  incubated	  for	  1	  h	  with	  MNNG	  at	  68	  μM,	  followed	  by	  a	  ‘‘chase’’	  with	  cycloheximide	  for	  15	  and	  30	  min,	  SDS–4–	  12%	  NuPAGE	  of	  cell	  extracts,	  and	  IB	  with	  anti-­‐flag	  and	  anti-­‐tubulin	  antibodies.	  (B)	  The	  in	  vivo	  levels	  of	  MGT11–	  100,f3	  (see	  Fig.	  S4A)	  were	  compared	  by	  IB,	  using	  anti-­‐flag	  and	  anti-­‐tubulin	  antibodies	  (the	  latter	  a	  loading	  control),	  with	  extracts	  from	  wt	  S.	  cerevisiae	  and	  its	  null	  mutants	  in	  either	  Ubr1	  or	  several	  HECT-­‐type	  E3	  Ub	  ligases	  (a	  ts	  mutant	  in	  the	  case	  of	  Rps5).	  MGT11–100,f3	  was	  expressed	  in	  these	  strains	  from	  pCH372	  (Table	  S2).	  Cultures	  were	  grown	  at	  30	  °C	  to	  an	  A600	  of	  ~0.8.	  Some	  IB	  assays	  (with	  rps5-­‐1	  cells)	  were	  also	  carried	  out	  with	  extracts	  from	  cells	  that	  were	  incubated	  for	  1	  h	  at	  37	  °C.	  Note	  an	  increase	  of	  MGT11–100,f3	  in	  ufd4Δ	  
anti-flag antibody (Fig. S4A). Mgt11–100,f3, which contained the
ribonuclease-like N-terminal domain ofMgt1 but lacked the active-
site Cys151, was undetectable in wt cells but readily detectable in
ubr1! cells (Fig. S4A, lanes 5 and 6), indicating the presence of a
Ubr1-specific degron in the N-terminal half of Mgt1. The results
withMgt11–144,f3 (Fig. S4A, lanes 3 and 4) were similar to those with
Mgt11–100,f3. Mgt184–188,f3, an N-terminally truncated Mgt1, could
not be expressed at detectable levels in either wt or ubr1! cells (Fig.
S4A, lanes 7 and 8).
UFD and N-End Rule Pathways Cotarget Mgt1 for Degradatio .Given
the residual instability of Mgt1 in the absence of Ubr1 (Fig. 2 A,
D, and E), we attempted to identify another E3 that may target
Mgt1. This search involved expression of the Mgt11–100,f3 frag-
ment from the PMGT1 promoter (Fig. S4A) and a set of S.
cerevisiae mutants in several E3s (ubr1!, ubr2!, hrd1!, hrd3!,
doa10!, ufd2!, tul1!, hul4!, hul5!, ufd4!, tom1!, rps5-1ts).
Among thesemutants, theMgt11–100,f3 fragment was significantly
stabilized in ubr1! cells (as expected), and also, remarkably, in
ufd4! cells (Fig. 3B, lane 3). Ufd4 is a 168-kDa HECT-domain
E3 Ub ligase that mediates the UFD pathway (see Introduction
and Fig. 1B). Given this result, we carried out cycloheximide-
chase assays with wt, ubr1!, and ubr1! ufd4! double-mutant
S. cerevisiae strains that expressed full-length Mgt1m13. The
absence of both Ubr1 and Ufd4 stabilized Mgt1 much more than
the absence of Ubr1 alone (Fig. 3C and Fig. S2F). The syner-
gistically enhanced stabilization of Mgt1m13 in ubr1! ufd4! cells
was observed either at 37 °C (Fig. S2F) or upon a treatment with
MNNG (Fig. 3C). Moreover, a conventional pulse–chase assay
at 37 °C with Mgt1f3 and either wt, ubr1!, or ubr1! ufd4! cells
has demonstrated a virtually complete stabilization of newly
formed Mgt1 in ubr1! ufd4! cells (Fig. 3 D and E). As would be
expected (given the results above), the absence of Ufd4 alone
partially stabilized Mgt1, especially in ufd4! versus wt cells that
were treated with MNNG (Fig. S2 G and H).
S. cer visiae lacking Ufd4 were "2.5-fold more r sistant to
MNNG than their wt counterparts (Fig. 3F and Fig. S4F). Double-
mutant ubr1! ufd4! cells, in whichMgt1 was particularly long-lived
(Fig. 3 C–E), grew slightly slower than congenic wt cells (Fig. S4 F
andG and data not shown). Moreover, overexpressing of Mgt1f3 in
either wt, ubr1!, or ufd4! cells did not significantly impair their
growth (data not shown) but led to a severe growth defect in ubr1!
ufd4! cells (Fig. S4 G and H). Thus, the inability to destroy Mgt1
is near-lethal upon overexpression of Mgt1 and is also likely to be
deleterious, to a lower extent, at physiological levels of Mgt1.
In Vitro Binding of Ubr1 and Ufd4 to Mgt1 and Cup9. The type 1 and
type 2 substrate-binding sites of Ubr1 are specific for basic N-
terminal residues (Arg, Lys,His) and bulky hydrophobicN-terminal
residues (Trp, Phe, Tyr, Leu, Ile), respectively. The third binding
site of Ubr1 recognizes an internal (non-N-degron) degradation
signal of Cup9, a transcriptional repressor of a regulon that includes
the Ptr2 transporter of di- and tripeptides (19, 22, 25). This binding
site ofUbr1 is autoinhibited but can be allosterically activated by the
binding of cognate peptides (including those imported into cells by
Ptr2) to the type 1/2 sites of Ubr1. The resulting down-regulation
of the Cup9 repressor, through its accelerated degradation by the
N-end rule pathway, up-regulates the expression f the Ptr2 trans-
porter. This positive-feedback circuit allows S. cerevisiae to detect
the presence of extracellular peptides and to react by increasing
their uptake (22, 23, 25). We used cup9!, ubr1!, and cup9! ubr1!
mutants to determine whether the observed effect of Ubr1 on the
in vivo degradation of Mgt1 (e.g., Fig. 2 A, B, D, and F) might be
influenced by a circuit controlled by Cup9, and found no such
influence (Fig. S4E).
In agreement with previous work, which used GST-pulldown
assays to demonstrate the dependence of interactions between
Ubr1 and GST-Cup9 on the presence of cognate (type 1/2) dipep-
tides (19, 22), the in vitro binding of fUbr1 to GST-Cup9 required
the presence of cognate dipeptides such as Arg-Ala (type 1 dipep-
Fig. 3. TheUFDpathway plays a role in degradation of
Mgt1. (A) CHY21 (mgt1!) S. cerevisiae expressingMgt1f3
(pCH336), Mgt1C151S,f3 (pCH337), or Mgt1C151M,f3
(pCH338) were grown to an A600 of "0.8 at 30 °C, then
incubated for 1 h with MNNG at 68 !M, followed by a
‘‘chase’’ with cycloheximide for 15 and 30 min, SDS–4–
12% NuPAGE of cell extracts, and IB with anti-flag and
anti-tubulin antibodies. (B) The in vivo levels of MGT11–
100,f3 (see Fig. S4A) were compared by IB, using anti-flag
andanti-tubulinantibodies (the lattera loadingcontrol),
with extracts fromwt S. cerevisiae and its nullmutants in
either Ubr1 or several HECT-type E3 Ub ligases (a tsmu-
tant in the case of Rps5). MGT11–100,f3 was expressed in
these strains from pCH372 (Table S2). Cultures were
grown at 30 °C to an A600 of "0.8. Some IB assays (with
rps5-1 cells) were also carried outwith extracts from cells
that were incubated for 1 h at 37 °C. Note an increase of
MGT11–100,f3 in ufd4! cells, in addition to ubr1! cells. (C)
Wt, ubr1!, and ubr1! ufd4! S. cerevisiae that expressed
chromosomally integrated MGT1m13 (see SI Materials
andMethods)weregrownat30 °CtoanA600of"0.8and
werefurther incubated inthepresenceofMNNG(68!M)
for 1 h, followed by a ‘‘chase’’ with cycloheximide for 20
and 40min, SDS–4–12%NuPAGE of cell extracts, and IB
with anti-myc and anti-tubulin antibodies. (D) Pulse–
chase assayswithMgt1f3 andwt (lanes 1–3),ubr1! (lanes
4–6), or ubr1! ufd4! (lanes 7–9) S. cerevisiae. Cells ex-
pressingMgt1f3 from the PMET25 promoter on a low copy
plasmid were labeled for 5 min with [35S]methionine/
cysteine and chased for 0, 20, or 40 min, followed by immunoprecipitation with anti-flag antibody, SDS/PAGE, and autoradiography (see SI Materials andMethods).
(E)Quantitationofdata inD, usingPhosphorImager. Circles,wt cells; triangles,ubr1! cells; squares,ubr1!ufd4! cells. 100%refers to the relative amountof 35S at time
0 (end of pulse) for each of 3 pulse–chases. (F) S. cerevisiae of the indicated genotypes were grown to an A600 of"0.6 in YPDmedium andwere further incubated in
either the presence or absence ofMNNG (0.34mM) for 1.5 h at 30 °C. Cell suspensions were dilutedwith PBS (PBS), spread on YPD plates, and incubated for 3 days at
30 °C. Survival refers to numbers of colonies in MNNG-treated samples as percentages of the corresponding numbers in untreated samples.
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cells,	  in	  addition	  to	  ubr1Δ	  cells.	  (C)	  Wt,	  ubr1Δ,	  and	  ubr1Δufd4Δ	  S.	  cerevisiae	  that	  expressed	  chromosomally	  integrated	  MGT1m13	  (see	  SI	  Materials	  and	  Methods)	  were	  grown	  at	  30	  °C	  to	  an	  A600	  of	  ~0.8	  and	  were	  further	  incubated	  in	  the	  presence	  of	  MNNG	  (68	  μM)	  for	  1	  h,	  followed	  by	  a	  ‘‘chase’’	  with	  cycloheximide	  for	  20	  and	  40	  min,	  SDS–	  4	  –12%	  NuPAGE	  of	  cell	  extracts,	  and	  IB	  with	  anti-­‐myc	  and	  anti-­‐tubulin	  antibodies.	  (D)	  Pulse–chase	  assays	  with	  Mgt1f3	  and	  wt	  (lanes	  1–3),	  ubr1Δ	  (lanes	  4–6),	  or	  ubr1Δufd4Δ	  (lanes	  7–9)	  S.	  cerevisiae.	  Cells	  expressing	  Mgt1f3	  from	  the	  PMET25	  promoter	  on	  a	  low	  copy	  plasmid	  were	  labeled	  for	  5	  min	  with	  [35S]methionine/	  cysteine	  and	  chased	  for	  0,	  20,	  or	  40	  min,	  followed	  by	  immunoprecipitation	  with	  anti-­‐flag	  antibody,	  SDS/PAGE,	  and	  autoradiography	  (see	  
SI	  Materials	  and	  Methods).	  (E)	  Quantitation	  of	  data	  in	  D,	  using	  PhosphorImager.	  Circles,	  wt	  cells;	  triangles,	  ubr1Δ	  cells;	  squares,	  ubr1Δ	  ufd4Δ	  cells.	  100%	  refers	  to	  the	  relative	  amount	  of	  35S	  at	  time	  0	  (end	  of	  pulse)	  for	  each	  of	  3	  pulse–chases.	  (F)	  S.	  
cerevisiae	  of	  the	  indicated	  genotypes	  were	  grown	  to	  an	  A600	  of	  ~0.6	  in	  YPD	  medium	  and	  were	  further	  incubated	  in	  either	  the	  presence	  or	  absence	  of	  MNNG	  (0.34	  mM)	  for	  1.5	  h	  at	  30	  °C.	  Cell	  suspensions	  were	  diluted	  with	  PBS	  (PBS),	  spread	  on	  YPD	  plates,	  and	  incubated	  for	  3	  days	  at	  30	  °C.	  Survival	  refers	  to	  numbers	  of	  colonies	  in	  MNNG-­‐treated	  samples	  as	  percentages	  of	  the	  corresponding	  numbers	  in	  untreated	  samples.	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  Figure	  A1.S1.	  (A)	  ‘‘Chases’’	  with	  cycloheximide	  to	  test	  putative	  Ubr1-­‐interacting	  proteins	  for	  their	  degradation	  by	  the	  N-­‐end	  rule	  pathway	  in	  vivo.	  The	  S.	  cerevisiae	  proteins	  examined	  in	  these	  experiments	  were	  described	  as	  proteins	  that	  could	  be	  coimmunoprecipitated	  with	  S.	  cerevisiae	  Ubr1	  in	  proteomic-­‐scale	  experiments	  (1–3).	  JD52	  (WT)	  and	  JD55	  (ubr1Δ)	  S.	  cerevisiae	  carrying	  plasmids	  (Table	  S2)	  that	  expressed	  the	  indicated	  proteins	  were	  grown	  at	  30	  °C	  to	  A600	  of	  ~1.0,	  followed	  by	  a	  
Fig. S1. (A) ‘‘Chases’’ with cycloheximide to test putative Ubr1-interacting proteins for their degradation by the N-end rule pathway in vivo. The S. cerevisiae
proteins examined in these experiments were described as proteins that could be coimmunoprecipitatedwith S. cerevisiaeUbr1 in proteomic-scale experiments
(1–3). JD52 (WT) and JD55 (ubr1!) S. cerevisiae carrying plasmids (Table S2) that expressed the indicated proteins were grown at 30 °C to A600 of"1.0, followed
by a ‘‘chase’’ with cycloheximide for 1 and 2 h, as described in SI Materials andMethods, using immunoblotting with anti-ha and anti-myc antibodies. Note that
although most of the tested proteins were apparently short-lived in vivo, only Mgt1 was significantly stabilized in the absence of Ubr1. (B) Accumulation of
ubiquitylated Mgt1m13 (Mgt1myc13) in the presence of MG132, a proteasome inhibitor. MG132-sensitive pdr5! S. cerevisiae (4) CHY115 cells (MGT1myc13::TRP1
pdr5!::KanMX6) (Table S1)weregrown toA600of"1and incubated further in thepresenceof eitherMG132 (50!M)ordimethyl sulfoxide (anequivalent amount
of solvent of the stock solution ofMG132) for indicated times at 30 °C. Cell extracts were fractionated by SDS/4–12%NuPAGE and immunoblottedwith anti-myc
and anti-tubulin antibodies. The (overexposed) band of full-length Mgt1m13 and its ubiquitylated derivatives are denoted on the right. Overexposure was used
to facilitate the detection of ubiquitylated Mgt1m13. An asterisk denotes a (presumed) proteolytic fragment of Mgt1m13. (C) WTMGT1was replaced by an ORF
encodingMgt1m13, a derivative C-terminally taggedwith themyc13 epitope and expressed from the native PMGT1 promoter. Mgt1m13 was indistinguishable from
WTMgt1 in its ability to protect cells fromMNNG.WTorubr1! strains expressing eitherWTMgt1orMgt1m13, and a congenicWT strain lackingMgt1weregrown
toA600 of"0.5 inYPDmediumand further growneither in thepresenceor absenceof 30!MMNNGfor 3h in the samemedium. The cultureswere serially diluted
5-fold, spotted on YPD plates, and incubated for 2 days at 30 °C. (D) The Rad6 E2 enzyme is required for Mgt1 degradation. A set of S. cerevisiae null mutants
in genes encoding specific E2 (Ub-conjugating) enzymes carried pCH336, which expressed Mgt1f3 from the PMGT1 promoter. Cells were grown to A600 of"0.8 at
30 °C, and thereafter incubated at 37 °C for 1 h (to increase the assay’s sensitivity; see the main text), followed by a ‘‘chase’’ with cycloheximide (50 !g/ml) for
30min. Cell extractswere fractionat dby SDS/4–12%NuPAGE, followedby IBwith anti-fl gandanti-tubulin antibodies. (E) Heat-induceddegradationofMgt1f3
is apparently independent of the identity of its residue at position 151. The same strains and procedures as in A, except that cells were not treated with MNNG,
and were incubated, instead, at 37 °C for 1 h, followed by a ‘‘chase’’ with cycloheximide, also at 37 °C.
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‘‘chase’’	  with	  cycloheximide	  for	  1	  and	  2	  h,	  as	  described	  in	  SI	  Materials	  and	  Methods,	  using	  immunoblotting	  with	  anti-­‐ha	  and	  anti-­‐myc	  antibodies.	  Note	  that	  although	  most	  of	  the	  tested	  proteins	  were	  apparently	  short-­‐lived	  in	  vivo,	  only	  Mgt1	  was	  significantly	  stabilized	  in	  the	  absence	  of	  Ubr1.	  (B)	  Accumulation	  of	  ubiquitylated	  Mgt1m13	  (Mgt1myc13)	  in	  the	  presence	  of	  MG132,	  a	  proteasome	  inhibitor.	  MG132-­‐sensitive	  pdr5Δ	  S.	  cerevisiae	  (4)	  CHY115	  cells	  (MGT1myc13::TRP1	  pdr5Δ::KanMX6)	  (Table	  S1)	  were	  grown	  to	  A600	  of	  ~1	  and	  incubated	  further	  in	  the	  presence	  of	  either	  MG132	  (50	  μM)	  or	  dimethyl	  sulfoxide	  (an	  equivalent	  amount	  of	  solvent	  of	  the	  stock	  solution	  of	  MG132)	  for	  indicated	  times	  at	  30	  °C.	  Cell	  extracts	  were	  fractionated	  by	  SDS/4	  –12%	  NuPAGE	  and	  immunoblotted	  with	  anti-­‐myc	  and	  anti-­‐tubulin	  antibodies.	  The	  (overexposed)	  band	  of	  full-­‐length	  Mgt1m13	  and	  its	  ubiquitylated	  derivatives	  are	  denoted	  on	  the	  right.	  Overexposure	  was	  used	  to	  facilitate	  the	  detection	  of	  ubiquitylated	  Mgt1m13.	  An	  asterisk	  denotes	  a	  (presumed)	  proteolytic	  fragment	  of	  Mgt1m13.	  (C)	  WT	  MGT1	  was	  replaced	  by	  an	  ORF	  encoding	  Mgt1m13,	  a	  derivative	  C-­‐terminally	  tagged	  with	  the	  myc13	  epitope	  and	  expressed	  from	  the	  native	  PMGT1	  promoter.	  Mgt1m13	  was	  indistinguishable	  from	  WT	  Mgt1	  in	  its	  ability	  to	  protect	  cells	  from	  MNNG.	  WT	  or	  ubr1Δ	  strains	  expressing	  either	  WT	  Mgt1	  or	  Mgt1m13,	  and	  a	  congenic	  WT	  strain	  lacking	  Mgt1	  were	  grown	  to	  A600	  of	  ~0.5	  in	  YPD	  medium	  and	  further	  grown	  either	  in	  the	  presence	  or	  absence	  of	  30	  μM	  MNNG	  for	  3	  h	  in	  the	  same	  medium.	  The	  cultures	  were	  serially	  diluted	  5-­‐fold,	  spotted	  on	  YPD	  plates,	  and	  incubated	  for	  2	  days	  at	  30	  °C.	  (D)	  The	  Rad6	  E2	  enzyme	  is	  required	  for	  Mgt1	  degradation.	  A	  set	  of	  S.	  cerevisiae	  null	  mutants	  in	  genes	  encoding	  specific	  E2	  (Ub-­‐conjugating)	  enzymes	  carried	  pCH336,	  which	  expressed	  Mgt1f3	  from	  the	  PMGT1	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promoter.	  Cells	  were	  grown	  to	  A600	  of	  ~0.8	  at	  30	  °C,	  and	  thereafter	  incubated	  at	  37	  °C	  for	  1	  h	  (to	  increase	  the	  assay’s	  sensitivity;	  see	  the	  main	  text),	  followed	  by	  a	  ‘‘chase’’	  with	  cycloheximide	  (50	  μg/ml)	  for	  30	  min.	  Cell	  extracts	  were	  fractionated	  by	  SDS/4	  –12%	  NuPAGE,	  followed	  by	  IB	  with	  anti-­‐flag	  and	  anti-­‐tubulin	  antibodies.	  (E)	  Heat-­‐induced	  degradation	  of	  Mgt1f3	  is	  apparently	  independent	  of	  the	  identity	  of	  its	  residue	  at	  position	  151.	  The	  same	  strains	  and	  procedures	  as	  in	  A,	  except	  that	  cells	  were	  not	  treated	  with	  MNNG,	  and	  were	  incubated,	  instead,	  at	  37	  °C	  for	  1	  h,	  followed	  by	  a	  ‘‘chase’’	  with	  cycloheximide,	  also	  at	  37	  °C.	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  Figure	  A1.S2.	  (A)	  Pulse–chase	  analysis,	  using	  the	  Ub-­‐reference	  (UR)	  technique,	  of	  flag-­‐tagged	  Mgt1f3.	  JD52	  (WT)	  cells	  (lanes	  1–3)	  and	  JD55	  (ubr1Δ)	  cells	  (lanes	  4	  –	  6)	  expressing	  fDHFR-­‐UbK48R-­‐Mgt1f	  (pCH281)	  were	  grown	  at	  30	  °C	  to	  A600	  of	  ~1,	  followed	  by	  labeling	  for	  5	  min	  with	  [35S]methionine/cysteine	  and	  a	  chase	  (in	  the	  presence	  of	  cycloheximide)	  for	  0,	  10	  or	  30	  min	  at	  30	  °C.	  Cell	  extracts	  were	  
Fig. S2. (A) Pulse–chase analysis, using the Ub-reference (UR) technique, of flag-tagged Mgt1f3. JD52 (WT) cells (lanes 1–3) and JD55 (ubr1!) cells (lanes 4–6)
expressing fDHFR-UbK48R-Mgt1f (pCH281) were grown at 30 °C to A600 of "1, followed by labeling for 5 min with [35S]methionine/cysteine and a chase (in the
presence of cycloheximide) for 0, 10 or 30 min at 30 °C. Cell extracts were precipitated with anti-flag antibody, followed by SDS/4–12% NuPAGE and
autoradiography. ‘‘Reference’’ on the left denotes the fDHFR-UbK48R moiety. (B) Cycloheximide ‘‘chase’’ assays with JD52 (WT), JD55 (ubr1!), or double-mutant
CHY134 (ubr1! ubr2!) S. cerevisiae strains expressing Mgt1f3. (C) WT S. cerevisiae expressing Mgt1m13 (Mgt1myc13) from the PMGT1 promoter were grown to A600
of"0.6, and thereafter preincubate for 1 h at 30 °C (lanes 1–3), or at 37 °C (lanes 4–6), or at 30 °C but in the presence of 1 mMH2O2 (lanes 7–9), with the same
(preincubation) conditionsduring cycloheximide ‘‘chases’’ for 20and40min. Cell extractswere fractionatedby SDS/4–12%NuPAGE, followedby IBwithanti-myc
and anti-tubulin antibodies. (D) Ubr1-lacking S. cerevisiae are more resistant toMNNG-inducedmutagenesis. JD52 (WT) (filled bar) and JD55 (ubr1!) (open bar)
S. cerevisiaewere se ded in YPDmedium at"200 cell/ml, and grown for"38 h to A600 of"5. Cell suspensions were incubated in the presence of 34 !MMNNG
for 30 min at 30 °C, then diluted with PBS and spread onto either YPD plates or arginine-lacking SC(-Arg) plates containing canavanine (60 !g/ml), to select for
canavanine-resistant cells. Plates were incubated for 3 days at 30 °C, and the resulting colonies were counted. (E) Cells of indicated genotypes (Table S1) were
grown to A600 of"0.6 in YPD medium at 30 °C, a d were further i cubated in the presence of 0.1 mMMNNG for 1 h. The cultures were serially diluted 5-fold,
spotted on YPD plates, and incubated for 2 days at 30 °C. (F) WT, ubr1! and double-mutant ubr1! ufd4! S. cerevisiae that expressed chromosomally integrated
MGT1m13 (see SI Materials and Methods) were grown at 30 °C to A600 of "0.8, and were further incubated for 1 h at 37 °C, followed by a ‘‘chase’’ with
cycloheximide, also at 37 °C. SDS/4–12% NuPAGE of cell extracts was followed by IB with anti-myc and anti-tubulin antibodies. (G and H) WT and ufd4! S.
cerevisiaewith chromosomally integratedMGT1m13 (see SIMaterials andMethods)were grown in SCmediumat 30 °C toA600 of"0.8 andwere further incubated
in the presence of MNNG (68 !M) for 1 h (panel G), or at 37 °C (panel H), followed by a ‘‘chase’’ with cycloheximide for 10, 20, and 40 min, fractionation of cell
extracts by SDS/4–12% NuPAGE, and IB with anti-myc and anti-tubulin antibodies.
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precipitated	  with	  anti-­‐flag	  antibody,	  followed	  by	  SDS/4	  –12%	  NuPAGE	  and	  autoradiography.	  ‘‘Reference’’	  on	  the	  left	  denotes	  the	  fDHFR-­‐UbK48R	  moiety.	  (B)	  Cycloheximide	  ‘‘chase’’	  assays	  with	  JD52	  (WT),	  JD55	  (ubr1Δ),	  or	  double-­‐mutant	  CHY134	  (ubr1Δubr2Δ)	  S.	  cerevisiae	  strains	  expressing	  Mgt1f3.	  (C)	  WT	  S.	  cerevisiae	  expressing	  Mgt1m13	  (Mgt1myc13)	  from	  the	  PMGT1	  promoter	  were	  grown	  to	  A600	  of	  ~0.6,	  and	  thereafter	  preincubated	  for	  1	  h	  at	  30	  °C	  (lanes	  1–3),	  or	  at	  37	  °C	  (lanes	  4	  –	  6),	  or	  at	  30	  °C	  but	  in	  the	  presence	  of	  1	  mM	  H2O2	  (lanes	  7–9),	  with	  the	  same	  (preincubation)	  conditions	  during	  cycloheximide	  ‘‘chases’’	  for	  20	  and	  40	  min.	  Cell	  extracts	  were	  fractionated	  by	  SDS/4	  –12%	  NuPAGE,	  followed	  by	  IB	  with	  anti-­‐myc	  and	  anti-­‐tubulin	  antibodies.	  (D)	  Ubr1-­‐lacking	  S.	  cerevisiae	  are	  more	  resistant	  to	  MNNG-­‐induced	  mutagenesis.	  JD52	  (WT)	  (filled	  bar)	  and	  JD55	  (ubr1Δ)	  (open	  bar)	  S.	  
cerevisiae	  were	  seeded	  in	  YPD	  medium	  at	  ~200	  cell/ml,	  and	  grown	  for	  ~38	  h	  to	  A600	  of	  ~5.	  Cell	  suspensions	  were	  incubated	  in	  the	  presence	  of	  34	  μM	  MNNG	  for	  30	  min	  at	  30	  °C,	  then	  diluted	  with	  PBS	  and	  spread	  onto	  either	  YPD	  plates	  or	  arginine-­‐lacking	  SC(-­‐Arg)	  plates	  containing	  canavanine	  (60	  μg/ml),	  to	  select	  for	  canavanine-­‐resistant	  cells.	  Plates	  were	  incubated	  for	  3	  days	  at	  30	  °C,	  and	  the	  resulting	  colonies	  were	  counted.	  (E)	  Cells	  of	  indicated	  genotypes	  (Table	  S1)	  were	  grown	  to	  A600	  of	  ~0.6	  in	  YPD	  medium	  at	  30	  °C,	  and	  were	  further	  incubated	  in	  the	  presence	  of	  0.1	  mM	  MNNG	  for	  1	  h.	  The	  cultures	  were	  serially	  diluted	  5-­‐fold,	  spotted	  on	  YPD	  plates,	  and	  incubated	  for	  2	  days	  at	  30	  °C.	  (F)	  WT,	  ubr1Δ	  and	  double-­‐mutant	  ubr1Δ	  ufd4Δ	  	  S.	  
cerevisiae	  that	  expressed	  chromosomally	  integrated	  MGT1m13	  (see	  SI	  Materials	  and	  
Methods)	  were	  grown	  at	  30	  °C	  to	  A600	  of	  ~0.8,	  and	  were	  further	  incubated	  for	  1	  h	  at	  37	  °C,	  followed	  by	  a	  ‘‘chase’’	  with	  cycloheximide,	  also	  at	  37	  °C.	  SDS/4	  –12%	  NuPAGE	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of	  cell	  extracts	  was	  followed	  by	  IB	  with	  anti-­‐myc	  and	  anti-­‐tubulin	  antibodies.	  (G	  and	  
H)	  WT	  and	  ufd4Δ	  S.	  cerevisiae	  with	  chromosomally	  integrated	  MGT1m13	  (see	  SI	  
Materials	  and	  Methods)	  were	  grown	  in	  SC	  medium	  at	  30	  °C	  to	  A600	  of	  ~0.8	  and	  were	  further	  incubated	  in	  the	  presence	  of	  MNNG	  (68	  μM)	  for	  1	  h	  (panel	  G),	  or	  at	  37	  °C	  (panel	  H),	  followed	  by	  a	  ‘‘chase’’	  with	  cycloheximide	  for	  10,	  20,	  and	  40	  min,	  fractionation	  of	  cell	  extracts	  by	  SDS/4	  –12%	  NuPAGE,	  and	  IB	  with	  anti-­‐myc	  and	  anti-­‐tubulin	  antibodies.	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  Figure	  A1.S3.	  (A)	  Four	  putative	  β-­‐sheets	  in	  the	  N-­‐terminal	  region	  of	  S.	  cerevisiae	  Mgt1	  that	  are	  sequelogous	  (similar	  in	  sequence),	  and	  probably	  also	  spalogous	  (spatially	  similar)	  (1)	  to	  the	  corresponding	  regions	  of	  human	  Mgmt	  (MGMT),	  the	  structure	  of	  which	  was	  determined	  previously	  (2).	  Residues	  identical	  between	  S.	  
cerevisiae	  Mgt1	  and	  human	  MGMT	  are	  in	  bold.	  (B)	  The	  structure	  of	  human	  Mgmt	  and	  a	  model	  of	  its	  interaction	  with	  DNA	  (2).	  Alkyl	  lesions	  are	  removed	  by	  Mgt1	  and	  Mgmt	  from	  DNA	  through	  a	  base-­‐flipping	  mechanism	  (3).	  (C)	  The	  hypothetical	  3D	  structure	  of	  S.	  cerevisiae	  Mgt1,	  produced	  by	  Modeller-­‐9v1	  (http://salilab.org/modeller/),	  using	  the	  structure	  of	  human	  Mgmt	  (1eh6.pdb)	  as	  its	  template,	  and	  displayed	  using	  PyMol	  (DeLano	  Scientific).	  (D)	  Sequence	  alignments	  among	  O6-­‐alkyguanine	  transferases	  of	  the	  yeasts	  (fungi)	  S.	  cerevisiae	  (Sc)	  and	  
Fig. S3. (A) Four putative !-sheets in the N-terminal region of S. cerevisiae Mgt1 that are sequelogous (similar in sequence), and probably also spalogous
(spatially similar) (1) to the corresponding regions of human Mgmt (MGMT), the structure of which was determined previously (2). Residues identical between
S. cerevisiaeMgt1 and human MGMT are in bold. (B) The structure of human Mgmt and a model of its interaction with DNA (2). Alkyl lesions are removed by
Mgt1 and Mgmt from DNA through a base-flipping mechanism (3). (C) The hypothetical 3D structure of S. cerevisiae Mgt1, produced by Modeller-9v1
(http://salilab.org/modeller/), using the structure of human Mgmt (1eh6.pdb) as its template, and displayed using PyMol (DeLano Scientific). (D) Sequence
alignments amongO6-alkyguanine transferases of the y a ts (fungi) S. cerevi iae (Sc) and Kluyveromyces lactis (Kl), the prokaryote E. coli (Ec), and themammal
Homo sapiens (Hs) and Mus musculus (Mm).
1. Varshavsky A (2004) Spalog and sequelog: Neutral terms for spatial and sequence similarity. Curr Biol 14:R181–R183.
2. Wibley JEA, Pegg AE, Moody PCE (2000) Crystal structure of the human O6-alkylguanine-DNA alkyltransferase. Nucl Acids Res 28:393–401.
3. Daniels DS, et al. (2004) DNA binding and nucleotide flipping by the human DNA repair protein AGT. Nat Struct Mol Biol 11:714–720.
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Kluyveromyces	  lactis	  (Kl),	  the	  prokaryote	  E.	  coli	  (Ec),	  and	  the	  mammals	  Homo	  
sapiens	  (Hs)	  and	  Mus	  musculus	  (Mm).	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  Fig.	  A1.S4.	  (A)	  JD52	  (WT)	  and	  JD55	  (ubr1Δ)	  S.	  cerevisiae	  expressing	  either	  full-­‐length	  Mgt1f3	  (from	  the	  PMGT1	  promoter	  on	  a	  low	  copy	  plasmid)	  or	  its	  C-­‐terminally	  truncated	  derivatives	  were	  grown	  to	  A600	  of	  ~0.8,	  followed	  by	  SDS/4	  –12%	  NuPAGE	  of	  cell	  extracts	  and	  IB	  with	  anti-­‐flag	  and	  anti-­‐tubulin	  antibodies.	  Lanes	  1	  and	  2,	  full-­‐
Fig. S4. (A) JD52 (WT) and JD55 (ubr1!)
S. cerevisiae expressing either full-length
Mgt1f3 (from the PMGT1 promoter on a low
copy plasmid) or its C-terminally truncated
derivatives were grown to A600 of "0.8,
followedby SDS/4–12%NuPAGEof cell ex-
tractsand IBwithanti-flagandanti-tubulin
antibodies. Lanes 1 and 2, full-length
Mgt11–188,f3 in WT and ubr1! cells, respec-
tively. Lanes 3 and 4, same as lanes 1 and 2,
respectively, but with Mgt11–144,f3. Lanes 5
and 6, same but with Mgt11–100,f3. Lanes 7
and 8, same but with Mgt184–188,f3. (B)
Equal amounts of extracts (50 !g) from S.
cerevisiae that expressed the N-terminally
flag-tagged Ubr1 (fUbr1) were incubated
ineither thepresenceorabsenceof specific
dipeptides (eachofthemat1mM)withGST
alone or specific GST fusions ("5 !g) that
were linked to glutathione-Sepharose
beads. Bound proteins were eluted from
the beads and fractionated by SDS/4–12%
NuPAGE, followed by IB with anti-flag an-
tibody. Lane 1, 2.5% of the initial (total)
input of fUbr1. Lane 2, GST alone. Lane 3,
GST-Mgt1. Lane 4, same as lane 3 but with
Arg-Ala (R-A, 1mM). Lane5, sameas lane 4
butwithAla-Arg (A-R, 1mM). Lane6, same
as lane3butwithLeu-Ala (L-A,1mM).Lane
7, same as lane 3 but with Ala-Leu (A-L, 1
mM). Lane 8, same as lane 3 but with both
Arg-Ala and Leu-Ala (R-A and L-A, 1 mM
each). Lane 9, same as lane 3 butwith both
Ala-Arg andAla-Leu (A-R,A-L, 1mMeach).
Lane 10, GST-Rad6. Lane 11, GST-Cup9.
Lane 12, same as lane 11 but with both
Arg-Ala and Leu-Ala (R-A and L-A, 1 mM
each). (C) Equal amounts of extracts (0.2
mg) from S. cerevisiae that expressed the
N-terminally ha-tagged Ufd4 (haUfd4)
were incubated with GST alone or specific
GST fusions ("5!g), andwereprocessedas
described in B, except that IB that haUfd4
was detected by was performed with an-
ti-ha antibody. Lane 1, 1% of the initial
(total) input of haUfd4. Lane 2, GST-Mgt1.
Lane 3, same as lane 2 but with Arg-Ala
(R-A,1mM).Lane4, sameas lane2butwith
Ala-Arg (A-R, 1mM). Lane5, sameas lane 2
butwith Leu-Ala (L-A, 1mM). Lane 6, same
as lane2butwithAla-Leu(A-L,1mM).Lane
7, sameas lane2butwithbothArg-Alaand
Leu-Ala (R-A and L-A 1 mM each). Lane 8,
same as lane 2 but with both Ala-Arg and
Ala-Leu (A-R and A-L, 1 mM each). Lane 9,
GSTalone. (D)Mgt1 interactswithUfd4.Extracts (1mg) fromS. cerevisiae cells coexpressinghaUfd4 (fromthepRS313CUP1haUFD4plasmid;TableS2)andeitheravector
aloneorMgt1f3 (fromtheplasmidpCH437)wereprecipitatedwithanti-flagantibody,usingproteinGlinkedtomagneticbeads. Immunoprecipitateswerefractionated
by SDS/4–12% NuPAGE, followed by IB with anti-ha and anti-flag antibodies. Lane 1, input sample (0.25% of extract used in immunoprecipitation assays) from cells
expressing haUfd4 and the (‘‘empty’’) vector p416MET25. Lane 2, same as lane 1 but from cells coexpressing haUfd4 andMgt1f3. Lane 3, haUfd4, immunoprecipitation
withanti-flagantibody in theabsenceof coexpressedMgt13f. Lane4, sameas lane3but haUfd4was coexpressedwithMgt1f3. Thebanddetected in lane3withanti-flag
antibody and marked by an arrow and asterisk, just below the position of Mgt1f3 (see lane 4), is the light chain of anti-flag antibody that was used for
immunoprecipitation aswell (see above). Because of light-chain’s abundance at that position on the IBmembrane, this otherwiseweak cross-reactionwas detectable
at the level of IB exposure shown (compare the level of the cross-reacting bandwith the levels of immunoprecipitatedMgt1 in lane 4). (E) Cup9-regulated circuits do
not influence theUbr1-mediateddegradationofMgt1.AVY16 (WT), AVY4 (ubr1!), AVY50 (cup9!), orAVY51 (ubr1! cup9!) S. cerevisiae (Table S2) expressingMgt1f3
from the PMGT1 promoter on a low copy plasmidwere grown toA600 of"0.8 in SC(-Ura)mediumat 30 °C, then incubated further at 37 °C for 1 h, followedby a 30-min
‘‘chase’’ with cycloheximide (at 50 !g/ml), fractionation of cell extracts by SDS/4–12% NuPAGE and IB with anti-flag and anti-tubulin antibodies. Note that Mgt1f3
remained short-lived in cup9! cells (lanes 5, 6). (F) JD52 (WT), JD55 (ubr1!), CHY194 (ufd4!), or CHY195 (ubr1! ufd4!) S. cerevisiae (Table S1) were grown to A600 of
"0.6, and treatedwithMNNG (170!M) for 1.5 h at 30 °C. The resulting cultures were serially diluted 5-fold, spotted on YPD plates, and incubated for 2 days at 30 °C.
Seealsothemain-textFig.3H. (G)Adouble-mutantubr1!ufd4! strainofS. cerevisiae ishypersensitive tooverexpressionofMgt1. JD52(WT)andCHY195(ubr1!ufd4!)
cells carrying a vector alone (pRS426MET25), or expressing eitherMgt1f3 (pCH440), orMgt1C151S,f3 (pCH441), orMgt1C151M,f3 (pCH442)were grown in SDmedium (with
essential amino acids) to A600 of"0.8, serially diluted, and spotted on SDmedium for 2 days at 30 °C. (H) Same as in C but single-colony growth assays with JD52 (WT)
and CHY195 (ubr1! ufd4!) cells carrying either a vector alone or expressing Mgt1f3 from the PMET25 promoter on a high copy plasmid.
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length	  Mgt11–188,f3	  in	  WT	  and	  ubr1Δ	  cells,	  respectively.	  Lanes	  3	  and	  4,	  same	  as	  lanes	  1	  and	  2,	  respectively,	  but	  with	  Mgt11–144,f3.	  Lanes	  5	  and	  6,	  same	  but	  with	  Mgt11–100,f3.	  Lanes	  7	  and	  8,	  same	  but	  with	  Mgt184–188,f3.	  (B)	  Equal	  amounts	  of	  extracts	  (50	  μg)	  from	  S.	  cerevisiae	  that	  expressed	  the	  N-­‐terminally	  flag-­‐tagged	  Ubr1	  (fUbr1)	  were	  incubated	  in	  either	  the	  presence	  or	  absence	  of	  specific	  dipeptides	  (each	  of	  them	  at	  1	  mM)	  with	  GST	  alone	  or	  specific	  GST	  fusions	  (~5	  μg)	  that	  were	  linked	  to	  glutathione-­‐Sepharose	  beads.	  Bound	  proteins	  were	  eluted	  from	  the	  beads	  and	  fractionated	  by	  SDS/4–12%	  NuPAGE,	  followed	  by	  IB	  with	  anti-­‐flag	  antibody.	  Lane	  1,	  2.5%	  of	  the	  initial	  (total)	  input	  of	  fUbr1.	  Lane	  2,	  GST	  alone.	  Lane	  3,	  GST-­‐Mgt1.	  Lane	  4,	  same	  as	  lane	  3	  but	  with	  Arg-­‐Ala	  (R-­‐A,	  1	  mM).	  Lane	  5,	  same	  as	  lane	  4	  but	  with	  Ala-­‐Arg	  (A-­‐R,	  1	  mM).	  Lane	  6,	  same	  as	  lane	  3	  but	  with	  Leu-­‐Ala	  (L-­‐A,	  1	  mM).	  Lane	  7,	  same	  as	  lane	  3	  but	  with	  Ala-­‐Leu	  (A-­‐L,	  1	  mM).	  Lane	  8,	  same	  as	  lane	  3	  but	  with	  both	  Arg-­‐Ala	  and	  Leu-­‐Ala	  (R-­‐A	  and	  L-­‐A,	  1	  mM	  each).	  Lane	  9,	  same	  as	  lane	  3	  but	  with	  both	  Ala-­‐Arg	  and	  Ala-­‐Leu	  (A-­‐R,	  A-­‐L,	  1	  mM	  each).	  Lane	  10,	  GST-­‐Rad6.	  Lane	  11,	  GST-­‐Cup9.	  Lane	  12,	  same	  as	  lane	  11	  but	  with	  both	  Arg-­‐Ala	  and	  Leu-­‐Ala	  (R-­‐A	  and	  L-­‐A,	  1	  mM	  each).	  (C)	  Equal	  amounts	  of	  extracts	  (0.2	  mg)	  from	  S.	  cerevisiae	  that	  expressed	  the	  N-­‐terminally	  ha-­‐tagged	  Ufd4	  (haUfd4)	  were	  incubated	  with	  GST	  alone	  or	  specific	  GST	  fusions	  (~5	  μg),	  and	  were	  processed	  as	  described	  in	  B,	  except	  that	  IB	  that	  haUfd4	  was	  detected	  by	  was	  performed	  with	  anti-­‐ha	  antibody.	  Lane	  1,	  1%	  of	  the	  initial	  (total)	  input	  of	  
haUfd4.	  Lane	  2,	  GST-­‐Mgt1.	  Lane	  3,	  same	  as	  lane	  2	  but	  with	  Arg-­‐Ala	  (R-­‐A,	  1	  mM).	  Lane	  4,	  same	  as	  lane	  2	  but	  with	  Ala-­‐Arg	  (A-­‐R,	  1	  mM).	  Lane	  5,	  same	  as	  lane	  2	  but	  with	  Leu-­‐Ala	  (L-­‐A,	  1	  mM).	  Lane	  6,	  same	  as	  lane	  2	  but	  with	  Ala-­‐Leu	  (A-­‐L,	  1	  mM).	  Lane	  7,	  same	  as	  lane	  2	  but	  with	  both	  Arg-­‐Ala	  and	  Leu-­‐Ala	  (R-­‐A	  and	  L-­‐A	  1	  mM	  each).	  Lane	  8,	  same	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as	  lane	  2	  but	  with	  both	  Ala-­‐Arg	  and	  Ala-­‐Leu	  (A-­‐R	  and	  A-­‐L,	  1	  mM	  each).	  Lane	  9,	  GST	  alone.	  (D)	  Mgt1	  interacts	  with	  Ufd4.	  Extracts	  (1	  mg)	  from	  S.	  cerevisiae	  cells	  coexpressing	  haUfd4	  (from	  the	  pRS313CUP1haUFD4	  plasmid;	  Table	  S2)	  and	  either	  a	  vector	  alone	  or	  Mgt1f3	  (from	  the	  plasmid	  pCH437)	  were	  precipitated	  with	  anti-­‐flag	  antibody,	  using	  protein	  G	  linked	  to	  magnetic	  beads.	  Immunoprecipitates	  were	  fractionated	  by	  SDS/4	  –12%	  NuPAGE,	  followed	  by	  IB	  with	  anti-­‐ha	  and	  anti-­‐flag	  antibodies.	  Lane	  1,	  input	  sample	  (0.25%	  of	  extract	  used	  in	  immunoprecipitation	  assays)	  from	  cells	  expressing	  haUfd4	  and	  the	  (‘‘empty’’)	  vector	  p416MET25.	  Lane	  2,	  same	  as	  lane	  1	  but	  from	  cells	  coexpressing	  haUfd4	  and	  Mgt1f3.	  Lane	  3,	  haUfd4,	  immunoprecipitation	  with	  anti-­‐flag	  antibody	  in	  the	  absence	  of	  coexpressed	  Mgt13f.	  Lane	  4,	  same	  as	  lane	  3	  but	  haUfd4	  was	  coexpressed	  with	  Mgt1f3.	  The	  band	  detected	  in	  lane	  3	  with	  anti-­‐flag	  antibody	  and	  marked	  by	  an	  arrow	  and	  asterisk,	  just	  below	  the	  position	  of	  Mgt1f3	  (see	  lane	  4),	  is	  the	  light	  chain	  of	  anti-­‐flag	  antibody	  that	  was	  used	  for	  immunoprecipitation	  as	  well	  (see	  above).	  Because	  of	  light-­‐chain’s	  abundance	  at	  that	  position	  on	  the	  IB	  membrane,	  this	  otherwise	  weak	  cross-­‐reaction	  was	  detectable	  at	  the	  level	  of	  IB	  exposure	  shown	  (compare	  the	  level	  of	  the	  cross-­‐reacting	  band	  with	  the	  levels	  of	  immunoprecipitated	  Mgt1	  in	  lane	  4).	  (E)	  Cup9-­‐regulated	  circuits	  do	  not	  influence	  the	  Ubr1-­‐mediated	  degradation	  of	  Mgt1.	  AVY16	  (WT),	  AVY4	  (ubr1Δ),	  AVY50	  (cup9Δ),	  or	  AVY51	  (ubr1Δcup9Δ)	  S.	  cerevisiae	  (Table	  S2)	  expressing	  Mgt1f3	  from	  the	  PMGT1	  promoter	  on	  a	  low	  copy	  plasmid	  were	  grown	  to	  A600	  of	  ~0.8	  in	  SC(-­‐Ura)	  medium	  at	  30	  °C,	  then	  incubated	  further	  at	  37	  °C	  for	  1	  h,	  followed	  by	  a	  30-­‐min	  ‘‘chase’’	  with	  cycloheximide	  (at	  50	  μg/ml),	  fractionation	  of	  cell	  extracts	  by	  SDS/4	  –12%	  NuPAGE	  and	  IB	  with	  anti-­‐flag	  and	  anti-­‐tubulin	  antibodies.	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Supplementary Table S1. S. cerevisiae strains used in this study. 
 
Strains Relevant genotypes Sources 
SC295 MATa  ura3-52 leu2-3,112 regl-501 gall pep4-3 ref. (79) 
JD52 MATa trp1- 63 ura3-52 his3- 200 leu2-3112. lys2-801 ref. (80) 
JD53 MATa trp1- 63 ura3-52 his3- 200 leu2-3112. lys2-801 ref. (81) 
JD55 ubr1D::HIS3 in JD52 ref. (80) 
JD83-1A ubr1D::HIS3 in JD53 ref. (80) 
AVY105 ubr2D::HIS3 in JD52 Lab collection 
CHY49 pdr5D::KanMX6 in JD52 This study 
CHY134 ubr1D::LEU2 ubr2D::HIS3 in JD52 This study 
CHY194 ufd4D::KanMX6 in JD52 This study 
CHY195 ubr1D::HIS3 ufd4D::KanMX6 in JD52 This study 
CHY223 doa10D::KanMX6 in JD53 This study 
CHY229 doa10D:KanMX6 ubr1D::HIS3 in JD53 This study 
CHY248 DOA10-13MYC:::KanMX6 in JD52 This study 
CHY287 ubc4D::LEU2 in BY4742 This study  
CHY288 ubc4D::LEU2 doa10D::KanMX6 in BY4742 This study 
BY4742 MATa his3-1 leu2-0 lys2-0 ura3-0 can1-100, Open Biosystems 
BY10976 ard1D::KanMX6 in BY4742 Open Biosystems 
BY12509 nat5D::KanMX6 in BY4742 Open Biosystems 
BY15470 mak3D::KanMX6 in BY4742 Open Biosystems 
BY15546 nat3D::KanMX6 in BY4742 Open Biosystems 
BY16202 nat4D::KanMX6 in BY4742 Open Biosystems 
BY17299 doa10D:KanMX6 in BY4742 Open Biosystems 
BY4741 MATa his3-1 leu2-0 met15-0 ura3-0 Open Biosystems 
BY4425 rad6D:: KanMX4 in BY4741 Open Biosystems 
BY3771 bre1D:: KanMX4 in BY4741 Open Biosystems 
BY5787 rad18D:: KanMX4 in BY4741 Open Biosystems 
BY4425 ufd2D:: KanMX4 in BY4741 Open Biosystems 
BY3216 ufd4D:: KanMX4 in BY4741 Open Biosystems 
BY3994 hul4D::KanMX4 in BY4741 Open Biosystems 
BY597 hul5D::KanMX4 in BY4741 Open Biosystems 
BY4763 hrd1D:: KanMX4 in BY4741 Open Biosystems 
BY4156 hrd3D:: KanMX4 in BY4741 Open Biosystems 
BY4883 tul1D:: KanMX4 in BY4741 Open Biosystems 
BY7299 doa10D::KanMX4 in BY4741 Open Biosystems 
BY4814 ubr1D:: KanMX4 in BY4741 Open Biosystems 
BY1579 ubr2D:: KanMX4 in BY4741 Open Biosystems 
BY3771 bre1D:: KanMX4 in BY4741 Open Biosystems 
BY5787 rad18D:: KanMX4 in BY4741 Open Biosystems 
FW1808 MAT  his4-912 R5 lys2-128  ura3-52 rps5-1 ref. (82) 
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Supplementary Table S2. Plasmids used in this study. 
 
Plasmids Descriptions Sources 
pBAM Ub-MH-eK-ha-Ura3 in p314CUP1 ref. (41) 
pMET416FUPR
CUP9NSF 
fDHFR-UbK48R-Cup9NSF in p416MET25 ref. (83) 
pEJJ1-M His6Ub-Met-eK-DHFRha from the T7 promoter  ref. (41) 
pCH178 UbK48R-CK-eK-ha-Ura3 in p314CUP1 This study 
pCH181 Ub-CZ-eK-ha-Ura3 in p314CUP1 This study 
pCH183 UbK48R-MK-eK-ha-Ura3 in p314CUP1 This study 
pCH194 Ub-CP-eK-ha-Ura3 in p314CUP1 This study 
pCH195 UbQ49R-CL-eK-ha-Ura3 in p314CUP1 This study 
pCH198 Ub-CV-eK-ha-Ura3 in p314CUP1 This study 
pCH499 UbK48R-CE-eK-ha-Ura3 in p314CUP1 This study 
pCH500 UbK48R-CG-eK-ha-Ura3 in p314CUP1 This study 
pCH501 UbK48R-CI-eK-ha-Ura3 in p314CUP1 This study 
pCH502 UbK48R-CL-eK-ha-Ura3 in p314CUP1 This study 
pCH503 UbK48R-CW-eK-ha-Ura3 in p314CUP1 This study 
pCH504 UbK48R-ML-eK-ha-Ura3 in p314CUP1 This study 
pCH505 UbK48R-SL-eK-ha-Ura3 in p314CUP1 This study 
pCH506 UbK48R-TL-eK-ha-Ura3 in p314CUP1 This study 
pCH507 UbQ49R-CL-eK-ha-Ura3 in p313CUP1 This study 
pCH508 UbK48R-SL-eK-ha-Ura3 in p313CUP1 This study 
pCH509 UbK48R-TL-eK-ha-Ura3 in p313CUP1 This study 
pCH535 UbK48R-MN-Mata3-67eK-ha-Ura3 in p314CUP1 This study 
pCH547 UbK48R-MK-Mata3-67eK-ha-Ura3 in p314CUP1 This study 
pCH548 UbK48R-ML-Mata3-67eK-ha-Ura3 in p314CUP1 This study 
pCH549 UbK48R-MQ-Mata3-67eK-ha-Ura3 in p314CUP1 This study 
pCH550 UbK48R-MD-Mata3-67eK-ha-Ura3 in p314CUP1 This study 
pCH551 UbK48R-MA-Mata3-67eK-ha-Ura3 in p314CUP1 This study 
pCH552 UbK48R-MP-Mata3-67eK-ha-Ura3 in pS314CUP1 This study 
pCH553 UbK48R-RN-Mata3-67eK-ha-Ura3 in p314CUP1 This study 
pCH554 UbK48R-LN-Mata3-67eK-ha-Ura3 in p314CUP1 This study 
pCH555 UbK48R-NN-Mata3-67eK-ha-Ura3 in p314CUP1 This study 
pCH556 UbK48R-DN-Mata3-67eK-ha-Ura3 in p314CUP1 This study 
pCH581 Ddoa10 in p425GAL1 This study 
pCH595 DOA10f in p425GAL1 This study 
pCH604 UbK48R-MK-eK-ha-Ura3-CL1 in p314CUP1 This study 
pCH605 UbK48R-GK-eK-ha-Ura3-CL1 in p314CUP1 This study 
pH10UE His10-Ub in pET15b ref. (23) 
pCH622 MN-Mata3-67eK-ha-Ura3 in pH10UE This study 
pCH623 GN-Mata3-67eK-ha-Ura3 in pH10UE This study 
pCH624 MK-Mata3-67eK-ha-Ura3 in pH10UE This study 
pCH625 RN-Mata3-67eK-ha-Ura3 in pH10UE This study 
pCH626 UbK48R-NN-Mata3-67eK-ha-Ura3 in p314CUP1 This study 
pCH641 UbK48R-MN-Mata3-67eK-ha-Ura3 in p413CUP1 This study 








pCH642 UbK48R-GN-Mata3-67eK-ha-Ura3 in p413CUP1 This study 
pCH643 UbK48R-MK-Mata3-67eK-ha-Ura3 in p413CUP1 This study 
pCH644 UbK48R-RN-Mata3-67eK-ha-Ura3 in p413CUP1 This study 
pCH645 MN-Mata3-67-eK-DHFRha in pH10UE This study 
pCH646 GN-Mata3-67-eK-DHFRha in pH10UE This study 
pCH647 MK-Mata3-67-eK-DHFRha in pH10UE This study 
pCH648 RN-Mata3-67-eK-DHFRha in pH10UE This study 
pCH666 UbK48R-MK-Pca3-392-eK-ha-Ura3 in p413CUP1 This study 
pCH667 UbK48R-GK-Pca3-392-eK-ha-Ura3 in p413CUP1 This study 
pCH668 UbK48R-MK-eK-ha-Ura3 in p313CUP1 This study 
pCH669 UbK48R-ML-eK-ha-Ura3 in p313CUP1 This study 
pCH685 UbK48R-GL-eK-ha-Ura3 in p313CUP1 This study 
pCH686 UbK48R-AL-eK-ha-Ura3 in p313CUP1 This study 
pCH687 UbK48R-VL-eK-ha-Ura3 in p313CUP1 This study 
pCH688 UbK48R-MPL-eK-ha-Ura3 in p313CUP1 This study 
pCH689 UbK48R-CL-eK-ha-Ura3 in p313CUP1 This study 
pCH704 Mata2flag in p416MET25 This study 
pCH705 MK-Mata23-210f in p416MET25 This study 
pCH706 MG- Mata23-210f in p416MET25 This study 
pCH707 Mata2f in p426GAL1 This study 
pCH719 fDHFR-UbK48R-MN-Mata2f in p416MET25 This study 
pCH720 fDHFR-UbK48R-MK-Mata2f in p416MET25 This study 
pCH721 fDHFR-UbK48R-GN-Mata2f in p416MET25 This study 
pCH731 UbK48R-MD-eK-ha-Ura3 in p313CUP1 This study 
pCH732 UbK48R-ME-eK-ha-Ura3 in p313CUP1 This study 
pCH733 UbK48R-MQ-eK-ha-Ura3 in p313CUP1 This study 
pCH734 UbK48R-MN-eK-ha-Ura3 in p313CUP1 This study 
pCH735 UbK48R-MF-eK-ha-Ura3 in p313CUP1 This study 
pCH736 UbK48R-MY-eK-ha-Ura3 in p313CUP1 This study 
pCH737 UbK48R-MW-eK-ha-Ura3 in p313CUP1 This study 
pCH738 UbK48R-MI-eK-ha-Ura3 in p313CUP1 This study 
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  Figure	  A2.2.	  Quantitation	  of	  cycloheximide-­‐chase	  assays.	  Cycloheximide	  (CHX)-­‐chase	  assays	  (Fig.	  1,	  Fig.	  3,	  fig.	  S3,	  fig.	  S4D-­‐G,	  and	  fig.	  S7)	  were	  carried	  out	  as	  described	  in	  Materials	  and	  Methods.	  Quantitations	  of	  the	  resulting	  immunoblots	  was	  performed	  using	  the	  ImageJ	  software	  (http://rsb.info.nih.gov/ij/index.html).	  For	  each	  time	  point,	  ImageJ	  was	  employed	  to	  determine	  the	  ratio	  of	  a	  test	  protein’s	  band	  intensity	  to	  that	  of	  tubulin	  loading	  control	  in	  the	  same	  lane.	  The	  resulting	  value	  at	  time	  zero	  was	  taken	  as	  100%.	  (A)	  ML-­‐Ura3	  and	  MK-­‐Ura3	  in	  wild-­‐type	  S.	  cerevisiae	  (see	  Fig.	  1C	  for	  corresponding	  immunoblots).	  (B)	  CL-­‐Ura3	  in	  wild-­‐type	  and	  doa10Δ	  S.	  cerevisiae	  (see	  Fig.	  1E	  for	  corresponding	  immunoblots).	  (C)	  His3	  (TE-­‐His3,	  with	  the	  wild-­‐type	  Thr-­‐Glu	  N-­‐terminal	  sequence)	  in	  wild-­‐type	  and	  doa10Δ	  S.	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  Figure	  A2.3.	  Cycloheximide-­‐chase	  assays	  with	  Ura3-­‐based	  reporters.	  (A)	  Cycloheximide	  (CHX)-­‐chases,	  for	  0	  and	  2	  hr,	  with	  CZ-­‐eK-­‐Ura3	  (CZ-­‐Ura3)	  (Z=Glu,	  Gly,	  Ile,	  Leu,	  Pro),	  in	  wild-­‐type	  versus	  ubr1Δ	  S.	  cerevisiae.	  CZ-­‐Ura3	  proteins	  were	  produced	  using	  the	  Ub	  fusion	  technique	  as	  described	  in	  fig.	  S1D	  and	  Methods.	  Cell	  extracts	  were	  fractionated	  by	  SDS-­‐PAGE,	  followed	  by	  immunoblotting	  with	  anti-­‐ha	  antibody,	  and	  also	  with	  antibody	  to	  tubulin	  (loading	  controls).	  (B)	  As	  in	  A	  but	  CHX-­‐chases	  for	  0,	  1	  and	  2	  hr	  with	  MZ-­‐Ura3	  (Z=Ile,	  Arg,	  Gln)	  in	  wild-­‐type	  S.	  cerevisiae.	  (C)	  As	  in	  B,	  with	  other	  MZ-­‐Ura3	  reporters	  (Z=Asp,	  Glu,	  Arg,	  Ile).	  (D)	  As	  in	  A,	  but	  with	  CV-­‐Ura3.	  (E)	  As	  in	  C,	  but	  with	  PL-­‐Ura3.	  (F)	  As	  in	  A,	  with	  CL-­‐Ura3	  (lanes	  1-­‐10)	  or	  SL-­‐
Fig. S3, revised (Hwang et al.)
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Ura3	  (lanes	  11-­‐20),	  in	  wild-­‐type	  versus	  ubr2Δ,	  ufd4,	  and	  double-­‐mutant	  ubr2Δ	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  Figure	  A2.4.	  35S-­‐pulse-­‐chase	  assays	  with	  XZ-­‐Ura3	  reporters	  and	  identification	  of	  Doa10	  as	  the	  cognate	  Ub	  ligase.	  (A)35S-­‐pulse-­‐chase	  assay	  with	  XZ-­‐Ura3	  (X=Cys,	  Met;	  Z=Leu,	  Lys).	  Wild-­‐type	  S.	  cerevisiae	  expressing	  XZ-­‐Ura3	  test	  proteins	  (produced	  using	  the	  Ub	  fusion	  technique	  as	  described	  in	  fig.	  S1D)	  were	  labeled	  for	  5	  min	  with	  [35S]methionine/cysteine,	  followed	  by	  a	  chase	  for	  20	  and	  60	  min	  (see	  Methods).	  Lane	  1-­‐3,	  CL-­‐Ura3.	  Lanes	  4-­‐6,	  CK-­‐Ura3.	  Lanes	  7-­‐9,	  ML-­‐Ura3.	  Lanes	  10-­‐12,	  MK-­‐Ura3.	  (B)	  Quantitation	  of	  data	  in	  A,	  using	  PhosphorImager,	  for	  CL-­‐Ura3	  and	  CK-­‐Ura3.	  (C)	  As	  in	  B,	  for	  ML-­‐Ura3	  and	  MK-­‐Ura3.	  (D)	  CHX-­‐chases	  for	  0	  and	  2	  hr	  with	  S.	  cerevisiae	  
Fig. S4, revised (Hwang et al.)
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null	  mutants	  in	  the	  indicated	  E2	  or	  E3	  enzymes	  that	  expressed	  CL-­‐Ura3.	  Note	  the	  virtually	  complete	  stabilization	  of	  CL-­‐Ura3	  in	  doa10Δ	  cells,	  but	  not	  in	  other	  tested	  mutants	  or	  wild-­‐type	  cells.	  (E)	  CHX-­‐chase	  for	  0,	  0.5,	  1	  and	  2	  hr	  with	  CL-­‐Ura3	  in	  wild-­‐type	  (lanes	  1-­‐4)	  versus	  doa10Δ	  cells	  (lanes	  5-­‐8).	  (F)	  As	  in	  E	  but	  with	  SL-­‐Ura3.	  (G)	  As	  in	  E	  but	  CHX-­‐chase	  for	  0,	  0.5	  and	  1	  hr	  with	  VL-­‐Ura3	  in	  wild-­‐type	  (lanes	  1-­‐3)	  and	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Figure	  A2.5.	  The	  MATα2	  repressor	  and	  the	  ML-­‐Ura3	  reporter	  are	  Nt-­‐acetylated	  in	  vivo.	  (A)	  Full-­‐length,	  C-­‐terminally	  flag-­‐tagged	  MATα2f	  was	  produced	  in	  doa10Δ	  
ubc4Δ	  S.	  cerevisiae,	  purified,	  and	  subjected	  to	  SDS-­‐PAGE.	  The	  band	  of	  MATα2f	  was	  excised,	  followed	  by	  in-­‐gel	  digestion	  with	  the	  Asp-­‐N	  protease	  and	  analysis	  by	  LC-­‐MS/MS	  (see	  Methods).	  Shown	  here,	  using	  standard	  MS	  notations,	  are	  both	  the	  Nt-­‐acetylated	  peptide	  of	  MATα2f	  (a	  doubly-­‐charged	  peptide	  ion,	  at	  443	  m/z;	  molecular	  mass	  886	  Da;	  see	  the	  diagram)	  and	  the	  MS/MS-­‐derived	  fragment	  ion	  spectrum	  of	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  Figure	  A2.6.	  The	  AcN-­‐degron	  of	  the	  MATα2	  repressor.	  (A)	  Upper	  panel:	  lane	  1,	  Ub-­‐MN-­‐α23-­‐67-­‐eK-­‐DHFRha	  was	  expressed	  in	  E.	  coli,	  purified,	  and	  deubiquitylated	  using	  a	  purified	  deubiquitylating	  enzyme.	  The	  resulting	  MN-­‐α23-­‐67-­‐eK-­‐DHFRha	  derived	  from	  the	  N-­‐terminal	  Deg1	  region	  of	  MATα2	  (see	  the	  main	  text),	  was	  bound	  to	  agarose	  beads	  containing	  anti-­‐ha	  antibody.	  Immobilized	  MN-­‐α23-­‐67-­‐eK-­‐DHFRha	  was	  incubated	  with	  buffer	  alone	  (negative	  control)	  in	  the	  presence	  of	  14C-­‐labeled	  acetyl-­‐CoA,	  followed	  by	  treatment	  of	  the	  beads	  with	  elution	  buffer,	  SDS-­‐PAGE	  and	  autoradiography.	  Lane	  2,	  same	  as	  lane	  1	  but	  incubation	  with	  extract	  from	  wild-­‐type	  
S.	  cerevisiae.	  Lanes	  3-­‐5,	  same	  as	  lane	  2	  but	  with	  MK-­‐α23-­‐67-­‐eK-­‐DHFRha,	  GN-­‐α23-­‐67-­‐eK-­‐DHFRha	  and	  RN-­‐α23-­‐67-­‐eK-­‐DHFRha,	  respectively.	  Note	  the	  absence	  of	  Nt-­‐acetylation	  of	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these	  reporters,	  in	  contrast	  to	  MN-­‐α23-­‐67-­‐eK-­‐DHFRha	  (lane	  2).	  Lane	  6,	  same	  as	  lane	  2	  but	  with	  extract	  from	  nat3Δ	  cells,	  which	  lacked	  the	  cognate	  NatB	  Nt-­‐acetylase.	  The	  lower	  panel	  shows	  a	  Coomassie-­‐stained	  gel	  that	  yielded	  autoradiographic	  data	  in	  the	  upper	  panel.	  The	  bands	  of	  XZ-­‐α23-­‐67-­‐eK-­‐DHFRha	  (XZ-­‐DHFR)	  reporters	  are	  indicated.	  Single	  and	  double	  asterisks	  denote	  an	  admixture	  of	  the	  light	  and	  heavy	  IgG	  chains,	  respectively,	  that	  partially	  leaked	  from	  agarose	  beads	  during	  the	  elution	  of	  reporters.	  (B)	  35S-­‐pulse-­‐chase	  assay	  with	  full-­‐length,	  C-­‐terminally	  flag-­‐tagged	  MATα2f.	  Lane	  1,	  vector	  alone.	  Lanes	  2-­‐4,	  ubc4Δ	  S.	  cerevisiae	  expressing	  wild-­‐type	  
MNMATα2f	  	  were	  labeled	  for	  5	  min	  at	  30°C	  with	  [35S]methionine/cysteine,	  followed	  by	  a	  chase	  for	  10	  and	  30	  min.	  Cell	  extracts	  were	  precipitated	  with	  anti-­‐flag	  antibody,	  followed	  by	  SDS-­‐PAGE	  and	  autoradiography.	  Lanes	  5-­‐7,	  same	  as	  lanes	  2-­‐4	  but	  with	  
MKMATα2f,	  containing	  Lys	  (instead	  of	  Asn)	  at	  position	  2.	  Lanes	  8-­‐10,	  same	  as	  lanes	  2-­‐4	  but	  in	  ubc4Δ	  doa10Δ	  cells.	  Lanes	  11-­‐13,	  same	  as	  lanes	  1-­‐4	  but	  with	  GNMATα2f	  (expressed	  as	  MGNMATα2f),	  containing	  N-­‐terminal	  Gly.	  (C)	  Quantitation	  of	  the	  data	  in	  B,	  using	  PhosphorImager.	  Solid	  and	  open	  circles,	  upright	  and	  inverted	  triangles:	  
MNMATα2f,	  MKMATα2f,	  GNMATα2f	  in	  ubc4Δ	  cells,	  and	  MKMATα2f	  in	  ubc4Δ	  doa10Δ	  cells,	  respectively	  (this	  is	  the	  same	  panel	  as	  Fig.	  2F).	  (D)	  35S-­‐pulse-­‐chase	  assay	  with	  full-­‐	  length,	  C-­‐terminally	  flag-­‐tagged	  MATα2f	  that	  differed	  from	  the	  assay	  in	  B,	  C	  by	  the	  utilization	  of	  a	  “built-­‐in”	  reference	  protein.	  Specifically,	  wild-­‐type	  MATα2f	  was	  expressed	  as	  a	  Ub	  fusion,	  fDHFR-­‐	  UbK48R-­‐MATα2f.	  The	  cotranslational	  cleavage	  of	  this	  fusion	  at	  the	  UbK48R-­‐MATα2f	  junction	  produced	  the	  long-­‐lived	  fDHFR-­‐UbK48R	  reference	  protein	  and	  the	  MATα2f	  test	  protein.	  For	  the	  Ub-­‐reference	  technique,	  see	  Methods	  and	  refs.	  (75-­‐78).	  The	  bands	  of	  MATα2f	  and	  fDHFR-­‐UbK48R	  (the	  reference	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protein)	  are	  indicated	  on	  the	  left.	  Lanes	  1-­‐3,	  wild-­‐type	  cells.	  Lanes	  4-­‐6,	  doa10Δ	  cells.	  Lanes	  7-­‐9,	  nat3Δ	  cells	  (lacking	  the	  cognate	  NatB	  Nt-­‐acetylase).	  (E)	  Quantitation	  of	  data	  in	  D,	  using	  PhosphorImager.	  Solid	  circles,	  solid	  squares,	  and	  open	  circles,	  MATα2f	  in	  wild-­‐type	  cells,	  in	  doa10Δ	  cells,	  and	  in	  nat3Δ	  cells,	  respectively.	  In	  the	  Ub-­‐reference	  technique	  (75-­‐78),	  the	  presence	  of	  a	  “built-­‐in”	  reference	  protein	  (fDHFR-­‐UbK48R)	  makes	  it	  possible	  to	  detect	  and	  measure	  the	  initial	  degradation	  of	  pulse-­‐labeled	  MATα2f	  (i.e.,	  its	  decay	  during	  the	  pulse).	  The	  degradation	  of	  MATα2f	  involved	  the	  targeting	  of	  AcN-­‐degron,	  as	  a	  significant	  part	  of	  this	  degradation	  was	  found	  to	  require	  the	  presence	  of	  the	  Doa10	  Ub	  ligase,	  and	  of	  the	  Nat3-­‐containing	  NatB	  Nt-­‐acetylase	  as	  well.	  Specifically,	  the	  level	  of	  MATα2f	  at	  0	  min	  (the	  end	  of	  pulse)	  in	  wild-­‐type	  cells	  was	  55%	  of	  the	  0-­‐min	  level	  of	  MATα2f	  in	  doa10Δ	  cells	  (the	  latter	  level	  was	  taken	  as	  100%).	  The	  0-­‐min	  level	  of	  MATα2f	  in	  nat3Δ	  cells	  was	  83%,	  
i.e.,	  MATα2f	  was	  significantly	  stabilized	  in	  nat3Δ	  cells	  as	  well,	  though	  not	  as	  strongly	  as	  in	  doa10Δ	  cells.	  The	  reason	  for	  a	  significant	  residual	  degradation	  of	  the	  full-­‐length	  MATα2f	  protein	  in	  doa10Δ	  cells	  is	  that	  MATα2f	  contains	  not	  only	  the	  Doa10-­‐dependent	  AcN-­‐degron	  but	  at	  least	  two	  other,	  Doa10-­‐independent	  degrons	  as	  well	  (see	  the	  main	  text).	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  Figure	  A2.7.	  AcN-­‐degrons	  in	  S.	  cerevisiae	  proteins.	  (A)	  Lanes	  1-­‐3,	  CHX-­‐chase,	  for	  0,	  1	  and	  2	  hr,	  in	  wild-­‐type	  cells	  expressing	  C-­‐terminally	  ha-­‐tagged	  Hsp104ha	  (N-­‐terminal	  Met-­‐Asn).	  Lanes	  4-­‐6,	  same	  as	  lanes	  1-­‐3	  but	  with	  MKHsp104ha,	  containing	  Lys	  (instead	  of	  Asn)	  at	  position	  2.	  Lanes	  7-­‐9,	  same	  as	  lanes	  1-­‐3	  but	  in	  doa10Δ	  cells.	  Lanes	  10-­‐12,	  same	  as	  lanes	  1-­‐3	  but	  in	  nat3Δ	  cells,	  lacking	  the	  cognate	  NatB	  Nt-­‐acetylase.	  (B)	  Lanes	  1-­‐3,	  CHX-­‐chase,	  for	  0,	  1	  and	  2	  hr,	  in	  wild-­‐type	  cells	  expressing	  C-­‐terminally	  ha-­‐tagged	  Pop2ha	  (N-­‐terminal	  Met-­‐Gln).	  Lanes	  4-­‐6,	  same	  as	  lanes	  1-­‐3	  but	  in	  doa10Δ	  cells.	  Note	  that	  Pop2ha	  remains	  short-­‐lived	  in	  the	  absence	  of	  Doa10.	  (C)	  CHX-­‐assays,	  for	  0,	  1	  and	  2	  hr,	  with	  Tbf1ha	  (N-­‐terminal	  Met-­‐Asp),	  a	  set	  of	  experiments	  independent	  from	  that	  in	  Fig.	  3A.	  Lanes	  1-­‐3,	  Tbf1ha	  in	  wild-­‐type	  cells.	  At	  this	  level	  of	  sensitivity,	  to	  avoid	  overexposures	  of	  other	  lanes,	  the	  band	  of	  short-­‐lived	  Tbf1ha	  is	  
Fig. S7, revised (Hwang et al.)
Fig. S2, Hwang et al.
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nearly	  undetectable	  even	  at	  time	  0.	  Lanes	  4-­‐6,	  same	  as	  lanes	  1-­‐3	  but	  with	  MKTbf1ha,	  containing	  Lys	  (instead	  of	  Asp)	  at	  position	  2.	  Lanes	  7-­‐9,	  same	  as	  lanes	  1-­‐3	  but	  with	  
GTbf1ha	  (MGTbf1ha),	  containing	  N-­‐terminal	  Gly.	  Lanes	  10-­‐12,	  same	  as	  lanes	  1-­‐3	  but	  in	  
doa10Δ	  cells.	  Lanes	  13-­‐15,	  same	  as	  lanes	  1-­‐3	  but	  in	  nat3Δ	  cells.	  (D)	  As	  in	  C,	  but	  CHX-­‐assay	  for	  0,	  0.5,	  1	  and	  2	  hr	  with	  Ubp6ha	  (N-­‐terminal	  Ser-­‐Gly)	  in	  wild-­‐type	  versus	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Figure	  A2.8.	  35S-­‐pulse-­‐chase	  of	  S.	  cerevisiae	  proteins	  fractionated	  by	  2-­‐D	  electrophoresis.	  (A)	  Wild-­‐type	  S.	  cerevisiae	  were	  pulse-­‐labeled	  for	  15	  min	  at	  30°C	  with	  35S-­‐methionine/cysteine,	  followed	  by	  extraction	  of	  proteins,	  2-­‐D	  electrophoresis	  and	  autoradiography	  (see	  Methods).	  (B)	  Same	  as	  in	  A	  but	  in	  a	  
doa10∆	  cells.	  As	  described	  in	  the	  main	  text,	  these	  and	  related	  35S-­‐pulse-­‐chase	  patterns	  (panels	  A,	  B,	  and	  data	  not	  shown)	  contained	  a	  number	  of	  protein	  spots	  with	  significantly	  higher	  relative	  levels	  of	  35S	  in	  samples	  from	  doa10∆	  versus	  wild-­‐type	  cells.	  Three	  of	  these	  spots	  (this	  survey	  continues	  to	  expand)	  were	  examined	  using	  standard	  MALDI-­‐MS	  fingerprinting	  techniques,	  thereby	  identifying	  His3,	  Aro8,	  and	  Ymr090w	  (see	  Methods	  and	  the	  main	  text)	  as	  putative	  substrates	  of	  the	  Doa10	  Ub	  ligase.	  The	  spots	  of	  His3,	  Aro8	  and	  Ymr090w	  are	  indicated	  by	  red	  arrows	  in	  B.	  Red	  circles	  in	  A	  demarcate	  the	  regions	  containing	  these	  35S-­‐labeled	  proteins	  in	  extract	  from	  wild-­‐type	  S.	  cerevisiae,	  at	  lower	  levels	  than	  in	  doa10∆	  cells	  (panel	  A	  and	  data	  not	  shown).	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  Figure	  A2.9.	  Cell	  growth	  assays	  with	  XZ-­‐α23-­‐67-­‐eK-­‐Ura3	  in	  wild-­‐type	  and	  mutant	  yeast.	  In	  vivo	  levels	  of	  Ura3	  determine	  S.	  cerevisiae	  growth	  rates	  in	  the	  absence	  of	  uracil	  in	  the	  medium,	  making	  it	  possible	  to	  compare	  the	  rates	  of	  degradation	  of	  Ura3	  fusions	  through	  the	  use	  of	  growth	  assays	  (25).	  We	  carried	  out	  such	  assays,	  shown	  here,	  in	  wild-­‐type,	  doa10∆	  and	  ubr1∆,	  and	  also	  in	  cells	  lacking	  specific	  subunits	  of	  Nt-­‐acetylases.	  The	  reporters	  were	  Deg1-­‐bearing	  XZ-­‐α23-­‐67-­‐eK-­‐Ura3	  fusions	  (X=Met,	  Gly,	  Leu,	  Asn,	  Asp,	  Arg;	  Z=Asn,	  Lys,	  Leu,	  Gln),	  with	  cell	  growth	  rates	  compared	  by	  serial	  dilutions	  on	  uracil-­‐containing	  (SC(-­‐Trp)	  versus	  uracil-­‐lacking	  (SC(-­‐Trp,	  -­‐Ura))	  plates.	  The	  results	  of	  these	  assays	  (panels	  A-­‐D)	  were	  entirely	  consistent	  with	  other	  findings,	  including	  the	  necessity	  of	  Nt-­‐acetylation	  of	  N-­‐terminal	  Met	  for	  the	  recognition	  of	  MZ-­‐α23-­‐67-­‐eK-­‐Ura3	  by	  Doa10.	  (A)	  XN-­‐α23-­‐67-­‐eK-­‐Ura3	  (X=	  Gly,	  Met,	  Leu,	  Asn,	  Asp,	  Arg)	  in	  wild-­‐type	  (wt)	  cells.	  (B)	  XN-­‐α23-­‐67-­‐eK-­‐Ura3	  (X=	  Gly,	  Met)	  and	  XN-­‐α23-­‐67-­‐eK-­‐Ura3	  (X=Met,	  Leu,	  Asn,	  Asp,	  Arg)	  in	  wild-­‐type	  and	  doa10Δ	  cells,	  respectively.	  (C)	  XN-­‐α23-­‐67-­‐eK-­‐Ura3	  (X=Gly,	  Met)	  and	  XN-­‐α23-­‐67-­‐eK-­‐Ura3	  (X=Met,	  Leu,	  Asn,	  Asp,	  Arg)	  in	  wild-­‐type	  and	  ubr1Δ	  cells,	  respectively.	  (D)	  XZ-­‐α23-­‐67-­‐eK-­‐Ura3	  (XZ=	  















































































	   257	  


















	   258	  
APPENDIX	  3:	  
SUPPLEMENTARY	  MATERIAL	  FOR	  CHAPTER	  5	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Figure	  A3.S1.	  The	  Ac/N-­‐End	  Rule	  Pathway,	  the	  Arg/N-­‐End	  Rule	  Pathway,	  and	  the	  Steric	  Sequestration	  of	  Nα-­‐Terminally	  Acetylated	  N-­‐Termini	  of	  Cellular	  Proteins.	  (A)	  The	  Ac/N-­‐end	  rule	  pathway	  in	  the	  yeast	  Saccharomyces	  cerevisiae	  (95,96).	  N-­‐terminal	  residues	  are	  indicated	  by	  single-­‐letter	  abbreviations	  for	  amino	  acids.	  A	  yellow	  oval	  denotes	  the	  rest	  of	  a	  protein	  substrate.	  E3	  ubiquitin	  (Ub)	  ligases	  of	  the	  N-­‐end	  rule	  pathway	  are	  called	  N-­‐recognins.	  Red	  arrow	  on	  the	  left	  indicates	  the	  removal	  of	  N-­‐terminal	  Met	  by	  Met-­‐aminopeptidases	  (MetAPs).	  N-­‐terminal	  Met	  is	  retained	  if	  a	  residue	  at	  position	  2	  is	  nonpermissive	  (too	  large)	  for	  MetAPs	  ((96)	  and	  references	  therein).	  If	  the	  retained	  N-­‐terminal	  Met	  or	  N-­‐terminal	  Ala,	  Val,	  Ser,	  Thr,	  and	  Cys	  are	  followed	  by	  acetylation-­‐permissive	  residues,	  the	  cited	  N-­‐terminal	  residues	  are	  usually	  Nα-­‐terminally	  acetylated	  (Nt-­‐acetylated)	  by	  the	  Nt-­‐acetylases	  NatA-­‐NatD,	  the	  bulk	  of	  which	  is	  associated	  with	  the	  ribosomes	  (86,87,89).	  Although	  second-­‐position	  Gly	  or	  Pro	  can	  be	  made	  N-­‐terminal	  by	  MetAPs	  and	  although	  the	  Doa10	  E3	  N-­‐recognin	  can	  recognize	  Nt-­‐acetylated	  Gly	  or	  Pro	  (95),	  few	  proteins	  with	  N-­‐terminal	  Gly	  or	  Pro	  are	  Nt-­‐acetylated.	  See	  Figure	  S2	  for	  a	  summary	  of	  Nt-­‐acetylation	  vis-­‐à-­‐vis	  specific	  N-­‐terminal	  residues.	  The	  Nt-­‐acetylation-­‐mediated	  N-­‐degrons	  are	  called	  Ac/N-­‐degrons,	  to	  distinguish	  them	  from	  other	  N-­‐degrons.	  The	  term	  “secondary”	  refers	  to	  the	  requirement	  for	  a	  modification	  (Nt-­‐acetylation)	  of	  a	  destabilizing	  N-­‐terminal	  residue	  before	  a	  protein	  can	  be	  recognized	  by	  a	  cognate	  N-­‐recognin.	  Nearly	  90%	  of	  human	  proteins	  are	  Nt-­‐acetylated.	  Thus,	  most	  eukaryotic	  proteins	  harbor	  a	  specific	  degradation	  signal	  from	  the	  moment	  of	  their	  birth	  (95,96).	  Physiological	  roles	  of	  the	  Ac/N-­‐end	  rule	  pathway	  are	  considered	  in	  the	  main	  text.	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(B)	  The	  Arg/N-­‐end	  rule	  pathway	  in	  S.	  cerevisiae	  (96,98-­‐102,133-­‐135).	  The	  Ubr1/Rad6	  E3-­‐E2	  N-­‐recognin	  Ub	  ligase	  directly	  recognizes	  (binds	  to)	  the	  “primary”	  destabilizing	  N-­‐terminal	  residues	  Arg,	  Lys,	  His,	  Leu,	  Phe,	  Tyr,	  Trp	  and	  Ile.	  In	  contrast,	  N-­‐terminal	  Asn,	  Gln,	  Asp,	  and	  Glu	  (as	  well	  as	  Cys,	  under	  some	  metabolic	  conditions)	  are	  destabilizing	  owing	  to	  their	  preliminary	  enzymatic	  modifications.	  These	  include	  the	  Nt-­‐deamidation	  of	  N-­‐terminal	  Asn	  and	  Gln	  by	  the	  Nta1	  Nt-­‐amidase	  and	  the	  Nt-­‐arginylation	  of	  N-­‐terminal	  Asp	  and	  Glu	  by	  the	  Ate1	  arginyltransferase	  (R-­‐transferase),	  which	  can	  also	  Nt-­‐arginylate	  oxidized	  Cys,	  either	  Cys-­‐sulfinate	  or	  Cys-­‐sulfonate.	  These	  derivatives	  of	  N-­‐terminal	  Cys	  can	  form	  in	  cells	  that	  produce	  nitric	  oxide	  (NO)	  and	  may	  also	  form	  in	  S.	  cerevisiae.	  One	  aspect	  of	  the	  S.	  
cerevisiae	  Arg/N-­‐end	  rule	  pathway	  that	  is	  not	  illustrated	  in	  this	  diagram	  is	  that	  there	  is	  a	  physical	  and	  functional	  interaction	  between	  the	  Ubr1	  E3	  of	  the	  Arg/N-­‐end	  rule	  pathway	  and	  the	  Ufd4	  E3	  of	  the	  previously	  known	  Ub-­‐fusion-­‐degradation	  (UFD)	  pathway.	  Specifically,	  the	  targeting	  apparatus	  of	  the	  Arg/N-­‐end	  rule	  pathway	  comprises	  a	  physical	  complex	  of	  the	  RING-­‐type	  E3	  Ubr1	  N-­‐recognin	  and	  the	  HECT-­‐type	  E3	  Ufd4,	  together	  with	  their	  cognate	  E2	  enzymes	  Rad6	  and	  Ubc4	  (or	  Ubc5),	  respectively	  (102).	  In	  addition	  to	  its	  two	  distinct	  binding	  sites	  that	  recognize	  type	  1	  (basic)	  and	  type	  2	  (bulky	  hydrophobic)	  destabilizing	  N-­‐terminal	  residues,	  the	  
S.	  cerevisiae	  Ubr1	  N-­‐recognin	  also	  contains	  (similarly	  to	  its	  counterparts	  in	  multicellular	  eukaryotes)	  at	  least	  one	  more	  binding	  site,	  which	  recognizes	  substrates	  that	  are	  targeted	  through	  their	  internal	  (non-­‐N-­‐terminal)	  degradation	  signals.	  One	  example	  of	  such	  a	  substrate	  is	  the	  Cup9	  transcriptional	  repressor	  (136-­‐138).	  Polyubiquitylated	  N-­‐end	  rule	  substrates	  are	  processively	  destroyed	  to	  short	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peptides	  by	  the	  26S	  proteasome.	  Hemin	  (Fe3+-­‐heme)	  binds	  to	  R-­‐transferase	  and	  inhibits	  its	  Nt-­‐arginylation	  activity.	  Hemin	  also	  binds	  to	  Ubr1	  and	  alters	  its	  functional	  properties,	  in	  ways	  that	  remain	  to	  be	  understood	  (139).	  Regulated	  degradation	  of	  specific	  proteins	  by	  the	  Arg/N-­‐end	  rule	  pathway	  mediates	  the	  sensing	  of	  heme,	  NO,	  oxygen	  and	  short	  peptides;	  the	  selective	  elimination	  of	  misfolded	  proteins;	  the	  regulation	  of	  DNA	  repair;	  the	  cohesion/segregation	  of	  chromosomes;	  the	  signaling	  by	  transmembrane	  receptors;	  the	  control	  of	  peptide	  import;	  the	  regulation	  of	  apoptosis,	  meiosis,	  viral	  and	  bacterial	  infections,	  fat	  metabolism,	  cell	  migration,	  actin	  filaments,	  cardiovascular	  development,	  spermatogenesis,	  neurogenesis	  and	  memory;	  the	  functioning	  of	  adult	  organs,	  including	  the	  brain,	  muscle,	  testis	  and	  pancreas;	  and	  the	  regulation	  of	  leaf	  and	  shoot	  development,	  leaf	  senescence,	  and	  many	  other	  functions	  in	  plants	  ((96-­‐100,102-­‐104,133-­‐135,139-­‐153)	  and	  references	  therein).	  (C)	  Steric	  shielding	  of	  the	  Nt-­‐acetylated	  N-­‐terminal	  residue	  of	  a	  subunit	  in	  a	  protein	  complex.	  Shown	  here	  is	  a	  part	  of	  the	  crystal	  structure,	  by	  the	  Barford	  laboratory,	  of	  a	  complex	  between	  the	  Hcn1	  and	  Cut9	  subunits	  of	  the	  
Schizosaccharomyces	  pombe	  APC/C	  Ub	  ligase	  (128).	  In	  this	  structure,	  the	  (indicated)	  Nt-­‐acetylated	  N-­‐terminal	  Met	  residue	  of	  Hcn1	  is	  enclosed	  within	  a	  deep	  cleft	  formed	  by	  the	  Cut9	  subunit,	  in	  the	  heterotetramer	  of	  Hcn1	  and	  Cut9.	  The	  N-­‐terminal	  region	  of	  Hcn1	  is	  shown	  in	  cyan	  as	  a	  stick	  model,	  and	  Cut9	  is	  depicted	  as	  a	  cut-­‐out	  surface	  representation,	  to	  show	  the	  chamber’s	  interior	  (128).	  	  (D)	  Model	  for	  interactions,	  based	  on	  single-­‐particle	  electron	  microscopy	  by	  the	  Hughson	  laboratory,	  among	  the	  subunits	  Cog1-­‐Cog4	  that	  form	  a	  specific	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Figure	  A3.2	  
 Figure	  A3.S2.	  N-­‐terminal	  Processing	  of	  Nascent	  Proteins,	  the	  N-­‐termini	  of	  COG	  Subunits,	  and	  the	  Nα-­‐Terminal	  Acetylation	  in	  S.	  cerevisiae.	  	  































Pro:  virtually never Nt-acetylated.
Cys: rarely Nt-acetylated.




Gly:  rarely Nt-acetylated; often N-myristoylated.









of S. cerevisiae Nt-acetylases:
NatB: Naa20 (Nat3); Naa25 (Mdm20).
NatC: Naa30 (Mak3); Naa35 (Mak10);
Naa38 (Mak31).


































	   265	  













	   266	  
Figure	  A3.3	  
 
Figure S3, Shemorry et al.
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Figure	  A3.S3.	  Degradation	  of	  Cog1	  by	  the	  Ac/N-­‐End	  Rule	  Pathway.	  (A)	  Cycloheximide	  (CHX)-­‐chases	  (related	  to	  the	  ones	  described	  in	  Figure	  1)	  were	  carried	  out	  at	  30°C	  with	  wild-­‐type	  (wt)	  (lanes	  1-­‐3),	  doa10Δ	  (lanes	  4-­‐6)	  and	  
naa20Δ	  (nat3Δ)	  (lanes	  7-­‐9)	  S.	  cerevisiae	  strains	  that	  expressed	  wt	  Cog1,	  termed	  MD-­‐Cog1wt,	  which	  was	  C-­‐terminally	  tagged	  with	  three	  flag	  epitopes.	  At	  the	  indicated	  times	  of	  chase,	  proteins	  in	  cell	  extracts	  were	  fractionated	  by	  SDS-­‐PAGE	  and	  assayed	  by	  immunoblotting	  with	  anti-­‐flag	  antibody.	  (B)	  CHX-­‐chases	  as	  in	  A,	  with	  wt	  cells	  that	  expressed	  MD-­‐Cog1wt	  (lanes	  1-­‐3)	  or	  its	  non-­‐Nt-­‐acetylatable	  P-­‐Cog1	  mutant	  (lane	  4-­‐6),	  both	  of	  which	  were	  C-­‐terminally	  tagged	  with	  three	  flag	  epitopes.	  See	  the	  main	  text	  for	  descriptions	  of	  P-­‐Cog1.	  Asterisk	  on	  the	  left	  denotes	  a	  crossreacting	  protein.	  (C)	  CHX-­‐chases	  as	  in	  A,	  with	  MD-­‐Cog1wt	  C-­‐terminally	  ha-­‐tagged	  and	  examined	  in	  naa50Δ	  (nat5Δ)	  (lanes	  1-­‐3),	  naa40Δ	  (nat4Δ)	  (lanes	  4-­‐6),	  naa20Δ	  (nat3Δ)	  (lanes	  7-­‐9),	  naa30Δ	  (mak3Δ)	  (lanes	  10-­‐12),	  and	  naa10Δ	  (ard1Δ)	  (lanes	  13-­‐15)	  S.	  cerevisiae	  strains.	  Each	  of	  these	  strains	  lacked	  the	  activity	  of	  a	  specific	  Nt-­‐acetylase	  (see	  Figure	  S2C),	  including	  the	  cognate	  (for	  MD-­‐Cog1wt)	  NatB	  Nt-­‐acetylase	  (lanes	  7-­‐9).	  (D)	  Left	  panel:	  Expression	  of	  MD-­‐Cog1wt	  C-­‐terminally	  tagged	  with	  three	  flag	  epitopes	  in	  pdr5Δ	  S.	  cerevisiae.	  Cells	  were	  incubated	  for	  1	  hr	  in	  SD	  medium	  containing	  either	  0.5%	  dimethylsulfoxide	  (DMSO)	  (the	  solvent	  for	  a	  stock	  solution	  of	  the	  proteasome	  inhibitor	  MG132)	  (lane	  1),	  or	  both	  50	  μM	  MG132	  and	  0.5%	  DMSO	  (lane	  2).	  The	  incubation	  was	  followed	  by	  preparation	  of	  extracts,	  SDS-­‐PAGE	  and	  immunoblotting	  with	  anti-­‐flag	  antibody.	  Right	  panel:	  same	  procedures	  as	  in	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experiments	  of	  the	  left	  panel	  but	  with	  erg6Δ	  S.	  cerevisiae	  incubated	  in	  SD	  containing	  either	  1%	  isopropanol	  (the	  solvent	  for	  a	  stock	  solution	  of	  phenylmethylsulfonyl	  fluoride	  (PMSF),	  an	  inhibitor	  of	  serine	  proteases)	  (lane	  1),	  or	  both	  1	  mM	  PMSF	  and	  1%	  isopropanol	  (lane	  2).	  (E)	  Quantification	  of	  data	  in	  D,	  left	  panel.	  (F)	  Quantification	  of	  data	  in	  D,	  right	  panel.	  (G)	  CHX-­‐chases	  with	  wt	  (lanes	  1-­‐3,	  7-­‐9)	  or	  naa20Δ	  (nat3Δ)	  (lanes	  4-­‐6,	  10-­‐12)	  
S.	  cerevisiae	  strains	  expressing	  MD-­‐Cog1wt	  C-­‐terminally	  tagged	  with	  three	  flag	  epitopes.	  Cells	  were	  grown	  for	  3	  hrs	  in	  SD	  medium	  containing	  0.003%	  SDS	  (to	  allow	  for	  the	  entry	  of	  MG132)	  and	  either	  0.5%	  DMSO	  (control,	  lanes	  1-­‐6)	  or	  both	  50	  μM	  MG132	  and	  0.5%	  DMSO.	  Note	  the	  metabolic	  stabilization	  of	  MD-­‐Cog1wt	  in	  wild-­‐type	  cells	  by	  MG132	  (lanes	  1-­‐3	  vs.	  lanes	  7-­‐9)	  and	  the	  metabolic	  stabilization	  of	  MD-­‐Cog1wt	  in	  naa20Δ	  cells	  (lacking	  the	  NatB	  Nt-­‐acetylase)	  irrespective	  of	  the	  absence	  or	  presence	  of	  MG132	  (lanes	  4-­‐6	  vs.	  lanes	  10-­‐12).	  (H)	  CHX-­‐chases	  with	  either	  wt	  or	  uba1-­‐204	  S.	  cerevisiae	  (the	  latter	  containing	  a	  temperature-­‐sensitive	  mutant	  of	  the	  Ub-­‐activating	  (E1)	  enzyme	  (125))	  expressing	  MD-­‐Cog1wt	  C-­‐terminally	  tagged	  with	  three	  flag	  epitopes.	  Lanes	  1-­‐3,	  wt	  cells	  at	  30°C.	  Lanes	  4-­‐5,	  uba1-­‐204	  cells	  at	  30°C.	  Lanes	  7-­‐8,	  same	  as	  in	  lanes	  1-­‐3	  but	  at	  37°C	  (nonpermissive	  temperature	  for	  uba1-­‐204	  cells).	  Lanes	  10-­‐12,	  same	  as	  lanes	  4-­‐6	  but	  at	  37°C.	  Note	  the	  metabolic	  stabilization	  of	  MD-­‐Cog1wt	  in	  uba1-­‐204	  cells	  at	  37°C	  (lanes	  10-­‐12).	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Figure	  A3.4.	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Figure	  A3.4.	  Antibody	  Specific	  for	  Nt-­‐Acetylated	  Cog1,	  and	  Interactions	  of	  Nt-­‐Acetylated	  and	  Unacetylated	  Cog1	  with	  Subunits	  of	  the	  COG	  Complex	  or	  with	  Membranes.	  (A)	  Characterization	  of	  the	  anti-­‐AcNtCog1	  antibody	  using	  a	  dot	  assay.	  Increasing	  amounts	  of	  the	  Nt-­‐acetylated	  Ac-­‐MDEVLPLFRDSC	  peptide	  and	  its	  non-­‐acetylated	  counterpart	  MDEVLPLFRDSC	  were	  spotted	  onto	  a	  nitrocellulose	  membrane,	  followed	  by	  immunoblotting	  with	  the	  rabbit	  anti-­‐AcNtCog1	  antibody	  that	  was	  raised	  against	  the	  Ac-­‐MDEVLPLFRDSC	  peptide	  and	  was	  then	  affinity-­‐purified	  both	  “positively”	  (against	  Ac-­‐MDEVLPLFRDSC)	  and	  “negatively”	  (against	  MDEVLPLFRDSC)	  (see	  Extended	  Experimental	  Procedures).	  (B)	  Wt,	  cog1Δ,	  and	  naa20Δ	  (nat3Δ)	  S.	  cerevisiae	  strains	  overexpressed	  either	  MD-­‐Cog1wt,	  P-­‐Cog1,	  or	  ME-­‐Tpk2	  (an	  Nt-­‐acetylated	  protein	  whose	  N-­‐terminal	  sequence	  is	  different	  from	  that	  of	  MD-­‐Cog1wt;	  a	  negative	  control)	  from	  the	  PCUP1	  promoter	  on	  low	  copy	  plasmids.	  Equal	  amounts	  of	  total	  protein	  in	  the	  extracts	  were	  fractionated	  by	  SDS-­‐PAGE	  and	  immunoblotted	  with	  the	  anti-­‐AcNtCog1	  antibody.	  Lane	  1,	  MD-­‐Cog1wt	  (C-­‐terminally	  tagged	  with	  three	  flag	  epitopes)	  was	  expressed	  in	  wt	  cells.	  Lane	  2,	  same	  as	  in	  lane	  1	  but	  the	  identically	  tagged	  P-­‐Cog1	  (MP-­‐Cog1).	  Lane	  3,	  same	  as	  in	  lane	  2	  but	  in	  cog1Δ	  cells.	  Lane	  4,	  same	  as	  in	  lane	  1	  but	  vector	  alone	  (no	  exogenously	  expressed	  MD-­‐Cog1wt).	  Lane	  5,	  ME-­‐Tpk2	  (C-­‐terminally	  tagged	  with	  three	  flag	  epitopes)	  was	  expressed	  in	  wt	  cells.	  Lane	  6,	  same	  as	  in	  lane	  5	  but	  ME-­‐Tpk2	  was	  expressed	  in	  naa20Δ	  (nat3Δ)	  cells	  lacking	  the	  cognate	  NatB	  Nt-­‐acetylase.	  Anti-­‐AcNtCog1	  detected	  the	  band	  of	  Nt-­‐acetylated	  MD-­‐Cog1wt	  in	  lane	  1.	  Consistently,	  there	  was	  virtually	  no	  signal	  in	  other	  lanes,	  except	  for	  the	  barely	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detectable	  band	  in	  lanes	  4	  and	  5	  (marked	  by	  asterisk	  on	  the	  right)	  that	  is	  likely	  to	  be	  the	  endogenous	  Nt-­‐acetylated	  MD-­‐Cog1wt	  (endogenous	  MD-­‐Cog1wt	  was	  expressed	  at	  levels	  significantly	  below	  those	  of	  exogenous	  MD-­‐Cog1wt).	  Consistent	  with	  the	  absence	  of	  three	  flag	  epitopes	  in	  the	  endogenous	  MD-­‐Cog1wt,	  its	  band	  migrated	  faster	  than	  the	  band	  of	  the	  exogenous	  (tagged)	  MD-­‐Cog1wt	  (lane	  1	  vs.	  lanes	  4	  and	  5).	  Note	  the	  absence	  of	  crossreaction	  of	  anti-­‐AcNtCog1	  with	  Nt-­‐acetylated	  ME-­‐Tpk2	  in	  wt	  cells	  (lane	  5).	  The	  anti-­‐AcNtCog1	  antibody	  also	  detected	  proteins	  larger	  than	  MD-­‐Cog1wt;	  they	  are	  marked	  by	  green	  arrowheads	  on	  the	  left.	  These	  proteins	  were	  not	  derivatives	  of	  MD-­‐Cog1wt,	  as	  they	  were	  present	  in	  cells	  not	  expressing	  MD-­‐Cog1wt	  (lane	  4).	  The	  three	  proteins	  were	  Nt-­‐acetylated	  by	  NatB,	  as	  they	  were	  absent	  in	  
naa20Δ	  (nat3Δ)	  cells	  (lane	  6).	  A	  likely	  and	  parsimonious	  interpretation	  is	  that	  the	  anti-­‐AcNtCog1	  antibody	  detected	  three	  specific	  Nt-­‐acetylated	  proteins	  whose	  cognate	  Nt-­‐acetylase	  (NatB)	  is	  the	  same	  as	  the	  one	  that	  Nt-­‐acetylates	  MD-­‐Cog1wt	  and	  whose	  N-­‐terminal	  sequences	  are	  sufficiently	  close	  to	  that	  of	  MD-­‐Cog1wt	  to	  have	  resulted	  in	  a	  crossreaction.	  (C)	  Same	  as	  in	  B,	  but	  the	  same	  membrane	  was	  re-­‐probed	  with	  anti-­‐flag	  antibody,	  to	  detect	  the	  bulk	  of	  triply	  flag-­‐tagged	  MD-­‐Cog1wt	  and	  ME-­‐Tpk2.	  (D)	  Equal	  amounts	  of	  total	  detergent-­‐free	  cell	  extracts	  from	  wt	  or	  naa20Δ	  (nat3Δ)	  S.	  cerevisiae	  were	  fractionated	  to	  yield	  the	  cytosolic	  (C)	  and	  membrane	  (M)	  fractions,	  followed	  by	  SDS-­‐PAGE	  and	  immunoblotting	  with	  anti-­‐flag	  antibody	  to	  detect	  the	  triply	  flag-­‐tagged	  MD-­‐Cog1wt.	  Lanes	  1-­‐3,	  wt	  total	  (T)	  extract	  and	  its	  C	  and	  M	  fractions,	  respectively.	  Lanes	  4-­‐6,	  same	  as	  in	  lanes	  1-­‐3	  but	  from	  naa20Δ	  (nat3Δ)	  cells.	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(E)	  Coomassie	  Blue	  staining	  of	  membrane	  probed	  by	  anti-­‐flag	  in	  D.	  	  (F)	  Quantification	  of	  the	  ratio	  of	  MD-­‐Cog1wt	  in	  the	  membrane	  versus	  cytosolic	  fractions	  in	  panel	  D,	  using	  Odyssey	  (Li-­‐Cor)	  (see	  Extended	  Experimental	  Procedures).	  (G)	  Coimmunoprecipitation	  of	  MD-­‐Cog1wt	  and	  Cog3	  in	  the	  presence	  and	  absence	  of	  Nt-­‐acetylation.	  Wt	  and	  naa20Δ	  (nat3Δ)	  S.	  cerevisiae	  strains	  carried	  either	  a	  PCUP1	  promoter-­‐containing	  low	  copy	  plasmid,	  or	  the	  otherwise	  identical	  plasmid	  expressing	  MD-­‐Cog1wt	  (C-­‐terminally	  tagged	  with	  three	  flag	  epitopes),	  or	  the	  plasmid	  expressing	  Cog3	  (C-­‐terminally	  ha-­‐tagged),	  in	  the	  indicated	  combinations	  of	  test	  proteins	  and	  genetic	  backgrounds	  of	  strains	  in	  which	  they	  were	  expressed.	  Extracts	  from	  these	  strains	  were	  immunoprecipitated	  using	  anti-­‐flag	  beads,	  followed	  by	  SDS-­‐PAGE	  and	  immunoblotting	  with	  anti-­‐ha	  (to	  detect	  Cog3;	  the	  upper	  panel,	  green	  color)	  or	  with	  anti-­‐flag	  (to	  detect	  MD-­‐Cog1wt;	  the	  lower	  panel,	  red	  color).	  As	  described	  in	  the	  main	  text,	  most	  Cog3	  in	  naa20Δ	  (nat3Δ)	  cells	  was	  converted	  into	  a	  derivative	  of	  lower	  electrophoretic	  mobility,	  indicated	  on	  the	  right	  as	  “modified	  Cog3”.	  The	  asterisk	  on	  the	  left	  indicates	  a	  protein	  crossreacting	  with	  anti-­‐ha	  antibody.	  The	  arrowhead	  on	  the	  right	  marks	  the	  position	  of	  the	  heavy	  IgG	  chain,	  above	  the	  band	  of	  immunoprecipitated	  MD-­‐Cog1wt.	  (H)	  Same	  as	  in	  G	  (including	  the	  same	  notations),	  but	  coimmunoprecipitation	  of	  MD-­‐Cog1wt	  (C-­‐terminally	  tagged	  with	  three	  flag	  epitopes)	  and	  Cog4	  (C-­‐terminally	  ha-­‐tagged).	  The	  asterisk	  in	  the	  top	  panel	  on	  the	  right	  indicates	  a	  protein	  crossreacting	  with	  anti-­‐ha.	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Figure	  A3.5.	  
 Figure	  A3.5.	  Degradation	  of	  MD-­‐Cog1wt	  by	  the	  Ac/N-­‐End	  Rule	  Pathway	  in	  S.	  
cerevisiae	  Mutants	  Lacking	  Specific	  E2	  or	  E3	  enzymes.	  Figure S5, Shemorry et al.
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(A)	  CHX-­‐chases	  with	  S.	  cerevisiae	  mutants	  in	  specific	  Ub-­‐conjugating	  (E2)	  enzymes	  that	  expressed	  MD-­‐Cog1wt	  C-­‐terminally	  tagged	  with	  three	  flag	  epitopes.	  Wt	  (lanes	  1-­‐3),	  mms2Δ	  (lanes	  4-­‐6),	  rad6Δ	  (lanes	  7-­‐9),	  ubc5Δ	  (lanes	  10-­‐12),	  ubc8Δ	  (lanes	  13-­‐15),	  and	  ubc10Δ	  (lanes	  16-­‐18)	  S.	  cerevisiae	  strains.	  (B)	  Same	  as	  in	  A	  but	  with	  ubc4Δ	  (lanes	  1-­‐3),	  ubc6Δ	  (lanes	  4-­‐6),	  ubc7Δ	  (lanes	  7-­‐9),	  ubc11Δ	  (lanes	  10-­‐12),	  ubc12Δ	  (lanes	  13-­‐15),	  and	  ubc13Δ	  (lanes	  16-­‐18)	  S.	  cerevisiae	  strains.	  (C)	  Same	  as	  in	  A	  but	  with	  wt	  (lanes	  1-­‐3)	  and	  ubc1Δ	  (lanes	  4-­‐6)	  S.	  cerevisiae	  strains.	  (D)	  CHX-­‐chases	  with	  mutants	  in	  two	  specific	  E3	  enzymes.	  Same	  as	  in	  A	  but	  with	  wt	  (lanes	  1-­‐3),	  doa10Δ	  (lanes	  4-­‐6),	  and	  san1Δ	  (lanes	  7-­‐9)	  S.	  cerevisiae	  strains.	  (E)	  Same	  as	  in	  D	  but	  with	  wt	  (lanes	  1-­‐3),	  ubr1Δ	  (lanes	  4-­‐6),	  doa10Δ	  (lanes	  7-­‐9),	  and	  double-­‐mutant	  ubr1Δ	  doa10Δ	  (lanes	  10-­‐12)	  S.	  cerevisiae	  strains.	  (F)	  Lanes	  1-­‐4,	  35S-­‐pulse	  chase	  with	  wt	  S.	  cerevisiae	  and	  MD-­‐Cog1wt	  (C-­‐terminally	  tagged	  with	  three	  flag	  epitopes	  modified	  to	  contain	  a	  Met	  residue	  in	  each	  epitope,	  to	  increase	  35S	  in	  Cog1;	  see	  Extended	  Experimental	  Procedures).	  Lanes	  5-­‐8,	  same	  as	  lanes	  1-­‐4	  but	  with	  a	  double	  mutant	  ubc6Δ	  ubc7Δ.	  (G)	  Quantification	  of	  data	  in	  F.	  Note	  the	  absence	  of	  significant	  effects	  of	  the	  tested	  mutant	  backgrounds	  on	  the	  degradation	  of	  MD-­‐Cog1wt	  by	  the	  Ac/N-­‐end	  rule	  pathway	  (see	  also	  Figure	  1	  and	  the	  main	  text).	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EXTENDED	  EXPERIMENTAL	  PROCEDURES	  	  
Yeast	  Strains,	  Media,	  and	  Genetic	  Techniques	  
S.	  cerevisiae	  strains	  used	  in	  this	  study	  are	  described	  in	  Table	  S1.	  Standard	  techniques	  (155,156)	  were	  employed	  for	  strain	  construction	  and	  transformation.	  
S.	  cerevisiae	  media	  included	  YPD	  (1%	  yeast	  extract,	  2%	  peptone,	  2%	  glucose;	  only	  most	  relevant	  components	  are	  cited);	  SD	  medium	  (0.17%	  yeast	  nitrogen	  base,	  0.5%	  ammonium	  sulfate,	  2%	  glucose);	  and	  synthetic	  complete	  (SC)	  medium	  (0.17%	  yeast	  nitrogen	  base,	  0.5%	  ammonium	  sulfate,	  2%	  glucose),	  plus	  a	  drop-­‐out	  mixture	  of	  compounds	  required	  by	  a	  given	  auxotrophic	  strain.	  The	  COG1-­‐3HA	  strains	  were	  made	  by	  standard	  PCR	  of	  the	  3HA-­‐HIS3MX6	  module	  (157)	  targeted	  to	  the	  3’	  coding	  region	  of	  COG1.	  The	  PCR	  product	  was	  transformed	  into	  BY4742,	  BY17299,	  and	  BY15546	  to	  create	  ASY101,	  ASY102,	  and	  ASY103,	  respectively.	  The	  double	  mutant	  
ubc6Δubc7Δ	  (ASY104)	  was	  made	  by	  transforming	  BBY67.3	  with	  a	  PCR	  product	  of	  the	  KanMX6	  module	  (157)	  targeted	  to	  the	  5’	  and	  3’	  regions	  of	  UBC7,	  thereby	  replacing	  the	  ORF	  of	  Ubc7	  with	  KanMX6.	  The	  ASY105	  strain	  was	  made	  by	  the	  standard	  integration	  of	  a	  PCR	  fragment	  derived	  from	  pFA6a-­‐13MYC	  with	  the	  HIS3MX6	  marker	  targeted	  to	  the	  3'	  end	  of	  the	  COG1	  gene.	  Proper	  tagging	  of	  COG1	  and	  its	  product	  was	  verified	  by	  PCR	  and	  immunoblotting	  with	  anti-­‐myc	  antibody.	  The	  resulting	  ASY105	  strain	  was	  transformed	  with	  pAS118	  or	  the	  control	  YEPlac181	  plasmid	  (Table	  S2).	  E1,	  E2,	  E3	  and	  Nt-­‐acetylase	  mutant	  strains	  used	  in	  this	  study	  were	  from	  the	  Varshavsky	  lab	  stock	  (CHY345,	  CHY346,	  BBY67.3),	  the	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T.	  Sommer	  lab	  stock	  (YW05),	  the	  Deshaies	  lab	  stock	  (RJD3268,	  RJD3269)	  or	  all	  others	  from	  Open	  Biosystems.	  Strains	  used	  in	  the	  proteasome	  and	  vacuole	  inhibitor	  studies	  were	  obtained	  from	  Open	  Biosystems	  (BY10568)	  or	  from	  the	  Varshavsky	  lab	  stock	  (JD52,	  CHY49).	  The	  cog1Δ	  mutant	  (BY14589)	  was	  obtained	  from	  Open	  Biosystems.	  	  	  
Construction	  of	  Plasmids	  The	  S.	  cerevisiae	  Cog1-­‐coding	  sequence	  was	  amplified	  by	  PCR	  from	  genomic	  DNA	  and	  the	  triple	  flag-­‐coding	  sequence	  was	  then	  added	  by	  PCR.	  Additional	  Met-­‐coding	  sequences	  were	  added	  in	  between	  the	  Cog1-­‐coding	  sequence	  and	  the	  triple	  flag-­‐coding	  sequence	  to	  increase	  the	  labeling	  of	  MD-­‐Cog1wt	  with	  35S-­‐Met.	  The	  3	  extra	  Met-­‐coding	  DNA	  sequences	  were	  separated	  by	  short	  Gly-­‐Ser	  linker	  sequences,	  the	  complete	  Met-­‐enriching	  sequence	  being	  MSGMGAM.	  pAS101	  was	  constructed	  	  by	  ligating	  the	  BamHI/Not1	  digested	  PCR	  fragment	  of	  Cog1-­‐3flag	  DNA	  into	  the	  low-­‐copy	  (CEN)	  plasmid	  pRS316	  with	  the	  PCUP1	  promoter	  (p316Cup1).	  pAS117	  was	  made	  by	  standard	  site-­‐directed	  mutagenesis	  of	  pAS101	  to	  insert	  a	  coding	  sequence	  for	  proline	  (P)	  in	  between	  the	  initiator	  Met	  (M)	  and	  Asp	  (D).	  pAS105	  was	  made	  by	  amplifying	  the	  Cog1-­‐coding	  sequence	  with	  a	  sequence	  encoding	  a	  single	  C-­‐terminal	  ha	  tag	  and	  ligating	  this	  PCR	  product	  into	  the	  BamHI/NotI-­‐cut	  p316Cup1	  plasmid.	  pAS118	  was	  made	  by	  standard	  point	  mutagenesis	  of	  pAS105	  to	  mutate	  the	  aspartic	  acid	  (D)	  coding	  sequence	  to	  lysine	  (K).	  pAS102	  was	  made	  by	  adding	  the	  3flag	  sequence	  to	  the	  3’	  end	  of	  the	  Cog2	  PCR	  product	  and	  ligating	  that	  product	  into	  p316Cup1.	  pAS115	  was	  made	  by	  inserting	  the	  Cog2-­‐3f	  sequence	  and	  the	  Cog3-­‐HA	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sequence	  on	  opposite	  sides	  of	  the	  PGAL1/10	  bidirectional	  promoter.	  pAS116	  was	  made	  by	  inserting	  the	  Cog4-­‐ha-­‐coding	  sequence	  into	  pRS425Gal1/10.	  pAS118	  was	  made	  by	  ligating	  the	  XbaI/PstI-­‐derived,	  PCR-­‐produced	  DNA	  fragment	  into	  XbaI/PstI-­‐cut	  pRB208.	  To	  construct	  pAS112	  (Table	  S2),	  the	  S.	  pombe	  HCN1	  coding	  sequence	  was	  amplified	  from	  pGAD424-­‐Hcn1.	  The	  triple	  flag-­‐coding	  DNA	  sequence	  was	  then	  added	  to	  the	  3’	  region	  of	  HCN1.	  The	  resulting	  PCR-­‐produced	  DNA	  fragment	  was	  ligated	  into	  the	  high	  copy	  plasmid	  pRS423	  (155)	  containing	  the	  PCUP1	  promoter.	  The	  same	  PCR	  fragment	  from	  pAS112	  was	  ligated	  into	  p413Met25	  to	  produce	  pAS113.	  The	  S.	  cerevisiae	  DNA	  encoding	  Cdc26	  was	  amplified	  from	  genomic	  DNA	  and	  the	  triple	  flag-­‐coding	  DNA	  sequence	  was	  added	  by	  PCR.	  The	  resulting	  DNA	  fragment	  was	  cloned	  into	  pRS423	  as	  described	  above	  to	  produce	  pAS119.	  DNA	  encoding	  
S.	  pombe	  Cut9	  was	  amplified	  from	  pGAD424-­‐Cut9,	  and	  the	  triple	  flag-­‐coding	  DNA	  sequence	  was	  added	  to	  the	  3’	  region	  of	  CUT9	  by	  PCR.	  The	  resulting	  DNA	  fragment	  was	  ligated	  into	  the	  high	  copy	  pRS425	  plasmid	  containing	  the	  PGAL1	  promoter,	  yielding	  pAS114.	  	  	  
Cycloheximide	  Chase	  Degradation	  Assays	  
S.	  cerevisiae	  were	  grown	  to	  A600	  of	  0.8	  to	  1.0	  in	  plasmid-­‐maintaining	  (selective)	  liquid	  media	  at	  30°C,	  followed	  by	  treatment	  with	  cycloheximide	  (CHX),	  at	  the	  final	  concentration	  of	  0.1	  mg/ml.	  At	  indicated	  times,	  cell	  samples	  (corresponding	  to	  1	  ml	  of	  cell	  suspension	  at	  A600	  of	  1)	  were	  harvested	  by	  centrifugation	  for	  1	  min	  at	  11,200g,	  and	  resuspended	  in	  1	  ml	  of	  0.2	  M	  NaOH,	  for	  20	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min	  on	  ice,	  or	  for	  5	  min	  at	  room	  temperature,	  followed	  by	  centrifugation	  for	  1	  min	  at	  11,200g.	  Pelleted	  cells	  were	  resuspended	  in	  50	  μl	  of	  1X	  LDS	  buffer	  (Invitrogen,	  Carlsbad,	  CA)	  with	  1X	  reducing	  agent	  and	  1x	  protease	  inhibitor	  cocktail	  “for	  use	  with	  fungal	  and	  yeast	  extracts”	  (Sigma),	  and	  heated	  for	  10	  min	  at	  70°C.	  After	  centrifugation	  at	  5	  min	  at	  11,200g,	  10	  μl	  of	  supernatant	  was	  fractionated	  by	  SDS-­‐4-­‐12%	  NuPAGE,	  followed	  by	  immunoblotting	  with	  an	  appropriate	  antibody.	  The	  antibodies	  used	  included	  anti-­‐ha	  (Sigma),	  anti-­‐flag	  (Stratagene,	  La	  Jolla,	  CA),	  anti-­‐tubulin	  (used	  for	  loading	  controls)	  (Sigma),	  and	  anti-­‐NtCog1,	  prepared	  and	  purified	  as	  described	  below.	  Immunoblots	  were	  processed	  using	  secondary	  antibodies	  labeled	  with	  different	  fluorophores.	  Visualized	  protein	  bands	  were	  quantified	  using	  the	  Odyssey	  Imaging	  System	  (Li-­‐Cor,	  Lincoln,	  NE).	  The	  near-­‐infrared	  fluorescence	  range	  and	  other	  features	  of	  the	  Odyssey	  scanner	  facilitate	  quantification	  of	  immunoblots.	  	  
35S-­‐Pulse-­‐Chase	  Degradation	  Assays	  These	  experiments	  were	  performed	  essentially	  as	  described	  previously	  (95,102,133).	  Unless	  stated	  otherwise,	  S.	  cerevisiae	  strains	  were	  grown	  at	  30°C	  to	  A600	  of	  ~1	  in	  10	  ml	  of	  SD	  medium	  with	  components	  required	  for	  auxotrophic	  growth.	  Cells	  were	  pelleted	  by	  centrifugation,	  gently	  resuspended,	  and	  washed	  in	  0.8	  ml	  of	  SD	  medium	  with	  required	  amino	  acids	  but	  without	  L-­‐Met	  and	  L-­‐Cys.	  Cell	  pellets	  were	  gently	  resuspended	  again	  in	  0.4	  ml	  of	  the	  same	  medium	  and	  labeled	  for	  5	  min	  at	  30°C	  with	  0.16	  mCi	  of	  35S-­‐EXPRESS	  (Perkin-­‐Elmer).	  Cells	  were	  pelleted	  again	  and	  resuspended	  in	  0.3	  ml	  of	  SD	  medium	  containing	  unlabeled	  10	  mM	  L-­‐Met,	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5	  mM	  unlabeled	  L-­‐Cys,	  and	  required	  amino	  acids.	  Samples	  (0.1	  ml)	  were	  taken	  at	  the	  indicated	  time	  points,	  followed	  by	  preparation	  of	  extracts	  by	  bead	  beating	  (FastPrep,	  20	  seconds	  at	  6.5	  M/s,	  4	  times	  each),	  immunoprecipitation	  with	  anti-­‐flag	  magnetic	  beads	  (Sigma),	  SDS-­‐4-­‐12%	  NuPAGE,	  electrophoretic	  transfer	  of	  proteins	  to	  a	  PVDF	  membrane	  (Invitrogen)	  and	  autoradiography.	  Quantification	  of	  35S-­‐pulse-­‐chases	  was	  carried	  out	  using	  Storm	  PhosphorImager	  and	  ImageQuant	  (GE	  Healthcare,	  Pittsburgh,	  PA).	  	  
Antibody	  Specific	  for	  Nt-­‐Acetylated	  Cog1	  Ac-­‐MDEVLPLFRDS,	  the	  Nt-­‐acetylated	  N-­‐terminal	  peptide	  of	  MD-­‐Cog1wt,	  was	  used	  to	  produce	  a	  rabbit	  antibody,	  termed	  anti-­‐Cog1AcNt,	  that	  recognized	  Ac-­‐MDEVLPLFRDS	  but	  not	  its	  unacetylated	  counterpart	  (Figures	  1E-­‐H	  and	  S4A-­‐C).	  The	  Nt-­‐acetylated	  synthetic	  peptide	  AcMDEVLPLFRDSC	  and	  its	  unacetylated	  counterpart	  MDEVLPLFRDSC	  (they	  bore	  C-­‐terminal	  Cys	  for	  crosslinking	  these	  peptides	  to	  the	  keyhole	  limpet	  hemocyanin	  carrier	  protein)	  were	  synthesized	  and	  purified	  by	  Abgent	  (San	  Diego,	  CA).	  Standard	  procedures	  were	  employed	  by	  Abgent	  to	  produce	  rabbit	  antisera	  to	  AcMDEVLPLFRDSC.	  The	  resulting	  antibody	  (its	  IgG	  fraction,	  produced	  using	  immobilized	  Protein	  A)	  was	  affinity-­‐purified,	  “positively”	  at	  first,	  against	  the	  immobilized	  AcMDEVLPLFRDSC	  peptide.	  The	  peptide-­‐bound	  antibody	  was	  eluted	  and	  thereafter	  “negatively”	  purified	  against	  the	  MDEVLPLFRDSC	  peptide	  (immobilized	  using	  SulfoLink	  Coupling	  Resin	  (Pierce)),	  with	  collection,	  this	  time,	  of	  the	  unbound	  antibody	  fraction.	  The	  resulting	  antibody,	  termed	  anti-­‐AcNtCog1,	  was	  highly	  specific	  for	  Nt-­‐acetylated	  MD-­‐Cog1wt	  (see	  Results).	  Immunoblotting	  with	  anti-­‐
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AcNtCog1	  (1:500	  dilution)	  was	  carried	  out	  for	  3	  h	  at	  room	  temperature	  (RT)	  in	  5%	  skim	  milk	  in	  PBST	  (PBS	  containing	  0.5%	  Tween-­‐20).	  The	  bound	  anti-­‐AcNtCog1	  was	  detected	  using	  the	  Odyssey	  Imaging	  System	  and	  a	  goat	  anti-­‐rabbit	  antibody	  (at	  1:5,000	  dilution)	  that	  was	  conjugated	  to	  IRDye-­‐800	  (Li-­‐Cor).	  	  
Partitioning	  of	  Nt-­‐Acetylated	  and	  Unacetylated	  MD-­‐Cog1wt	  Between	  
Membranes	  and	  Cytosol	  	  This	  assay	  (Figure	  S4D-­‐F)	  used	  a	  slight	  modification	  of	  the	  previously	  described	  procedure	  (119).	  Wild-­‐type	  and	  naa20Δ	  (nat3Δ)	  S.	  cerevisiae	  expressing	  MD-­‐Cog1wt	  (C-­‐terminally	  tagged	  with	  three	  flag	  epitopes)	  were	  grown	  at	  30°C	  in	  200	  ml	  of	  SD	  to	  A600	  between	  1	  and	  2.	  Cells	  were	  collected	  by	  centrifugation	  and	  washed	  twice	  with	  ice-­‐cold	  distilled	  water.	  Cells	  were	  disrupted	  in	  1	  ml	  of	  lysis	  buffer	  (1	  mM	  dithiothreitol	  (DTT),	  20	  mM	  HEPES,	  (pH	  7.0),	  1	  mM	  PMSF,	  and	  protease	  inhibitor	  cocktail	  (Sigma)),	  using	  1	  ml	  of	  glass	  beads	  and	  vortexing	  3	  times	  for	  1	  min	  each.	  The	  extract	  was	  clarified	  by	  centrifugation	  at	  3000g	  for	  5	  min,	  followed	  by	  centrifugation	  in	  the	  TL100	  ultracentrifuge	  (Beckman)	  at	  150,000g	  for	  1	  h	  to	  obtain	  crude	  “cytosolic”	  (supernatant)	  and	  “membrane”	  (pellet)	  fractions.	  Membrane	  fractions	  were	  resuspended	  in	  1	  ml	  of	  Tris-­‐Buffered	  Saline	  (TBS).	  Total	  clarified	  extracts	  and	  equal	  total	  protein	  amounts	  of	  cytosolic	  and	  membrane	  fractions	  (as	  determined	  by	  the	  Bradford	  assay)	  were	  fractionated	  by	  SDS-­‐4-­‐12%	  NuPAGE	  (Invitrogen),	  followed	  by	  immunoblotting	  with	  anti-­‐flag	  antibody.	  The	  relative	  amounts	  of	  MD-­‐Cog1wt	  in	  cytosolic	  and	  membrane	  fractions	  were	  quantified	  using	  the	  Odyssey	  Imaging	  System.	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Coimmunoprecipitation	  of	  Cog1	  with	  Cog3	  and	  Cog4	  Wild-­‐type	  and	  naa20Δ	  (nat3Δ)	  S.	  cerevisiae	  expressing	  specific	  combinations	  of	  either	  vector	  alone,	  MD-­‐Cog1wt	  (C-­‐terminally	  tagged	  with	  three	  flag	  epitopes),	  Cog3	  (C-­‐terminally	  ha-­‐tagged),	  or	  Cog4	  (C-­‐terminally	  ha-­‐tagged)	  (Figure	  S4G,	  H)	  were	  grown	  at	  30°C	  to	  A600	  of	  ~1	  in	  50	  ml	  of	  SD	  containing	  or	  lacking	  appropriate	  metabolic	  markers.	  Cells	  were	  collected	  by	  centrifugation	  and	  resuspended	  in	  0.8	  ml	  of	  lysis	  buffer	  (0.1%	  NP-­‐40,	  10%	  glycerol,	  0.1	  M	  NaCl,	  0.5	  mM	  EDTA,	  25	  mM	  HEPES,	  pH	  7.5)	  containing	  1X	  protease	  inhibitor	  cocktail	  and	  1	  mM	  PMSF.	  Cells	  were	  disrupted	  using	  the	  FastPrep	  lysing	  matrix	  and	  bead	  beating	  (FastPrep).	  The	  extract	  was	  clarified	  by	  centrifugation	  at	  12,000g	  for	  15	  min	  at	  4°C.	  The	  total	  protein	  concentration	  was	  measured	  by	  the	  Bradford	  assay.	  Equal	  amounts	  of	  total	  protein	  were	  incubated	  with	  anti-­‐flag	  magnetic	  beads	  (Sigma)	  for	  2	  hrs	  at	  4°C.	  The	  beads	  were	  washed	  3	  times	  with	  lysis	  buffer,	  followed	  by	  the	  elution	  of	  beads-­‐bound	  proteins	  with	  12	  μl	  of	  2X	  NuPAGE	  LDS	  sample	  buffer	  (containing	  lithium	  dodecyl	  sulfate	  instead	  of	  SDS)	  with	  protease	  inhibitors.	  Sample	  were	  heated	  at	  95°C	  for	  5	  min,	  clarified	  by	  centrifugation,	  and	  fractionated	  by	  SDS-­‐4-­‐12%	  NuPAGE,	  followed	  by	  immunoblotting	  with	  anti-­‐ha	  antibody	  and	  thereafter	  with	  anti-­‐flag	  antibody.	  	  	  
Assays	  with	  Protease	  Inhibitors	  	  MD-­‐Cog1wt	  C-­‐terminally	  tagged	  with	  three	  flag	  epitopes	  was	  expressed	  from	  the	  low	  copy	  plasmid	  pRS316Cup1-­‐Cog1-­‐3flag	  and	  its	  PCUP1	  promoter	  in	  pdr5Δ	  S.	  
cerevisiae	  (the	  absence	  of	  the	  Pdr5	  pump	  in	  this	  mutant	  allowed	  for	  the	  intracellular	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Table	  S1:	  S.	  cerevisiae	  Strains	  Used	  in	  This	  Study	  
Strain	   Relevant	  Genotype	   Source	  BY4742	   MATα	  his3-­‐1	  leu2-­‐0	  lys2-­‐0	  ura3-­‐0	  can1-­‐100,	   Open	  Biosystems	  BY10976	   ard1Δ::KanMX6	  in	  BY4742	   Open	  Biosystems	  BY15470	   mak3Δ::KanMX6	  in	  BY4742	   Open	  Biosystems	  BY15546	   nat3Δ::KanMX6	  in	  BY4742	   Open	  Biosystems	  BY17299	   doa10Δ:KanMX6	  in	  BY4742	   Open	  Biosystems	  BY4741	   MATa	  his3-­‐1	  leu2-­‐0	  met15-­‐0	  ura3-­‐0	   Open	  Biosystems	  BY4425	   rad6Δ::	  KanMX4	  in	  BY4741	   Open	  Biosystems	  BY14589	   cog1Δ::KanMX4	  in	  BY4742	   Open	  Biosystems	  ASY101	   COG1-­‐3HA::HIS3MX6	  in	  BY4742	   This	  Study	  ASY102	   COG1-­‐3HA::HIS3MX6	  in	  BY17299	   This	  Study	  ASY103	   COG1-­‐3HA::HIS3MX6	  in	  BY15546	   This	  Study	  ASY105	   COG1-­‐13MYC::HIS3MX6	  in	  BY4742	   This	  Study	  YW05	   ubc1Δ::	  HIS3	  JD52	   T.	  Sommers	  lab	  collection	  BY4454	  	   mms2Δ::KanMX6	  in	  BY4741	   Open	  Biosystems	  BY3994	   ubc5Δ::KanMX6	  in	  BY4741	   Open	  Biosystems	  BY3219	   ubc4Δ::KanMX6	  in	  BY4741	   Open	  Biosystems	  BBY67.3	   ubc6Δ::HIS3	  in	  JD52	   Varshavsky	  lab	  collection	  BY597	   ubc7Δ::KanMX6	  in	  BY4741	   Open	  Biosystems	  BY6577	   ubc8Δ::	  KanMX6	  in	  BY4741	   Open	  Biosystems	  BY4763	   ubc10Δ::	  KanMX6	  in	  BY4741	   Open	  Biosystems	  BY1636	   ubc11Δ::	  KanMX6	  in	  BY4741	   Open	  Biosystems	  BY5214	   ubc12Δ::	  KanMX6	  in	  BY4741	   Open	  Biosystems	  BY4027	   ubc13Δ::	  KanMX6	  in	  BY4741	   Open	  Biosystems	  AS104	   ubc6Δ::HIS3,	  ubc7Δ::KanMX6	  in	  JD52	   This	  Study	  BY10568	   erg6Δ::KanMX6	  in	  BY4742	   Open	  Biosystems	  RJD3268	   MATa,	  uba1::KANMX	  [pRS313	  -­‐	  UBA1-­‐HIS],	  can1-­‐100,	  
leu2-­‐3,	  -­‐112,	  his3-­‐11,	  -­‐15,	  trp1-­‐1,	  ura3-­‐1,	  ade2-­‐1	  
(125)	  RJD3269	  	   MATa,	  uba1Δ::KanMX	  [pRS313-­‐uba1-­‐204-­‐HIS],	  can1-­‐
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Table	  S2:	  Plasmids	  Used	  in	  This	  Study	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